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Abstract 
 
Aims 
 
In this thesis, we shall discus the reporting of harms in randomised controlled trials 
using the CONSORT statement for harms 2004. To determine if reporting has changed 
since the introduction of this standard.  
 
To evaluate the effects of lacosamide when used as an add-on for drug resistant 
epilepsy in a systematic review and use it as a model to test hypothesis if harms. 
 
Develop new tools and methodologies in analysing harms in systematic reviews and to 
test of harms across indications can be used for antiepileptic drugs in systematic 
reviews 
 
 
Methods  
 
Statistical analyses were conducted using SPSS version 17, RevMan version 5.0 and 
Comprehensive Meta-analysis version 3.0 to analyses data.  
 
Continuous variables were compared with means using the Student t-tests analyses of 
variance (ANOVA). Proportion data were compared using relative risks. These were 
calculated using either and random or fixed effects models where appropriate.  
 
Heterogeneity was explored using statistical tests of heterogeneity and meta-
regression.  
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One hundred and fifty two RCTs published between 1999 and 2008 were included for 
analysis. Three epilepsy RCTs published between 2007 and 2010 were include for 
systematic reviews of lacosamide and an additional four neuropathy trials were 
included. One hundred and six randomised controlled trials of antiepileptic drugs were 
included to analyses harms across indications. 
 
Results 
 
We identified 23 criteria in the CONSORT statements. The mean number of criteria 
met per trial was 11.3 (95%CI 10.6—12.0). Commercially funded studies met 12.6 and 
non-commercially funded met 9.4 (p < 0.001). Trials recruiting adults met 12.5 and 
trials recruiting children met 9.3 (p < 0.001). Trials published before 2004 met 11.6 
and trials published after 2004 met 11.1 (p = 0.53). Commercially funded trials met the 
majority of criteria more than non-commercially sponsored trials, particularly for 
definition of AEs (RR 3.15, CI 1.67—5.95) and the use of a validated dictionary of 
terms (RR 3.46, CI 1.41—8.44). Definitions for AEs (RR 2.32, CI 1.07—5.02) and 
details of analyses (RR 2.05, CI 1.01—4.15) were reported in adult trials more often 
than trials in children. 
 
Three lacosamide trials were included in systematic reviews. The overall risk ratio for 
a 50% or greater reduction in seizure frequency for all doses of lacosamide compared 
to placebo was 1.70 (CI 1.38 to 2.10). The overall risk ratio for seizure freedom for all 
doses of lacosamide compared to placebo was 2.50 (CI 0.85 to 7.34). The overall risk 
ratio for treatment withdrawal for all doses of lacosamide compared to placebo was 
1.88 (CI 1.40 to 2.52). Adverse effects, which were significantly associated with 
lacosamide, were abnormal coordination, blurred vision, diplopia, dizziness, fatigue, 
nausea and vomiting.  
 
Four lacosamide trials of neuropathy were selected and harms data form these were 
incorporated to data from epilepsy trials. The following harms outcomes: Any adverse 
events, dizziness, fatigue, headache, nasophryngitis, nausea, somnolence, tremor, 
vertigo, vision blurred, vomiting and withdraws due to adverse events were meta-
analyzed. Only tremor (I2 of 0-64%) and nasophryngitis (I2 of 27-64%) showed 
significant heterogeneity in statistical tests. only outcome that changed effect size to 
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yield a significant result when neuropathy trials were combined was fatigue. For the 
400mg dose of lacosamide, the summary measures were 2.0 (95% CI of 1.0 to 4.03) 
and this changed to 1.98 (95% CI of 1.11 to 3.52) when neuropathy trials were 
combined. Therefore, harms across indications could be used for lacosamide. 
 
To test the hypothesis if harms across indications such as headache and neuropathy 
trials of other antiseptic drugs, meta-regression was used to further explore 
heterogeneity. Only lacosamide and lamotrigine could have harms across indications 
summated in systematic reviews but not for pregabalin and gabapentin due to 
significant heterogeneity, which could be explained by dose effects. 
 
Conclusion 
 
Reporting of AEs in RCTs of AEDs is poor and has not improved since the publication 
of the CONSORT guidelines on the reporting of harms. Commercially funded trials 
were better reported than non-commercially funded trials and trials recruiting adults 
were better reported than trials recruiting children. These findings have serious 
implications as poor reporting precludes bias being detected and hinders adequate risk 
benefit analyses. Journal editors, authors and reviewers should be encouraged to 
follow current guidance. 
 
Lacosamide is effective in treating partial epilepsy versus placebo for the 200mg, 
400mg and 600mg doses. Harms from neuropathy trials can be used to improve harms 
reporting in systematic reviews of lacosamide. Harms across indications could also be 
used for lamotrigine but not for pregabalin and gabapentin. Novel methods need to be 
developed for incorporating observational studies in systemic reviews.  
 
Clinicians and Journal Editors need to have a greater awareness of poor harms 
reporting in RCTs and this needs to be more transparent. 
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Outline of thesis chapters 
 
This thesis explored the reporting of harms in randomised controlled trials and 
provides recommendations for reporting of harms in trials and systematic reviews.  
 
This work has provided novel insights into how harms caused by antiepileptic drugs 
are reported in randomised controlled trials. We suggest ways in which the reporting of 
harms can be improved in randomised controlled trials. A systematic review of 
lacosamide provided novel insights on how harms are analysed in systematic reviews. 
This model was used to explore ways in which analyses of harms in systematic 
reviews can be improved with suggestions for further work.  
 
Chapter 1- Defines epilepsy and seizures and how epilepsy is diagnosed. Common 
antiepileptic drugs are discussed and studies of risk of seizure recurrence after a first 
and second seizure. This is illustrated in the MESS study and how this adds to how one 
manages patients with a first unprovoked seizure.  
 
Chapter 2- Discusses clinical trials and evidence based medicine with descriptions of 
common clinical trials. Findings from the SANAD studies are discussed, regarding the 
best treatment for focal and generalised epilepsy.  
 
Chapter 3- Discusses harms of antiepileptic drugs, the definition of harms and how 
harms are analysed in randomised controlled trials. Describes the recent developments 
in classification of harms, and recent quality of life measures used in a clinical setting 
to record and elicit adverse events like the Liverpool Adverse Event Profile (LEAP). 
Discusses a recent case comparison study of these tools in patients newly diagnosed in 
epilepsy. 
 
Chapter 4- Discusses the CONSORT statements. Describes the history of the 
CONSORT group and describe the CONSORT statements and the extensions of the 
CONSORT statements. Reviews a number of studies that have used the CONSORT 
guidelines as a benchmarking tool. Results from these studies were analysed 
narratively.  
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Chapter 5- Discusses the rationale behind systematic reviews, meta-analyses and meta-
regression methods. Some of these methods I will use in this thesis. 
 
Chapter 6- This chapter discusses the reporting of harms in randomised controlled 
trials of antiepileptic drugs. They will discuss the methods used in analysing trials and 
describe the reporting of harms using the CONSORT statement. Factors such as type 
of journal source of funding and publication date as possible predictors on the quality 
of harms reporting are explored.  
 
Chapter 7- In this chapter I discuss the use of lacosamide and its used as an 
antiepileptic drug. I describe a systematic review of lacosamide as add-on therapy in 
partial epilepsy. The results of this review may be further evaluated in the next chapter 
will be describe harms across indications for lacosamide. 
 
Chapter 8- Here, I will discuss lacosamide as an example of how harms across 
indications can be better analysed. My aims are to determine if estimates of effect sizes 
increase in proportion to dose increases. The presence of significant heterogeneity 
would imply that harms across indications, cannot be used. I used meta-analyses 
software to make judgements. 
 
Chapter 9 –Discusses if harms data across indications of other AEDs can be meta-
analysed. I hypothesised that harms across indications cannot be used for AEDs other 
than lacosamide I used both meta-analysis and meta-regression methods to explore 
heterogeneity and used outputs from these to accept or reject the null hypothesis.  
 
Chapter 10- A discussion of major finding of my work, and recommendation for 
improving he reporting of harms.  
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Chapter 1 
 
 
 
 
What is epilepsy and how are seizures treated? 
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1.1 What is epilepsy? 
 
The word epilepsy comes from the Greek word επιαµβανεν, which means ‘being 
seized’ or overwhelmed by surprise (Temkin 1945). Epilepsy and seizures are well 
described in the Hammurabi code dated 1780 B.C. The texts describe seizures in great 
detail and they were thought to be punishments for sin. This negative view of epilepsy 
remained until the nineteenth century when Jackson hypothesised that seizures are due 
to alterations in neuronal function. Since then an organic basis of epilepsy has been 
increasingly recognised and consequently treatment methods changed.  
 
Seizures are the physical manifestation of epilepsy, but patients commonly suffer 
social isolation, depression and adverse events due to medications. Other implications 
of epilepsy include higher rates of unemployment, inability to drive and implications 
on human reproduction (Shovron et al 2011).  
 
To meet a diagnosis of epilepsy by convention, a patient must have had at least two 
unprovoked seizures. Seizures are defined as brief sudden attacks with alteration of 
consciousness with motor, sensory, cognitive, psychic or autonomic disturbances 
caused by abnormal excessive or synchronous neuronal activity in the brain (Fisher et 
al 2005). Reaching a definition for a heterogeneous condition like epilepsy has been 
difficult. The International League Against Epilepsy (ILEA) formulated a definition of 
epilepsy as:  
 
“..a disorder of the brain characterised by an enduring predisposition to 
generate epileptic seizures, and by the neurobiological, cognitive, 
psychological, and social consequences of the condition” (Fisher et al 2005).  
 
The diagnosis of epilepsy can be made with a minimum of one seizure and provoked 
seizures are not included unless the provocation is enduring like a tumour. To resolve 
issues that arise with symptomatic epilepsy a new operational definition of epilepsy 
has been proposed: 
 
Epilepsy is a disease of the brain defined by any of the following conditions: 
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1. At least two unprovoked (or reflex) seizures occurring more than 24 hours 
apart. 
2. One unprovoked (or reflex) seizure and a probability of further seizures similar 
to the general recurrence risk (at least 60%) after two unprovoked seizures, 
occurring over the next 10 years. 
3. Diagnosis of an epilepsy syndrome. 
These definitions of epilepsy and seizures are useful guidelines but the clinical 
diagnosis of epilepsy is fraught with challenges.  
 
1.2 How are seizures and epilepsies classified? 
 
Seizures can be broadly classified as partial seizures, generalised seizures or 
unclassified seizures. Individual classification of seizures can be very simple as shown 
in table 1 
 
Seizure classification  
I Focal Seizures  
A Simple partial seizures 
 B Complex partial seizures 
II Generalised seizures 
 A Absence seizures 
 B Atypical absence seizures 
 C Tonic-clonic seizures 
 D Myoclonic seizures 
 E Tonic seizures 
 F Clonic seizures 
              G Atonic seizures 
III Unclassified seizures 
Table 1 Classification of Seizures. 
 
Partial seizures are due to a focal abnormally in the brain that may or may not spread 
to other areas of the brain. These can be simple partial seizures where there is no 
alteration of consciousness or complex partial seizures where an alternation of 
consciousness occurs.  
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Generalised seizures are those that have no identifiable onset like simple partial or 
complex partial seizures. They affect both sides of the brain simultaneously. 
Generalised seizures can be composed of absence seizures where patients have a 
sudden behavioural arrest, which typically lasts up to 30 seconds.  
 
Tonic-clonic seizures are well known to the layman as grand-mal seizures. Here there 
is an abrupt loss of consciousness followed by a tonic contraction of muscles, which 
result in an exhalation of air followed by upward eye deviation. This is followed by 
flexion of the elbows of the upper extremities and extension of the lower extremities. 
These seizures can arise either independently or they can arise from spread of simple 
partial or complex partial seizures. The identification of a focal seizure or one that has 
a focal onset is important as this may have implications for surgical removal of the 
epileptic zone. Figure 1 further outline seizure classification. 
 
	
Figure 1 International classification of seizures: Adopted from Schmidt & Elger 2008. 
 
Merlis attempted the first classification of the epilepsies in 1970 as shown in table 2 
page 5 (Merlis 1970). This classification was simple with three main axes. This 
classification was simple and was based on the semiology of seizures.  
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I. Generalised epilepsies 
a. Primary generalised epilepsies 
b. Secondary generalised epilepsies 
c. Undetermined generalised epilepsies 
II. Partial epilepsies 
III. Unclassified epilepsy. 
Table 2 Classification of epilepsy proposed by Merlis 1970. 
 
This classification was difficult to use as secondary generalised seizures were confused 
with secondary generalised epilepsy. Moreover, the classification was dependent on 
EEG characteristics of the patient. As more epilepsy conditions were discovered then 
the classification had to be revised. Subsequent revisions of the classification of 
seizures and epilepsies occurred in 1981 and 1989, but this was reviewed in 2001 
(Bancaud et al 1981) (ILAE 1989). 
 
Engel proposed a revision to the earlier classification and proposed that an elaboration 
by adding other dimensions to the simplistic classification. He proposed five axes, 
which could be considered when making a diagnosis (table 3 page 6). Firstly, the 
history and phenomenology of seizures should be obtained from patients. Secondly the 
seizures should be classified based on semiology and thirdly the epilepsy syndrome 
should be classified along with the aetiology of epilepsy if possible. A final attempt, 
although optional is the classification of the degree of impairment (Engel 2001).  
 
Some changes in the terms used have occurred to reflect a pragmatic approach to 
epilepsy classification. The terms idiopathic, symptomatic and cryptogenic have been 
replaced with genetic, metabolic/structural and unknown. Further changes to seizure 
classification included a replacement of the term simple partial to focal sensory or 
focal motor seizure; and complex partial seizures to focal dyscognitive seizures (Berg 
et al 2010).  
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Diagnostic scheme of Epilepsy based on five Axes	
Axis 1 Ictal phenomenology, from the Glossary of Descriptive	Ictal Terminology, can be used to 
describe ictal events with any	degree of detail needed.	
Axis 2 Seizure types, from the List of Epileptic Seizures.	Localization within the brain and 
precipitating stimuli for reflex	seizures should be specified when appropriate.	
Axis 3 Syndrome, from the List of Epilepsy Syndromes, with the	understanding that a syndrome 
based diagnosis may not always be	possible.	
Axis 4 Aetiology, from a Classification of Diseases Frequently	Associated with Epileptic Seizures or 
Epilepsy Syndromes when	possible, genetic defects, or specific pathologic substrates for	
symptomatic focal epilepsies.	
Axis 5 Impairment or disability caused by epilepsy. This can be optional, but often useful. Additional	
diagnostic parameters can be derived from an impairment	classification adapted from the 
WHO ICIDH-2. 
Table 3 Diagnostic Scheme of the Epilepsies by Engel 2001. 
 
1.3 Epidemiology of epilepsy 
 
Four hundred and fifty million people suffer from neurologic or psychiatric disease 
globally. The proportion of these with epilepsies is estimated to be 50 million. The 
World Health Organisation, the International League Against Epilepsy (ILAE) and the 
international bureau for epilepsy have in partnership published a report whose aim was 
to bring epilepsy ‘Out of the Shadows’ (WHO 2003). Several studies have calculated 
the rates of incidence and prevalence.  Incidence is expressed as the number of new 
cases of disease in a population per unit of time. Commonly this is given as the 
number of cases per 100 000 of population per year. Prevalence is the total number of 
persons with the disease at a specific moment of time. This is expressed as per 1000 
population.  
 
The lifetime prevalence of epilepsy is 5-8 per 1000 in high-income countries; the 
prevalence of epilepsy in the UK according to 2005 figures is 9.5 per 1000. The point 
prevalence of epilepsy is the proportion of a given population having epilepsy at a 
given time. This is estimated to be 0.4 to 0.8% in Europe (Sander & Shovron 1996).  
About 1% of the population have active epilepsy at any given point in time.  
 
Incidence of epilepsy on the other hand varies with age. The age specific incidence 
rate of non-febrile seizures is high in childhood and declines between ages of twenty to 
fifty followed by an increase after the age of fifty. The Rochester Minnesota registry 
estimates that the age-adjusted incidence of epilepsy was 44 per 100,000 person-years. 
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The most common antecedent to seizures was stroke in 11% of patients. The 
cumulative incidence of epilepsy up to 74 years is 3.1% (Hauser et al 1993). 
 
Epilepsy is associated with an increased mortality. It is estimated that the mortality of 
epilepsy is 2-3 times greater than that of the general population (Lhatoo et al 2001). 
Causes of death from epilepsy ranges from deaths due to underlying disease, deaths 
due to seizures due to status epilepticus, drowning and trauma. Deaths can occur due to 
sudden unexpected death in epilepsy (SUDEP). Also, deaths can occur due to surgical 
and medical treatments of epilepsy due to adverse events. The magnitude of deaths due 
to SUDEP has been well described and this is the commonest cause of death in 
epilepsy (Smithson et al 2014). Population based studies suggest that the incidence of 
SUDEP is between 0.09 to 2.31 per 1000 patient years (Smithson et al 2014).  
 
Deaths can also occur due to harm of antiepileptic drugs, the incidence of these is not 
fully described. Other deaths can occur due to suicide in epilepsy and this too can have 
varying causes. Epilepsy is still a disease that is associated with considerable stigma 
for patients and this is due to the pervasiveness of negative perception of the disease 
(Baxendale & O’Toole 2007). 
 
1.4 Natural history of untreated and treated epilepsy 
 
Kwan and Brodie were the first to prospectively determine the natural history of 
treated epilepsy (Kwan & Brodie 2000). Sixty three percent of patients were seizure 
free after the first AED. In their study, they found that 47% of untreated patients 
became sire free after the first AED and 14% became seizure free after the second 
drug.  Questions therefore arise on the natural history of untreated epilepsy. 
 
1.4.1 Natural history of untreated epilepsy 
 
A discussion of untreated epilepsy has many aspects to consider. First is the risk of 
seizures after a first seizure, this then followed to the risk of seizures after second and 
third seizure. Once one has considered this, then the next logical question is if patients 
after a first seizure should be treated or not. These issues will now be discussed in turn.  
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If a patient has had two seizures, then there is little debate that antiepileptic drugs are 
indicated. However, if only one seizure has occurred then there is significant debate on 
the need to commence AEDs. Earlier studies have shown that only 30% of patients 
will have seizures in 3 years (Hauser 1982) as shown in the figure below (figure 2). 
Pooled estimates from other studies show that the risk of seizure recurrence increases 
as time goes by but this is greatest in the first year (fig 3) (Krumholz et al 2015). Other 
studies have quoted proportions from 23% to 71%. A qualitative review by Berg and 
Shinar summated Kaplan Meir survival estimates from various studies (Berg & 
Shinnar 1991). They included sixteen studies with a mixture of methods used to 
ascertain the risk estimates. However, they used data from 13 studies to calculate an 
estimate. Their results showed that the 2-year recurrence risk was 46% (95% CI of 44-
49%). A consistent trend was seen across the studies where abnormal 
electroencephalogram (EEG) and seizure aetiology were strong predictors of seizure 
recurrence. 
 
	
Figure 2 Cumulative percentage risk of seizure at three years after first seizure: Adopted from Hauser et 
al 1981.	
		 9	
	
Figure 3 Percentage of patients with first seizure experiencing a recurrent seizure over time showing the 
cumulative risks from twelve studies: Adopted from Krumholz et al 2015. 
	
There have been three other studies that have looked into the treatments of first 
seizures. These include the FIRST study followed by the MESS study. 
 
The FIRST study was a multicentre Italian study that reported the risk of recurrent 
seizure after an untreated or treated first unprovoked seizure (FIR.S.T group 1993).  
This trial evaluated the risk of having a subsequent seizure after having a first 
unprovoked seizure that was not treated and compared this to a treated group. The risk 
of recurrence was 18% at 3 months, 28% at 6 months and 41% at 12 months. The risk 
of seizure at 24 months was 51%.  This study also showed that having an abnormal 
neurologic exam was not associated with an increased risk of relapse (HR 0.8 95% CI 
of 0.4-1.6). Also, there was no increased risk of relapse if there were abnormalities on 
EEG. Compared to the MESS study the FIRST study recruited 204 patients in the 
treated arm and 193 patients in the untreated arm. Therefore, this was a comparatively 
smaller study and could explain why the hazard ratios were not significant in many of 
the covariates studied (figure 4 page 10). 
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Figure 4 Probability of remaining seizure free by treatment allocated: Adopted from the FIR.S.T study 
1993 
 
1.4.2 The MESS study and the natural history of untreated epilepsy 
 
The earlier studies examined the risk of recurrence of seizures after a first seizure. The 
MESS study sought the answer the question on the risk of seizures if patients are 
started on treatment early or if treatment is deferred. This was a multicentre open 
labelled study (Marson et al 2005).  
 
Patients that were suitable for the MESS study included those patients where both the 
clinician and the patient were in a state of clinical equipoise regarding initiation of 
treatment. Patients were allocated to either deferred or immediate treatment with 
AEDs. The primary outcomes were: 
1. Time from randomisation to first seizure of any type 
2. Time from randomisation to first tonic clonic seizure 
3. Time from randomisation to the second and fifth seizures  
4. Time from randomisation to 2-year remission of seizures 
5. Proportion of patients who were seizure free for 2 years between 1 and 3 years 
after randomisation and between 3 and 5 years after randomisation.  
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Immediate treatment increased time to first seizure compared with deferred treatment 
with a hazard ratio of 1.4 (95% CI of 1.2 to 1.7) and to second seizure hazard ratio of 
1.3 (95% CI of 1.1 to 1.6). For patients with a single seizure, the risk of relapse is 32% 
for immediate treatment and 39% for deferred treatment. This risk difference after five 
years to is 42% for immediate treatment and 51% for deferred treatment. Although 
immediate therapy had a beneficial effect this effect was lost at 4 years (Marson et al 
2005). This data is shown in the Kaplan Meir plot below (figure 5).  
 
The actuarial estimate of achieving a 2-year remission was different too in the 
treatment groups with a 69% of patients entering remission in the immediate treatment 
group and 61% of patients in the deferred treatment group for single seizures.   
 
	
Figure 5 Cumulative probabilities of seizures versus years since randomisation: Adopted from Marson 
et al 2007. 
 
Further to the initial report of the MESS study, prognostic tools were developed to 
predict the risk of seizures into low, medium and high risk (Kim et al 2006). The 
model developed factors to predict the risk of seizures. Low-risk patients were those 
that had a single seizure, with no neurologic deficit and a normal EEG. Medium-risk 
patients are those with 2-3 seizures or no neurologic deficit or an abnormal EEG. 
High-risk patients were those with four or more seizures with or without neurologic 
deficit and or an abnormal EEG  
 
Overall the results of the MESS study were in agreement with other studies in that 
seizures beget seizures and repeated seizures have a negative impact on the central 
nervous system homeostasis. The experimental evidence from rat models doesn’t 
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support this view (Sills 2007). However, the MESS study also shows that deferred 
treatment of patients that are in low risk is no different to patients that have immediate 
treatment. The implication of this is that some patients can be deferred treatment with 
AED as this may prevent patients being exposed to adverse events.  
 
A study by Hauser et al evaluated the risk of seizures after a second seizure. They 
calculated the risk of a second seizure after a first seizure was 33%. The risk of a third 
seizure after a second seizure was 32% at 3 months, 41% at six months, 57% after one 
year and 73% after four years (Hauser et al 1998) (fig 6). The risk of a third seizure 
after the second seizure was greater in patients with remote symptomatic epilepsies 
(87% at five years) versus idiopathic (64% at five years) (fig 7 page 13).  
 
	
Figure 6 Risk of second, third and fourth unprovoked seizure after a first, second and third unprovoked 
seizure: Adopted from Hauser et al 1998. 
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Figure 7 Risk of third unprovoked seizure after a second unprovoked seizure in patients with remote 
symptomatic and idiopathic epilepsy: Adopted from Hauser et al 1998. 
 
Including the FIRST study and the MESS studies there are four other trials that 
compared the risk of seizure after first unprovoked seizures. All studies compared the 
risk in treated and untreated patients. The largest of these is the MESS study followed 
by the FIRST study. A summary of the findings are shown below where it is clear that 
there is significant heterogeneity between the studies and this was confirmed by a 
narrative review of this data (Sathasivam & Nicolson 2008) (fig 8). A further 
systematic review of the risk of seizure reduction after treatment of the first seizure by 
Wiebe et al found that the absolute risk reduction of seizures 34% (95% CI 15-52) 
when six trials are meta-analysed (Wiebe et al 2008) (fig 9 page 14). 
 
Study Seizures Seizure 
recurrence 
treated 
Seizure 
recurrence 
untreated 
Difference 
(untreated minus 
treated) 
Camfield et al GTCS, 
SGTC, CPS. 
14.3 % 52.9% 38.6% 
Chandra  GTCS, 
SGTC, CPS. 
4.3% 55.7% 51.4% 
FIR.S.T GTCS, 
SGTC 
18% 39% 21% 
Gilad et al GTCS. 22% 71% 49% 
Das et al  GS 11.1 45% 33.9% 
Marson et al GTCS, 
SGTC, CPS, 
M, A. 
18% at 6 months 
46% at 8yrs 
26% at 6 months 
52% at 8 yrs 
8% at 6 months 
6% at 8 years 
Figure 8 Randomised trials of treatment of patients with single unprovoked seizures: Adopted from 
Sathiasivam & Nicholson 2008. GTCS -generalised tonic clonic seizures, SGTC- secondary generalised 
tonic clonic seizures, CPS -complex partial seizures, GS- generalised seizures, M- myoclonic seizures, 
A- absence seizures. 
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Figure 9 Meta-analysis of randomised trials of treatment of AEDs versus no treatment in patients with 
first unprovoked seizure: adopted from Wiebe et al 2008. 
 
1.4.3 Response of treated epilepsy 
 
Several studies including the MESS studies have elaborated on the risk of seizures 
after the first or second seizure.  However, patients also ask about the likelihood they 
will become seizure free after treatments and the probability of treatment response.  
 
Patients who are prescribed antiepileptic drugs for the first time respond very well 
(Brodie et al 2009).  Approximately 50% of patients will be seizure free after the first 
drug and this will occur at a modest dose. This response decreases with subsequent 
AEDs, see table 4 page 15. The authors compared seizure freedom rates for 
monotherapy and polytherapy regimens (Brodie et al 2009) see table four below. A 
total of 1098 patients were enrolled in their study. Of the patients included, 49.4% 
were seizure free after the first AED. This was reduced to 36% after a second drug and 
then 25% of the third drug and 16% on the fourth drug.  
 
Epilepsy treatment response can therefore be thought of three groups, each in a state of 
flux. The first is the responsive group comprises 50% of patients. The second group 
consists of about 20% of patients and these will reach seizure remission after a further 
AED. Finally, the third group that do not remit and continue to have seizures despite 
multiple AEDs, this comprises about 20% of patients, see figure 10 page 15. 
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Newly Diagnosed Epilepsy. Seizure freedom rates (%) according to regimen 
 N One AED Multiple AEDs Total 
First AED 1098 49.4 0 49.4 
Second Regimens 398 25.4 11.3 36.7 
Third Regimen 168 15.5 8.9 24.4 
Fourth regimens 68 8.8 7.4 16.2 
Subsequent regimens 46 6.5 10.8 17.3 
AED regimens were selected according to clinical practice  
Table 4 Seizure freedom according the AED regime: Adopted from Brodie et al 2009		
Despite this evidence, the authors also conclude that additional AEDs can be 
recommended to patients with epilepsy who fail on two drugs and who are not 
candidates for epilepsy surgery. The overall the authors suggest that the natural history 
of epilepsy is that 30% of the patients will be seizure free without treatment and 
continuing seizures will occur in 40% of patients (Kwan and Sander 2004). 
 
	
Figure 10 Treatment response to AEDs: Data from Kwan and Brodie: Figure adopted from Schmidt & 
Elger 2008. 
 
1.4.4 Patients with relapsing and remitting epilepsy  
 
Further work done by Mohanraj and Brodie showed that patients who have responded 
to AEDs can either be in remission or may relapse (Mohanraj and Brodie 2005). They 
defined remission is having no further seizures after responding to treatment and 
relapse was defined as when initial control was lost and patients became treatment 
unresponsive. The study showed that 57% of patients enter remission when 
commenced on AEDs.  Five percent of patients relapse after a period of response and 
develop refractory epilepsy and 38% of patients never become seizure free. Rates of 
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remission were no different in pats with symptomatic epilepsy compared to idiopathic 
epilepsy.  
 
1.4.5 Seizure freedom and drug resistant epilepsy 
 
A brief discussion of seizure freedom and drug resistant epilepsy is important here as 
they represent opposites of a continuum of treatment response. Also it is important to 
define these terms are they have significance in how outcomes are analysed in clinical 
trials.  
 
The goal of epilepsy treatment is to render the patient seizure free. Kwan et al recently 
defined what constitutes seizure freedom; this is defined as any patient who is seizure 
free for at least three times the longest pre-intervention inter-seizure interval in the 
preceding 12 months. Simply stated, this was named the rule of three. This definition 
although novel is not clinically useful, it is well known that if seizure freedom is to 
occur, it would occur early but even patients with chronic epilepsy can become seizure 
free in 28% of cases (Lucaiano & Shovron 2007). Seizure freedom and reduction in 
seizure frequency have been the primary goals of epilepsy treatment but quality of life 
in epilepsy has become important in clinical decision-making. 
 
The converse of seizure freedom is where the patient continues to have seizures 
despite treatment. This is commonly referred to as drug resistant epilepsy. The 
mechanism of drug resistance is explained by efflux of drugs by transporter proteins 
that are found more commonly in patients with multidrug resistant epilepsy. Examples 
of such protein include multi-drug resistance gene-1 P-glycoprotein (MDR1) and 
multidrug resistance –associated protein 1 (MDRP1) (Sisodiya et al 2002).  
 
Drug resistant epilepsy was difficult to define as this is regarded as a dynamic state 
rather than a static state (Téllez-Zenteno, et al 2014). Any definition for drug 
resistance epilepsy would therefore hold at only one specific period of time. Mohanraj 
et al suggest that if a patient has failed on at least two AEDs, he or she can be labelled 
with drug resistant epilepsy (Mohanraj & Brodie 2006). In terms of harms outcomes, 
one could suggest that some randomised trials that recruit patients that have failed two 
or more AEDs could provide a useful model for studying harms in drug resistant 
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epilepsy. The current ILAE accepted definition of drug resistant epilepsy is a “ the 
failure of adequate trials of two tolerated and appropriately chosen and used AED 
schedules -whether used as monotherapy or in combination, to achieve sustained 
seizure freedom (Kwan et al 2010).  
 
In many randomised controlled trials that report harms outcomes, included patients 
would have trials more than one AED and have failed. These trials therefore would 
provide a model for studying drugs resistant epilepsy.  
 
Up to 30% of patients with drug resistant epilepsy may take a combination of drugs. 
This will invariably result in drug-drug interactions, particularly with the older AEDs. 
Classical interactions include the interaction between valproate and lamotrigine where 
concentration of lamotrigine may increase to toxic levels and cause Stevens Johnson 
Syndrome (SJS). Another classic interaction is carbamazepine and valproate where 
adequate levels of valproate are difficult to reach as carbamazepine with lower 
valproate levels (Schmidt 2009).  
 
The newer AEDs however have less interactions and therefore are less likely to have 
pharmacokinetic interactions, but this dose not necessarily mean that their harms 
profile is better than older drugs. It is not clear if the newer AED are able to convert 
drug resistant to drug responsive epilepsy. Currently however this is no 
recommendation on which drugs to use in drug resistant epilepsy. However, as we will 
discuss in chapter seven, several new drugs like lacosamide demonstrated that some 
patients with drug resistant epilepsy do become seizure free (Weston et al 2015). 
Similar response in drug resistant epilepsy was noted in trials of perampanel (Faulkner 
& Burke 2013)  
 
1.4.6 Treatment options in refractory epilepsy 
 
The goal of epilepsy treatment is to render the patient seizure free. There is no single 
treatment for epilepsy, but there are numerous options depending on the epilepsy 
syndrome or the stage of the disease.  
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1.4.7 Surgical options in epilepsy 
 
In general surgery is considered in individuals who have not responded to medical 
therapy or have had several intolerable harms from antiepileptic drugs or a 
combination of both reasons. The seizures should be of the type that is amenable to 
surgical therapy and other electrographic; radiologic and psychological background 
should support the feasibility of surgical therapy. A decision to proceed with surgery is 
a multi-disciplinary effort (Spencer & Huh 2008).  
 
Options in surgical therapies include resection therapies where part of the brain or 
hemisphere is removed. Other options would also include measures to prevent the 
spread of seizures like corpus callosotomy or subpial resections. If these measures fail 
then palliative measures such as vagus nerve stimulation is warranted (Ramey et al 
2013).  
 
1.5 Alternate Mono-therapy or Add-on therapy? 
 
We know from Brodie’s research that with every additional AED used in patients with 
epilepsy the probability of seizure freedom diminishes with each additional AED 
(Brodie et al 2009). Their data consisted of two groups of patients; first was a group of 
patients treated with monotherapy and another groups with polytherapy. The data 
suggested no significant difference between the two groups with regard to seizure 
freedom rates. This hypothesis needed to be explored in a randomised controlled trial.  
 
A pragmatic randomised trial carried out by Beghi et al compared adjunctive therapy 
versus alternative therapy with respect to seizure freedom and tolerability outcomes 
(Beghi et al 2003). The first figure below shows no statistically significant difference 
between the two groups with respect to retention (fig 11 page 19). The cumulative 
probability at 3 months of continuing the drug was 77% for alternative monotherapy 
and 87% for adjunctive therapy. At 12 months, this was 55% for alternative 
monotherapy and 65% for adjunctive therapy.  
 
With regard to seizure freedom, this is shown in the figure 12 page 19. The results 
show no difference between the two groups with respect to seizure freedom. A total of 
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158 adverse events were noted in the monotherapy group and 111 in the adjunctive 
therapy group.  
 
	
Figure 11 Cumulative probability of remaining on allocated treatment in add-on therapy group versus 
alternative monotherapy group Adopted from Beghi et al 2003.	
	
Figure 12 Cumulative probability of remaining seizure-free after achieving target dose in two groups 
Adopted from Beghi et al 2003. 
 
The mainstay of epilepsy treatment is medical using antiepileptic drugs. Methods for 
more intractable epilepsy involve either surgical interventions or neuromodulatory 
treatments. Antiepileptic drugs are significant as they represent about 13% of 
outpatients’ prescriptions in the USA, which is comparable to antibiotics (Raofi & 
Schappert 2006). Other methods when drugs fail include surgical methods or 
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neuromodulator methods. The remaining sections discuss the medical and surgical 
treatment of epilepsy. 
 
1.6 Antiepileptic drugs 
 
There has been a rapid increase in the number of antiepileptic drugs for the treatment 
of epilepsy in the recent two decades (figure 13). Increasing research by commercial 
and non-commercial organisations has largely fuelled this growth. The figure below 
shows that the number of drugs produced has increased exponentially with most of the 
newer drugs developed in the last decade. Most of the drugs shown here have been 
modelled on a mouse model of epilepsy and developed under the Anticonvulsant Drug 
Development Programme in the USA.  
 
	
Figure 13 Chronology of antiepileptic drug introduction over the past 150 years. Adapted from Brodie, 
M. 2010. 
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1.6.1 Early Antiepileptic drugs  
 
Medications to control seizures were a novel concept in the nineteenth century. The 
first drug to be used for the treatment of epilepsy was discovered by Charles Locock. 
He used potassium bromide to treat women with “hysterical epilepsy connected to the 
menstrual period” and he found that it significantly improved their seizures as well. 
Thomas Clouston then showed a dose response relationship with potassium bromide in 
patients with epilepsy in 1868 (Pearce 2002) and since then it has been marketed as a 
new drug.  
 
Other drugs that were the early AEDs include phenytoin, phenobarbitone, sodium 
valproate and carbamazepine. Alfred Hauptmann discovered phenobarbitone 
serendipitously in 1912 by using it as a hypnotic agent in his patients. He observed that 
patients had significant reductions in daytime seizures and slept better at night too 
(Hauptmann 1912). Carbamazepine was developed as an antipsychotic drug in 1953 
but it was studied in epilepsy in 1963 and gained a licence for use in 1965.  
Tracy Putman discovered phenytoin serendipitously in 1934 where he tried to find an 
alternative to phenobarbitone (Brodie 2010). Phenytoin came into routine clinical use 
in 1938. Pierre Eymard discovered valproate serendipitously in 1963. The drug was 
used in Europe as an anti-seizure drug and a modified version of it was used in the 
USA a decade later.   
 
Levetiracetam was developed as a candidate molecule but it did not show efficacy in 
many standard models of epilepsy in rodents. However, it did provide protection in 
two models of epilepsy kindling this was therefore it is only property of levetiracetam 
(Klitgaard et al 1998).    
 
With the developed of the new AEDs, epileptologists have informally called the older 
AEDs as the Standard AEDs and the new drugs as the New AEDs (table 5 page 22).  
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Standard AEDs Newer AEDs 
Bromides 
Oxazolidinediones 
Phenobarbital 
Phenytoin 
Primidone 
Ethosuximide 
Benzodiazepines 
Carbamazepine 
Valproate 
Eslicarbazepine 
Ezogabine 
Felbamate 
Gabapentin 
Lacosamide 
Lamotrigine 
Levetiracetam 
Oxcarbazepine 
Pregabalin 
Preampanel 
Rufinamide 
Tiagabine 
Topiramate 
Vigabatrin 
Zonisamide 
Table 5 List of New and Old Antiepileptic drugs: Adopted from Engel 2013. 
 
1.6.2 How Antiepileptic drugs work 
 
There are three major classes of AED mechanisms that are recognised (Sills & Brodie 
2001). These include the modulation of voltage gated ion channels; gamma-
aminobutyric acid medicated inhibition and attenuation of glutamate mediated 
excitatory neurotransmission. Current targets include the voltage gated sodium 
channels, which are also implicated in epilepsies like severe myoclonic epilepsy of 
infancy, primary pain syndrome like erythermalgia and some dystonias. Sodium 
channels are predominantly responsible for action potential generation. Advances in 
molecular biology have shown a wide number of these channels and how AEDs can 
interact with them. Some of the newer AEDs interact with sodium channels in a novel 
way but inactivation of slow channels. Other targets for AEDs include voltage gated 
potassium channels, calcium channels by modulating their effects on the action 
potential. The table below outlines the mechanism of the common AEDs used in the 
past and in current clinical practice (table 6 page 23).  
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AED Main Mechanism(s) of Action Year of 
Approval 
(USA) 
Old AEDs  
Bromides Unknown probably stabilises neuronal membranes 1857 
Phenobarbital  Enhances GABA inhibition 1920-1940 
Phenytoin  Inhibition of sodium channels therefore limiting repetitive firing 1938 
Ethosuximide  Reduction of T type calcium channel thresholds in the thalamus, 
therefore inhibitory effect 
1960 
Carbamazepine  Inhibition of sodium channels and therefore reducing firing 1974 
Valproate  The precise mechanism unknown; multiple GABA related actions 
and NMDA receptor antagonist. 
1978 
Newer AEDs  
Vigabatrin  Irreversible inhibition of GABA receptors and stimulates GABA 
release 
2009 
Felbamate  Binds to NMDA glutamate receptors and therefore blocking 
sodium and calcium and conduction 
1993 
Gabapentin  Precise mechanism is unknown but may bind to voltage gated 
calcium channels 
1993 
Lamotrigine  Blocks sodium channels and inhibits voltage gated calcium 
channels 
1994 
Tiagabine  Enhances GABA mediated inhibition by blocking GABA reuptake 1997 
Topiramate  Multiple mechanisms: it blocks AMPA glutamate receptors, blocks 
of voltage activated sodium channels; enhances GABA mediated 
chloride flux and enhances potassium conduction. 
1997 
Levetiracetam  The precise mechanism unknown but it binds to SV2A presynaptic 
protein on synaptic vesicles.  
1999 
Oxcarbazepine Blocks of voltage gated sodium potassium and calcium conduction.  2000 
Zonisamide  Blocks T type calcium channels, inhibit release of glutamate. 2000 
Rufinamide  Exact mechanism unknown but prolongs the inactivation of 
voltage-dependent sodium channels 
2005 
Lacosamide  Selectively alters the slow inactivation of voltage gated sodium 
channels. 
2008 
Perampanel AMPA receptor antagonist but not NMDA receptors  2012 
Table 6 Antiepileptic drugs mechanisms of action. Adopted from French & Gazzola 2011.	
 
1.6.3 Specific AEDs 
 
To discuss all the AEDs used in clinical practice is not the scope of this thesis. 
However lacosamide will be discussed as it is the focus of chapter six . 
 
1.6.3.1 Lacosamide-mechanism of action 
 
The mechanism of action of lacosamide remains unknown, however there are a 
number of potential theories. Lacosamide was developed from a bank of compounds 
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designed to interact with voltage gated sodium channels (Stoehr 2004). Lacosamide is 
related to a d-serine amino acid, its chemical name is (R)-2-acetamido-N-benzyl-
methoxypropionamide. It has been shown to modulate voltage gates gated sodium 
channels by a dual mechanism. Lacosamide increases the inactivation of slow sodium 
channels with no effect on fast inactivation. Fast inactivation that lasts a few 
milliseconds is how other sodium channel blockers work but lacosamide works by 
increasing slow inactivation, which lasts up to a second. This dual mechanism effects 
neuronal hyper-excitability and therefore on the propagation of seizures (De-Biase et a 
2014).  
 
Finally, lacosamide may also interact with N-type calcium channels and influencing 
calcium currents in epilepsy. However recent experiments by Khanna and Wang did 
not prove any change in calcium currents when lacosamide was studies using patch 
clamp methods (Wang & Khanna 2011).   
 
1.6.3.2 Lacosamide- pharmacokinetics 
 
Lacosamide is rapidly absorbed after oral administration. Absorption is not affected by 
food intake (Contin et al 2013).  Maximal plasma levels of lacosamide are reached 
between 1 and 4 hours after oral intake. Dose kinetics is linear and 40% of the drug is 
excreted unchanged in the urine. Thirty percent of lacosamide is metabolized to an 
inactive metabolite. The plasma half-life of lacosamide is 13 hours allowing for twice 
daily dosing. Multiple dosing did not change the basic pharmacokinetic properties 
(Cawello et al). 
 
Given lacosamide have different interactions with sodium channels when compared to 
other AEDs; it therefore does not interfere with the action of other AEDs at other sites 
of sodium channel binding. There are no drug to drug interactions reported however 
longer term studies have indicated that drug inducing AEDs like phenytoin, 
carbamazepine and phenobarbital can decrease the dose of lacosamide by 25%. This 
result was borne out in a recent study (Contin et al 2013). 
 
 
 
		 25	
1.6.4 Other AEDs in development 
 
The development of new models in epilepsy has produced a number of molecules that 
have recently undergone phase three trials. Development of these newer AEDs has 
paralleled with new in vitro and in vivo models for epilepsy.  Some new AEDs are 
made from modifying existing AEDs and these are developed as new molecules or 
serendipitously. Examples of AEDs with new chemical structures include; ganaxolone, 
rufinamide and YKP3089. AEDs that have undergone modification of existing AEDs 
include bivaracetam, which is a modified form of levetiracetam. Other modified novel 
AEDs include ICA 27243, JZP-4, licarbazepine and MTMCD.  
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1.7 Conclusion 
 
Epilepsy is a chronic condition that affects both the physical and social aspects of a 
patient’s life. Patients with epilepsy are faced with long term treatments, which may be 
toxic or associated with cognitive impairment. Epilepsy is a common disease and 
accounts for a large number of hospital and clinic admissions. All age groups are 
affected by epilepsy, but the incidence of epilepsy peaks in young children and the 
elderly.  
 
This chapter discussed the current developments in epilepsy. Some of these advances 
have been profound, as they have changed clinical practice. These changes have 
revised some the fundamentals of epileptology like the definition of epilepsy and when 
to initiate treatment. Alongside this, there has been an explosion of new antiepileptic 
drugs and a greater understanding of the molecular mechanisms of epilepsy (Doeser et 
al 2015). Alongside this new research into when to treat epilepsy and seizures have led 
to novel research on when to treat seizures and epilepsy.  
 
Having a first seizure can be frightening to many patients. Patients would often ask 
about the odds of having a subsequent seizure and if they indeed have epilepsy. 
Certainly, one can make a diagnosis of epilepsy if two or more seizures have occurred. 
Whereas if only one seizure has occurred then recent data from large studies like the 
MESS study have informed us that the risk of immediate versus deferred treatment 
after a first seizure overall is not different. This is clinically important as it highlights 
that deferring treatments will not worsen the prospects of becoming seizure free. This 
is especially important if the patient is at a low to medium risk in having further 
seizures. Other studies have been able to stratify this risk using findings from 
neurologic exam, EEG and imaging criteria. Such risk factors include a history of 
trauma, remote history of febrile seizures and generalised spike and wave activity in 
the EEG.  
 
Recent changes to the definition of seizure freedom have occurred also in light of 
studies by Kwan and Brodie et al (2009). Their data examined the proportion of 
patients rendered free of seizure after the first and second antiepileptic drug.  Despite 
many attempts to formulate a definition of seizure freedom, this recent definition is 
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interesting but not clinically useful. The likelihood of becoming seizure free is good 
with 50% of patients being seizure free after first monotherapy drug and 20% after the 
second drug is added. This decreases to 18% when the third a subsequent drug is added 
and there may be patients that may never be seizure free no matter what drug is given 
to them. Data like this is also useful in epilepsy clinics when patients are unsure about 
whether they want to continue treatment or when they want to initiate treatment. 
Logically the next question patients ask is which drug out of a large number of drugs is 
the best choice for their particular type of epilepsy. Information of the best drugs for 
epilepsy has been informed by clinical trials and by clinical guidelines. 
 
Much of the evidence for this is from observation and traditional practice. 
Furthermore, the population of patients that are seen in the first seizure clinic are not 
the same as the patients that are recruited into clinical trials. The sheer number of new 
AEDs makes deciding the best treatment for a given patients more difficult. 
Randomised controlled trials so far have comparative information on whether a drug is 
preferable to placebo. They however lack data on when these drugs should be started 
and there is little data on which drugs are better than others. Other potential sources of 
evidence are clinical practice guidelines (CPG). A recent review of guidelines of the 
initial management of epilepsy by Payakachat et al showed that many of the guidelines 
included evidence for trials published between 1980 and 2006 but the key 
organisations like NICE, AAN and SIGN mentioned older AEDs and the AAN 
advised using AEDs which not under licenced for their indications (Payakachat et al 
2006).  
 
This chapter introduced epilepsy, seizures and the numerous drugs that have been 
developed so far. Nonetheless, one quintessential aspect of the doctor-patient 
consultation is the issue of harms. It is very common for patients to ask about side 
effects of AEDs especially if the duration of treatment is lifelong. Data for harms of 
antiepileptic drugs is lacking and this needs to be addressed. This will be the focus of 
chapter four. The next two chapters discuss the concept of clinical trials and the 
rationale behind clinical trials. 
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Chapter 2 
 
 
 
 
Evaluating harms in clinical studies of antiepileptic drugs 
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2.1 Introduction 
 
The previous chapter discussed the diagnosis of epilepsy and its management and how 
research has changed the management of a patient with a first seizure. Patients are also 
faced with various treatment options Differing mechanisms of actions of antiepileptic 
drugs have led to ideas such as rational polytherapy where certain combinations of 
medications of drugs may produce better outcomes in patients with epilepsy. Clinical 
trials in epilepsy have provided answers to many of these questions. This chapter 
considers the various sources of evidence that clinicians have used to make treatment 
options, the concept of evidence-based medicine and the pivotal trials in epilepsy.  
 
2.2 Hierarchy of evidence 
 
Any observation made could be counted as evidence. Evidence can vary from simple 
observations to more complex constructs like randomised controlled trials (RCTs). The 
key step in evidence-based medicine is to grade the evidence into meaningful 
hierarchies. This then allows for recommendations based on the strength of evidence.  
 
In 1992, the journal JAMA discussed in a paper of a paradigm shift in medicine where 
decision-making is supported on evidence rather than clinical experience. The 
Evidence Based Medicine group who are authors of this article called the new 
paradigm as evidence base medicine (Guyatt et al 1999).  
 
The centre of evidence-based medicine in Oxford describes a hierarchy of evidence 
(Oxford Centre for Evidence Based Medicine 2009). The highest level of evidence is a 
well-conducted systematic review. Individual patient data systematic reviews are the 
highest level of evidence (Stewart & Parmar 1993). In relation to AEDs Chadwick and 
Marson discussed that the hierarchy of evidence is similar but not the same as 
described above. The relative hierarchy of the expert opinion is higher than the case 
report (Chadwick & Marson 2007).  
 
The lowest form of evidence is unsystematic observations; this is where observations 
of patient’s response to a given treatment are utilised to guide treatments in other 
patients. Some clinicians call this form of evidence - an “expert opinion”. The next 
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level in the hierarchy is where a number of observations are collected into a case report 
or even a series of observations found in different patients to form a case series. Case 
reports are by themselves useful for rare and uncommon diseases but they are prone to 
bias. A collection of case reports can be further elaborated into a review article but this 
does not decrease bias as the selection of cases by authors may lead to alternate 
conclusions. Case controlled study designs are the next level of evidence. They are 
useful when the conditions are rare and the aims are to identify the risk factors for the 
development of disease. These studies are retrospective in design where comparison 
between cases and controls helps elucidate risk factors.  
 
2.3 4 Clinical trials 
 
The word clinical comes from the Greek kline which means bedside. Clinical 
knowledge was traditionally based on the collective experience of doctors and from 
observations and based on pathophysiological data. The theoretic background to this is 
based on established biology, pathology and pharmacology. Mathematical and 
statistical sciences are based on objective data supported by theorems and 
mathematical models. When the two disciplines of clinical medicine and mathematical 
statistics were combined, one can argue that this formed the basis of clinical trials.  
 
Societal expectations and pressures have also meant that doctors can no longer use 
their experience to make treatment decisions. Increasingly doctors and drug companies 
alike need to persuade patients and licencing bodies that the treatments they offer are 
safe and effective for patients. Austin Bradford- conducted the first clinical trial in 
1948 (Hill 1961) (Yoshioka 1998). He compared streptomycin for the treatment of 
pulmonary tuberculosis. Over the past century, there has been an explosion in the 
number of trials. 
 
2.3.1 Design of a Clinical Trial 
 
There are several ways in which a clinical trial can be conceived. Conventional trials 
have an active intervention and a comparator group (fig 14 page 31). They can be 
conceptualised as having a baseline phase, a titration phase and a maintenance phase. 
Patients can be randomised into one or more arms where one is an active intervention 
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and the other is a comparator, which may or may not be placebo. Trials can have 
several active intervention arms and one comparator or can have several arms allowing 
for multiple pairwise comparisons. 
 
 
 
 
 
 
 
 
 
A key concept of a clinical trial is that patients differ only with respect to treatment 
allocated and not any other characteristics.  If the treatment groups differ in some way 
other than the comparison of treatment, then the comparison is referred to as biased. 
Randomised clinical trials, patients and trial administrators are kept unaware of the 
nature and type of intervention. The key goal of clinical trials is to demonstrate the 
efficacy of a drug or intervention. This is achieved in comparison with placebo to 
demonstrate superiority or another active intervention to demonstrate either superiority 
or equivalence. Consequently trial methodologies have evolved to answer specific 
questions.  
 
How treatments are allocated to patients is quintessential to the validity of RCTs. The 
generation of unpredictable allocation sequence is an essential element of 
randomisation in a RCT. Randomisation eliminates selection bias; randomisation also 
permits the use of probability theory to explain any differences in outcomes that occur 
(Schultz et al 1995). This is achieved by adequate generation of allocation. The 
allocation should be concealed from patients and assessors. Allocation concealment 
also reduces bias in ascertainment where treatments don’t influence the assessment of 
patients (Schultz & Grimes 2002).  
 
Randomisation can be simple randomisation, blocked randomisation or stratified 
randomisation. Simple randomisation is with a single ratio i.e. a 1:1 ratio of equal 
Active Intervention 
Comparator 
Baseline 
Randomisation 
Figure 14 Conceptual framework of a clinical trial: Adapted from Systematic reviews of 
randomised controlled trials of antiepileptic drugs, (Marson 2000). 
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number of patients assigned to interventions. Blocked randomisation is where a block 
of patients with one variable, are entered and this eliminates nuisance factors as a 
source of variability. Stratified randomisation is where a set of characteristics of 
patients is randomised in such a way to allow subgroup analysis to occur. Strata like 
age and sex can be utilised.  
 
Blinding of trials is important to reduce bias. Blinding can be single blinded where the 
allocation is hidden from either the patients or the assessor or double blinded with both 
assessor and patients are blinded to the allocated treatment (Sibbald & Roland 1998).  
 
Allocation bias is where the treatment is given to patient in a random manner and there 
is no way of predicting which treatment will be allocated to a given patient. The types 
of biases that are reduced by blinding include allocation bias and ascertainment bias. 
 
2.3.2 Types of trials 
 
There are various ways in which to classify clinical trials. For the purpose of this 
thesis, this classification has been simplified (table 7 page 33). Parallel group trials are 
the commonest trials where there are at least two parallel arms. These could include a 
placebo or another active comparator. Parallel trials can be either mono-therapy studies 
where the intervention arm is a single drug or add-on therapy where the intervention is 
added to a pre-existing intervention. 
 
Selai & Trimble discussed the notion that antiepileptic drugs can be prescribed as an 
add-on to an existing AED in 1998. In their study, they interviewed patients with 
epilepsy and observed that 17% of patients with add-on therapy had benefited from the 
newer AED (Selai & Trimble 1998). Add-on trials are common because most AEDs 
would need to obtain an add-on licence and then be approved for monotherapy. The 
reasons for this are that it would be unethical to study a new AED as monotherapy 
before it is awarded an add-on licence.   
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Common trial type Description 
Placebo controlled add on studies A study in which the drug is compared with the 
effect of a placebo. Experimental drug is taken 
with other regular medications affecting the 
intended outcome. Outcome are predefined and 
adverse events are usually short term adverse 
events 
Placebo controlled mono therapy studies A study in which the drug is compared with the 
effect of placebo. Patients are not on any other 
drugs that may mimic the effect of the 
intervention 
Actively controlled studies No placebo in the comparator group but two or 
more active interventions 
Pragmatic studies Here the trial explores differences between 
treatments, where the allocated treatments are 
used routinely used in clinical practice 
Observational Studies There is no comparator arm and patients are 
allocated the active intervention or interventions. 
There are useful for detecting long term outcomes 
or adverse events 
Table 7 Common types of Clinical Trials. 
 
2.3.3 Other Clinical Trials in Epilepsy 
 
This section briefly discusses other trial types used in epilepsy. A brief note here is 
necessary as some of these trials are mentioned in chapter three. Examples of such 
trials include: Pre-surgical trial where patients intending to have surgery are withdrawn 
from AED and may be given another intervention or placebo for a short period of time. 
Conversion to monotherapy trial is where the drug of interest is maintained and any 
add-on drugs taken by the patient is one withdrawn. This is one way of transforming 
an add-on trial to a monotherapy trial. An actively controlled trial is where the 
comparator is not placebo but a different AED. The outcome of such a trial is to 
demonstrate equivalence.  
 
2.3.4 Special Clinical trials: Pragmatic, trials 
 
The term pragmatic trial was coined by Schwartz and Lellouch (1967). These trials 
assess interventions in that natural clinical setting compared to parallel trials where the 
conditions are strictly controlled. These trials are designed reflect the real world and as 
such are highly sought after by policy makers and patients. Usually the interventions 
do not include a placebo group and intervention in pragmatic trials could be a drug 
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intervention or any other intervention. Pragmatic trials are however open to bias, as 
they may not blinded (Zwarenstein et al 2008). The table below illustrates the 
differences between pragmatic and exploratory trials. 	
Item Exploratory trial Pragmatic trial 
Question Efficacy- can the intervention work? Effectiveness- does the intervention work 
when used in normal practice? 
Setting Highly selected. Poorly Adherent 
participants and those with conditions 
that might dilute the effect are 
excluded  
Little or no selection beyond the clinical 
indication of interest 
Intervention Strictly enforced and adherence 
monitored 
Allows flexibly as would be normal 
practice 
Outcomes Often short term surrogates or process 
measures 
Directly relevant to practitioners, funders, 
communities, and healthcare practitioners 
Relevance to 
practice 
 
Indirect relevance Direct relevance and is the key reason for 
trial conduct.  
Table 8 Key differences between trials with explanatory and pragmatic stidies, adapted from 
Zwarenstein et al 2008. 
 
2.4 Clinical Drug Development 
 
Clinical trials are often classified into four main phases (table 9 page 35). These take 
into account development of the drug of interest and communicate the extent of drug 
development. These have been called Phase I, II, III and IV. Regulatory trials are 
phase IIa, IIb and phase III studies. Phase 2a studies evaluate the efficacy and safety of 
the intervention with the aim to assess dose range and response. Phase 2b is a definite 
dose finding studies. Regulatory trials are also called exploratory trials, which 
contrasts them with pragmatic trials. Phase IV is a post marketing study after the 
licence is approved and the sponsors are interested in long-term outcomes or adverse 
events.  
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Old terminology Descriptive terminology 
None Translational studies 
Phase I Treatment Mechanism TM studies 
Phase I Dose Finding DF studies 
Phase I Dose Ranging studies 
Phase II Safety and activity studies SA 
Phase IIa Safety and activity studies SA 
Phase IIb Comparative Studies CTE 
Phase III Comparative Studies CTE 
Phase IV Expanded safety ES 
Large Simple Large Scale studies 
Table 9 Classification of clinical trials by phases.	
 
The Medicines Healthcare Products Regulatory Agency (MHRA) is the local UK 
based regulatory authority that issues licences to market drugs for clinical use. The 
Food and Drug Administration (FDA) is the authority based in the USA and the 
European Medicine’s Agency (EMEA) is located in the European Union. An EMEA 
approved drug would also automatically meet MHRA approval.  A licence would be 
issued if the drug sponsors provide two phase III trials that have proved efficacy and 
safety.  
 
When antiepileptic drugs are considered, the EMEA has produced a draft guideline in 
the development of drugs as add on therapy and for the development of drugs to 
specific epilepsy syndromes as advised by the ILAE. The EMEA would allow the 
registration for an add-on indication if two or more trials show proven efficacy and 
safety. A monotherapy indication is granted if the drug has been given a licence as an 
add-on indication in newly or recently diagnosed patients. If a drug has a trial in 
another indication, then the regulatory authorities need only one successful trial to 
show further efficacy (French 2012). Monotherapy trials are relatively uncommon, but 
if they were more common, then they would provide good evidence of efficacy against 
placebo. Some of these trials have been not been sponsored by drug companies and 
compare older AEDs like carbamazepine or valproate where the comparator is not 
placebo but a low functioning dose of the active drug. Monotherapy trials of newer 
AEDs are uncommon as it would be unethical to subject some patients to placebo.  
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Regulatory authorities store unpublished trial data provided by drug sponsors Recent 
unpublished data for clinical trials can be accessed from the websites of the EMEA and 
the FDA, but these are hampered by the complex nature of their webpages. Further 
they do not index trial data making it difficult to match data to published reports 
available to the researcher (Schroll et al 2015) (Howie et al 2013). 
 
The Clinical Trials Directive number 536/2014 of the European Union comes to force 
in 2016. This directive will let the EMA to form a single portal of entry for documents 
to be submitted. The directive also requires that there be transparency of outcome 
measures however they fall short with harms outcomes and requires that not al harms 
outcomes need be reported for regulatory approval (European Commission 2014). 
 
2.5 Outcome measures in clinical trials of epilepsy 
 
There are several outcome measures used in trials of epilepsy. A report by the 
commission on outcome measurement in epilepsy in 1998 outlined these outcome 
measures (Baker et al 1997). The key outcomes are described here. Outcomes in 
epilepsy can be broadly classified as efficacy outcomes, harms outcomes and quality 
of life outcomes. When considering efficacy and harms outcomes one must distinguish 
between outcomes that are needed for regulatory trials and outcomes that are reported 
in non-regulatory trials.  
 
2.5.1 Efficacy Outcomes 
 
Types of efficacy outcomes needed in regulatory studies could vary if the trial is an 
add-on study or a monotherapy study.  In add-on studies, the duration during which 
seizures are assessed need to be predefined. The commonest primary outcome is a 
percent reduction of seizure frequency and the proportion of patients with seizures 
decreased by a pre-defined amount over a defined period. Typically, this is a 50% 
reduction in seizure frequency over 12 weeks. Other secondary measures outlined by 
the EMA could include:  
 
1. > 25% worsening, no change, > 25% reduction, > 75% reduction  
2. Seizure severity and duration of seizures 
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3. Validated scaling measures 
4. EEG patterns 
5. Seizure counts by the patient or caregiver 
6. Seizure freedom 
 
Critics of these standard measures state that outcomes such as seizure frequency will 
underestimate the true treatment effect; they argue that if patients have two seizures in 
the same day, it may be counted as one seizure if recorded in diaries. A better estimate 
is the 50% reduction in seizure frequency as this can allow for comparisons across and 
between trials (Baker et al 1997). 
 
Other time to event outcomes used in trials include time to 12-month seizure remission 
and time to withdrawal due to harms. 
  
2.6.2 Tolerability Outcomes 
 
Usually tolerability outcomes are secondary measures. The most common is the 
proportion of patients that withdrew from the study due to any reason including 
adverse events. Trials would commonly report the number withdrew due to a violation 
of protocol and would report then number that withdrew due to harms separately. 
Some trial would further elaborate on the specific adverse event or events, which lead 
to withdrawal of the patient. 
 
2.6.3 Harms Outcomes and Adverse Events 
 
Harms data of adverse events are usually reported in clinical trials with varying levels 
of detail and completeness. Trials differ in the number of adverse events reported and 
in the degree of detail they provide regarding each adverse event.  
 
Commonly the measure of tolerability of treatment is reflected in the proportion of 
patients withdrawn due to adverse events. This is usually expressed as a total number 
of patients or as a percentage of patients withdrawing due to adverse events. Trials 
quote specific adverse events that have occurred during the treatment period. 
Commonly these would include dose related adverse events like nausea or dizziness. 
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Rare and idiosyncratic adverse events are sometimes reported; examples of these 
include Toxic Epidermal Necrolysis (TEN) or Steven’s Johnson Syndrome (SJS).  
 
The level of detail provided by individual trials differs too. Some trials will only 
provide summary measures of discrete adverse events as a percentage figure. Some 
trials are more specific and provide the number of adverse events, but this does not 
provide details if they occurred in the same patient or not. Uncommonly trials would 
mention if patients reported two or more adverse events with elaborate details. 
 
Majority of adverse events reported in RCTs are dose related and therefore transient. 
One study by Majkowski in 2005, examined the incidence of harms from unpublished 
data obtained from several topiramate studies. Their findings illustrate that most harms 
occur during the titration period as opposed to the baseline phase, but the types of 
adverse events do not differ between trial phases. They conclude that dose related 
harms are common and could be reduced in RCTs with slower titration. (Majkowski 
2005). This study shall be discussed in detail later as it provides a useful model of 
analysing adverse events.  
 
2.5.4 Quality of Life measures 
 
It is noteworthy that regulatory trials are not required by the EMA to provide quality of 
life data. There are a large number of quality of life measures that can be employed in 
RCTs. These scales are designed to assess the patient in the inter-ictal state where they 
may suffer from the psychosocial consequences of epilepsy and side effects of 
treatment. A summary of the common measures is set out in the table below (table 10 
page 39).  
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Scale Reference 
Quality of life in epilepsy QOLIE-31, 10, AD-48 Cramer et al 1998, 1996, 1999 
Liverpool HRQOL Battery Baker et al 1994 
Impact of epilepsy scale Jacoby et al 1993 
NEWQOL Abetz et al 2000 
Epilepsy surgery inventory ESI-55 Vickrey et al 1992 
Impact of Childhood illness Hoare& Russell 1995 
Children’s QOL in Epilepsy Survey Wildrick et al 1996 
Epilepsy foundation of America (EFA) Concerns index Gilliam et al 1999 
QOL in Paediatric Epilepsy Scale Arunkumar et al 2000 
Table 10 Epilepsy specific health related quality of life outcomes: adapted from Privitera & Ficker 
2004.	
	
2.5.5 Liverpool Adverse Events Profile 
 
The Liverpool Adverse Events Profile (LAEP) is a self-assessment questionnaire that 
is commonly used in clinical trials for the assessment of adverse events. The LAEP 
consists of 19 items using a four point Likert scale. It is valuable as it only takes ten 
minutes to complete. It proves useful as it can extract specific adverse events from 
patients. A study by Gilliam in 2004 showed that if patients were asked to complete 
the LAEP in clinic; they are three times more likely to report harms to their doctor in 
consultation and are three times more likely to have their medication reduced as a 
consequence (Gilliam et al 2004b). The study also showed that the use of the LAEP 
resulted in a significant reduction in adverse events in the four months following the 
completion of the initial use of the LAEP. Interestingly in this study, secondary 
outcomes showed that 31% of patients in routine clinical practice have adverse events. 
 A major drawback of the LAEP is it may not capture all adverse events.  
 
2.6 Limitations of RCTs informing on harms of AEDs 
 
Randomised controlled trials and observational studies are the most common source of 
evidence for efficacy and harms outcomes. This section discusses the merits of both 
RCTs and observational studies. 
 
Randomised controlled trials are better at providing more accurate estimates or 
information about treatment effects. They are less prone to bias due to the design 
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features of RCTs and therefore provide better estimates. One of the disadvantages of 
RCTs is that they will not detect long-term harms, as trials are short duration. RCTs 
are better at efficacy outcomes and short-term harms but not for long terms harms 
outcomes. These other outcomes may be better studied in observational studies.  
 
Commonly observational studies are follow-up studies at the end of a randomised 
controlled trial or they can be independent studies. They are usually unblinded and 
they lack allocation concealment and random allocation in their design. As a 
consequence of this, they are open to bias and owing to the heterogeneous nature of 
these trials, it is not always possible to synthesise them in to a higher form of evidence 
like a systemic review.  
 
Observational studies have been known to overestimate treatment effects. This has 
hitherto been the main argument of not including these studies in systematic reviews. 
Nonetheless, a study by Ioannidis (2001) has found very good correlation between 
randomised and non-randomised studies; in one study the Pearsosn’s correlation 
between summary odd ratios of randomised and non-randomised trials was 0.75 with a 
p value of < 0.01 (Ioannidis et al 2001) this suggested that summary measures do not 
differ much.  In contrast to this study, Maguire et al combined summary measures 
from observational studies of AEDs and found, they varied extensively, treatment 
estimates were therefore unreliable and therefore cannot be used in systematic reviews 
(Maguire et al 2008).  
 
Observational studies have benefits over RCTs in that they are longer in duration and 
do not possess fixed doses and titration schedules. Other arguments that favour 
observational studies over RCTs are that they as more closely related to clinical 
practice. RCTs also ignore patient’s characteristics and just compare survival curves or 
the outcomes therefore this allows generalizability of results across trials into 
systematic reviews. One example of where observational studies has been useful is the 
description of persistent visual field defects found in patients taking long term 
vigabatrin. The association of visual field defects was noted in a case reports of 
patients and then this was confirmed in a large scale observational study (Lawden et al 
1999) (Comaish et al 2000) This association of visual fields defect was not found in 
randomised controlled trials.  
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Other sources of harms data include large databases like the yellow card reporting 
system. Such systems are pharmaco-vigilance systems set up either by drug companies 
or by other organisations to collect and publish alerts of rare and potentially serious 
adverse events caused by drugs.  
 
The remainder of the chapter discusses important trials in epilepsy and epilepsy and 
information on which drugs to choose for their patients. The evidence pertaining to 
best drugs after first and second seizure was discussed earlier. The next section 
discusses evidence of the best AED for a given group of patients with epilepsy.  
 
2.7 Pragmatic studies in Epilepsy. 
 
Clinical guidelines published by organisations like the AAN or ILAE have been 
informed by RCTs and some of the older published guidelines were difficult to 
assimilate as they were informed by placebo-controlled trials. These recruited patients 
often refractory to treatment and this population was considered somewhat artificial. 
Pragmatic studies were developed to study an AED or a group of AEDs in a mixed 
population of patients that simulated routine clinical practice. Unlike RCTs these were 
longer in duration too and allowed long term AE to be assessed. The largest pragmatic 
study to date is the SANAD study.  
 
The Veterans studies conducted in the USA were the first studies that looked at the 
best choices of AEDs would be in patients with epilepsy. A study by Mattson et al 
compared phenytoin, phenobarbital, primidone and carbamazepine in a randomised 
manner and found that they differed not in efficacy but in their side effects profiles 
(Mattson et al 1996). Another study by Heller et al compared valproate, phenobarbital, 
phenytoin, and carbamazepine in patients with generalised tonic clonic and partial 
seizure. This study found no difference in time to 12-month seizure freedom but they 
differed in terms of adverse events (Heller et al 1995). The overall conclusion we can 
make is that likely drugs do not differ much in their efficacy measure but only adverse 
events. Head to head comparison of randomised controlled trial also can be 
misleading. One study comparing carbamazepine and lamotrigine could not be 
considered as reasonable evidence as the steep escalation phase showed a large number 
of patients that dropped out of the trial the outcome at the end of this trial showed that 
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there was no difference between the two drugs (Brodie et al 1995). A recent review 
using individual patient data was the best source of evidence comparing one drug over 
another this showed no difference between carbamazepine versus valproate (Marson et 
al 2002) but the methods used in the meta-analyses was carried over to determine the 
efficacy of one drug over another trial in a prospective manner. This was the SANAD 
study.   
 
2.8 The SANAD study 
 
In routine clinical practice drugs such as valproate, topiramate, lamotrigine and 
possibly levetiracetam are useful in patients with both generalised and focal epilepsy. 
Other drugs like carbamazepine, phenytoin and ethosuximide can aggravate seizures in 
idiopathic epilepsy but are useful in focal epilepsy. One large pragmatic study called 
the Standard And New Antiepileptic Drug study (SANAD). 
 
The aim of the SANAD study was to compare one standard drug for focal epilepsy 
(carbamazepine) in arm A with newer AEDs, and one standard drug for generalised 
epilepsy (valproate) in arm B with newer AEDs (Marson et al 2007) (Marson et al 
2007).  
 
The SANAD study was an unblinded multicentre study where at the time of diagnosis 
the clinician would need to make a decision whether patient’s epilepsy would be better 
treated with either carbamazepine or valproate. Also, there was no evidence on the best 
drug for partial epilepsy, as there existed only one individual patient data systematic 
review of carbamazepine. For generalised epilepsy, the evidence of valproate being 
superior to other AEDs was from observational studies. Clearly this lack of evidence 
needed addressing.  
 
The SANAD study was composed of two arms. 1721 patients were recruited into arm 
A and 716 patients were recruited into arm B.  Primary outcomes were the time to 
treatment failure (due to adverse events or inadequate seizure control or combination 
of the two) and time to achieve a 12-month remission of seizure.  Other outcomes were 
time from randomisation to first seizure; time to achieve a two-year remission and 
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frequency of clinically important adverse events. This study was partly funded by 
commercial sponsors.  
 
For time to treatment failure in SANAD arm A, two plots are displayed due to 
oxcarbazepine being introduced later in the trial (Marson et al 2007). For time to 
treatment failure lamotrigine performed better than the other drugs. Pairwise 
comparisons showed hazard ratios in favour for lamotrigine against carbamazepine, 
gabapentin and topiramate (see fig 15 page 43). For time to 12-month remission one 
sees that topiramate and oxcarbazepine are the least favoured and carbamazepine and 
lamotrigine are most favoured. The lower treatment failure rates for lamotrigine was 
due to better tolerability therefore the balance of risks would therefore favour 
lamotrigine over carbamazepine for treatment of partial seizures (see fig 16 page 44). 
 
	
Figure 15 Time to treatment failure in patients enrolled in SANAD arm A. First graph shows whole 
population and second shows data including oxcarbazepine. Hazard ratios of failure of drug when added 
to baseline drug (Marson et al 2007) 
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Figure 16 Time to 12-month remission for whole population and for oxcarbazepine data. Hazard ratio of 
greater than 1 indicates failure occurs more rapidly on drug compared with baseline (Marson et al 2007) 
	
SANAD arm B evaluated valproate, lamotrigine and topiramate in patients with 
generalised or unclassifiable epilepsies. In arm B, the time to treatment failure for 
valproate was significantly better than topiramate but there was no difference between 
lamotrigine and valproate. This was noted in pair wise comparisons and noted when 
the probability of staying on lamotrigine, valproate and topiramate was plotted against 
the duration of the trial, see fig 17 page 45. 
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Figure 17 Time to treatment failure for patients allocated to lamotrigine, topiramate or valproate in 
patients with idiopathic generalised epilepsy or unclassified epilepsy. Plotted as the probability of 
staying on treatment (Marson et al 2007) 
 
For time to 12-month remission, about 80% of patients entered into 12-month 
remission in the first year. The probability was greatest for valproate followed by 
topiramate and followed by lamotrigine for the duration of the trial (fig 18 page 46). 
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Figure 18 Time to 12-month remission for patients randomised to valproate, topiramate and lamotrigine 
(Marson et al 2007) 
 
A number of critics of the SANAD studies have stated that carbamazepine was titrated 
to a high dose and therefore there were many drop outs with carbamazepine in arm A 
(French 2012). Also, the critics of SANAD state that it is not good evidence in 
particular for childhood epilepsies where the diagnosis of the epilepsy syndrome needs 
to be made meticulously.  
 
In terms of adverse events, the SANAD studies were important as one of the outcomes 
was treatment failure and this provided a good comparative estimate of the risk of 
adverse events between drugs.  
 
Overall the SANAD study is the largest trial to date informing clinicians on the cost 
benefits of treatments with one outcome for efficacy and one outcome for harms and a 
trade-offs made in the conclusions with the best drug for both partial and generalised 
seizures. In SANAD arm B, 36% of patients taking valproate and 45% of patients 
taking topiramate reported adverse events. These included psychiatric symptoms 
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related to topiramate and weight gain for valproate. Rash was the most common 
adverse event associated with treatment failure due to lamotrigine in arm B. The 
proportion of patients that withdrew due to rash was 4%. The proportion of patients 
with rash in arm A was 15% and proportion of patients with rash in arm B was 12%.  
 
2.9 Trials of AEDs for other indications 
 
Increasingly AEDs are used for the treatment of conditions other than epilepsy. These 
conditions can range from headache disorders, psychiatric conditions and peripheral 
nerve disorders. The reasons for this is due to the underlying mechanisms of some of 
the AEDs in blocking ion channels (Spina & Perugi 2004) Drugs such as 
carbamazepine have been used for trigeminal neuralgia and this was first used in 1962 
by Blom (1962) and was only later undergone scrutiny with several RCTs (Killian & 
Fromm 1968) (Nicol 1969). 
 
The list of possible conditions for which AEDs are used is extensive but can be 
broadly categorised as treatments for neuropathic pain, trigeminal neuralgia, migraine 
and essential tremor. Other uncommon indications are the use of AEDs in HIV related 
neuropathy and Guillian Barre Syndrome.  
 
Psychiatric conditions where AEDs are used include bipolar disorder where 
carbamazepine, valproate and lamotrigine have mood stabilising effects (Bowden et al 
2003). Valproate is considered one of the first line drugs for the treatment of acute 
mania and was found to be comparable to lithium.  
 
The use of AEDs in other indications is important as RCTs in other indications may 
provide additional information on harms and is the topic of chapter nine. 
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2.10 Conclusion 
 
In the past two decades, evidence based medicine has played a significant role in how 
treatments are evaluated. This is due to a cultural change in how doctors and patients 
interact with each other and a reduction in the importance of the clinical opinion in 
favour of judgments based on evidence. Tradition and clinical observations are no 
longer regarded as absolute truths in medicine and these have been replaced by the 
scientific method. Other factors that have facilitated the importance of evidence based 
medicine is the need for regulation of new products by regulatory authorities. This 
ensures the safety and efficacy of new treatments and helps regulators estimate the cost 
effectiveness of treatment.  
 
The units of evidence-based medicine are composed of clinical trials, observational 
studies and other sources of evidence like case reports or case series. These units can 
be analysed into either narrative reviews or systematic reviews. Other types of 
evidence that can be used are health technology appraisals and guidelines. Various 
clinical trials reflect the tensions that exist between the needs of regulators and 
clinicians. Regulatory trials provide short-term results of efficacy to obtain a licence 
whereas clinicians need longer-term trials to demonstrate efficacy. One way to bridge 
this gap is to conduct systematic reviews that combine the results of several trials to 
produce a summary measure but these do not inform us of long term outcomes like 
seizure freedom or time to 12-month remission. Recently there has been collaboration 
between industry and local research bodies to fund large scale pragmatic studies like 
the SANAD study. The success of the SANAD study in demonstrating long term 
efficacy of lamotrigine in focal epilepsy and valproate in generalised and unclassified 
epilepsies has paved the way for a repeat of this large-scale study to include newer 
AEDs like levetiracetam and zonisamide (SANAD II protocol 2013).  
 
Long term trials like SANAD have provided us with new outcomes like time to 12-
month remission and time to treatment withdrawal. Secondary outcomes in the 
SANAD studies included adverse events and these were similar for lamotrigine in both 
arms A and B Such long term pragmatic trials are important as they reflect clinical 
practice and are of a longer duration that ordinary trials allowing for uncommon 
adverse events to be detected. The rates of rash for example in SANAD arm A and B 
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were similar (15% and 12% respectively), however the proportion of patients with rash 
in SANAD was higher than other RCTs of a shorter duration (Messenheimer et al 
1998).  
 
The current repository of harms data exists in several places ranging from regulatory 
databases, national databases, commercial databases, published randomised studies, 
observational studies and case reports. Each of these has strengths and weakness. The 
vast majority of this data is contained in randomised trials and observational studies 
and this may be mirrored in their corresponding databases. To date there are no studies 
comparing harms in RCTs versus observational studies.  
 
Antiepileptic drugs are also used in other indications. The efficacy and safety of these 
AEDs in RCTs may be important in informing about harms.  
 
The next chapter discusses adverse events, the corpus of knowledge regarding adverse 
events and adverse events in clinical trials of epilepsy. 
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Chapter 3 
 
 
 
 
Harms due to Antiepileptic Drugs 
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3.1 Why study Adverse Events? 
 
Epilepsy is a chronic disease and like any chronic disease there are many dimensions 
of the disease and its treatment that impact the patient. Patients with epilepsy face the 
burden of the physical and social consequences of seizures. Harms from seizures may 
occur during the ictal phase where patients can injury themselves or could die due to 
SUDEP. Harms can also occur during the inter-ictal phase and these comprise many of 
the psychosocial consequences of seizures. Harms due to adverse events are included 
in this category as conceptualised in the figure below. One can see that harms due to 
AEDs add to the burden of patients with epilepsy (fig 19).  
 
	
Figure 19 Conceptual framework of adverse events in relation to other co-morbidities in epilepsy 
. 
Epilepsy is routinely treated with antiepileptic drugs with a 60-70% chance of patients 
achieving seizure control (Kwan & Brodie 2000). One must remember that 60% of 
those patients who may become seizure free will still experience side effects. A 
European survey found that 88% of patients taking AEDs had at least one adverse 
event (Baker et al 1997). The proportion of patients that have discontinued a drug due 
to an adverse event on their first drug is about 10-27% (Kwan and Brodie 2000).  
 
Patients can be treated as monotherapy, or polytherapy. Clinicians must balance the 
risk of harms of adding another AED and weight this up with the potential benefits of 
prescribing additional AEDs. One must consider that each additional AED prescribed 
to a patient may have a marginal benefit, as compared to potential side effects. A 
recent study by Kwan and Boride found that harms occurred in 12% of patients that 
were given add-on therapy and this when compared to patients who were prescribed 
		 52	
alternate monotherapy; they found that the latter group had a 26% chance of reporting 
adverse events. There was no difference in seizure outcomes between alternate mono-
therapy and add-on therapy (Kwan & Brodie 2000). 
 
Adverse drug reactions can differ from drug to drug and each drug can have its 
distinctive idiosyncratic drug reactions. However, many drugs still share common 
adverse drug reactions. It is accepted that the older AEDs cause more side effects than 
the newer drugs.  The evidence that the older AEDs do not differ much between each 
other in terms of efficacy but differ considerably in terms of harms was noted in the 
Veterans studies of epilepsy in the late 1990s (Mattson et al 1996. The Veterans study 
of AEDs was published in 1997 and this was a head to head comparison. These studies 
were important in that they allocated treatment based on seizure types. For focal 
seizures, these studies showed no difference between AEDs. However, there were 
differences in AEDs in patients with generalised seizures. All the studies showed that 
AEDs differed in terms of adverse events (Mattson et al 1996). There is evidence to 
suggest that the newer AEDs are better tolerated due to their unique pharmacokinetics 
and pharmacodynamic interactions (Lee 2014). 
 
3.2 Clinical importance of Adverse Events 
 
Adverse events are a leading cause of failure of AED therapy. Adverse events can 
result in discontinuation of treatment in about 25% of patients (Lazaro et al 1998). 
According to the World Health Organisation, adverse drug events account for the sixth 
largest cause of mortality in the USA (Lazaro et al 1998). Adverse events can limit 
dose increases of AEDS leading to treatment failure and patients may not adhere to 
treatments for fear of adverse events. 
 
Some methods of minimising adverse events include choosing a drug that is 
individualised to the patient. Rates of drug escalation should be slow to prevent dose 
related adverse events, this is particularly important when increasing lamotrigine in the 
presence of valproate (Messenheimer et al 1998).  
 
Psychiatric adverse events are common with some AEDs. This is particularly true with 
levetiracetam; a study by Mula et al has shown that up to 10% of patients prescribed 
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levetiracetam develop psychiatric side effects (Mula et al 2003). This risk was 
increased slightly if there was a previous history of psychiatric disorder (Relative risk 
of 1.19 95% CI of 1.07 to 1.33). Antiepileptic drugs such as lamotrigine and valproate 
may conversely have mood stabilising effects and are useful in patients with 
psychiatric co-morbidities.  
 
Some serious adverse drug reactions like Steven's Johnson syndrome due to 
carbamazepine can be predicted. Recent research has found two genetic variants of 
carbamazepine induced hypersensitivity reactions associated with HLA-B*15:02 and 
HLA-A*31:01 (McCormack et al 2011). Genetic testing of HLA-B*15:20 is 
recommended for patients with Asian ancestry. HLA-B*31:01 is common with this 
testing even though the positive predictive value of the test is low. The positive 
predictive value (PPV) of this in the Han Chinese population was estimated to be 7.7% 
and a negative predictive value (NPV) was estimated to be 100% (Ferrel & McLeod 
2008). The PPV is low but due to the high morbidity and mortality of the adverse 
event, it would still be negligent if patients were not tested. If patients at risk are 
already taking carbamazepine for more than 3 months, they do not have to be tested 
(Amstutz et al 2014). Other efforts to find a genetic link to cognitive adverse events 
caused by topiramate have not found any association with ethnicity (Cirulli et al 2012).  
 
Measures to manage adverse drug reaction in patients include careful monitoring, 
reducing dose when needed or drug discontinuation. Recent advances in genomic 
medicine may help predict the chances of harm in any patient before a drug is 
prescribed. 
 
3.3 Definition of Adverse Events 
 
Various bodies have defined this and these include the Food and Drug Administration, 
the World Health Organisation (WHO) and the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human use (ICH). The first thing to clarify is the difference between adverse events 
and adverse drug reactions. These two bodies state that the term adverse event is not 
helpful for physicians and they prefer the term adverse drug reaction. The World 
Health Organisation defines adverse events as: 
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“..any noxious, unintended and undesired effect of a drug which occurs at a dose used 
in man for the prophylaxis , diagnosis or therapy” (WHO 2015)  
 
The ICH defines adverse events as; 
“..any untoward medical occurrence that may present during treatment with a 
pharmaceutical product but which does not necessarily have a causal relationship with 
this treatment” 
 
On the contrary, it can be argued that the term adverse drug reaction may not be 
entirely appropriate as some harms can be due to excess dose related or but a 
predicable occurrence so the term adverse event is favoured in the medical literature. 
The relationship between adverse events and medical errors is linked in that some 
adverse events are due to medical errors but not all (fig 20). Bates et al formulated a 
conceptual framework on the relationship between adverse events, adverse drug 
reactions and medication errors this is shown in the figure below (Bates et al 1995). 
They also set definitions for the terms and definitions of levels of causality. This is 
shown in the table below (table 11). The terms harms and adverse events can be used 
synonymously.  
 
	
Figure 20 Relationship between adverse drug reactions, adverse events and medication errors: Adopted 
from Bates et al 1995 		
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Adverse event and adverse drug reaction are regulatory terms; the first does not require a causal 
link between the drug and the events, the second does. 
 
Adverse drug events extend beyond adverse drug reactions to include harms from overdoses and 
underdoses usually related to medication errors. A minority of adverse drug events are 
medication errors, and medication errors rarely result is adverse drug events. 
 
The term side effect should be avoided 
Table 11 Definition of adverse events and adverse reactions, grades of causal assessment of adverse 
events: Adopted from Nebeker et al 2004 
 
3.4 Classification of Harms from AEDs 
 
There are two commonly used ways of classifying adverse events: by cause or by 
severity. The Food and Drug Administration (FDA) prefers to classify adverse events 
by severity (Aronson 2002). In this thesis, adverse events will be presented by cause. 
The two main events to consider are type A and type B adverse drug reactions (table 
12). Type A events constitute approximately 80% of all adverse drug reactions and 
they are consequences of pharmacological interactions or low therapeutic indices. 
Type A events are dose-related and usually mild in severity although they can be 
serious or fatal. Most type A events involve the central nervous system (Perucca & 
Meador 2005). Type B events are idiosyncratic events and these are those independent 
and unpredictable. Type A event can be acute in onset and resolution whereas type B 
reactions can be slow in onset and remit slowly.  
 
Adverse Drug Reaction Description 
Type A Augmented Pharmacologic events  
Type B Bizarre and Idiosyncratic 
Type C Chemical effects 
Type D Delayed effects 
Type E End of treatment effects 
Type F Failure of therapy  
Type G Genetic reactions 
Type I Idiosyncratic 
Table 12 Classification of Adverse drug reactions. Adapted from Davidson's Principles and practice of 
medicine 19th edition 
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3.5 Pharmacodynamic and pharmacokinetic Adverse Events 
 
Patients can vary in how they respond to antiepileptic drugs. Even when factors such 
as age and dose are controlled, the inter-patient variability of AED concentration can 
vary widely (Cloyd et al 1993). These are type A reactions. Pharmacodynamic 
interaction is when one drug alters the activity of another drug without a change in 
concentration. This can occur due to the interaction of one AED over the metabolism 
and protein binding of another AED. One example of this is the interaction of 
phenytoin and valproate. Phenytoin increases the metabolism of valproate and 
reducing its level if both are prescribed together.  
 
Pharmacokinetic interactions are dose related and these can be either linear or non-
linear. A linear response is when the serum concentration of drugs increases 
incrementally with dose increase and this can be predicted. Non–linear 
pharmacokinetics is when a unit change in dose can have an exponential increase 
serum concentration.  
 
3.6 Adverse Events that affect seizures and epilepsy 
 
Some adverse events can be due to an increase in seizures caused by antiepileptic 
drugs. This could be due to an increase in the number of seizures or a new seizure type 
developing. Types of seizures that typically occur due to AEDs are absence or 
myoclonic seizures. Drugs can precipitate seizures when prescribed in some situations. 
This typically occurs when carbamazepine, phenobarbital, vigabatrin and gabapentin 
are prescribed in patients with idiopathic generalised epilepsy. These would be 
considered as type A reactions as they are related to the AED interactions with ion 
channels. Other effects related to AEDs include psychosis and encephalopathy in 
association with valproate use and is dose related (Segura-Bruna et al 2006).  
 
3.7 Life threatening adverse events 
 
Most randomised controlled trials are conducted in the pre-marketing phase and 
therefore these trials at quite short in duration and are unlikely to report life-
threatening adverse events. Adverse events from observational studies and reporting 
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agencies are more likely to report life-threatening adverse events. Life threatening 
adverse events can be either long-term adverse events, or idiosyncratic events.  
 
An idiosyncratic drug reaction is one where the reaction cannot be predicted and 
happens uncommonly. They are also known as type B reactions. Cutaneous drug 
reactions could be thought of as an idiosyncratic drug reaction particularly if they 
occur late in treatment phase. Idiosyncratic drug reactions are a common source of 
morbidity and mortality. They account for 6-10% of all drug reactions (Pirmohamed & 
Park 1997). The vast majority of these reactions are due to AEDs.  Adverse drug 
reactions can be described as being fatal and non-fatal. Non-fatal drug reactions are 
also associated with significant disability due to drug withdrawal. Life threatening 
adverse effects include serious rashes; aplastic anaemia due to felbamate and 
agranulocytosis due to carbamazepine. Drugs induced hepatic necrosis is another 
example of type B reactions that occurs with valproate and it occurs in every 26000 
exposures. Similar to hepatotoxicity, valproate can cause pancreatitis that occurs one 
in 40000 cases.  
 
3.8 Rashes from AEDs 
 
Drug reactions due to rashes are common and can occur in 8% of patients, these can 
vary from morbilliform rashes to macular-papular eruptions. These are again type B or 
type I reactions. With regards to AEDs, these reactions occur with aromatic AEDs like 
phenytoin, phenobarbitone and carbamazepine. In most cases, the rashes are self-
limiting and fade away after stopping the offending drug (Chadwick et al 1984). The 
aetiology of rashes is the result of an immunologic response to the drug and is 
therefore a type B reaction. Examples of this include rashes that occur with 
carbamazepine, and lamotrigine. 
 
Severe drug reactions include Stevens Johnson Syndrome (SJS), Drug Reaction with 
Eosinophilia & Systemic Symptoms (DRESS) and Toxic epidermal necrolysis (TEN). 
Recent figures state that in the incidence of DRESS is 1 in 5000 patients taking 
carbamazepine (Arroyo & De La Morena 2001).  
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Genetic studies have demonstrated an association between hypersensitivity reactions 
and human leucocyte antigen HLA B*1502 in various Asian populations (Man et al 
2007) (Metha et al 2009).  This was first described by Chung et al in a case controlled 
analysis of HLA B*1502 (Chung et al 2004). This has been validated in numerous 
studies and since has led to an increasing scientific interest in the Food and Drug 
Administration updated the label for carbamazepine and recommends any patient of 
Asian background be tested for this allele before treatment. Mortality from these drug 
reactions can be high and recent efforts have led to the development of prognostic 
scores, which can predict mortality based on clinical features of the reaction (Bastuji-
Garin et al 2000). Other risks factors for cutaneous skin reactions include; female 
gender; young age and having a learning disability (Alvestad et al 2007).  
 
3.9 Cognitive Adverse Events from AEDs 
 
All AEDs produce cognitive effects to some degree (Perucca & Meador 2005). 
Cognitive adverse events are the most common of all adverse events and can affect up 
to 60% of patients taking AEDs. (Gilliam et al 2004) (Baker et al 1997). Common 
cognitive effects of AEDs include concentration impairment and memory impairment. 
These are type A reactions. Older AEDs like phenobarbitone phenytoin and primidone 
are associated with cognitive side effects. Populations of patients that may have 
frequent cognitive side effects include the elderly and patients with learning disability. 
There is a suggestion that cognitive adverse events caused by topiramate may be 
genetically determined. Observational studies suggested that some ethnic groups are 
more likely to report side effects (Cirulli et al 2012). However, a genome wide 
association study did not find any association between ethnicity and cognitive side 
effects (Cirulli et al 2012).    
 
3.10 Chronic Adverse Events 
 
These adverse events are insidious but are significant in the long-term impact on the 
patient’s quality of life. They are classified as type C or type D adverse events. 
Chronic adverse events include loss of bone mineral density caused by drug inducing 
AEDs, weight gain due to appetite stimulation due to sodium valproate, Polycystic 
Ovarian Syndrome caused by valproate, gingival hyperplasia due to phenytoin use and 
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barbiturate induced shoulder hand syndrome. Topiramate, felbamate and zonisamide 
on the other hand can cause long-term weight loss that can be reversible after stopping 
these AEDs. However, some of these type C events are not reversible and- an example 
of this is weight gain induced by valproate. Vigabatrin can cause insidious visual loss 
due to retinal degeneration (Perucca & Gilliam 2012).  
 
Antiepileptic drugs pose a major teratogenic risk to the foetus when a pregnant mother 
has epilepsy takes medication at the time of conception or continues to do so during 
pregnancy. The risk is not solely related to major malformations but can have long 
lasting cognitive and developmental consequences on the baby (Shallcross et al 2014). 
 
3.11 Reporting and assessment of harms in clinical trials 
 
3.11.1 How is data on Adverse Events collected? 
 
Source data for adverse events can vary from individual clinical trials to drug 
regulatory bodies. The collection of harms data in clinical trials is heterogeneous in the 
methods used. Some clinical trials use spontaneously reported adverse events whereas 
some clinical trials use validated tools for adverse events. The quality of reports is thus 
dependent on the methodology used in clinical trial (Perucca & Meador 2005). Some 
trials use spontaneous reporting of harms and other used a validated tool like the 
Liverpool Adverse Event Profile.  
 
3.11.2 Clustering of Adverse Events: A new taxonomy 
 
It is observed in clinical practice that some adverse events caused by AEDs may 
cluster in any given patient. A study by Perucca et al (2009) showed that 88% of 
patients in an outpatient cohort reported at least one adverse event and 82% reported 
two adverse events. They also found the mean number of adverse events per subject 
was 6.5. Certain adverse events can cluster in the same patients and the authors 
suggested that adverse events should be grouped into five classes these are illustrated 
in figures 21 to 22 on pages 60-61. These include; Cognition & coordination; sleep; 
skin & mucosal; mood & emotional and finally weight & cephalgia. This classification 
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is a significant step forward as taxonomy would allow for standardised recording of 
harms in a randomised controlled trial.  
 	
	
Figure 21 Correlation among the 19 adverse event profile items in LEAP in the entire cohort showing all 
correlations are significant except weight gain and hair loss (Perucca et al 2009) 
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Figure 22 Radial plots illustrating the segregation of adverse events within each class as identified by 
factor analysis in entire cohort (Perucca et al 2009)	
 
3.11.3 Adverse events in patients with newly diagnosed epilepsy: a comparison of 
treated and untreated patients 
 
A recent study used the taxonomy for Adverse Events postulated by Perucca et al 
(2009). The authors created an adverse event profile (Perucca et al 2011). The Adverse 
Events Profile (AEP) is validated 19-item questionnaires that assess the frequency of 
the most common adverse events due to antiepileptic drugs. This is a questionnaire that 
is filled out by patients in clinic to provide a score of harms they may have 
experienced due to antiepileptic drugs. Scores of items ranged from 19 to 76.  
 
A case controlled analysis of using the AEP was carried out in patients with new onset 
seizure. The patients compared of two groups, one group as treated immediately and 
another group was not treated. (Perucca et al 2011). They found that there was no 
difference in the AEP score and no difference in each of the six factor scores. This 
study suggested that in the newly treated population, there were no differences in the 
AEP score due to the low dose of AEDs. The authors suggested that of the 50% of 
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patients who become seizure free due to AEDs are not different to patients who are not 
treated with respect to adverse events.   
 
This study is an important step, which elaborated on harms outcomes using two large 
datasets of patients with newly diagnosed epilepsy. This study demonstrated that 
useful data could be obtained from a clinical trial if the correct outcome measure is 
used. This study found that other factors influence AEP scores and therefore reporting 
of adverse events; these include young age of seizure onset; history of febrile seizures; 
symptomatic aetiology and female gender. The authors suggest that the history of 
febrile seizures reported more headaches and they hypothesised that this was due to 
sodium channel mutations that predispose patients to migraine (Perucca et al 2011). 
 
3.11.4 Adverse Events reporting over time: Topiramate as a model  
 
Most AE reported in RCTs mention the proportion of patients with adverse events and 
the proportion of patients withdrawn due to adverse events. There is little data in the 
time frame of adverse events. A recent study by Majkowski et al conducted post hoc 
analyses of data from topiramate trials. The authors plotted the time course of common 
CNS harms reported in a randomised placebo controlled trial of topiramate (fig 23, 
page 62). Patients were taking carbamazepine concomitantly as the first drug and 
topiramate was used as an add-on drug. Topiramate doses used in this trial do not 
reflect doses used in clinical practice as the studies used here have higher doses (dose 
range of topiramate was 200 to 1000mg per day whereas in clinical practice the doses 
are a lot lower).  
	
Figure 23 Incidence of somnolence and loss of appetite in a trial of topiramate versus placebo 
(Makkowski et al 2005)  
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The key outcomes were the total days in which patients had adverse events called AE 
days, the occurrence rate of AE which was the daily incidence of a given AE. They 
also calculated the AE time, which is the total number of days, divided by the number 
of subjects in that treatment group.  
 
The results showed that common side effects occur at initiation of the drug and 80% of 
the side effects resolve after the 12 weeks of the double-blind period (figure 24) also 
the number of adverse events compared to placebo are the same after the titration 
period is over. However as one would expect, the number of patients with paraesthesia 
was higher in the topiramate group regardless of the phase of the trial.  The incidence 
of weight loss also increases with time as would be expected (Majkowski et al 2005).  
 
This study demonstrates an alternate method of analysing harms data and this will 
have implications on how Cochrane reviews handle harms data. However, this would 
involve a significant effort on drug sponsors and clinical trials to disclose more data. 
 
Adverse events occur during the titration and maintenance phases but are more 
common in the titration phase. This trial provides a model of adverse events in plotting 
the incidence of harms over time rather than provide summary measures.  
 
3.12 Observational studies of adverse events 
 
Chapter two discusses the merits of RCTs and observational studies in relation to 
harms but the next section discusses this subject further. 
 
There is no consensus to suggest that RTCs are better than observational studies when 
it comes to reporting of harms. Advantage of RCTs is that they are less prone to bias 
compared to observational studies. On the other hand, observational studies are 
cheaper and have a less restricted choice of patients for inclusion (Benson & Hartz 
2000). Observational studies may have significant heterogeneity in harms measures 
therefore at this juncture we will limit ourselves to RCTs.  
 
However, one of the largest studies to evaluate adverse events was a multicentre 
observational study (Cramer et al 2011). This compared newer and older AEDs in the 
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prevalence of each adverse event type. The primary outcome was the proportion of 
patients with greater than one adverse event and the prevalence of AE based on a 
rating scale called N&SAERS (Cramer et al 2011). A total of 1019 patients were 
recruited into this study. The results showed that overall 68.3 percent of patients 
reported one or more adverse event. Fifty eight percent of patients report one or more 
neurological adverse events and 40% of patients report one or more systemic adverse 
event. Patients are less likely to have adverse events if they were taking a newer AED 
compared with an older AED (odd ratio favouring newer AED was 0.64 with 95% CI 
of 0.46 to 0.89). Patients taking polytherapy reported more adverse events compared to 
monotherapy (odds ratio of 1.23 with 95% CI of 0.89 to 1.68). The results also showed 
that patients on AEDs are less likely to change treatments if the seizure occurred more 
than one year ago and this was related to fewer medical changes if patients were 
prescribed a new AED versus an older AED.  
 
Some adverse events are noted to occur more often with specific AEDs. This type of 
data too is from large-scale observational studies. Examples of these adverse events 
include; headache associated with lamotrigine; depression with levetiracetam; 
anhydrosis and metabolic acidosis associated with AEDs that block carbonic 
anhydrase like topiramate and zonisamide (Brodie et al 2011).  
 
Vigabatrin associated visual field defects were mentioned in chapter two. A review of 
observational studies by Maguire et al 2010 found significant heterogeneity in patients 
suffering visual field loss (Maguire et al 2010). Meta-regression to outline causes for 
this heterogeneity showed that dose and age were important predictors.  Higher dose 
and increased age was associated with field loss. This study illustrated that for certain 
long-term harms outcomes like visual field defects, observational studies are better 
than RCTs in detecting these harms. However, they have significant heterogeneity that 
may need to be explored further.  
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3.13 “Placebo Drift”: a phenomenon just in AED trials? 
 
The new AEDs when compared to older antiepileptic drugs (like phenytoin and 
phenobarbitone) has improved in efficacy. This is despite the phenomenon of a rising 
placebo effect in randomized controlled trials. This placebo effect is not just known in 
epilepsy but has been noted in various other conditions including gastrointestinal 
disorders, migraine, dementia, depression and Parkinson’s disease. There are several 
studies that have evaluated the placebo response in epilepsy (Schmidt et al 2013) 
(Rhimes et al 2008) (Burneo et al 2002). The most recent study by Guekht et al 
explored if there were any co-factors influencing this and if this was related to types of 
seizures and to examine if the phenomenon of placebo drift is still valid and current. 
The correlation between the placebo response rate and year of publication was linear 
with a Spearman’s correlation of 0.36 (p = 0.064) (Guekht et al 2010). 
 
Placebo drift has implications for harms, as rising placebo effect that is noted in 
efficacy outcomes is not in parallel with a placebo effect when harms outcomes are 
compared (Guekhat et al 2010).  
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3.14 Conclusion 
 
This chapter explored a number of issues pertaining to adverse events. Firstly, the 
definition of adverse events is difficult and adverse events include adverse drug 
reactions and other events that may not be directly related to the drug in question. This 
chapter also discussed adverse events and its relation to side effects and harms. The 
term side effect is a subset of the term adverse events. In this thesis, adverse events is 
defined using the WHO definition and the ICH definition. Both of these have their 
merits. The WHO definition gives us a broad view of what an adverse event is and the 
ICH definition is an operational definition for use in clinical trials.  
 
There existed a need for the harmonisation of what harms are in relation to trials. This 
therefore has led to the creation of multiple validate dictionaries like World Health 
Organisation adverse reaction terminology (WHOART) and the medical dictionary for 
regulatory activities (MEDRA). Therefore, the collection of harms data may be 
harmonised and uniform across some trials, this does not mean that trials are reporting 
this data to an appropriate end consumer. 
 
Adverse events in RCTs are common and some of these are dose related harms like 
dizziness, somnolence and fatigue amongst others. These are usually dose related and 
transient. Other adverse events are long term events like weight gain and bone mineral 
loss. Some AEDs have now been associated to specific adverse events like visual field 
loss related to vigabatrin and gum hypertrophy due to phenytoin (Pellock et al 2011). 
Transient adverse events may influence a patient’s decision to continue with treatment 
or not and this can have significant consequences on their wellbeing.  
 
A recent development is the discovery that some harms cluster together and these can 
be categorised into five major groups. The new taxonomy will allow a clumping of 
harms data collection in trial of AEDs and may produce more meaningful results. This 
could be used to replace existing dictionaries like WHOART and MEDRA. The 
advantages of a new taxonomy would be that terms which are synonymous like 
asthenia, fatigue and weakness may become obsolete. This would make clarify 
systemic reviews of harms and may allow for novel outcomes and tools for analysing 
harms in systemic reviews.  
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The study by Majkowski et al examined harms over the duration of the clinical trial 
and this found that harms commonly occur in the titration period of the study and that 
near the end of the trial these are no different to placebo. This raises questions on how 
harms data is collected in RCTs. This study provided a novel method in analysing and 
reporting harms (Majkowski et al 2005). 
 
And finally harms form part of quality of life measure tools like the AEP (Perucca et al 
2009). The use of the AEP in a recent trial has shown to increase the reporting of harm 
caused by AEDs and this has led to changes in dose or alteration of treatment 
regimens. A further study also showed that newly diagnosed patients with epilepsy if 
given AEDs do not have significant difference in side effects compared to those that 
are not treated. This is likely because they are started on low dose of AEDs (Perucca et 
al 2011). 
 
The next chapter discusses the reporting of harms in randomised controlled trial and 
the CONSORT statements for harms. 
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Chapter 4 
 
 
 
 
The CONSORT statements: Reporting of Adverse Events in 
Clinical Trials 
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4.1 Introduction 
 
Harms caused by antiepileptic drugs are caused by common and cause significant 
morbidity and mortality. The previous chapter discussed the various types of harms 
caused by antiepileptic drugs. Data on harms can be obtained from either RCTs or 
observational studies. Our focus is on harms reported in RCTs, as these are the pivotal 
units used in systemic reviews over observational studies.  
 
This section discusses evidence-based medicine and the reporting of RCTs, the 
reporting of harms in RCTs and the CONSORT statements.  
 
4.2 Evidence Based Medicine 
 
Current medical decisions are usually based on traditional teaching and 
pathophysiological understanding of the disease process. This method may still be the 
norm for some routinely made medical decisions, but clinicians may be faced with 
situations where information is from hard evidence such as clinical trials.  This 
information is guided by evidence-based medicine (EBM). 
 
Rosenberg and Donald introduced the concept of evidence-based medicine in 1995 to 
the research community (Rosenberg & Donald 1995) (Sackett et al 1996). They 
defined evidence-based medicine as a conscientious, explicit and judicious use of the 
best evidence in making decisions about the care of an individual patient. One must 
note that evidence based medicine does not entirely replace clinical experience, but 
clinical experience will raise questions and these can be refined, validated or refuted. 
EMB therefore supplements sound clinical practice. These also existed a gap between 
published research and how medicine was practised. Evidence based medicine 
therefore contributed to bridge the gap between research and applying the evidence 
into medical practice. There are gaps in the different direction of evidence and also the 
large number of trials that are published. The practice of evidence-based medicine can 
be summarised in four steps: 
 
1) Formulate a clear clinical question from the patient’s problem 
2) Search the literature for relevant clinical articles 
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3) Evaluate (critically appraise) the evidence for its validity and usefulness 
4) Implement useful findings in clinical practice 
 
It is important to emphasise that evidence-based medicine is not synonymous with 
critical appraisal as the former combines research evidence with clinical skills, 
patients’ values and preferences (Smith & Rennie 2014). The evolution of EMB has 
been such that there is more emphasis put into patients’ values and this is reflected in 
how at least one peer reviewer needs to be a member of the lay public and a greater 
demand for reviews of pragmatic trials.  
 
In this chapter evidence based medicine shall be discussed and how evidence based 
medicine (EBM) has contributed to the study of adverse events. Firstly, one is required 
to discuss the hierarchy of evidence.  
 
4.3 History of the CONSORT Group 
 
In 1993, a group of scientists spent four days in Ottawa to reassess the science of 
clinical trials methodology. The motivation for this meeting was to address and 
improve the reporting of randomised controlled trials in the medical literature. They 
developed a set of guiding principles on what constitutes a suitable trial report and 
published this in a document outlining the discussion of the meeting (Cook et al 1995). 
The guideline was developed by collaboration of the Standardized Reporting of Trials 
(SROT) group and the Asilomar Working Group on Recommendations for Reporting 
of Clinical Trials in the Biomedical Literature. They drafted a consolidated guideline 
and called it the CONSORT statement. The original draft of the CONSORT statement 
was published in 1996 in JAMA and the BMJ (Begg et al 1996) (Altman 1996). The 
letters CONSORT stand for Consolidated Statement of Reporting of Trials. 
 
The statements are available online from the CONSORT website and it is translated 
into eleven different languages (CONSORT 2010). Since their publication, the World 
Association of Medical Editors, International Committee of Medical Journal Editors 
(ICMJE) and the Council of Science Editors (Altman 2005) have endorsed these for 
instruction to authors. Subsequently there has been significant adoption of these 
statements by the medical press in general.  
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4.4 CONSORT Statements 
 
It is a widely held notion that clinical trials are not reported adequately and this means 
that inadequate reporting leads to bias (Moher et al 2001). DerSimonian et al first 
made the original motion that editors could improve reporting in randomised 
controlled trials. They analysed four key journals for RCTs published between 1979 to 
1980, the authors suggested that editors should provide a list of items that should be 
reported (DerSimonian et al 1982).  
 
Since their inception in 1993, the CONSORT statements have undergone significant 
elaboration and revision. These revisions have sought to cover many aspects of 
randomised controlled trials. Following this the group has published several guidelines 
and these have been supplemented by providing extensions to current guidelines. 
The original checklist of the CONSORT statement published in 1996 (Altman 1996) 
and was amended in May 1999. Table 1 shows the original checklist. This consisted of 
22 items and a flow diagram. The changes made included: if authors used intention to 
treat analysis and a review flow diagram of clinical trials. It was envisaged that the 
CONSORT statements would eliminate poor reporting. The approach used in 
developing the guideline was not just by consensus of authors but in an evidence based 
manner. Authors were asked to provide some evidence if items included in the 
guidelines would improve reporting in RCTs. This approach in creating the guidelines 
also helped in the creating of other guidelines.  
 
The updated guidelines of 2001 were also published with accompanying documents, 
which gave explanations and elaborations of the statements. The guidelines were 
updated in 2010 with elaboration and extension of the guidelines. These now are the 
current guidelines with nine extensions published separately. 
 
The CONSORT website was established in order to identify which journal endorse the 
CONSORT guidelines. At the time of drafting this thesis, there are 585 journals that 
endorse the CONSORT statements. It is not just medical journals that have adopted the 
CONSORT statements, but they have been adopted by the nursing literature as well. 
(Smith et al 2008).  
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Many authors have used the CONSORT checklist as a benchmarking tool to generate a 
total score to compare individual trials. This score is used to summarise in some way 
the level of adherence to the CONSORT statements. This has been done a number of 
times using the original 22 item checklist. The table below shows items in the 
CONSORT checklist (table 13, page 73).  
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Heading Subheading Descriptor 
Title  Identify the study as a randomised trial 
Abstract Use a structured format 
Introduction State prospectively defined hypothesis, clinical objectives, and planned subgroup or covariate analyses 
Methods Protocol Plan study population, together with inclusion or exclusion criteria 
Planned interventions and their timing 
Primary and secondary outcome measure(s) and the minimum important differences and indicate how the target sample was projected 
Rationale and methods for statistical analyses, detailing main comparative analyses and whether they were completed on an intention to 
treat basis 
Prospectively defined stopping rules (if warranted)  
Assignment Unit of randomisation (for example, individual, cluster geographic) 
Method used to generate the allocation schedule 
Method of allocation concealment and timing of assignment 
Method to separate the generator from the executor of assignment 
Masking 
(blinding)  
Mechanism (e.g. capsules tablets)  
Similarity of treatment characteristics (for example, appearance, taste etc) 
Allocation schedule control (location of code during trial and when broken) 
Evidence of successful blinding among participants, person doing intervention, outcome assessors and data analysis 
Participant 
flow and 
follow up 
Provide a trial profile summarising participant flow numbers and timing of randomisation assignment, interventions and measurements 
for each randomised group 
 
Analysis State estimate effect of intervention on primary and secondary outcome measures, including a point estimate and measure of precision 
(confidence intervals) 
State results in absolute measures when feasible  
Presents summary data and appropriate descriptive and inferential statistics in sufficient detail to permit alternative analyses and 
replication 
Describe prognostic variables by treatment group and any attempt to adjust for them 
Describe protocol deviations from the study as planned together with reasons  
Discussion  State interpretations of study, including sources of bias and internal validity and the discussion of external validity including 
quantitative measures when possible 
State general interpretation of the data in the light of totality of the available evidence 
Table 13 CONSORT Checklist 1996, Items that should be included in reports of randomised trials: Reproduced from Begg et al 1996. 
.
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4.5 Recent update of the CONSORT Statements 2010 
 
The original CONSORT statement for parallel trials was published in 1996. It was 
revised in 2001 and updated in 2010. The aims of the guidelines are to offer guidance 
on how trials should be reported and they also provide guidance on how trials should 
be interpreted for quality. So the statements can serve as both a guideline and as a 
benchmarking tool. The new guidelines included some substantive changes. These 
changes include; addition of three times for registration of clinical trials or protocol 
and funding. Other sub items that were inserted were reporting if trials had any 
changes to methods after trial commencement and reasons for this, reasons for why 
the trial is stopped or ended.  
 
4.6 Extensions of the CONSORT statements 
 
The CONSORT statements provide guidance on standard parallel randomised 
controlled trials. However, there are other aspects of clinical trials that needed further 
elaboration. These extensions include areas of harms and other areas. The table below 
(table 14, page 75) shows the various extensions of the CONSORT statements 
produced.  
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Area Reference Description 
Cluster trials Campbell et al 
2012 
This updated the 2004 guidelines on cluster trials with 
updating on how abstracts are to be reported.  
Non- Inferiority and 
Equivalence trials 
Piaggio et al 2012 This updates the 2006 guideline on reporting of non-
inferiority trials and equivalence trials. Specified items 
in methodology which indicated that the trials were a 
non-inferiority trial.   
Pragmatic trials Zwarenstein et al 
2008 
Older CONSORT items: background, participants, 
interventions, outcomes sample size blinding 
participant flow and generalisability of findings were 
extended   and a new 22 item checklist was made for 
pragmatic trials 
Herbal remedies Gagnier et al 2006 Original recommendations were elaborated, including 
Latin and botanical names of interventions. 
Non- Pharmacological 
treatments 
Boutron et al 2008 Non-pharmacologic therapy includes surgical, medical 
devices, technical procedures 
Conference Abstracts Hopewell et al 
2008 
Journal abstracts may be the only piece of the article 
some readers may read. Therefore, this needs to be 
improved. A minimum set of criteria to help reporting 
in abstracts.  
Patient reported 
outcomes 
Calvert et al 2013 Patients reported outcome include those outcomes 
related to the quality of life  
Harms Ioannidis 2004 Emphasis for harms in 10 recommendations 
Acupuncture  
 
MacPherson 2010 This guideline elaborated on trials of acupuncture by 
providing 6 new items and 17 sub items 
Allergen Specific 
immunology 
Bousquet et al 
2009 
Not a true extension of the CONSORT statements but 
an adaption of the 1996 statement to immunology 
trials 
Table 14 List of CONSORT extensions published to date 
 
4.7 Harms research leading to the CONSORT extension for harms  
 
The first paper to examine harms reporting was published as a letter to the Lancet in 
1998. In this letter, Ioannidis and Ioannidis reviewed harms and toxicity of treatments 
for HIV-1 infection (Ioannidis & Contopoulos-Ioannidis 1998). In their review, they 
found that 87% of trials reported the proportion of patients withdrawn due to harms 
but only 38.3% of trials gave specify harms information for this.  Definition of 
adverse events and toxicities were defined in some of the trials and only some trials 
discussed known validated toxicity scales. The authors concluded that the proportion 
of space used to list contributors of the article dwarfed the proportion of journal space 
for harms. The authors felt that similar work need to be replicated in other areas to 
highlight the deficiencies in harms reporting.  
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Consequent to the Lancet article on HIV infection, Ioannidis published a review in 
seven other areas of medicine including HIV infection in the journal JAMA 
(Ioannidis & Lau 2001). They found that similar results of poor reporting were found 
in trials of sinusitis, acute MI, arthritis, hypertension, helicobacter pylori and 
selective decontamination of the GI tract. Univariate analysis found that the odds of 
adequate reporting were higher if the trial was double blinded versus single blinded. 
Reporting was better if trials were larger and reporting improved over time. The 
authors discussed that their study highlighted deficiencies in reporting of harms and 
there needs to be an extension to the CONSORT statements to spread awareness of 
this issue.   
 
4.8 CONSORT extension for Harms 2004 
 
The original CONSORT statements contained only one item that mentions harms and 
due to this bias, an extension for harms was published (Ioannidis et al 2004). The 
paper fist defined that harms should be used instead of adverse events and a glossary 
of terminology was provided. They defined harms as:  
 
“The totality of possible adverse consequences of an intervention or therapy: 
they are the direct opposite of benefits against which they must be compared” 
 
The CONSORT guidelines discuss the common poor reporting practises that occur 
with harms related data. Some of these are discussed in the recommendations but they 
are not all explicitly mentioned in the ten recommendations. A list of the poor 
practices and an elaboration of their meaning is shown in the table below (table 15).  
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Reporting Practice Explanation 
Using vague terms such as the” the drug was well 
tolerated”  
Some trials will lack quantitative data on harms 
and may only report this qualitatively. The 
content of this however can be poor making it 
impossible to make comparisons between 
interventions 
Failing to provide separate data Important to allow comparisons between 
interventions 
Providing summed numbers for all adverse events 
for each arm 
Individual adverse events cannot be compared 
or analysed 
Providing summed numbers of specific type of 
adverse events of the severity and seriousness of 
the events 
Serious adverse events are not reported 
separately 
Reporting adverse events that occur above a 
threshold or frequency 
Only common and dose related adverse events 
are reported 
Reporting adverse events that reach a significant 
P value 
This it where trials report only significant 
outcomes  
Reporting only measures of central tendency 
without indication on extreme values 
Here only percentage of patients with harms 
without absolute values and confidence 
intervals 
Not distinguishing between patients and one 
adverse event and participants with multiple 
adverse events 
This stems for earlier errors where only the 
proportion of patients with adverse events are 
reported and not the absolute number of adverse 
events 
Table 15 Common errors in harms reporting. 
 
The statements proved ten recommendations pertaining to each section of the trial. 
They recommend that harms should be addressed, defined and analysed in each 
publication. The ten recommendations are associated with different sections of a 
publication. The first concerns the title of abstract; the second pertains to harms 
reporting in the introduction. Recommendations 3,4 and 5 are associated with the 
methods sections. Recommendation 6, 7, 8 and 9 are for the results section and 
recommendation 10 is related to the discussion section.  Extracted items from the 
CONSORT statements are displayed below (table 16). 
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Section of 
paper  
CONSORT 
Recommenda
tion 
Descriptor of CONSORT recommendations for harms Items Evaluable 
Title & 
Abstract 
1 If the study collected data on harms and benefits, the title or 
abstract should so state 
1 Adverse events mentioned in title or abstract 
Introduction 2 If the trial addresses both harms and benefits, the introduction 
should so state 
2 Information on harms mentioned in introduction 
Methods 3 List addresses adverse events with definitions for each (with 
attention, when relevant to grading expected vs. unexpected events, 
reference to standardised and validated definitions and 
descriptions of new definitions) 
3 Definition of AE mentioned 
4 If article mentioned all or selected sample of AE 
5 If article mentions treatment emergent AE (TEAE) 
6 Use of validated instrument to report AE 
7 Use of dictionaries for coding of AE  
 4 Clarify how harms related information is collected (mode of data 
collection, timing, attribution methods, intensity of ascertainment, 
and harms related monitoring and stopping rules if pertinent) 
8 Description of how harms data were collected e.g. diaries, phone 
interviews or face-to-face interviews. 
9 Description of when harms data were collected  
10 Description of how adverse events were attributed to trial drugs 
 5 Describe any plans for presenting and analysing information on 
harms (including coding, handling of recurrent events, 
specification of timing issues, handling of continuous measures and 
any statistical analysis) 
11 Description of methods for presenting and analysing harms in 
methods section. 
12 Description of approach for the handling of recurrent events 
Results 6 Describe for each arm the participant withdrawals that are due to 
harms and the experience with the allocated treatment. 
13 Description of withdrawals due to harms in each arm.   
14 Report contains data on serious adverse events and death. 
 7 Provides denominators for describing harms 16 Provide denominators for harms 
17 Provide definitions used for analysis set. 
18 If trial states same analysis set used for efficacy and safety. 
Results 8 Present the absolute risk of each adverse event (specifying type, 
grade and seriousness per arm) and present appropriate metrics 
for recurrent events, continuous variables and scale variables 
whenever pertinent. 
18 Results presented separately for each group 
19 Severity and grading of adverse events 
20 Provide both number of events and number of patient with 
events.  
 9 Describe any subgroup analysis and exploratory analysis for harms Data not collected as very few trials conduct sub-group analysis 
Discussion 10 Provide a balanced discussion of benefits and harms with emphasis 
on study limitations, generalizability and other sources of 
information on harms 
21 If prior literature is cited in the discussion in relation to adverse 
events. 
22 If the discussion is balanced with regards to efficacy and harms. 
23 If limitations of the study are discussed  
Table 16 Extracted items from CONSORT extension for harms
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4.9 Manuscript length 
 
Manuscript length is an issue also discussed by the CONSORT statements. Adequate 
harms reporting need not make the manuscript excessively long. This apparent 
contradiction is negated by the assertion that if the methods and results sections are 
standardised, then there would be no need for long manuscripts Methods suggested to 
save space also include: publishing harms data in a separate article or in a webpage. 
Authors are also encouraged to give examples or case reports of serious adverse 
events in the discussion section. 
 
4.10 Have the CONSORT statements made any difference to the reporting of 
randomised controlled trials? 
 
One study compared RCTs published pre and post CONSORT using the 1996 
statements (Moher et al 2001). The authors also compared the journals that were early 
adopters of the CONSORT statements (BMJ, JAMA and the Lancet) with a late 
adopter (NEJM). Their results show that after the CONSORT statements were 
published, there was an increase in the number of checklist items reported with a 
mean change in the number of items of 3.7 with a 95% CI of 2.1-5.3. This may seem 
like a modest increase in reporting but to the authors this was significant.  
 
A similar study evaluated 98 articles across 4 nursing journals were benchmarked 
against the statements, the authors of this study found that the mean CONSORT score 
out of 48 was 24.7 with a range of 12-35 items. They also found that the quality of 
reporting did not improve from 2000 to 2005. They found that the items that were 
best reported included items from the title abstract, background and discussion (Smith 
et al 2008). These suggest that the reporting of harms overall is heterogeneous with 
poor reporting in some studies but adequate in others. 
 
4.11 Systematic review of studies using the CONSORT statements 
 
Plint et al conducted a systemic review of the studies that used the 2001 CONSORT 
statements in several areas of medicine (Plint et al 2006). They included eight studies 
that used the CONSORT checklist as a benchmarking tool. They extracted summary 
		 80	
measures of studies comparing trials adopting CONSORT and compared them to 
trials that do not adopt CONSORT (Plint et al 2006) see figure 24 below. They also 
extracted data on trials published before and after publication of the CONSORT 
statements. They concluded that CONSORT adopting journals are more likely to 
display data on sequence generation and participant flow and that the reporting of 
trials has consequently improved after publication of the CONSORT statements. This 
study is important because it was the first to quantitatively review some of the studies 
that used the CONSORT statement in their analysis. This has not been done for those 
studies that have used the CONSORT statements for harms but this was recently 
reviewed by Hodkinson et al (2013).   
  
	
Figure 24 Analysis of CONSORT adopters compared to non-adopters: Data from five studies using 
CONSORT statements. This shows that CONSORT adopters analysed are better at reporting sequence 
generation and reporting, allocation concealments. But there was no difference with regards to 
participant flow and blinding (Plint et al 2001)  
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4.12 Endorsement of CONSORT statements by medical journals 
 
There is evidence to suggest that the CONSORT studies have helped to improve the 
quality of RCTs. Here the authors tried to look at those journals that endorsed the 
CONSORT statements. A total of 167 journals were evaluated. Only 22% of journals 
mentioned the CONSORT statements in instruction to authors, this was worse in 
specialty journals (18% CW 22%). Only 43% of journals mention the ICMJE website 
but none of these provided a link to the ICMJE website (Altman D 2005). 
 
4.13 Studies that have used the CONSORT statements as a benchmark: A 
qualitative review 
 
This section qualitatively reviews all the studies that have used either CONSORT 
statements or the CONSORT extensions for harms. The aim is to summarise the data 
so far on the use of the statements as a benchmarking tool.  
 
In the current literature, there are seventeen studies for inclusion after a search of the 
literature. Seven studies used the CONSORT 1996 guidelines. Two studies used the 
CONSORT extension for abstracts and eight studies used the CONSORT extension 
for harms. These are summarised in tables 17 to 19 for CONSORT guidelines and 
tables 20 to 22 for CONSORT guidelines on harms (pages 87 to 92).  
 
4.13.1 CONSORT 1996/2001 guidelines & extension for abstracts 
 
Nine studies evaluated the reporting of abstracts. These studies did not use the 
extension for harms but either the original CONSORT statements or an extension for 
abstracts. Studies were conducted in general medical and surgical journals but some 
were studies carried out in specialist areas ranging from paediatric trials, 
anaesthesiology trials, neurosurgical trials, and the dopamine agonist trials.  
 
Two studies used the CONSORT extension for abstracts. One study by Bernal-
Delgado & Fisher analysed 365 general medical journals and another study by Can et 
al analysed 527 abstracts form anaesthesiology journals (Bernal-Delgado & Fisher 
2008) (Can et al 2011). Seven studies used the CONSORT 1996/2001 statements. 
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Only three out of nine studies carried out analyses of reporting pre and post 
CONSORT. Only one study compared commercially funded and non-commercially 
funded trials.  
 
Each study used various items from the CONSORT statements, the use of items 
varied from study to study. The number of CONSORT checklist items used ranged 
from 11 items to 44 items.  
 
Overall reporting of CONSORT items is poor. Two studies deemed that reporting has 
not changed since publication of CONSORT (Anttilla et al 2006 & Can et al 2011) 
whereas one study showed an improvement of 17 out of 22 items since publication of 
the CONSORT statement (Kane et al 2007). 
 
Two studies compared general and specialty journals. Both of these studies found 
general medical journals were better than subspecialty journals (Mills et al 2005 and 
Kiehana et al 2011). Two studies compared CONSORT adopters versus non-
adopters. Both found that CONSORT adopting journals are better at reporting items 
than non-adopters (Deveraux et al 2002) (Kane et al 2007). 
 
4.13.2 CONSORT extension for harms 2004 
 
Eight studies used the CONSORT harms extension as a benchmarking tool (see tables 
20, 21 and 22 for references). Reporting of harms across studies and specialties. The 
percentage of trials reporting harm items ranged from 72% to 83%.   
 
Four studies reported how withdrawals due to harms were reported. Withdrawal of 
patients due to harms was reported heterogeneously. Withdrawal data ranged from 
25% of trials in one study to 70% in another. Five percent of trials reported harms in 
a supplementary webpage. 
 
A comparison of commercial and non-commercial studies was conducted in two 
studies; both of these found that commercial studies were better at reporting harms 
than non-commercial studies. Two studies compared harms reporting pre and post 
CONSORT. Both studies did not find any change in harms post CONSORT.  
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Serious adverse events were reported in 20% of trials. A method of collection of 
harms was reported in 34% of trials. A table of adverse events was reported in 33% to 
49% of trials. Twenty two percent of trials reported the severity of adverse events.  
  
Reporting of harms in each arm also varied according to study. Percentage of studies 
reporting harms in each trial arm ranged from 27% to 87%.  
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4.14 Conclusion 
 
The randomised controlled trial is the most important unit of evidence-based 
medicine. Here we discussed the development of the CONSORT statements and how 
they have been used as a quality assessment tool.  
 
Reporting practices of journals with regard to randomised controlled trials were 
thought to be poor. This occurred during the time when academic institutions like the 
Cochrane group were reviewing how RCTs are used in systematic reviews. They 
noted that authors of RCTs have poor reporting practices and the evidence of poor 
reporting practices came to light after the authors carried out reviews of common 
drug interventions. Due to these concerns were raised in both sides of the Atlantic and 
change was needed. Due to these concerns, it was deemed that that change was 
needed to improve reporting. As a first step the need for highlighting inadequate 
reporting is needed. 
 
In response to these issues, a collection of journal editors, statisticians and clinicians 
formulated the CONSORT statements whose primary aim was to inform trial authors 
on the minimum requirements expected for articles before they could be published. 
The secondary aims of the CONSORT statements were to serve as a tool to help 
readers critically appraise randomised controlled trials and to act as a quality 
assessment tool.  
 
Poor reports of published trials carry a number of implications. The most obvious is 
that a poor report suggests that either the peer review process has been compromised 
or journal editors need to review their publishing practices. This therefore has 
implications on the validity of these trials. One cannot be sure if a trial is valid if the 
report of these trials did not mention key items such as allocation sequence and 
randomisation procedures.  
 
Several studies have consistently shown that there is no change in the quality of 
reporting of trials since the publication of the CONSORT statement or its extensions. 
Journals that endorse the CONSORT statements are less likely to report RCTs poorly 
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compared to non-endorsers. This is probably due to the need for potential authors to 
format articles to conform to statements before they are accepted for publication.  
 
Extensions of the statements have addressed issues of poor reporting and of these 
harms were a key area that needed review. The CONSORT statements for harms 
were published in 2004 and several authors have used it as a benchmarking tool. 
From these we learn that reporting of harms can vary with some trials reporting about 
50% of items. Items are reported heterogeneously and this also varies by therapeutic 
area.  
 
Eight studies outlined earlier used the CONSORT statements for reporting harms as a 
benchmark tool. It is not possible to summarise them quantitatively due to marked 
heterogeneity. These studies were selective in picking outcomes form the CONSORT 
statements making summation of outcomes difficult.  Some studies like Breau et al 
found that reporting of harms in the urological literature is overall good but certain 
aspects of harms reporting of harms is poor (Breau et al 2010). Three studies 
compared commercial and non-commercial trials (Breau et al 2010) (De Vries et al 
2010) (Faggion et al 2013). Two studies compared trials before and after the 
publication of the CONSORT statements (Breau et al 2010) (Faggion et al 2013). 
None of these studies examined antiepileptic drugs and this will be the focus of 
chapter six.  
 
There are a number of questions that the extensions for the CONSORT statements 
raise. Firstly, one can argue that there are possibly too many statements now 
published. Authors may find it difficult to implement all of these. It is not possible a 
reader or author may be aware of all of these when writing his/her article. Secondly 
the statements are not adopted by journals that do not endorse these and the uptake of 
the statements should be encouraged. Journal websites should provide guidance using 
the statements on key items that would be desirable. The CONSORT statements 
should also be incorporated into the peer review process. 
 
Specialty journal are unlikely to endorse the CONSORT statements. At the time of 
writing this thesis, a number of neurology sub-specialty journals do not endorse the 
CONSORT statements. Epilepsy is a specialty area. The potential for antiepileptic 
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drugs causing harms cannot be over stated. Clearly there is a need to assess the 
reporting of harms in epilepsy.  
 
The next chapter discusses research methodology before a discussion of harms 
reporting in trials of AEDs.  
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Table 17 Studies using CONSORT guidelines. 
Study Author Benchmark  Therapeutic 
area. Journals 
N
um
ber of 
studies 
N
um
ber of 
checklist item
s 
Pre/Post 
C
O
N
SO
R
T 
C
om
m
ercial/N
on -com
m
ercial 
 
 
H
arm
s 
analysed? 
Key Conclusions 
Quality of 
Reporting of 
Randomized 
Controlled Trials in 
Cerebral palsy 
Anttilla 
et al 
2006 
CONSORT 
1996 
Pediatric 
cerebral palsy 
15 34 Yes No No • Most trials reported items relating to introduction; 
participants in each group; and tables of results 
• Poor reporting of treatment allocation and methods 
of allocation generation 
• Only 50% of trials reported harms items  
• Pre & Post CONSORT no different in reporting 
Abstracts in high 
Profile Journals 
often fail to report 
harm 
Bernal-
Delgado 
& Fisher 
2008 
CONSORT 
extension for 
abstracts 2008 
Nil, RCTs 
chosen based 
on Journal 
impact factor 
363 N/S No Yes Yes • Harms reported in 37.2% of abstracts 
• 9% of abstracts reported p-values for harms data 
• 53.5% of abstracts report harms in journal text and 
abstracts.46.5% report harms in journal text but 
not in abstracts 
• If harms outcomes are statistically significant, they 
are more likely to be reported in the abstract 
• Commercially funded abstracts more likely to 
report harms due to larger patient populations. 
Has the quality of 
abstracts for RCTs 
improved since the 
release of the 
CONSORT 
guideline for 
abstract reporting? 
A survey of 4 high-
profile anesthesia 
journals 
Can et al 
2011 
CONSORT 
extension for 
abstracts 2008  
Anesthesiology 
RCTs 
527 16 Yes No Yes • Items that improved post CONSORT in abstracts 
was blinding and adverse events (adverse events 
improved from 31.2 to 42.5% p 0.009) 
• Overall there was no change in reporting post 
CONSORT 
• Trial registrations are rarely reported 
• Quality of reporting is also predicted by the 
journal of publication 
• Word limits restrict reporting in abstracts.  
		 88	
Table 18 Studies using CONSORT guidelines. 
Study Author Benchmark  Therapeutic 
area. Journals 
N
um
ber of 
studies  
N
um
ber of 
checklist item
s 
Pre/Post 
C
O
N
SO
R
T 
C
om
m
ercial/N
on-com
m
ercial  
 
 
H
arm
s 
analysed? 
Key Conclusions 
Reporting in 
Randomized 
clinical trials 
improved after 
adoption of the 
CONSORT 
statement 
Kane et 
al 2007 
CONSORT 
1996 
Nil, Comparison 
of two journals 
one adopting 
and non-
adopting  
776 22 Yes No No • Comparison made between JAMA which is a 
CONSORT adopter and NEJM which is a non-adopter  
• Seventeen out of 22 items analysed showed a 
significant increase in adherence to the statements 
post CONSORT 
• This was better in journal that adopted CONSORT 
and therefore adoption of the statements leads to 
improved reporting 
Standards for 
reporting 
randomised 
controlled trials in 
neurosurgery 
Kiehna et 
al 2011 
CONSORT 
1996 
Five 
neurosurgical 
and three 
general medical 
journals 
27 44 No No Yes • CONSORT Score of a total of 44 was used 
• Comparison with general journals and sub-specialty 
journal showed that the general medical journal had a 
mean score of 41 and the sub-specialty journals scored 
26.4 (p <0.0001) 
• Journals which endorsed CONSORT had a higher 
impact factor 
An Analysis of 
general medical 
and specialist 
journals that 
endorse 
CONSORT found 
that reporting was 
not enforced 
consistently 
 
Mills et 
al 2005 
CONSORT 
1996 
Comparison 
between general 
and specialist 
journals 
200 11 No No No • A comparison of 5 general journals and 10 specialty 
journals 
• General journal reported more items than specialist 
journals, mean score of 7.9 vs. 6.5 p = 0.02.  
• Odds ratio comparing the two groups for each item 
showed that four items out of 11 were statistically 
more reported in general journals than in specialist 
journals and these included; flow diagram OR 6.74; 
Sample size calculations OR 2.53 and sequence 
generation OR 2.9.  
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Table 19 Studies using CONSORT guidelines 
Study Author Benchmark  Therapeutic 
area. Journals 
N
um
ber of 
studies 
N
um
ber of 
checklist item
s 
Pre/Post 
C
O
N
SO
R
T 
C
om
m
ercial/N
on -com
m
ercial 
 
 
H
arm
s 
analysed? 
Key Conclusions 
The reporting of 
methodological 
factors in 
randomized 
controlled trials 
and the association 
with a journal 
policy to promote 
adherence to the 
CONSORT 
checklist 
Devereau
x et al 
2002 
CONSORT 
1996 
Comparison of 
general 
medical journal 
that do and 
don’t endorse 
CONSORT 
105 11 No No No • Compared journals that do and do not endorse 
CONSORT on an 11 item checklist scale 
• Journals endorsing CONSORT report 6.0 items vs. 
5.1 for journals that do not (p = 0.03). 
• 60% of all trials reported methods used to generate 
allocation sequence 
• Reporting of allocation sequence was 76% in 
CONSORT endorsing journals vs. 45% in those 
that don’t (p < 0.001). 
• Details of blinding was reported better in 
CONSORT endorsing journals 46% vs. 22% (p 
=0.001)  
Quality of Reports 
on Randomized 
controlled trials 
conducted in Japan: 
Evaluation of 
Adherence to the 
CONSORT 
statement 
Uetani et 
al 2009 
CONSORT 
1996 
Evaluation of 
RCTs 
published in 
Japan 
98 29 No No No • Reporting of trials conducted in Japan is poor  
• 39% of trials reported random sequence generation 
• 17% reported allocation concealment  
• Some items were reported better in CONSORT 
adopters versus non-adopters.  
Randomsied Trials of 
Dopamine agonists in 
restless leg 
syndrome: A 
systematic Review, 
quality assessment 
and Meta-analsysis 
Zintzaraz 
et al 
2010 
CONSORT 
1996 
Dopamine 
agonists 
18 17 No No Yes • Sequence generation was reported in 61% of trials 
• Allocation concealment was reported in 38.95 of 
trials  
• Participant flow was reported in 88.9% of trials 
• Adverse events were reported in 100% of trials 
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Table 20 Studies using CONSORT extension for Harms. 
Study Author Benchmark  Therapeutic 
area. Journals 
N
um
ber of 
studies 
N
um
ber of 
checklist item
s 
Pre/Post 
C
O
N
SO
R
T 
C
om
m
ercial/N
on- com
m
ercial 
 
 
H
arm
s 
analysed? 
Key Conclusions 
Reporting of 
Harm in 
Randomised 
controlled trial 
Published in 
the Urological 
Literature 
Breau et al 
2010 
CONSORT 
extension for 
Harms 2004 
Urology 152 16 Yes Yes Yes • 72% of trial reported harms outcomes 
• No change in harms reporting pre and post 
CONSORT 
• 32% reported reason for withdrawal.22% reported 
severity of harms. 82% reported harms in title or 
abstract 
• Commercially funded trials met more harms criteria  
• 61.5% of trials mentioned harms in the discussion 
section 
Endocrinology 
trial design: 
Adverse event 
reporting in 
randomised 
controlled 
trials of 
recombinant 
human GH in 
GH deficient 
adults 
Bryant et al 
2002 
CONSORT 
addendum for 
harms 2001 
Human Growth 
Hormone trials 
17 N/S No No Yes • 29% of trial reported withdrawal due to adverse 
events 
• 59% reported results separately 
• 41% of trial reported the specific number of adverse 
events 
Adverse event 
reporting in 
Acupuncture 
clinical trials 
focusing on 
pain 
Capili et al 
2010 
CONSORT 
extension for 
Harms 2004 
Acupuncture 
trials 
10 12 No No Yes • 70% of trial reported withdrawals  
• 60% of trials mentioned adverse events overall 
• 20% reported serious adverse events 
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Table 21 Studies using CONSORT extension for Harms. 
Study Author Benchmark  Therapeutic 
area. Journals 
N
um
ber of 
studies 
N
um
ber of 
checklist item
s  
Pre/Post 
C
O
N
SO
R
T 
C
om
m
ercial/N
on- com
m
ercial 
 
 
H
arm
s 
analysed? 
Key Conclusions 
Low quality of 
reporting adverse 
drug reactions in 
paediatric 
randomsied 
controlled trials 
De Vries et 
al 2010 
CONSORT 
extension for 
Harms 2004 
Paediatric 
studies 
107 15 No Yes Yes • Created a CONSORT score of 5 points in total 
• 78% of trials mentioned adverse events 
• 25% of trials reported withdrawals due to harms  
• 65% of trials reported harms separately 
• Commercial trials scored 4.3 versus 2.7 for non-
commercial studies (p <0.05). 
• 33% of trials reported a table for harms data 
• 34% of trials reported a standard method for 
collecting harms data  
Reporting of 
harms in 
randomized 
controlled trials 
evaluating stents 
for percutaneous 
coronary 
intervention 
Ethgen et al 
2009 
CONSORT 
extension for 
Harms 2004 
Coronary Stents 132 N/S No No Yes • 83% of trials described the nature of adverse 
events 
• 36% gave a definition of adverse events 
• 87% of trials reported harms separately 
• 14% of trials mentioned a data safety monitoring 
board 
• Provided mean percentage space for harms in each 
section of the trial report 
The quality of 
Reporting 
Harms-Related 
Data in clinical 
trials of Adjuvant 
Trastuzumab in 
early-stage breast 
caner 
Mahinbakht 
et al 2013 
CONSORT 
extension for 
Harms 2004 
Adjuvant 
Trastuzumab 
5 10 No No Yes • Analysed five trials using Trastuzumab 
• Adherence to CONSORT by section of papers 
was: Title and abstract was 40%; introduction was 
60%; methods was 49%; results was 36% and 
discussion was 73% 
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Table 22 Studies using CONSORT extension for Harms. 
Study Author Benchmark  Therapeutic 
area. Journals 
N
um
ber of 
studies 
N
um
ber of 
checklist item
s 
Pre/Post 
C
O
N
SO
R
T 
C
om
m
ercial/N
on -com
m
ercial 
 
 
H
arm
s 
analysed? 
Key Conclusions 
Reporting of 
adverse events in 
randomised 
controlled trials 
in 
periodontology: 
A systematic 
review.  
Faggion et 
al 2013 
CONSORT 
extension for 
Harms 2004 
Studies in 
Periodontology 
246 10 Yes Yes Yes •  This study compared periodontal studies as a 
group of trials published between 2002-2003 
with trials published between 2011-2012.  
• No significant change pre and post CONSORT 
except for mode of harms collection, 
denominators and subgroup analysis. 
• No difference in scores between commercially 
and non-commercially funded studies.  
The Reporting of 
harms in 
randomised 
controlled trials 
of hypertension 
using the 
CONSORT 
criteria for harms 
Bagul & 
Kirkham 
2012 
CONSORT 
extension for 
Harms 2004 
Studies in 
Hypertension 
107 24 No No Yes • Mean CONSORT score out of 19 was 9.85 (95% 
CI of 8.06 to 11.6).  
• Reporting of items is heterogeneous  
• Only participant flow had reporting of > 50% 
• 49% of trial reported AE in a table 
• 29% of trials reported harms in each arm 
• 2 out of 41 studies (5%) provided harms 
information in a supplementary webpage. 
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Chapter 5 
 
 
 
 
Evaluating harms in systematic reviews of randomised controlled 
trials 
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5.1 What is a systematic review? 
 
Systematic reviews attempt to collate all the empirical evidence that fits pre-specified 
eligibility criteria in order to answer a specific research question. The methods used 
aim to reduce bias (Altman 1996). Systematic reviews: 
 
• Use a clearly stated set of objectives 
• Are explicit and reproducible in their methodology 
• Use search criteria seeks to identify all possible studies that meet eligibility 
criteria 
 
The definition of a Systematic review is: 
‘A review that has been prepared using a systematic approach to minimizing biases 
and random errors which is documented in a materials and methods section.’ 
 
Meta-analysis is the use of statistical methods to summarise the results of independent 
studies to produce a single estimate of treatment effect. Not all systematic reviews 
include a meta-analysis. Systematic reviews should not be confused with narrative 
reviews where the selection of studies is not rigorous and smaller studies are excluded 
giving a biased opinion.  
 
5.2 Why do Meta-analysis? 
 
Clinicians may need information on the effectiveness of treatments for interventions. 
This information is usually obtained from several resources. This may be obtained 
from clinical trials, guidelines, case reports and conference meetings. Clinicians may 
find the plethora of sources of evidence daunting and these vary in grades of quality 
bias and scope. The best source of evidence of interventions is randomised controlled 
trials. However, RCTs may be prone to bias. The main aim of meta-analysis is to 
produce an unbiased and accurate estimate of the effect of a given intervention.  
 
There are four key reasons to carry out a meta-analysis and these include: 
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1. To increase the power by combining trial there may be a statistically significant 
result which may be useful for clinical decision making 
2. To improve precision of the treatment effect estimation 
3. To answer questions not posed by individual studies. These can be done by 
examining subgroups from individual studies 4. To settle controversies from potentially conflicting studies	
 
5.3 History of the Cochrane Collaboration 
 
The Cochrane Collaboration is an international organization whose primary aim is to 
help people make well informed decisions about health care and preparing, 
maintaining and promoting the accessibility of systematic reviews of evidence 
(Higgins et al 2008). 
 
The concept of the Cochrane Collaboration began with Archie Cochrane. He published 
a monograph “Effectiveness and Efficacy. Random reflexion on the Health Service” in 
1972 (Cochrane 1973). This monograph was first published in book form in 1989. The 
electronic form of this forms the basis of the Pregnancy and Childbirth module of the 
Cochrane Library (Marson 2000). Subsequently this evolved into the National 
Perinatal Epidemiology Unit and after changing its remit. It evolved into the Cochrane 
Collaboration in 1992.   
 
5.4 Cochrane Review Group 
 
Systematic reviews are published in many journals. However, the Cochrane 
Collaboration is the leader in publishing quality reviews. The Cochrane Collaboration 
is consisting of groups of people from diverse medical fields that undertake and 
disseminate quality systematic reviews in its own area of interest. These groups 
collaborate with each other when needed. The number of different groups is large and 
each varies in size. These are called Collaborative Review Group; examples of these 
include the musculoskeletal disease, stroke, diabetes and epilepsy. All collaborative 
review groups have editorial teams and are answerable to a steering committee.  Over 
the past three decades, the outputs of the review groups have been exponential in the 
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production of quality reviews. See figures 25 and 26 below. The review groups also 
maintain and develop software for producing systematic reviews. The latest version 
includes RevMan 5.0.  
	
Figure 25 Growth of the number of systemic reviews produced by the Cochrane Group. Adapted from 
the ICHCA foundation webpage (2015). 	
	
Figure 26 Growth of number of RCTs and meta-analysis indexed by PubMed. Adopted from Da Costa 
& Jüni 2014 
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5.5 The Cochrane Epilepsy Group 
 
In January of 1996, a meeting was held in the Instituto de Mario Negri in Milan, to 
explore the possibility of setting up a Cochrane Epilepsy Group. Considerable 
enthusiasm was expected and following formal application the group was registered 
with the collaboration in September 1996. The editorial base for the group is in 
Liverpool UK, where staff includes a Review Group Coordinator, Assistant Review 
Group Coordinator and Coordinating Editors. The editorial base is currently funded by 
a grant from the NHS. 
 
This scope of the group has been defined as follows: 
 
‘. reviews randomized controlled trials and controlled clinical trials assessing the 
outcomes (including harms) of interventions that are designed to prevent and manage 
childhood and adulthood seizures and epilepsy.’ 
 
Much of the work focuses upon antiepileptic drugs however there are other 
interventions which are covered including the ketogenic diet, surgery, counselling, 
specialist nurses and clinics. 
 
The editorial base has two main responsibilities. The first is processing a systematic 
review undertaken by members of the group. The editorial process of the group is 
outlined in the Groups Module on the Cochrane Library. In summary, the process 
starts with the registration of title and then the development of a protocol. The protocol 
is sent for external peer review, and then published on the Cochrane library. After 
completion of the review this is then published in the Cochrane Library. Each review 
should then be updated every 12 months.  
 
At the time of writing, there are 85 published reviews and 24 published protocols 
(Cochrane Epilepsy Group 2015). 
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5.6 Systematic Review Methodology 
 
Carefully conducted systematic reviews are essential to reduce bias. These are a series 
of steps that should be followed in creating a review. If the review is a Cochrane 
review then steps one to four form part of the protocol development stage.  
 
1. Formulate and research/review question- this can be framed informally but this 
can be structured with subsections and have clear objectives. The research 
question is formulated by the PICO strategy as shown below. 
2. Create a Protocol by using PICO and defining inclusion and exclusion criteria. 
3. Define inclusion and exclusion criteria. 
4. Identify studies and select studies. 
5. Assess the study quality. 
6. Extract the data from included studies. 
7. Analyse and present the results. 
 
5.7 PICO 
 
The PICO strategy is a useful way of conceptualizing the research question. The 
acronym PICO stands for: 
 
P- patient or problem 
I- intervention of indications 
C- Comparator 
O- Outcome  
 
This helps formulate separate parts of the question and refines it into a complete 
question. 
 
5.8 What is a Systematic Review Protocol? 
Given that a systematic review is a retrospective research study, a need to eliminate 
bias dictates that a protocol be created a priori. A protocol therefore reduces bias in the 
review. Protocols for a Cochrane review undergoes a peer-review process before the 
analysis occurs. The aim of this twofold: firstly, to help reduce bias and secondly as 
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part of the peer review process. Therefore, it is not surprising that Cochrane reviews 
when compared to industry-sponsored reviews are less biased in terms of results and in 
terms of methodological reporting (Jorgensen et al 2006). 
 
Items included in a protocol are author’s details and affiliation of the authors. 
Protocols will also include the methods used for selection of studies, selection of 
participants included in the studies and details of the interventions. Authors also 
include the background of the intervention and background of the clinical problem that 
is being studied. Protocol registration also stops duplication of systematic reviews.  
PROSPERO is an international database of prospectively registered systematic reviews 
in health and social care. The aim of this is to create a permanent record of protocol to 
prevent duplication. Registration of protocol also reduces bias by displaying any 
deviation from the protocol and the final published review. PROSPERO is based in 
York UK (University of York Centre for Reviews and Dissemination 2015).  
 
5.9 Searches for studies 
 
A valid systematic review would need to be backed up by a rigorous and unbiased 
search of studies. For this to occur the researcher has to be clear on the research 
question being asked, as this will affect the data needed for the summary estimate.  
Any loss of studies will introduce bias in a review.  
 
The search for studies and decisions for inclusion and exclusion of studies involves 
electronic or hand searches. Given the availability of Internet and other technologies, 
the is use of hand searches have diminished, however single electronic searches are not 
enough as more trials can be included by other methods (Smith et al 1992). 
 
Electronic searches are made via Medline and the Cochrane library. Here clinical trials 
are appropriately tagged as clinical trials, or randomised controlled trials. Searches in 
Medline will provide options for displaying only controlled trials. These tagged terms 
were only introduced in 1991. Therefore, trials before 1991 may not have been 
appropriately tagged.  
 
Current tags include: 
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Clinical trial 
Clinical trial phase 1 
Clinical trial phase 2 
Clinical trial phase 3 
Clinical trial phase 4  
Randomised clinical trial 
 
Other search methods include searching for conference proceedings and contacting 
experts in the field. To further minimize bias two authors should search for trials 
independently for inclusion or exclusion.  
 
5.10 Data extraction: How to choose outcomes from studies 
 
Data extraction depends on the type of data and outcome. Majority of data in clinical 
trials is either continuous or binary. For the purposes of this thesis, I will restrict the 
discussion to binary variables. When outcomes are binary variables then treatment 
effect measures would include relative risks, odds ratios or risk differences. Examples 
of binary data are when there are two possible outcomes for a given patient. Outcomes 
would include if a particular event occurred or not or if there is clinical improvement 
or not.  
 
5.11 Random Effects versus Fixed Effects Models 
 
Models by their very nature are mathematical constructs with a series of assumptions 
to solve a given problem.  When comparing effect sizes from randomised controlled 
trials there are two models used for meta-analysis, the fixed effects and the random 
effects model. The models were created to take account of heterogeneity in the 
analysis. In particular, it takes into account the different sizes of the studies in the 
model. Borenstein et al (2010) illustrates the two models as thus: 
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Figure 27 Fixed Effects model. Here all the studies share a common effect size represented by  
(Borenstein et al 2010). 
 
In the Fixed effects model, all the studies are derived from the same population 
therefore they share the same common summary measure (fig 27). This effect is 
‘fixed’ across studies. Here the effect size from each study estimate is a single 
common mean designated by µ. 
 
In the random effects model each study has its own mean and the population 
distribution has its own variance (fig 28). Thus, the effect size has two components of 
variation and this is due to sampling error and due to variance in the underlying 
distribution. The mean is denoted by θ. 
	
Figure 28 Random Effects Model. Here all studies dont have a common effect size because the 
studies are derived from different populations and therefore the common effect size is not one measure 
but a range of measures represented by the values between the mean value  (Borenstein et al 2010). 
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A fixed effects model gives a more precise estimate of the summary effect whereas the 
random effects model provides a less precise result. Both models may give different 
estimates on the same set of studies and this is because of weighting. 
 
5.11.1 How do weights affect the model? 
 
Meta-analysis produces an average treatment effect pooled across multiple studies. 
Small studies may estimate treatment effects less precise than larger trials and this 
varying precision needs to be taken into account in the meta-analysis calculation. This 
can be achieved by weighting studies according to their precision, allocating greater 
weight to those studies that provide more precise estimates. The exact calculation of 
weight will depend on the meta-analysis method. For example, the inverse variance 
method assumes that the weight of the study is equal to the inverse of the variance.  
The pooling of the individual estimates has to undergo a weighting process where the 
weighted average is defined as the sum of estimates multiplied by the weights and is 
divided by the sums of the weights. !"#$ℎ&"'	)*"+,$" = 	 ./0	12	(".&#0,&"	 × 	5"#$ℎ&)./0	12	5"#$ℎ&.  
 Therefore, statistical weight used in meta-analysis takes into account the statistical 
precision of each trial and gives more weight to larger trials in the fixed effects model.  
In addition, we can make two different assumptions about the variability of treatment 
effects between studies. Firstly, a fixed effect model assumes that there is only one 
common treatment effect, which is estimated by each of the trials in the analysis. Any 
observed variation between the treatment effects is assumed to be due to sampling 
variation. This assumption can be examined using a test of heterogeneity. The 
alternative random effects model assumes that studies are estimating different 
underlying treatment effects that vary about a common effect. This therefore allows for 
heterogeneity between studies. 
 
5.11.2 Which model should be used? 
 
The choice between the random and the fixed effect models is based on how the effect 
sizes may vary between studies meta-analysed. This will of course depend on clinical 
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factors like types of patients across studies and on trial factors like how the allocation 
was carried out. 
 
The two models therefore depend on different assumptions about the nature of 
variation among effect sizes. The fixed effect model should be used when studies are 
close replicates of one another and are using the same procedures and measures. The 
random effects model should be used when we anticipate variation in studies for a 
number of reasons.  
 
5.12 Odds ratio versus Risk ratio 
 
Dichotomous outcomes could be shown by arranging them into a 2X2 table this is able 
to calculate the odds ratio. The Mantel-Henszel is a method where by the odds ratios or 
relative risks can be pooled together. This method can be used for a fixed effects 
model. A 2x2 square is shown below: 
 
 Outcome present Outcome absent Total 
Risk Factor present a b A+B 
Risk Factor absent c d C+D 
 A+C B+D N 
  
 
Risk ratio 77 = ,/(, + :);/(; + ') 
Odds ratio <7	 = ,/:;/' = ,':;  
There are two possible ways where binary outcome in systematic reviews are 
presented. The first is an odds ratio. An odds is defined as the number of patients who 
fulfil the criteria for a given endpoint divided by the number who do not. Risk is 
calculated as the number of patients meeting a endpoint divided by the total number of 
patients. Therefore, the odds ratio is the odds of the outcome in the intervention group 
compared to the control group. 
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Other ways of summarizing the relative effect for binary outcomes are Relative risks 
(also called risk ratios), risk difference and number needed to treat.  
 
Risk ratio is the risk of an event in the experimental group divided by the risk in the 
control group. Odds ratio is the odds of an event in the experimental groups divided by 
the odds in the control group. If both ratios give a value of 1, then this means that there 
is no difference between the odds or risk of the event on experimental and control 
groups. The table below shows the various methods used for continuous and binary 
outcomes.  
 
Type of Data Summary Statistic Method (F: fixed effect, R: 
Random effects) 
Dichotomous 
 
Odds ratio 
 
 
 
Risk ratio 
 
 
Risk difference 
Mantel-Haenszel (F) 
Peto (F) 
DerSimonian and Laird (R) 
 
Mantel-Haenszel (F) 
DerSimonian and Laird (R) 
 
Mantel-Haenszel (F) 
DerSimonian and Laird (R) 
 
Continuous  
 
 
 
Weighted mean difference 
 
 
Standardized mean difference 
Inverse Variance (F) 
DerSimonian and Laird (R) 
 
Inverse Variance (F) 
DerSimonian and Laird (R) 
 
Time to event  Odds/Hazard ratio Peto (F) 
 
Table 23 Summary of Meta-analysis methods available in RevMan 5.0 
5.13 Displaying meta-analysis: Forest Plots 
 
The results of a meta-analysis can be displayed as a forest plot.  Here each treatment 
effect from a given trial can be displayed like branches of a tree. The horizontal lines 
represent the 95% confidence interval with the box showing the odds or risk ratio. The 
size of the box is proportional to the weight of the study in the meta-analysis. The 
diamond represents the pooled summary estimate and the width of the diamond 
corresponds to the confidence interval of the summary estimate or the overall effect. 
The vertical line represents unity of relative risk or odds ratio and if the horizontal line 
or domain touches the vertical line, it indicated that the confidence interval incudes 
unity.  
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The figure below (fig 29) shows forest plots of meta-analysis of intravenous 
magnesium with placebo on mortality in patients with acute myocardial infraction. 
Both fixed effects and random effects models are shown. The fixed effect model is 
dominated by the largest trial and the overall relative risk is 1.01 suggesting that there 
are no beneficial effects from magnesium on mortality. On the other hand, in the 
random effects model where individual trial weights are reduced the results show that 
intravenous magnesium has a beneficial effect on mortality. This has therefore 
changed the notion that magnesium is not beneficial (Da Costa & Jüni 2014).  
 
	
Figure 29 Mortality in patients treated with intravenous magnesium using random or fixed effects model 
(Da Costa & Jüni 2014). 
 
5.14 Heterogeneity in systematic reviews 
 
Meta-analysis combines to create a summary estimate. When trials are combined in 
this way it is possible that there may be heterogeneity between studies. Heterogeneity 
can be described as clinical, methodological, statistical or play of chance. A useful way 
of looking at heterogeneity is shown in the figure below (fig 30 page 106). Clinical 
heterogeneity is due to differences in patient characteristics or treatment regimens. 
Methodological heterogeneity is due to variations in study design or duration of 
follow-up. Statistical heterogeneity is true treatments effects across studies and finally 
the play of chance is due to uncontrollable factors.  
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Figure 30 Spectrum of Heterogeneity. 
 
Heterogeneity also depends on the number of studies evaluated, if a large number of 
studies are included, then heterogeneity may increase significantly. So large reviews 
with many studies might show a large variance in effect sizes and therefore show 
significant heterogeneity On the other hand a smaller review may show insignificant 
heterogeneity.   
 
Recommendations for assessing, reporting and exploring heterogeneity was made by 
Pettiti in her paper in 2001 (Petitti DB 2001): the steps she described include: 
1. Do a test of statistical heterogeneity 
2. Report the results of the test statistic even if only qualitatively 
3. State the p value used to reject the null hypothesis of homogeneity 
4. State the rationale for using a fixed or random effects model based on 
consideration of the question addressed or alternatively do an analysis based on 
both random and fixed effects models and use this information for sensitivity 
5. Where there is significant statistical heterogeneity then formally explore 
possible reasons for this 
 
There are two ways of assessing heterogeneity in meta-analysis the first is the Q 
statistic and the next is the I2 index. William Cochran developed the Q tests in 1950 
(Cochran 1950). The Q test is calculated by summing the squared deviation of each 
study estimate from the overall effect estimate, weighting the contribution of each 
study by its inverse variance. A low p-value of the Q test means significant 
heterogeneous results among different studies. Usually a p-value at 0.10 is used as the 
cut-off.  However, the Q test is not good to detect heterogeneity if there are few 
studies. 
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Another method used to quantify the degree of heterogeneity is the tau square statistic 
(τ2). This measures the between study variance. If this > 1.0, this suggests significant 
statistical heterogeneity. A summary of how the tau squared and I2 statistic are related 
is shown in figure 31. 
 
	
Figure 31 Interpretation of statistical Heterogeneity. Adapted from Da Costa & Jüni 2014 
 
Formally, a statistical test of heterogeneity is found included in forest plots of 
Cochrane reviews. Higgins notes that statistical heterogeneity is inevitable in clinical 
trials due to methodological differences between trials and that clinical heterogeneity 
is due to the variation of true effects between studies (Higgins & Thompson 2002).  
 
One method of quantifying heterogeneity is given by the I2 statistic. It is calculated as: =>	 = 	?@ − (B − 1)@ D × 	100% 
 
Where Q is the chi-squared statistic and   k is the number of studies. Therefore (K-1) is 
also known as degrees of freedom. The I2 is expressed as a percentage.  The I2 can 
range from 0 to 100%. To interpret the I2 the original thresholds were changed and new 
threshold was published in the Cochrane handbook. They are shown below: 
• 0% to 40%: might not be important 
• 30% to 60% might represent moderate heterogeneity 
• 50% to 60% may represent substantial heterogeneity  
• 75% to 100%: represents considerable heterogeneity  
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An I2 of 40% means that 40% of the observed variance is due to real heterogeneity and 
60% of the variance is due to chance. 
 
Q squared is a chi-squared statistic that is interpreted with the number of degrees of 
freedom. If the value of Q equals the number of degrees of freedom then the null 
hypothesis is true.  
 
I2 is a measure of inconsistencies in the effect sizes and reflects variances in effect 
sizes whereas Q squared is dependent on the precision of the trials An I2 of 40% 
indicated that 40% of the observed variation is due to real heterogeneity and 60% is 
due to chance. 
 
5.14.1 Clinical Heterogeneity 
 
This is described as differences between trials that exist due to characteristics of the 
studies such as trial design, characteristics of study subjects such as age of patients, 
severity of illness and dose of interventions and duration of treatment. Clinical 
heterogeneity may therefore explain some of the statistical heterogeneity. 
 
5.14.2 Investigating heterogeneity: Subgroup analysis 
 
One method of investigating heterogeneity is by using subgroup analysis. Using this 
method, the analysis is conducted for a subset of patients or a subset of studies. using 
this method, we can observe if the Effect sizes change in degree or direction. If the 
effect changes in direction from beneficial in one subgroup to harmful in another, then 
this is called a qualitative interaction. If the effect changes in magnitude between 
subgroups and not direction then this is a qualitative interaction (Yusuf 1991). Another 
method to explore heterogeneity is to use meta-regression.  
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5.14.3 Meta-regression and dealing with heterogeneity 
 
Meta-regression is like simple regression where the outcome variable is predicted 
according to the values of one or more explanatory variables. Meta-regression was first 
used by Berkey et al to investigate the effect of latitude on the effectiveness of the 
BCG vaccine for tuberculosis (Berkley et al 1995). The initial use of meta-regression 
was to explore heterogeneity but recent use of meta-regression is to explore the effects 
of covariates and provide a clearer interpretation of the effects of covariates to the 
study outcome.  
 
A minimum of ten studies is needed to carry out a meta-regression. If the studies 
selected for meta-regression have patients obtained for the sample population then the 
fixed effects model should be used as it is expected that there is a common treatment 
effect. If the populations are heterogeneous then a random effects model is used. 
Under the fixed effect model, a common effect size is calculated and under the random 
effects model, a mean of the effect sizes is calculated. In addition, under the fixed 
effects model, larger studies have a greater effect on the effect size but in the random 
effects model the relative weights are the same.   
 
In simplistic terms, a regression equation is a modification of the equation: 
 G = ,: + H 
 
Where G is the outcome, H is the intercept and ,	is the exploratory variable.  
The regression equation is elaborated into:  
 G = 		IJ +	IKLK 	+	I>L> + ⋯+	IN	LN + 	O  
 
Where G is the dependent variable, IJ is the regression intercept, H is the exploratory 
variable and this is used to predict the dependent variable G. I is the regression coefficient and IJ is the intercept and O is the residual.  
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The outcome variable G is the effect estimate and is usually computed into a log risk or 
log odds ratio. The explanatory variable is some other variable or characteristics of the 
study that might influence the effect size. Explanatory variables can be continuous or 
categorical. If they are continuous then a regression equation can be calculated. If the 
exploratory variables are categorical then the regression line/lines is the mean of the 
log of effect sizes. Then if the intercept is not zero then this could be a residual or IJ. 
Both the intercept and residuals can be calculated using relevant software.  
 
5.14.4 Meta-regression software 
 
Consider figure 32 on page 111. The top panel illustrates all the possible data from a 
number of studies that could be plotted on a regression line. To do this, we can plot the 
dependent variable on the y-axis and the covariates on the x-axis and then plot a 
regression line. New software (CMA version 3.0) can plot the covariates as either 
continuous variables or categorical variables. The figure illustrates that data spilt into 
hot or cold as categorical variables in the bottom left panel or as a continuous variable 
as shown in the bottom right panel.  
 
In the first case, the regression line is the mean of the effect sizes for each of the 
groups. The mean of each group is the intercept also. The variance of the data in each 
category can also be obtained. The variance of each of the categories can be compared 
to the variance of all the data and this will give us an estimate of how much of the 
variance can be explained by the model and how much of the variance is due to 
random error. These can be expressed as a ratio to quantify how much of the variance 
is explained by the model when covariates are plotted on a regression line.  
 
One can calculate the p-value of how much of the model explains the data, the p-value 
of the goodness of fit of the variables on the regression line and we can calculate the 
intercept. This method of meta-regression shall be used in the final chapter.  
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Figure 32 Data before and after meta-regression. The figure on the left is where data is plotted using 
categorical covariates and on the right, is using continuous covariates. Note that in both models the 
variance of data decreases when data is plotted against a regression line (Bornstein et. Al 2010)	
 
5.15 Improving the quality of reporting of Meta-analysis: QUOROM statement  
 
As stated earlier, the results of the meta-analysis can be flawed for a number of varied 
reasons. A discordant meta-analysis in a review occurs when the methodology of 
reviews is poor, producing summary estimates that are clinically misleading. Le-Lorier 
et al evaluated the issue of discordant meta-analyses. They compared and contrasted 
summary measures from a sample of RCTs and their corresponding systematic review 
in the Cochrane database. They found that in 33% of cases the meta-analysis have led 
to the adoption of ineffective treatments and in 32% of cases the meta-analyses has 
found an ineffective treatment to be effective (Le Lorier et al 1997).  
Given the importance clinicians place on systematic reviews and meta-analysis, the 
need to assess the quality of systematic reviews became important. The QUOROM 
statement was established to address this issue. The QUOROM statement is an 18-
point checklist. Similar to the CONSORT checklist, the QUOROM statement seeks to 
improve the reporting and production of reviews (Moher et al 1999).  
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5.16 Bias in clinical trials 
 
Trials with inadequate allocation concealment or lack of blinding may exaggerate the 
estimates of intervention effects. However, this is not shown in all studies and may 
vary based on the design of the study. Flaws in the conduct of randomized controlled 
trials such as allocation concealment and lack of blinding may introduce bias to the 
results, which may lead to exaggerated results of estimates of effects of interventions 
(Wood et al 2008).  
 
One method to reduce the risk of bias is to use tools and methods suggested by the 
Cochrane Collaboration. They identify six domains of clinical trial conduct and they 
include: 
1) Sequence generation 
2) Allocation concealment  
3) Blinding of participants 
4) Incomplete outcome data 
5) Selective reporting 
6) Other factors 
 
Higgins at al describe several sources of bias in clinical trials A list of items were 
described in his seminal paper, a summary of which is shown in the table 24 on page 
113  (Higgins et al 2008)(Higgins et al 2011).  
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Bias Domain Source of bias Support for Judgment 
Selection bias Random sequence generation Describe the method for 
allocation sequence in sufficient 
detail to allow whether should 
produce comparable groups 
 
Selection bias- Allocation concealment As above 
Performance bias Blinding of participants and 
personnel 
Describe all measures used to 
blind trial participants and 
researches from interventions a 
participant received 
Detection bias Blinding of outcome assessment Describe all measures used if 
any to blind outcome 
assessment  
Attrition bias Incomplete outcome data for 
each outcome 
Describe completeness of 
outcome data for each main 
outcome including attrition and 
exclusion s from analysis 
Reporting bias Selective reporting State how selective outcome 
reporting was examine and what 
was found 
Other bias 
 
Any other Bias State any other important 
sources of bias not described 
earlier 
Table 24 Cochrane collaboration tool on assessing the risk of bias from Higgins et al 2011. 
 
Authors are then asked to make summary assessments of the risk of bias for each 
individual item or outcome and this is categorized into low risk unclear risk of bias or 
high risk of bias. The risk of bias is then shown in a figure, an example of which is 
shown below (fig 33).  
 
	
Figure 33 Example of risk of bias tool used in systematic reviews 
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Another similar form of outcome reporting bias is called the “tower of babel bias” here 
only those trials which are in English are included in systematic reviews and therefore 
any potential negative study will not affect the outcome (Grégoire et al 1995). It has 
been estimated that English only meta-analyses may overestimate the treatment effect 
by 2% (Moher et al 1998). 
 
5.16.1 Outcome reporting bias: the ORBIT tool 
 
Published studies are more likely to contain results that are statistically significant than 
unpublished studies. In addition, many studies have outcomes that are analysed but are 
not reported. It is estimated that between 42 -60% of trials changed, introduced or 
omitted at least one primary outcome (Dwan et al 2008). Outcome reporting bias can 
affect systematic review when some studies that are not statically significant are not 
published at all or if they are published then not all measures outcomes are reported. 
This incomplete reporting leads to reporting bias. This bias may affect systematic 
reviews as if only those outcomes that are significant are reported the effects of that 
outcome may be additive when meta-analysed and if other outcome were used, it 
might have had an impact of the outcome. Outcome reporting bias is not only 
restricted to RCTs but is also seen in systematic reviews. There is evidence that some 
meta-analyses that are not statistically significant are not published (Moher et al 1999).  
Systematic reviews by their very nature will amplify effect sizes. This happens 
because if non-significant studies are not reported or analyses will not distort a 
summary measure whose confidence interval is increasingly getting smaller. Estimates 
of how much outcome reporting bias may affect estimates has been determined to 
overestimate outcomes by 12% (McAuley et al 2000). Measures developed to reduce 
outcome-reporting bias include mandatory registration of trials in 
www.clinicaltrials.gov with publication of all planned outcomes in protocol before 
publication of the clinical trial results.  
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5.17 Other limitations to Cochrane systematic reviews 
 
Mark Wilson the CEO of the Cochrane collaboration discusses the limitation of the 
Cochrane systematic review process (Wilson 2014). Some of these include: 
1. Reviews are not focused on key issues of the day, they are focused on the 
reviewer and not the end user.  
2. Are inflexible 
3. The emphasis on randomised trials only limits other sources of evidence like 
observational studies and therefore the Cochrane group need to develop other 
tools for these 
4. Cochrane centre gives the impression of an exclusive club 
5. Limited awareness outside academic circles 
 
In its strategy document, the Cochrane Collaboration aims to produce other forms of 
evidence apart from the current systematic reviews. They however have not explicitly 
divulged what this might be. The strategy also aims to explore new mobile 
technologies like iPads and iPhones and therefore create “softer” versions of its 
database for mobile and use by non-academics. (2014, Cochrane Strategy to 2020).  
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5.18 Conclusion 
 
Systematic reviews are structured documents with a protocol stage followed by an 
initial peer-review of the protocol. This is followed by a formulation of the documents 
and a second peer-review stage before publication. In this way, any potential bias in 
selection of studies and biases in data extraction is reduced. Other means of reducing 
bias is blinding when data is extracted from clinical trials. Trials are meticulously 
analysed to reveal any biases in methodology and these are displayed in a standard 
format approved by the Cochrane Collaboration. Software provided by the Cochrane 
collaboration allows for the publication of quality reviews with the option of including 
meta-analysis software, which is free of charge.  
 
This chapter focused on the statistics behind meta-analysis. Concepts and 
methodologies described here will be used in chapters to come. The aims and 
objectives of the remaining chapters are: 
 
• To evaluate CONSORT adherence on reporting harms in RCTs of AEDs 
• To explore the impact of reporting standards on the conductance of systematic 
reviews of AEDs 
• To explore the utility of using lacosamide trials for different indications in 
enhancing the accuracy of information about harms 
• To explore utility of using meta-regression techniques of other AED trials for 
different indications on informing about harms 
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Chapter 6 
 
 
 
 
Reporting of harms in randomised controlled trial of antiepileptic 
drugs 
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6.1 INTRODUCTION  
 
The primary outcomes of RCTs are measures of benefits and secondary outcomes 
include a mixture of benefits and/or harms outcomes. Harms outcomes usually 
included common adverse events as RCTs only can report events that occur for the 
duration of the clinical trial. RCTs therefore may not be the best method to assess 
harms outcomes of interventions and these are better reported in observational studies. 
These studies have a longer duration in comparison to RCTs but they lack a placebo 
arm therefore making a judgment of relative risks impossible. Therefore, RCTs are 
able to compare harms between interventions and placebo, which allows informed 
decision making regarding risks and benefits.  
 
Informed treatment decisions are important for chronic interventions for conditions 
such as epilepsy as the treatment may be taken for many years. Adverse events of 
antiepileptic drugs can have lifelong effects with a significant impact on quality of life 
and patients and doctors need to have an informed discussion about the potential risks 
and benefits of AEDs. Patients also are more informed of the likelihood of a drug 
having long-term effects and commonly ask about adverse events.  
 
There is a growing consensus that reporting of adverse events in randomised controlled 
trials is not adequate (Breau et al 2010) (Bagul &Kirkham 2012) (Faggion et al 2013). 
This issue has been discussed in several forums by clinicians and trial methodologists 
alike. To address this issue, the CONSORT group outlined a guideline and a checklist 
of minimum standard of adverse event reporting in RCTs.  Several studies have used 
the CONSORT checklist as a benchmark to report on the quality of adverse events 
reporting; however there have been no studies to establish this in trials of AEDs. In 
this section, I will discuss the reporting of adverse events in randomised controlled 
trials of antiepileptic drugs.   
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6.2 AIMS  
 
The aims of the chapter are to:   
• Report the quality of reporting of adverse events in RCTs using the extension 
of CONSORT statements pertaining to harms.  
• Secondary aims are  
a. To compare the quality of trials  
i. Funded by industry vs. not funded by industry  
ii. Trials recruiting adults vs. those recruiting children  
iii. Trials published before and after the publication of the amended 
CONSORT guidelines of 2004  
iv. Trials published in epilepsy and non-epilepsy journals  
v. Trials published in speciality and non-specialty journals 
vi. Other outcomes stated in the CONSORT statements for harms 
 
 
6.3 METHODS  	
6.3.1 Eligibility and identification of studies 
 
This review analysed randomised controlled trials of anti-epileptic drugs for this 
review. A brief outline of the process is shown below. The first task involved outlining 
the inclusion and exclusion criteria. Once this was defined, one reviewer carried out 
searches for the remainder of the trials. However, to ensure reproducibility of searches, 
a comparison between two researchers was made; if there was good agreement 
between researchers, all trials were searched by one reviewer.   
 
Data extraction from clinical trials had to be reproducible and this was assessed by 
inter-rater agreement statistics. To ensure the quality of the data extraction process, 
two reviewers carried out inter-rater comparison. Following this, one reviewer 
extracted data from the remainder of the trials.   
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The CONSORT statement had to be analysed to create an operational checklist. This is 
needed to include all possible items that could be audited. Next the data from clinical 
trials were extracted for further analysis.  
 
The analysis stage involved a number of processes, which included comparison of 
mean scores across all trials, analysis of mean scores amongst subgroups of trials and 
lastly analysis of individual CONSORT items in the trial population.  
 
 
 
6.3.2 Inclusion and exclusion criteria  
 
To be included trials would need to have been published between January 1999 and 
December 2008 inclusive. This interval period was used because the CONSORT 
criteria were published in 2004 and comparisons could be made of trials published 
before and after this date. Trials published before 1999 were not selected because they 
are less likely to be subjected to regulatory scrutiny therefore harms reporting may be 
poorer in this era. Furthermore, these trials would pertain to first generation AEDs 
where harms data is likely to be very poorly reported. At the time of writing of this 
thesis additional trials were published but these trials published beyond 2008 were not 
the scope of this thesis.  
 
Data	analsyis	and	results
Data	extraction	from	selected	trialsInter-rater	relaiablity Extraction	and	storage	of	data
Selection	of	randomised	controlled	trials	of	AEDsInclusioand	and	exclusion	criteria	 Searches	for	RCTs	
Review	of	CONSORT	statements	for	reporting	of	harmsInclusion	and	exclusion	of	items	from	CONSORT	statemetns Extraction	of	items	from	CONSORT	statements	for	inclusion	and	creation	of	a	Performa
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A list of inclusion and exclusion criteria is shown below and search protocol is shown 
in the table below and appendices. 
 
Inclusion Criteria 
• Randomised controlled trials- trials where allocation of interventions was 
randomly assigned to patients.  
• Studies published between January 1999 and December 2008 inclusive 
• Randomised trials comparing an AED or another AED or placebo 
• Patients suffering from epilepsy 
• Adults ≥ 18 years old or children <18 years old with epilepsy 
• English language 
• Commercially funded and non-funded trials 
• Outcomes included any seizure related or harms outcome  
 
Exclusion Criteria 
• RCTs assessing surgical interventions and/or vagus nerve stimulation 
• RCTs of AEDs with neuropsychological outcomes as the primary outcome 
measure. 
• RCTs of AEDs where the primary outcome was a pharmacodynamics or 
pharmacokinetic measure. 
• Observational studies 
• Non-human trials 
• Non-English studies 
 
6.3.3 Search Methods 
 
Key words in searches used were: “epilepsy”, “antiepileptic drugs” and “randomized 
controlled trials.” Limitation functions in search engines automatically excluded trials 
that were observational studies due to in-built tagging of abstracts. Searches’ were 
limited to trials published between 1999 and 2008. This made search results easier to 
manage as a large number of trials could be excluded without the need to read 
abstracts. A search strategy is shown in the appendix G page 317. 
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 6.3.4 Resources used  
 
Searches for trials were made using the following databases:  
1. MEDLINE via the PubMed interface,  
2. OVID via its home page  
3. The Cochrane Registry of Clinical Trials via its online databases of journals. 
 
All studies collected were cross-referenced with the Cochrane library, any duplicates 
found, were removed.   
 
6.3.5 Selection of studies 
 
To ensure reproducibility of searches, two reviewers searched for RCTs published 
between January 2003 and December 2003, if the results of searched were comparable 
then one reviewers searched for the remaining trials. Any disagreements regarding 
inclusion were resolved after discussion following selection of all trials in the data set.  
Abstracts were scrutinised for each trial and in some cases the full text of the trial was 
read. 
 
EpiInfo software was used in epidemiology studies to create an electronic Proforma. 
This software is available for free download from the CDC website. A paper version of 
items of data is shown in the appendix. I page 353. EpiInfo was used to collect data 
from clinical trials and this was exported into an excel file. Raw data was stored in an 
Excel file. Data was inputted into SPSS databases for further analysis.  
 
6.3.6 Data extraction and management  
 
The CONSORT extension for harms outlines ten recommendations for reporting of 
harms in clinical trials. These pertain to parts of any given trial report for example the 
title, abstract, introduction and so on. Each CONSORT recommendation therefore 
would contain many items. All possible items from each of the ten recommendations 
were extracted by faculty staff and by means of consensus; we included and excluded 
some items. Therefore, not all items were included. Items for inclusion depended on 
myself and faculty members or appropriateness for this study (table 25). 
		 123	
Of the ten recommendations, only nine were selected. CONSORT recommendation 
nine was excluded and not audited Each recommendation has several items and these 
were extracted from the statements and shown in the table below.  
 
Using the checklist, we screened each RCT for adherence. Two reviewers did this for 
fourteen trials and Cohen’s Kappa statistic was calculated to quantify inter-rater 
agreement. If inter-rate agreement was deemed acceptable between two reviewers, 
then one reviewer carried out extraction for the remainder of the trials. To simplify the 
calculation of κ, we used SPSS version 21 to calculate Cohen’s Kappa. We selected 
fourteen trials for comparison; therefore 322 items in total were compared between 
two readers. An explanation of Cohen’s Kappa is included in the appendix B page 334. 
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Section of 
paper  
CONSORT 
Recommendation 
Descriptor of CONSORT recommendations for harms Items Evaluable 
Title & 
Abstract 
1 If the study collected data on harms and benefits, the title or abstract 
should so state 
1 Adverse events mentioned in title or abstract 
Introduction 2 If the trial addresses both harms and benefits, the introduction should 
so state 
2 Information on harms mentioned in introduction 
Methods 3 List addresses adverse events with definitions for each (with 
attention, when relevant to grading expected vs. unexpected events, 
reference to standardised and validated definitions and descriptions 
of new definitions) 
3 Definition of AE mentioned 
4 If article mentioned all or selected sample of AE 
5 If article mentions treatment emergent AE (TEAE) 
6 Use of validated instrument to report AE 
7 Use of dictionaries for coding of AE  
 4 Clarify how harms related information is collected (mode of data 
collection, timing, attribution methods, intensity of ascertainment, 
and harms related monitoring and stopping rules if pertinent) 
8 Description of how harms data were collected e.g. diaries, 
phone interviews or face-to-face interviews. 
9 Description of when harms data were collected  
10 Description of how adverse events were attributed to trial 
drugs 
 5 Describe any plans for presenting and analysing information on 
harms (including coding, handling of recurrent events, specification 
of timing issues, handling of continuous measures and any statistical 
analysis) 
11 Description of methods for presenting and analysing harms in 
methods section. 
12 Description of approach for the handling of recurrent events 
Results 6 Describe for each arm the participant withdrawals that are due to 
harms and the experience with the allocated treatment. 
13 Description of withdrawals due to harms in each arm.   
14 Report contains data on serious adverse events and death. 
 7 Provides denominators for describing harms 16 Provide denominators for harms 
17 Provide definitions used for analysis set. 
18 If trial states same analysis set used for efficacy and safety. 
 8 Present the absolute risk of each adverse event (specifying type, 
grade and seriousness per arm) and present appropriate metrics for 
recurrent events, continuous variables and scale variables whenever 
pertinent. 
18 Results presented separately for each group 
19 Severity and grading of adverse events 
20 Provide both number of events and number of patient with 
events.  
 9 Describe any subgroup analysis and exploratory analysis for harms Data not collected as very few trials conduct sub-group analysis 
Discussion 10 Provide a balanced discussion of benefits and harms with emphasis 
on study limitations, generalizability and other sources of 
information on harms 
21 If prior literature is cited in the discussion in relation to 
adverse events. 
22 If the discussion is balanced with regards to efficacy and 
harms. 
23 If limitations of the study are discussed  
Table 25 CONSORT recommendations for harms and description of items used- Modified from Ioannidis et al 2004
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6.3.7 Assessment of risk of bias in included studies 
 
Each RCT was analysed by one reviewer and the CONSORT score was calculated for 
each trial. Using the checklist, fourteen studies were analysed and Cohen’s Kappa 
statistical analyses were used to levels of agreement and therefore the risk of selection 
bias. Selection bias was deemed to be low based on the results of the Kappa statistic. 
Analysing each trial twice on different occasions further reduced errors in data 
collection.  
 
Unfortunately, the reviewer was not blinded when extracting data from the trials and 
this may introduce bias.  
 
6.3.8 Outcome Measures 
 
Two types of data were collected from studies. The first type includes items of data 
pertaining to the CONSORT score and its calculation. This included a yes and no 
answers to the 23 items included in the checklist of questions for each trial. It is from 
this primary data, I conducted the main analysis.  
 
The second type of data from trial reports was supportive data used to further analyse 
the CONSORT score. Supportive data could be either categorical or numeric. These 
items included characteristics of individual trials and details of harms reporting in the 
methods, results and discussion sections. Details of this data are given in section 6.3.12. 
Data collected was inputted into EpiInfo, which severed as an electronic data collection 
tool, and output of raw data was in the form of Microsoft Access and Microsoft Excel 
files.   
 
The CONSORT score was calculated from the yes and no answers to 23 items.. Mean 
CONSORT score was calculated for each trial and for each subgroup within each trial. 
Subgroups were;  
1. Commercially funded vs. Non-commercially funded trials,  
2. Trials in adults vs. trials in children versus trial with both adults and children; 
3. Studies published before and after the CONSORT statements were published, 
4. Trials published in subspecialty journal and general journals.  
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6.3.9 Other items of data collected 
 
Other items of data were collected as part of the analysis. These items would provide 
additional data on the reporting of harms. A list of these items is shown in appendix C 
page 336. 
 
6.3.10 Planned data and statistical analyses  
 
Summary data included the relative risks of trials meeting individual items relating to 
the CONSORT score and percentage of trials meeting individual items. SPSS and 
RevMan 5 software were used. Continuous variables were described using arithmetic 
mean and medians. Frequency distribution of primary and secondary data was displayed 
using appropriate charts and tables.  
 
Comparisons of CONSORT mean scores of trials published with commercial and non-
commercial trials. Pre and post CONSORT studies, trials in adults and children and 
trials with adults and children. Comparisons were made between trials published in 
epilepsy and non-epilepsy journal. Additional comparisons were made between trials 
published in specialty journals and non-speciality journals.  
 
Other analyses performed included; comparison of CONSORT scores between add-on 
and mono-therapy trials, between multi-centre and single centre studies and between 
trials that did or did not report a dictionary for harms. I also carried out comparisons 
between trial using types of seizures, scope of study and number of authors as 
covariates.  
 
Assuming CONSORT scores followed a normal distribution, unpaired t-test was used to 
compare means of CONSORT scores between subgroups. Analysis of variance 
(ANOVA) to compare more than two groups. Equation of the t-test is shown in 
appendix D page 338. 
 
Student t-test was used to compare the CONSORT scores between subgroups 
mentioned earlier; therefore, these are independent groups of data.  
 
		 127	
Pearson’s correlation (r) and Scatter plots to illustrate the relationship between 
continuous variables. Pearson’s correlation statistics is explained in appendix E page 
339. 
 
Comparisons were made between proportions of items met between subgroups. These 
proportions were expressed as a percentage of the whole sample size. However, 
percentages and proportions do not provide confidence intervals where we can assess 
statistical significance. Thus, one had to convert parentages into relative risks (Morris 
and Gardner 1988).  
 
Relative risks were chosen over odds ratios as they are not affected by the size of the 
denominator and they are comparatively easier to understand. Furthermore, relative 
risks are earlier to transform to logarithmically if needed for future analysis.  
 
Relative risks were quoted with the 95% confidence intervals. When calculating relative 
risks of individual items, we were not constrained in choosing a fixed or random effects 
models as summary measures were not to be summated.  
 
6.4 RESULTS 
 
6.4.1 Selection of Clinical trials  
 
Two reviewers searched for trials published in 2007. Two hundred and fifty-seven 
epilepsy trials were available in that year. Two reviewers assessed for eligibility. One 
reviewer selected 13 articles and the other reviewer selected the same 13 articles plus 
one additional article. This was excluded by mutual agreement and one reviewer carried 
out the remainder of the searches. Therefore, one reviewer could carry out the selection 
of trials for inclusion.  
 
6.4.2. Results of searches  
 
One hundred and fifty-two trials published between 1999 and 2008 inclusive were 
selected for analysis. Searches resulted in 2052 citations out of which 1400 were not 
randomised controlled trials. 76 trials were not in English; 138 trials of other drugs like 
		 128	
galantamine and antidepressant medications were excluded. Excluded also were 146 
non-drug interventions and 140 trials with a neuropsychological outcome. The selection 
of studies in shown in the figure below (fig 34).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.3 Inter-rater agreement for data extraction 
 
Two reviewers extracted data from trials published in 2007. Overall there was good 
agreement with the reviewers. The reviewers disagreed in the interpretation of 
CONSORT recommendation three for reporting of all or selected samples of AEs. After 
further discussion, all 13 trials were re-assessed by both reviewers and results compared 
again.  
The value of the kappa statistic was 0.78 (95% CI of 0.64 – 0.92) indicating good 
agreement. The remainder of the trials were analysed by one reviewer. Table 26 shows 
the results for inter-rater agreement.  
 
 
 
 
140 Neuropsychological outcomes 
2052 citations 
652 citations 
576 citations 
292 citations 
1400 Not RCTs 
76 Not English 
Non-AED studies  
138 Other drugs 
146 Non-Drug interventions 
 
 
152 AED Trials 
Included 
 
Figure 34 Disposition of clinical trials: Reporting of Harms. 
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Reviewer B x Reviewer A      Cross tabulation 
 Reviewer A Total 
Yes No 
Reviewe
r 
Yes Count 231 6 237 
Expected Count 184.7 52.3 237.0 
No Count 20 65 85 
Expected Count 66.3 18.7 85.0 
Total Count 251 71 322 
Expected Count 251.0 71.0 322.0 
Symmetric Measures 
 Value Asymp. Std. 
Errora 
Approx. Tb Approx. 
Sig. 
Measure of Agreement Kappa 0.781 .041 14.106 .000 
N of Valid Cases 322    
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 
Table 26 Results of inter-rater agreement 
 
6.4.4 Characteristics of studies 
 
One hundred and fifty-two studies were included in this review. Details of included 
studies are shown in the appendix A page 317. They randomised a total of 30,650 
patients with a median number of 135 patients. 
 
The results demonstrate that on a yearly basis approximately 10 to 21 trials in epilepsy 
were published. There was no pattern on the number of trial published per year (fig 35 
page 130).  
 
Of the 152 trials, 94 (61%) were commercially funded and 58 (39%) were non-
commercially funded (table 27 page 131). Eighty-six trials (57%) were published before 
the CONSORT recommendations and 66 (43%) were published after. Eighty-seven 
trials (57%) were add-on therapy studies and 65 (43%) were mono-therapy studies. 
Seventy-six were placebo-controlled studies and 76 were not placebo controlled. One 
hundred and twenty-six trials were multicentre and 26 were single centred. The median 
duration of trials was 26 weeks the minimum duration was 2 weeks and the maximum 
was 294 weeks.  
 
Forty nine percent of trials were published in epilepsy journals and 51% in non-epilepsy 
journals. Fifty eight percent of trials were published in speciality journals and 42% in 
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non-specialty journals. Thirty-eight articles were published in the journal Neurology 
and 37 were published in the journal Epilepsia. Seventeen articles were published in the 
journal Seizure and eleven were published in Epilepsy Research (fig 36 page 131) .  
 
Thirty-five trials reported the dictionary used for harms data, one hundred and 
seventeen trials did not mention the use of a dictionary.  
 
Some trials quoted the threshold above which adverse events were reported. Forty-six 
percent of trials mentioned harms thresholds whereas 54% did not report this. Of the 
trials that reported a threshold, 41 out of 70 trials reported adverse events above a 
threshold of >10% and 29 out of 70 trials reported adverse events above a threshold of 
>5%.  
 
Figure 35 Number of RCTs by year of publication 	
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Figure 36 Frequency of trials by journal name: Epilepsy journals are in red and non-epilepsy journals in 
green 
 
Characteristics of studies 
  Number of trials (%). Total 
=152 
Demographics  Adults 
Children 
Both adults and children 
79 (52) 
35 (23) 
38 (25) 
Blinding Double blinded trials 
Single blinded trials 
Open label trials 
120 (79) 
4 (3)  
28 (18) 
Epilepsy type in 
population 
Focal epilepsy 
Generalised epilepsy 
Both focal and generalised epilepsy 
102 (67) 
8 (5) 
42 (28) 
Funding Commercially funded 
Non-commercially funded 
94 (62) 
58 (38) 
Centre Multi-centre 
Single-centre 
126 (83) 
26 (17) 
Comparator Placebo controlled 
Actively controlled 
75 (49) 
77 (51) 
Active Intervention Add-on AED 
Mono therapy 
87 (57) 
65 (43) 
Journal type Epilepsy Journal 
Non-epilepsy Journal 
75 (49) 
77 (51) 
Journal type Specialty Journal 
Non-Specialty journal 
88 (58) 
64 (42) 
Dictionary reported Yes 
No/not reported 
35 (23) 
117 (77) 
Harms above a certain 
threshold  
Yes 
No/Not stated 
 
70 (46%) 
82 (54%)  
(41 trials >10%; 29 trials >5%) 
Table 27 Characteristics of studies included in analysis 
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6.4.5 Characteristics of patients  
 
Seventy-nine trials recruited adults, 35 recruited children and 38 recruited adults and 
children. Seventy-five trials were published in epilepsy journals and 77 in non-epilepsy 
journals. The median number of patients randomised was 135 and the mean number of 
patients randomised was 201 patients (fig 37 page 133).  
 
Patients were heterogeneous in the type of epilepsy. Eight trials included patients with 
generalised epilepsy and 102 trials with focal epilepsy. Forty-two trials had unclassified 
seizures and were called both focal and generalised.  
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Figure 37 Distribution of number of patients recruited in RCTs of epilepsy 	
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6.4.6 Description of active intervention/interventions 
 
In some of the studies, the active intervention/s or were compared against placebo. 
Some studies were actively controlled against another AED. Two trials included in the 
analysis were the SANAD studies, arm A and B.  The largest group of trial were trials 
of topiramate, levetiracetam and lamotrigine (table 28).  
 
Active Intervention Frequency 
Topiramate 21 
Levetiracetam 19 
Lamotrigine 19 
Valproate 12 
Vigabatrin 11 
Oxcarbazepine 11 
Gabapentin 10 
Pregabalin 6 
Racemaide 6 
Tiagabine 5 
Midazolam 3 
Table 28 Description of active intervention group 	
6.4.7 Percentage of published document relating to harms data 
 
Using word counts, the total number of words in the results section of the article text 
and the total number of words used for harms data was calculated. The amount of words 
was calculated as a percentage. The minimum percent was 0% and the maximum was 
70%. The mean percentage was 27% (95% CI of 24.19 to 28.6) (fig 38 page 135). 
Seven trials did not have any section of the paper for harms results reporting. There is 
no clear guidance on what constitute the minimum space for reporting of harms data.   
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Figure 38 Percentage of the results devoted to harms reporting 
 
	
Figure 39 Number of adverse events reported per publication 
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6.4.8 Number of adverse events reported 
 
Each trial report would cite a table or a list of adverse events. Most trials would report a 
number of adverse events above a certain threshold of patients reporting these events. 
Commonly this would be either >5 to 10% of all adverse events obtained from patients. 
The range of adverse events ranged from 0 to 28. Figure 39 (page 135) shows the 
frequency distribution of adverse events against number of trial reports. The median 
number of discrete adverse events reported was nine. 
 
6.4.9 Number of authors per publication 
 
Total number of authors per publication was counted. If the list of authors included a 
study group, then this was not counted as a single author. Only individuals were 
counted. If no specific person was mentioned, then the number of authors was counted 
as missing data. The median number of authors per trial was six.  
 
6.4.10 Distribution of CONSORT scores across all the studies 
 
Twenty-three items from the CONSORT statements were used to create a composite 
score. The minimum score was 0 and the maximum was 22 (fig 40 page 137). No trial 
met all 23 items. The mean score was 11.3. A distribution of scores is shown in the 
graph below. The range of CONSORT scores is from 0 to 22. The median score was 12. 
The mode is 14. The mean CONSORT score plus one standard deviation gave a score 
of 16.  
 
A Q-Q plot shows that the distribution of scores is normally distributed without a 
positive or negative skew (fig 41 page 137). The Shapiro–Wilk test of normality 
showed a normal distribution rejecting the hypothesis that the distribution is not 
normally distributed, p value of 0.154. Therefore, this data set would be amenable to 
further statistical analysis using parametric test such as independent t-test comparing the 
means of CONSORT scores. 
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Figure 40 Distribution of CONSORT scores 
 
	
Figure 41 Q-Q plot for normality 
 
The result of CONSORT scores compered between subgroups is shown in table 29 
(page 138) and the corresponding error bar plots shown in figure 42 and figure 43 on 
page 139 to 140. 
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 Number 
of trials 
Mean 
CONSORT 
score 
Range of items Difference 
of Means 
95% confidence 
intervals for 
difference of means 
P-value 
Commercially funded 
trials 
Non-Commercially 
funded trials 
94 
 
 
58 
12.6 
 
 
9.4 
1-21 
 
 
0-17 
3.2 1.8 to 4.5 < 0.001 
Pre-CONSORT trials 
 
Post CONSORT trials 
86 
 
66 
11.6 
 
11.1 
0-19 
 
3-21 
0.5 -0.9 to 1.8 0.529 
Adults 
Children 
79 
35 
12.5 
9.3 
3-21 
3-16 
3.2 1.6 to 4.7 <0.001 
Epilepsy Journals 
 
Non- Epilepsy Journals 
75 
 
77 
11.4 
 
11.4 
 0 NA NA 
Non- Specialty Journal 
 
 
Specialty journal  
64 
 
 
88 
11.5 
 
 
11.3 
3-19 
 
 
0-22 
0.2 -1.2 to 1.7 0.756 
Journals endorsing 
CONSORT 
 
Journals not endorsing 
CONSORT 
97 
 
 
 
55 
11.1 
 
 
 
11.9 
3-19 
 
 
 
0-22 
-0.8 -0.6 to 2.2 0.279 
Table 29 Mean CONSORT Score and comparison of subgroups
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Figure 42 Error bar plots of comparisons of CONSORT scores. Commercial vs. non-commercial; Pre-
CONSORT vs. post CONSORT; adult and paediatric studies 
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Figure 43 Error bar plots of comparison of CONSORT scores. Journal type; Journal Specialty and journal 
that do or do not endorse CONSORT 
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6.4.11 Commercially and non-commercially funded trials 
 
Commercially funded trials reported more items than non-commercially funded trials 
(mean CONSORT score of 12.6 and 9.4 respectively) with a difference in means of 3.2 
(95% confidence interval of 1.8-4.5) this difference was statically significant, p < 0.001 
See table 29 on page 138 and fig 42 on page 139.  
 
6.4.11.1 Percentage of trials meeting individual items (Commercially and non-
commercially funded trials) 
 
For each item, the proportion of trials meeting individual items varied considerably.  
This ranged from 87.5% for mentioning harms data in title or abstract to 7.2% for 
handling of recurrent adverse events. Harms in title and abstract were reported best, 
followed by denominators for adverse events. Other items that were reported well were 
harms in introduction, timing of adverse events early or late withdrawals, serious 
adverse events or deaths.  
 
These percentages indicate that meeting of individual items not only is heterogeneous 
within trials but also between trials there are some items of harms reporting are reported 
better than others (table 30 page 142). 
 
Harms in introduction and abstracts were described well with percentages of 87.5 and 
74.3%. Harms reporting in the methods section corresponding to items 3 to 12 
comparably were lower. In this section, the percentages ranged from 15% to 76.3%. 
Harms reporting in the results section corresponding to items 13 to 20 were also better 
reported with percentages ranging from 19.1% to 78.3%. Harms reporting in discussion 
section-items 21, 22 and 23 was also reported well with percentages ranging from 
40.8% to 67.8%. 
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CONSORT item Item Percentage of total 
number of trials 
meeting item % 
CONSORT item Item Percentage of total number of trials meeting item % 
Harms in title or abstract 1 87.5 Early or late 
withdrawals 
13 71.0 
Harms in introduction 2 74.3 Serious AEs or death 14 72.3 
Definition of AE 3 36.2 Provide denominators 
for AEs 
15 78.3 
All or selected sample 4 31.2 Provide definitions 
used for analysis set 
16 40.1 
Treatment emergent AE 5 46.7 Same analysis set 
used for efficacy and 
safety 
17 34.9 
Validated instrument 6 15.8 Results presented 
separately 
18 68.4 
Validated dictionary 7 21.7 Severity and grading 
of AEs 
19 47.3 
Mode of AE collection 8 56.6 Provide both number 
of AEs and number of 
patients with AEs 
20 19.1 
Timing of AE 9 76.3 Discusses prior AE 
data 
21 67.8 
Details of Attribution 10 33.3 Discussion is 
balanced 
22 61.2 
Details of presentation and analysis 11 35.5 Discussion of 
limitations 
23 40.8 
Handling of recurrent AE 12 7.2    
Table 30 Percentage of Trials meeting individual CONSORT checklist items	
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6.4.11.2 Relative risks of meeting individual items (Commercially and non-
commercially funded trials). 
 
Eleven items were reported more in commercially funded studies than non–
commercially funded studies. Details are shown in the table below (table 31 page 144). 
These eleven items were statistically significant. Relative risks that were significant 
ranged from 1.01 to 3.46.  
Items that were reported better in commercially funded trial were: 
1. The definition of adverse events 
2. All or a selected sample of adverse events 
3. Treatment emergent adverse events 
4. Use of the validated dictionary 
5. Details of attribution 
6. Serious adverse events or death 
7. Providing definitions used for analysis set 
8. Providing details if the same analysis set used for efficacy or safety 
9. Results presented separately 
10. The severity and grading of adverse events reported 
11. Discussions are balanced 
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CONSORT Item Item  Clinical trial section Relative risk of commercially vs. non-commercially funded trials (95% C.I.) 
Harms in title or abstract 1 Introduction 1.09 (0.96-1.25) 
Harms in introduction 2 Introduction 0.93 (0.77-1.12) 
Definition of AE 3 Methods 3.15 (1.67-5.95) 
All or selected sample 4 Methods 2.34 (1.27-4.34) 
Treatment emergent AE 5 Methods 1.69 (1.12-2.55) 
Validated instrument 6 Methods 1.23 (0.56-2.70) 
Validated dictionary 7 Methods 3.46 (1.41-8.44) 
Mode of AE collection 8 Methods 1.09 (0.82-1.21) 
Timing of AE 9 Methods 1.01 (0.84-1.21) 
Details of Attribution 10 Methods 1.85 (1.08-3.16) 
Details of presentation and analysis 11 Methods 1.05 (0.67-1.64) 
Handling of recurrent AE 12 Methods 2.78 (0.62-12.40) 
Early or late withdrawals 13 Results 1.09 (0.88-1.36) 
Serious AEs or death 14 Results 1.27 (1.01-1.59) 
Provide denominators for AEs 15 Results 1.17 (0.97-1.42) 
Provide definitions used for analysis set 16 Results 2.07 (1.26-3.41) 
Same analysis set used for efficacy and safety 17 Results 2.04 (1.09-3.81) 
Results presented separately 18 Results 1.45 (1.12-1.89) 
Severity and grading of AEs 19 Results 1.50 (1.02- 2.21) 
Provide both number of AEs and number of patients with AEs 20 Results 1.62 (0.77- 3.41) 
Discusses prior AE data 21 Discussion 1.25 (0.98-1.60) 
Discussion is balanced 22 Discussion 1.51 (1.11-2.05) 
Discussion of limitations 23 Discussion 1.20 (0.80-1.82) 
Table 31 Relative risk of Meeting individual items, commercial and non-commercial studies: Significant items are in bold.
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6.4.12 Pre-CONSORT and Post-CONSORT studies 
 
Pre and post-CONSORT scores were compared and I found no statistical difference in 
the mean scores between groups. The Mean score was 11.6 in the Pre-CONSORT 
groups and 11.1 in the post-CONSORT group. The difference of means was 0.5 and this 
was found to be not statistically different (CI of the difference in means was -0.9 to 1.8) 
(table 29 and fig 42 page 138-9).  
 
6.4.12.1 Sensitivity analysis: Pre-CONSORT and Post-CONSORT 
 
As trial may take time to adopt the CONSORT statements, we carried out a second 
analysis where post-CONSORT we defined as trials published after December 2006. 
This analysis showed no significant differences between pre-and post CONSORT 
scores. There were 124 pre-CONSORT studies and 28 post-CONSORT studies. The 
mean score pre-CONSORT was 11.6 and the post CONSORT score was 12.4. The 
difference of means was 1.2 with a 95% CI for difference of means of -3.0 to 0.5. 
Therefore, this difference was not statistically significant.   
 
6.4.12.2 Relative risks of meeting individual items (Pre-CONSORT and Post-
CONOSRT trials). 
 
When comparing the relative risks of pre and post CONSORT studies, only one out of 
23 items was statistically significant with a validated dictionary reported better in pre 
CONSORT studies (RR 0.35 CI 0.16- 0.76). The other items the relative risk estimates 
was greater than one in some and less than one in some items but these included unity 
in the 95% confidence intervals therefore the difference in relative risks was not 
statistically significant (table 32 page 146). 
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CONSORT Item Item  Clinical trial section Relative risk of Pre-CONSORT vs. Post CONSORT studies (95% C.I.) 
Harms in title or abstract 1 Introduction 1.01 (0.89-1.13) 
Harms in introduction 2 Introduction 1.11 (0.92-1.34) 
Definition of AE 3 Methods 0.63 (0.69-1.76) 
All or selected sample 4 Methods 1.10 (0.69-1.76) 
Treatment emergent AE 5 Methods 1.34 (0.96-1.88) 
Validated instrument 6 Methods 1.10 (0.53-2.30) 
Validated dictionary 7 Methods 0.35 (0.16-0.76) 
Mode of AE collection 8 Methods 0.94 (0.71-1.25) 
Timing of AE 9 Methods 0.95 (0.79-1.14) 
Details of Attribution 10 Methods 1.30 (0.84-2.02) 
Details of presentation and analysis 11 Methods 0.83 (0.53-1.29) 
Handling of recurrent AE 12 Methods 0.29 (0.06-1.30) 
Early or late withdrawals 13 Results 1.80 (0.64-1.30) 
Serious AEs or death 14 Results 1.11 (0.97-1.28) 
Provide denominators for AEs 15 Results 0.96 (0.80-1.59) 
Provide definitions used for analysis set 16 Results 0.90 (0.61-1.35) 
Same analysis set used for efficacy and safety 17 Results 0.94 (0.56-1.57) 
Results presented separately 18 Results 0.99 (0.80-1.24) 
Severity and grading of AEs 19 Results 0.83 (0.59- 1.18) 
Provide both number of AEs and number of patients with AEs 20 Results 1.22 (0.63- 2.34) 
Discusses prior AE data 21 Discussion 1.14 (0.92-1.41) 
Discussion is balanced 22 Discussion 1.07 (0.83-1.38) 
Discussion of limitations 23 Discussion 0.94 (0.64-1.39) 
Table 32 Relative risk of meeting individual items pre and post CONSORT: Significant items are in bold 
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6.4.13 Adults versus Children 
 
Seventy-nine trials recruiting adults and 35 trials recruiting children were found. Thirty-
eight trials recruited both adults’ and children and these trials were excluded from the 
analysis. Mean CONSORT score of trials recruiting adults was 12.5 and the mean score 
of trials recurring children was 9.3 (table 29 and fig 42). The difference in means was 
3.2 with a 95% confidence interval of 1.6 to 4.7. This result was statistically significant 
at a p value of <0.001.  
 
When comparing which items were reported better in adult trials, we found that four 
items were reported better in adult trials: Definition of adverse events; details of 
presentation and analysis; early and late withdrawals and results presented separately. 
The relative risks for these items did not include unity in the confidence intervals (table 
33 page 148).  
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CONSORT Item Item  Clinical trial section Relative risk of Adults trials vs. trials of children (95% C.I.) 
Harms in title or abstract 1 Introduction 1.09 (0.91-1.31) 
Harms in introduction 2 Introduction 1.13 (0.88-1.45) 
Definition of AE 3 Methods 2.32 (1.07-5.02) 
All or selected sample 4 Methods 1.44 (0.73-2.84) 
Treatment emergent AE 5 Methods 1.33 (0.79-2.21) 
Validated instrument 6 Methods 1.39 (0.49-3.49) 
Validated dictionary 7 Methods 1.67 (0.68-4.08) 
Mode of AE collection 8 Methods 1.32 (0.88-1.96) 
Timing of AE 9 Methods 1.18 (0.90-1.53) 
Details of Attribution 10 Methods 1.27 (0.70-2.30) 
Details of presentation and analysis 11 Methods 2.05 (1.01-4.15) 
Handling of recurrent AE 12 Methods 1.59 (0.36-7.12) 
Early or late withdrawals 13 Results 1.66 (1.16-2.37) 
Serious AEs or death 14 Results 0.99 (0.79-1.25) 
Provide denominators for AEs 15 Results 1.23 (0.95-1.59) 
Provide definitions used for analysis set 16 Results 1.77 (0.96-3.25) 
Same analysis set used for efficacy and safety 17 Results 1.53 (0.74-3.19) 
Results presented separately 18 Results 1.80 (1.21-2.69) 
Severity and grading of AEs 19 Results 0.88 (0.60-1.31) 
Provide both number of AEs and number of patients with AEs 20 Results 2.09 (0.77-5.65) 
Discusses prior AE data 21 Discussion 0.91 (0.70-1.18) 
Discussion is balanced 22 Discussion 1.13 (0.82-1.57) 
Discussion of limitations 23 Discussion 1.10 (0.67-1.81) 
Table 33 Relative risk of meeting individual items, adults vs. children: Significant items are in bold
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6.4.14 Epilepsy Journals versus non- Epilepsy Journals 
 
One might expect that trials reported in subspecialty journals would be better than 
general journals such as JAMA or Neurology. Overall trials published in epilepsy 
journal scored 11.4 and trials published in non-epilepsy journals scores 11.4 with a 
difference of means of zero (table 29 fig 43). Therefore, there were no overall 
differences. When individual items were compared, no item showed a significant 
difference because the confidence interval included unity, see table 34 page 150. 
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CONSORT Item Item  Clinical trial section Relative risk of Epilepsy vs. Non-Epilepsy Journals (95% C.I.) 
Harms in title or abstract 1 Introduction 1.04 (0.94-1.16) 
Harms in introduction 2 Introduction 1.04 (0.87-1.26) 
Definition of AE 3 Methods 1.15 (0.70-1.78) 
All or selected sample 4 Methods 1.12 (0.80-1.57) 
Treatment emergent AE 5 Methods 1.12 (0.80-1.57) 
Validated instrument 6 Methods 1.21 (0.58-2.54) 
Validated dictionary 7 Methods 1.23 (0.67-2.26) 
Mode of AE collection 8 Methods 0.98 (0.74-1.29) 
Timing of AE 9 Methods 0.99 (0.83-1.18) 
Details of Attribution 10 Methods 0.88 (0.57-1.37) 
Details of presentation and analysis 11 Methods 0.71 (0.45-1.10) 
Handling of recurrent AE 12 Methods 1.23 (0.39-3.87) 
Early or late withdrawals 13 Results 0.79 (0.64-0.97) 
Serious AEs or death 14 Results 0.99 (0.81-1.21) 
Provide denominators for AEs 15 Results 1.01 (0.85-1.19) 
Provide definitions used for analysis set 16 Results 0.99 (0.67-1.47) 
Same analysis set used for efficacy and safety 17 Results 0.98 (0.59-1.63) 
Results presented separately 18 Results 1.11 (0.89-1.38) 
Severity and grading of AEs 19 Results 0.73 (0.52-1.03) 
Provide both number of AEs and number of patients with AEs 20 Results 0.63 (0.32-1.24) 
Discusses prior AE data 21 Discussion 1.23 (0.39-3.87) 
Discussion is balanced 22 Discussion 0.79 (0.64-0.97) 
Discussion of limitations 23 Discussion 0.99 (0.81-1.21) 
Table 34 Relative Risk of meeting individual item, epilepsy vs. non-epilepsy journals: significant items are shown in bold. 
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6.4.15 Specialty and Non-Specialty Journals 
 
Comparisons of trials published in specialty and non-specialty journals were made. I 
found that in terms of reporting, there was no overall difference in CONSORT scores. 
We expected the specialty journal to score lower than non-specialty journal due to the 
fact that specialty journals are less likely to endorse the CONSORT statements.  
Specialty journals scored 11.3, compared to specialty journals, which scored 11.5. The 
difference in means was -0.2 with a 95% CI of -1.2 to 1.7 (table 29 fig 43).  
 
As stated earlier the 67% of the trials were published in four leading journals. These 
include in order of frequency: Neurology followed by Epilepsia, Seizure and Epilepsy 
Research. Only Neurology has endorsed the CONSORT statements. 
 
Comparisons were made between journals that do and do not endorse CONSORT. 
RCTs in journals endorsing CONSORT scored 11.1 versus 11.9 in journal that do not 
endorse CONSORT. Therefore, the difference in means was not significant between 
these two groups. 
 
6.4.16 Which items matter in the subgroups? 
 
Items that were reported well and reached statistical significance are shown in table 35 
page 152. Thirteen items were reported well in commercially funded trials versus non-
commercial funded trials. Only validated dictionary was reported well in pre-
CONSORT studies. Four items were reported well in adult trials and one item was 
reported well in Epilepsy journals.    
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 Commercial vs. non-
commercial 
Post CONSORT vs. Pre 
CONSORT 
Adults vs. children Epilepsy Vs. Non-epilepsy 
journals 
Items reported well and 
reached statistical 
significance 
Definitions of AE 
All or selected sample 
Treatment emergent AE 
Validated Dictionary 
Details of attribution 
Serious AE or death 
Provide definitions used for 
analysis set 
Same analysis set used for 
efficacy and safety 
Results presented separately 
Severity and grading of AE  
Discussion is balanced 
Validated dictionary  Definition of AE 
Details of presentation and 
analysis 
Early of late withdrawals 
Results presented separately 
 
Early or late withdrawals  
 
Direction of effect Items favours Commercially 
funded studies 
Item favoured Pre-CONSORT 
studies 
Items favoured trials recruiting 
adults 
Favoured non-epilepsy journal 
Table 35 Items that were statistically significant between groups 
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6.4.17 Other Comparisons made 
 
Covariates Number of 
trials per 
group 
Mean CONSORT 
Scores  
Difference in 
means 
P value (t test 
or ANOVA) 
Add-on vs.  
Mono-therapy 
87 
65 
11.8 
10.8 
1 0.18 
Multi-centre 
Single centre 
126 
26 
11.8 
9.4 
2.4 0.007 
Dictionary 
mentioned 
Yes 
No/not stated 
 
 
117 
35 
 
 
13.9 
10.7 
3.2 <0.001 
Epilepsy type 
Focal 
Generalized 
Focal and 
Generalized 
Other 
 
89 
 
40 
15 
8 
 
12.2 
11.6 
10.4 
9.2 
10 
 
3 
2.4 
1.2 
0 
0.8 
0.032 
Scope of trial 
Efficacy and 
Safety 
Efficacy only 
Safety only 
Not stated 
 
126 
 
13 
10 
3 
 
14.3 
10.8 
10.7 
8.5 
9 
 
5.8 
2.3 
2.2 
0 
0.5 
<0.001 
Table 36 Other comparisons made 
 
A comparison of add-on vs. Mono-therapy trials did not reveal any difference in means 
of scores. Trials that were multicentre scores better than single-centre studies. Trial 
with focal epilepsy scored higher that trials with other epilepsies and trials where the 
outcome was efficacy and safety scored better than trials with safety only (table 36). 
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6.4.18 CONSORT score and interventions 
 
When CONSORT score is plotted against interventions one trial of retigabine had the 
highest CONSORT score and the lowest score was one trial of Phenytoin. (fig 44).  
 
	
Figure 44 CONSORT Score versus intervention (see abbreviation list on page x) 
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6.4.19 Study predictors of CONSORT scores  
 
This section discusses the relationship between the CONSORT score and other 
continuous variables. Comparisons were made between CONSORT score and number 
of patients randomized, number of adverse events reported and CONSORT Score.  
 
6.4.19.1 Correlation between CONSORT score and number of patients 
randomised 
 
Pearson’s correlation was carried out between the numbers of patients randomized to 
each trial. Three trials were very large trials that could be considered outliers for this 
analysis. Therefore, the two SANAD and MESS studies were excluded from this 
analysis and one other study that randomized approximately a thousand patients was 
also excluded (Marson et al 2006). A Pearson’s correlation of 0.3 was obtained. This 
means that the correlation between the number of patients randomized and CONSORT 
score was medium. If the three excluded trials were used the Pearson’s correlation 
showed an R-value of 0.286 (fig 45). 
 
	
Figure 45 Correlation between CONSORT Score and number of patients randomized 
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6.4.19.2 Correlation between CONSORT score and percentage of document used 
for harms data 
 
A correlation between CONSORT score and percentage of document used to report 
harms was a positive one. The scatter plot below shows a possible positive correlation. 
A Pearson’s correlation showed as positive relationship with a Pearson’s correlation of 
0.42 (fig 46).  
 
	
Figure 46 Correlation between CONSORT score and percentage of trial document space used to report 
harms data 
 
 
 
 
 
 
 
 
 
 
		 157	
6.4.19.3 Correlation between the CONSORT score and the number of AE 
reported. 
 
One might expect a linear correlation between the quality of reporting and the number 
of adverse events reported. This analysis showed a positive correlation but the strength 
of the correlation was weak; Pearson’s R = 0.2 (fig 47).  
 
	
Figure 47 Correlation between the CONSORT score and the number of AE categories reported 
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6.4.20 Other data items 
 
Only eight trials reported evidence of priming of harms during collection of harms data 
(table 37). Only ten trials reported if the person attributing harms to intervention or 
comparator was blinded to the allocated treatment. Eighty-one percent of trials 
expressed harms data with mean median or percentages. Twenty-eight trials reported 
the cumulative incidence of adverse events. Only 37.5 percent of trials reported if 
deaths occurred or not. Only two trials gave additional data of harms on a webpage or 
in appendices. A tabular description of adverse events was reported in 114 (75%) of 
trials. 
 
CONSORT 
Recommendation 
Descriptive Results 
Number of trials (%) N = 
152 
3 Evidence of priming  8 (5.3) 
4 Was attribution blinded to 
the assigned treatment? 
10 (6.6) 
5 Mean medians and 
descriptive data of harms 
reported  
123 (81.0) 
6 Kaplan Meir cumulative 
incidence of AE  
31 (20.3) 
6 Authors always report 
deaths  
57 (37.5) 
8 Present graphical 
representation of the number 
of events per patient or time 
to event 
31 (20.3) 
10 Additional harms data in 
webpage 
2 (1.3) 
Table 37 Additional items analysed 
 
 
 
 
 
 
 
 
 
		 159	
6.5 DISCUSSION 
 
Epilepsy is a chronic condition where treatment is expected to be life-long. 
Information on possible harms of AEDs is useful when discussing this with patients. 
Common questions patients ask is whether to start treatment and what the best 
treatments are. The MESS and SANAD studies provide the best answers to some of 
these questions (Marson et al 2007) (Kurmholtz et al 2015).  
 
Randomised controlled trials provide information of harms on short-term harms. 
Harms are important in making informed treatment decisions; however, reporting of 
harms in trials may be insufficient.  
 
This study examined the reporting of adverse events in trials of antiepileptic drugs. 
Presented here are the findings: 
 
6.5.1 Epilepsy trials 
 
One hundred and fifty-two trials were selected for inclusion. In the interests of time, 
trials beyond 2008 were not analysed. The top four journals were: Neurology – a 
general neurology journal and in three subspecialty journals- Epilepsia, Epilepsy 
Research and Seizure. It is expected that journal editors have a considerable influence 
of the content of RCT reporting. The International Committee of Medical Journal 
Editors endorses the CONSORT statements. At the time of writing Epilepsia and 
Epilepsy Research do not endorse CONSORT statements. This study demonstrated if 
journal type could be a covariate and we found that there was no significant difference 
by journal type or if it was a specialty or a general journal. This is not in keeping with 
data from other studies, which showed that journals that endorse CONSORT are better, 
compared with non-endorsers (Kane et al 2007) (Kiehna et al 2011).  
 
These RCTs ranged from small to large studies. The most common intervention was 
topiramate followed by levetiracetam and lamotrigine. The data-set included in this 
study was therefore a mixed population of specialty and non-specialty journals. The 
most common trial was topiramate and this reflects the time period chosen for 
inclusion of trials. Many trials of older AEDs like valproate, phenytoin and 
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carbamazepine were published before 1999. Trials published before 1999 were not 
included, as these trials are very likely to be poorly reported.  
 
6.5.2 Quality of harms reporting 
 
A composite score was created from items suggested in the CONSORT 
recommendations for harms. Unlike the original CONSORT statements, the extension 
for harms did not include a checklist as an appendix. Therefore, we had to create our 
own checklist as displayed in this chapter. Other studies have also created a composite 
score from items in the CONSORT recommendations (Siverndran et al 2014, 
Cornelius et al 2013, Faggion et al 2013, Breau et al 2010 and Bagul & Kirkham 
2011). This checklist is by no means a fully comprehensive checklist. Therefore, 
checklists are not uniform across studies and although there were similarities, there 
were also many differences. It would be useful if the authors of the CONSORT 
statements for harms provided a standard checklist. This would make comparisons 
across studies more meaningful.  
 
This study is the first on harm reporting in epilepsy. The methods used here were 
similar to methods used by others in creating a composite score. This study considered 
23 items from the CONSORT statements for harms and no trial reported all 23 items. 
Mean CONSORT score was 11.3. A score of 16 includes the mean plus one standard 
deviation. The proportion of trials in the dataset that scored greater or equal to 16.0 
was 17%. It would therefore not be unreasonable to suggest that the remaining 83% of 
trials are deficient in their reporting.  
 
The mean number of items reported across all trials was eleven. The median score was 
twelve. Distribution of the CONSORT score followed a Gaussian distribution 
therefore statistical assumptions for t-tests and ANOVA were met. Sivendran et al 
found a similar spread of CONSORT score for harms, but they included only 14 items 
in their analysis (Sivendran et al 2014). It is evident that reporting of harms is 
heterogeneous and other authors noted this with similar work in this area (Smith et al 
2008).   
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One trial of retigabine scored the best followed by the SANAD studies. The study that 
scored the least was a phenytoin trial. One hypothesizes that phenytoin study scored 
poorly as harms may not have been a primary outcome of the study. Only two trials 
mentioned the CONSORT statements explicitly in the text of the report. However, 
none of the trials analysed mentioned the CONSORT extension statements for harms 
explicitly. 
 
6.5.3 Commercially funded trials 
 
Comparisons of subgroups of studies revealed that there was a consistent trend of 
better harms reporting in commercially funded studies versus non-commercially 
funded studies. Specific items were best reported in commercially funded studies. 
Commercially funded trials were better in reporting all 23 items when compared to 
non-commercial studies however only eleven of these items were statistically 
significant. Although this may seem obvious that commercially funded would diminish 
harms data in trial reports to improve the chance of obtaining a commercial license, 
but we see that the opposite is true. One can explain this by saying that commercially 
funded trials would report harms better as they would aim for significant disclosure to 
facilitate the granting of a license. Also, commercially funded trials will have the 
necessary resources to collect and therefore present harms.  
 
Of the eleven items that were better reported were serious adverse events and 
providing adverse events separately. These items are important when trials are used in 
systematic reviews and the implication is that non-commercial studies would therefore 
be less likely to be meta-analysed if the outcomes are not reported properly. 
Commercially funded trials report a dictionary more than non-commercially funded 
studies. This is expected as regulatory authorities expect that clinical trials have used 
the preferred terms for adverse events. MEDRA and WHOART are examples of 
dictionaries that are approved by the EMA and MRHA in the UK for drug licensing.  
 
Similar work done by Faggion et al compared 10 items from the CONSORT 
statements for harms in two hundred and forty-six trials. They compared commercial 
and non-commercially funded periodontology trials and they found that the quality of 
the studies did not differ between the two groups (Faggion et al 2013).  
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Breau et al compared industry and non-industry trials of harms reported in the 
urological literature and found that there was a significant difference between the two 
groups but they did not comment on the magnitude of difference and they did not 
elaborate on which items were better reported (Breau et al 2010).  
 
Jones et al explored the reasons for why commercially funded trials are better in 
another study. Their hypothesis was that commercial funded trials would be of a lower 
quality than non-commercially funded studies. However, their study showed that 
commercial trials were better. They concluded that commercially funded trials are 
larger and therefore would be more likely to avoid key biases required for Cochrane 
reviews (Jones et al 2010). They explain this because commercial trials have an 
incentive to increase the quality of their work.  
 
One might expect that commercial funded trials might report harms poorly. A recent 
study by Nieto et al showed that adverse drug reactions in commercial trials were less 
frequent than non-commercial studies (34.5% vs. 65.1%) (Nieto et al 2007). Reasons 
cited for this include financial conflict of interest with regard to authors of studies. 
Trials published by commercial sponsors were not different in methodological aspects 
but differed in the results. Commercially funded trials were superior to non-funded 
trials with respect to methodology but are more likely to have a placebo as a 
comparator therefore are more likely to yield positive results than non-commercial 
studies. (Schott et al 2010).  
 
6.5.4 Has reporting improved after the 2004 extension statements? 
 
This study demonstrated that there has been there has no improvement or change in 
reporting of adverse events pre and post CONSORT publication. The mean score pre 
CONSORT was 11.6 and 11.1 post CONSORT. When comparing individual items pre 
and post CONSORT we found that all expect one item (use of a validated dictionary) 
had relative risk including unity therefore were not statistically significant. The use of 
a validated dictionary was reported better in pre CONSORT studies. Reasons for why 
this is unclear.  
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Cornelius et al compared the reporting of harms before and after the publication of the 
CONSORT guidelines (2013). Their study compared the quality of reporting before 
and after 2004 but they did not comment if the quality of reporting had improved pre 
or post CONSORT. A study by Faggion evaluated trials published in 2001-2003 with 
trials published between 2011 and 2012 inclusive (Faggion 2013). They found that 
there were no differences in reporting of harms pre and post CONSORT. Anttila et al 
compared the 1996 CONSORT statements and found no change before and after 
reporting of trial reporting in paediatric journals (2006). They cite the reason being that 
paediatric studies are reported in specialty journals and not general journals therefore 
the quality of reporting is poorer (Anttila et al 2006). 
 
Some evidence that the CONSORT statements have helped with the reporting of trials 
comes from a paper by Altman et al (2005). They evaluated only CONSORT 
endorsing journals. One hundred and sixty-seven journals were evaluated. Only 22% 
of journals mentioned the CONSORT statements in instruction to authors, this was 
worse in specialty journals (18%) compared with general journals (22%). Forty three 
percent of journals mentioned the ICMJE website but they didn't mention the ICJME 
guidelines. (Altman et al 2005). 
 
A sensitivity analysis was conducted to see if changing post CONOSRT studies to 
include studies published in 2006 and beyond had any difference to the CONSORT 
score. With this amended benchmark, no difference was found between pre and post 
CONSORT reporting. However, this may be due to lack of precision and we may need 
more trials. Nevertheless, when one compared our findings to other studies, they too 
found no change in reporting post-CONSORT.  
 
There was no difference in CONSORT scores between CONSORT endorsers and non-
endorsers. A study by Plint et al only looked at journal that do endorse consort and 
they concluded that the guidelines have improved reporting (2006).  
 
It is therefore clear that a pooled meta-analysis needs to be made to determine if any 
change has occurred from 2004 onwards. Alternatively, one could analyse trials 
published from 2009 onwards and include this in the current dataset.  
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6.5.5 Poor reporting in Paediatric trials  
 
This study found significantly poor reporting of trials in children with epilepsy. A 
literature search did not find any studies that used the CONSORT statements to 
analyses paediatric studies. Items that were poorly reported included definition of 
adverse events and details of presentation of statistical analysis and if the results were 
presented separately in each arm. Poor reporting of these items therefore introduces 
bias in trials in the paediatric age group.  
 
Drugs used in children were usually drugs which were trialled in adults and are 
currently used as an off-license indication New EU legislation makes financial 
incentives for drug companies to perform clinical trials for the paediatric population 
with similar incentives provided by the FDA (EU regulation No 1902/2006). 
Therefore, it is predicted that the number of paediatric clinical trials is likely to 
increase as drug companies would need to provide data on children to obtain a drug 
license. Therefore, new regulation is needed to ensure that the quality of harms 
reporting is on par with trials performed in adults.  
 
6.5.6 Quality of harms in sections of the trial report 
 
There was marked heterogeneity in reporting of harm outcomes. This study showed 
that the reporting of harms in the results section was better than the methods section. 
The methods section included CONSORT items 3 to 12 and the average percent of 
items met, ranged from 7.2% to 76.3%. If one did not include the timing of AE as an 
item, it is clear that harms in methods section is relatively poorer in compared to harms 
reporting in results section. Such heterogeneity is reported in other studies as well 
(Smith et al 2008).   
 
Items that were reported best were providing denominators for AE (78.3%) and the 
item reported the poorest, was handling of recurrent adverse events (7.2%). The 
CONSORT Statements recommend that any additional harms data can be presented as 
an appendix or a webpage. Only two trials published data on an additional webpage.  
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It was noted that 75% of epilepsy trials provided a table of harms. This is a very good 
figure compared to studies in other areas like hypertension where Bagbul & Kirkham 
(2012) reported a figure of 49% of trials provide an AE table. A table of harms is a 
useful addition to a trial report as it allows a reader to quickly make judgments on 
harms and if a trial is to undergoes meta-analysis this data would be very valuable if 
raw data was not available.  
 
Withdrawal due to adverse events is a useful measure of tolerability; the results 
showed that 71% of all trials reported withdrawals. There was no difference in the 
subgroups for reporting of withdrawal data. Other studies that examined withdrawal 
data found similar rates of reporting. Byrant found the 29% of human growth hormone 
trial report withdrawals data whereas Capili found 70% of acupuncture trials report 
withdrawal data (Byrant et al 2002) (Capili et al 2010). Therefore, one can thus 
conclude that withdrawal data is reported well in epilepsy trials compared to other 
therapeutic areas. This is an important finding as tolerability measures are commonly 
incorporated in systematic reviews.  
 
6.5.7 Is Journal space a limiting factor? 
 
The CONSORT recommendations state that harms outcomes should not be published 
in a separate paper as this may prevent readers having a balanced view of efficacy and 
harms. The statements recognize that editors are under pressure to conserve manuscript 
length. The statements do not provide recommendations on how much of journal space 
should be devoted to this. They recommend a table for harms may save journal space. 
The analyses presented here showed that the mean percentage of journal space for 
harms outcomes was 26.8% of the results section. This ranged from 0% where no 
harms were discussed to 70% in one article. A correlation between percentage of 
document for harms and CONSORT Score was positive with an R-value of medium 
strength (r = 0.42) (fig 46). One hundred and fourteen trials out of 152 (75%) used a 
table to describe adverse events. This compared to other areas is significantly greater 
suggesting that journal have limited space for harms in the text and prefer to display 
this data as a table. 
 
 
		 166	
6.5.8 Other miscellaneous aspects of reporting 
 
Trials may not report every AE and trials report adverse events above a certain 
threshold. Typically, this is 5 to 10% of all adverse events. This means that if an AE is 
a relatively infrequent in the trial population, then it will not be reported. Despite this 
threshold, one would expect a large list of discrete adverse events in trial reports. This 
study found that 54% of trials did not report the thresholds and 46% did. Forty-one 
trials reported harms above a > 10% threshold and 29 trials reported harms above a > 
5% threshold.  
 
Eight trials did not report any discrete adverse events. The median number of discrete 
adverse events reported per trial was 9. The maximum number of discrete adverse 
events was reported in one trial that reported 28 discrete adverse events. There was a 
weak positive correlation between CONSORT score and number of adverse events, 
Pearson’s R was 0.20 (fig 47).  
 
The CONSORT statements recommend that priming methods may improve reporting. 
The study by Gilliam et al suggest that using the AEP provided priming for patients 
subsequently improving reporting of harms in clinic. Only eight trials out of 152 
reported priming methods.  
 
Means and descriptive statistics regarding harms were mentioned in 81% of trials. This 
on the face of it is indicative of good reporting across studies.  
 
The occurrence of deaths in a trial or if no deaths occurred was reported in only 57 
trials. Deaths if they occur or not is an important issue that needs reporting explicitly. 
A recent analysis carried out by Earley et al showed 27% of trials out of 500 published 
in clincialtrials.gov mentioned deaths, these were reported in either participant flow or 
primary and secondary outcomes (Earley et al 2013). Deaths were reported crudely in 
their study and they recommend that crude number of deaths and time to event rates be 
made mandatory in trial reporting. Trials that do not report deaths may have difficulty 
in obtaining a licence. 
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Severity and grading of harms was reported in nearly half of the studies (47.3%) and 
this was more likely to be reported in commercially funded studies. Also serious 
adverse events were better reported in commercially funded studies than non-
commercially funded studies. 
 
A significant number of trials report harm descriptively and this is what the 
CONSORT statements recommend as a minimum requirement However, the analyses 
presented here found 20% of trials report harms as a time to event outcome using 
graphical or Kaplan Meir curves. This is an important outcome measure of harms. One 
example of how Kaplan Meir curves have been critical is illustrated with celecoxib and 
rofecoxib in the risk of cardiovascular events (Mukherjee et al 2001). The use of these 
metrics highlighted the risk of long-term adverse events and led to withdrawal of these 
drugs from the market. 
 
6.6 Comparison with reporting of harms in Systematic reviews 
 
Zorsela et al evaluated the reporting of harms in systematic reviews. They found 
similar level of poor reporting of harms in Cochrane reviews. They included trials 
between 2008 and 2010 and they identified 309 reviews for inclusion. The CONSORT 
guidelines were not used for this study but a similar guideline called the PRISMA 
statement (Zorsela et al 2014). They found that the reporting of the methods section 
was good in only 40% of systematic reviews, only 50% of reviews reported harms 
adequately in the results section where the proportions of good reporting was higher in 
the title, abstract, introduction and discussion section was 70%, 60%, 75% and 80% 
respectively. These proportions are similar to the results in this study. 
 
6.7 Methodology limitations 
 
This work is the first in the reporting of harms in RCTs of AEDs. However, there are a 
number of limitations.  
• For selection of studies involving two reviewers to select studies for inclusion 
reduced bias. Cohen’s Kappa was used to quantify the level of agreement 
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between reviewers, however this method does not completely eliminate 
ascertainment bias.  
• Removing the headings and authors from printed copies of included trials could 
have reduced ascertainment bias. 
• There were problems in interpretation of some items in the statements and 
whether some items were relevant for epilepsy trials. For example, in the 
statistical section recommendations number 5 states that authors should 
describe the development of Quality of life and harms scales used. It was noted 
that the reporting of this was poor but it was decided to keep this 
recommendation. Conversely, the CONSORT recommendations state that 
subgroups analysis when present for harms data should be reported. From 
previous experience of trials reporting this item was not included as very few 
trials report this Therefore this was excluded this from the checklist by mutual 
agreement.   
• Some studies like Mahinbakht et al used only 10 CONSORT items in their 
checklist and others used 44 items (Kiehna et al 2011) using the CONSORT 
checklist use only 10 items where as others used 43. The selection of 
CONSORT items used in this study was arrived after several discussions with 
team members and a final checklist was approved. After the writing of this 
work a number of additional items could have been included but it is expected 
not to have changed to results significantly (Shukralla et al 2011). 
• The CONSORT recommendation number 10 states that trials should “ .provide 
a balanced discussion of benefits and harms with emphasis on study 
limitations, generalizability and other sources of information on harms”. For 
this recommendation, a checklist of four items was created. How these are 
interpreted is subject to individual biases, which would be difficult to overcome 
despite efforts to reduce this.  
• The statistics were not adjusted for multiple comparisons. This could lead to 
statistically significant results when indeed there may not be one. Nevertheless, 
the magnitude of the p-values indicates that there is a true difference in the 
reporting of harms in commercially funded trials and trials between adults and 
children.  
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• Several authors use the CONSORT guidelines and others have used checklists 
as benchmarking tools to compare trials (Plint et al 2001). However, the 
checklist and the CONSORT statements are not validated as a scoring system. 
The original authors of the CONSORT checklist did not envisage that they 
would be used as a benchmarking tool but rather as a guide for clinicians in 
helping them understand clinical trials better.  
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6.8 CONCLUSIONS 
 
• Reporting of harms in RCTs of antiepileptic drugs is poor and this has not 
improved since the publication of the CONSORT statements 
• A good predictor of poor reporting is if the study is a non-commercial study or 
a paediatric study 
• Journal of publication is not a predictor of harms reporting in this study 
• Journals that endorse CONSORT are more likely to report harms better 
• Poor reporting practices could lead to erroneous and biased reviews 
 
6.9 Recommendations for improving the reporting of harms in RCTs of AEDs 
 
• Increased awareness of the CONSORT guidelines 
• Greater uptake of the CONSORT guidelines by journal editors 
• Greater involvement of authors of commercially funded studies in the writing 
of the content of trials reports as they may not be directly involved in the 
drafting of reports 
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Chapter 7 
 
 
 
 
Lacosamide: Systematic Review and Meta-analysis 
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7.1 INTRODUCTION 
 
The reporting of harms in randomised controlled trials is poor as demonstrated in the 
previous chapter. This is also demonstrated in other studies that show no change in 
reporting since the publications of the CONSORT guidelines. Poor reporting of trials 
could have an adverse effect on systematic reviews of clinical trials. Data for reviews 
are usually obtained from unpublished data, but when such data is not available, then 
reviewers have to obtain data from the published reports. It is also established that 
poor outcome reporting can lead to inaccurate estimates in systematic reviews 
(Kirkham et al 2009).  
 
Lacosamide is a new drug developed by UCB for the treatment of partial epilepsy in 
2008. The FDA and EMEA approved a licence for its use in patients with partial 
epilepsy but not neuropathic pain. Lacosamide is available in tablet, syrup and 
intravenous formulations. Its intravenous use allows it to be given to patients who are 
intolerant of oral intake or it can be used to top up an oral dose if patient cannot take it 
via that route (Biton et al 2008). In clinical practice lacosamide is started at 100mg 
once a day and gradually increased up to 400mg at weekly increments. The maximum 
licenced dose is 400mg once a day but some clinicians have used up to 600mg once 
day (Novy et al 2011). Lacosamide is available as a tablet from in 200mg, 400mg and 
600mg doses and is available as an intravenous preparation. The pharmacology of 
lacosamide was discussed in chapter one. 
 
 Lacosamide does not need any dose adjustments in patients with mild or moderate 
renal failure. A maximum dose of 300mg is used for patients with severe renal failure. 
Patients with cardiac disease should not be prescribed lacosamide if there is any 
evidence of AV node dysfunction. 
 
There are current trials underway for its use as monotherapy in partial epilepsy. The 
use of lacosamide in primary generalised epilepsy is not recommended as it may 
increase seizure frequency. 
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This chapter summarises the efficacy and safety of lacosamide by conducting a 
systemic review, the review will also assess the impact of reporting issues on 
conducting systematic reviews.  
 
7.2 Aims 
 
This chapter assess the evidence for Lacosamide and its efficacy and safety in treating 
patients with partial onset seizures. There have been a number of trials of lacosamide 
and this chapter summarises the evidence for its use in partial epilepsy in a systematic 
manner.  
 
7.3 METHODS  
 
7.3.1 Search strategy. 
 
To be eligible in this review, trials of lacosamide as add-on therapy were searched for.. 
Clinical trials had to be RCTs to ensure that bias was reduced. An explanation of bias 
and trials suitable for systematic reviews was explained in chapter. Trials of 
lacosamide where it was used as monotherapy were excluded. Search strategy for 
RCTs in lacosamide is shown in appendix H, page 352 
 
At the time of writing, UCB was the sponsor of the clinical trials included in this 
review. UCB was contacted to provide unpublished data, as this would decrease the 
risk of publication bias. Any clarification of data provided was made via email to the 
medical informatics department of UCB. Outcome data and data regarding allocation 
and concealment and randomisation was obtained directly from study sponsors. Any 
additional data was obtained from the published trials. Unpublished data was defined 
as trial data obtained from manufacturers that are not reported in peer-reviewed 
journals. Experts in the filed were also contacted if there were any other trials of 
lacosamide for inclusion.  
 
7.3.2 Inclusion and exclusion criteria 
 
These are outlined below 
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Inclusion criteria 
1. Randomised controlled clinical trials of lacosamide  
2. Lacosamide used as add-on therapy only 
3. Trials in English 
4. Placebo or actively controlled trials 
5. Double blinded or single blinded studies 
6. Minimum period of studies of at least 8 weeks 
 
Exclusion criteria 
1. Lacosamide monotherapy trials 
2. Observational studies where there was no comparator group 
 
7.3.3 Outcome measures 
 
As outlined in earlier chapters, there are a number of outcome measures that are used 
in systematic reviews of antiepileptic drugs. The key outcome in epilepsy trials is 
proportion of patients with ≥50% of reduction of seizures.  
 
7.3.4 Primary outcomes 
 
The key outcome in systematic review of antiepileptic drugs is the 50% reduction in 
seizure frequency. This is the proportion of people with a 50% reduction in seizure 
frequency in the treatment period compared to the baseline period. Details of why this 
outcome was selected as the primary outcome is given in chapter 5 section 5.10.  
 
Seizure frequency is a difficult outcome to analyse in meta-analysis because this would 
need a comparison of means. Furthermore, seizure frequency is subject to recall bias 
and other biases., seizure frequency is also not uniformly measured across clinical 
trials. Proportion of patients with a reduction of seizure frequency on the other hand is 
less prone to bias. 
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7.3.5 Secondary outcomes  
 
The following secondary outcome measures were used; seizure freedom, proportion of 
patients withdrawing from the study, proportion of patients with adverse events, 
quality of life and cognitive outcomes.  
 
Seizure freedom, this included the proportion of patients who were free of seizures in 
the treatment period compared to the baseline period. This outcome is not used 
traditionally in systematic reviews, as the probability of seizure freedom in most 
clinical trials is rare. It was included in this study as the outcome was reported in a 
number of lacosamide trials. One study by Zaccara et al (Zaccara et al 2006) suggest 
that seizure freedom is not traditionally meta analysed in systematic reviews and 
should be considered but this can be used if the minimum follow up is 6 months and 
that a typical short study of 12-week duration can still be used to evaluate this 
outcome.  Furthermore, clinicians may be interested in the review of this outcome, as 
lacosamide would be given to patients with intractable epilepsy.   
 
Treatment withdrawal is the proportion of patients who withdrew for any cause during 
the treatment period and is the key outcome measure used in systematic reviews. 
Treatment withdrawal can be due to any cause including adverse events. This has been 
used in several other Cochrane reviews and is a good marker of tolerability (Zaccara et 
al 2006).  
 
7.3.6 Adverse Events 
 
A comparison of the proportion of patients that withdrew due to harms was made, the 
total number of adverse events in each group and finally a comparison of the 
proportion of patients who experienced the specific adverse events was made. These 
outcomes were obtained from unpublished data provided from UCB.  
 
Names of adverse events were not altered and synonymous adverse events were not 
combined. The selected list of adverse events was chosen, as these were common to at 
least two of the selected trials. Adverse events described in the published literature 
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were called treatment emergent adverse events. The following adverse events were 
used: 
 
1. Any adverse event 
2. Accidental injury 
3. Ataxia 
4. Blurred vision 
5. Coordination abnormal 
6. Diplopia 
7. Dizziness 
8. Fatigue 
9. Headache 
10. Nasopharyngitis 
11. Nausea 
12. Nystagmus 
13. Peripheral oedema 
14. Rash 
15. Somnolence 
16. Tremor 
17. Upper respiratory tract infection 
18. Vertigo 
19. Vomiting 
 
Some harms outcomes like ataxia and coordination abnormal may intuitively be 
synonymous but these were not summated.  
 
7.3.7 Other outcomes  
 
Other outcomes that were included in thesis included quality of life measures and 
cognitive changes experienced by patients. Quality of life measures included quality of 
life scores and standardised cognitive scores. These outcomes were presented 
narratively.  
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7.3.8 How outcomes are presented 
 
Outcomes will be presented in three domains 
1. Efficacy of lacosamide versus placebo 
a. Proportion of patients with a ≥ 50% reduction in seizure frequency 
b. Proportion of patients seizure free during the 12-week maintenance 
period 
2. Tolerability of Lacosamide versus placebo 
a. Proportion of patients having treatment withdrawn during the 
maintenance period 
3. Adverse events 
 
Given clinical trials present outcomes by dose subgroups, all outcomes were presented 
using the following doses: 
• Lacosamide 200mg 
• Lacosamide 400mg  
• Lacosamide 600mg 
• Lacosamide any dose 
 
7.3.9 Participants 
 
Patients included must have epilepsy. These were patients of any age and must have at 
least one antiepileptic drug. Patients need to have a specified minimum frequency of 
seizures to be included into the trial. Pregnant patients were excluded and progressive 
epilepsies were excluded from the study. If patient could not comply with protocols, 
they were also excluded.  
 
7.3.10 Search Methods 
 
Electronic searches were made for lacosamide trials. One did not need to carry hand 
searches as the intervention is adequately tagged in MEDLINE. Other searches 
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included the specialised register contains trial of epilepsy in the Cochrane database. 
Trials had to meet the following criteria: 
 
1. Trials had to use an adequate method of randomisation 
2. Trials had to use a method of blinding 
3. Trials had to be of lacosamide 
4. Comparator group had to include placebo 
 
To reduce bias in the search strategy and selection of trials, this was carried out by two 
reviewers and any disagreements were resolved after mutual discussion.   
 
 
7.3.11 Selection of studies  
 
Selection of trials was carried out by two persons. Any differences were resolved by 
mutual agreement.  
 
7.3.12 Data extraction  
 
Items of data for systematic reviews include two main categories. The first is data 
relating to the methodological vigour of selected trials and ascertaining the risk of bias. 
The second is data relating to results and outcomes. Data was extracted into a data 
extraction form. A list of subheadings is shown below.  
 
1. Methodological and trial design 
2. Patient demographic data 
3. Primary and secondary outcome data including harms data 
4. Ascertainment of risk of bias 
5. Ascertainment of clinical heterogeneity  
 
Two authors extracted data from trials for details of method of randomisation. 
Methods of allocation concealment, methods of blinding and missing participants. 
Other data relating to methods included length of the baseline period, length of 
treatment period and dose of lacosamide used. This data was obtained from the 
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published reports of trials selected. If this data was not available the trial sponsor was 
contacted to respond to queries posed to them. UCB were contacted for medical 
information on details of allocation and blinding as this was not reported in published 
reports.  
 
7.3.13 Demographic data collection 
 
Demographic data from the published reports and from unpublished data was 
collected. If there were any disparities, then the unpublished data was used for the item 
concerned. Items of data included: 
1. Participant age 
2. Ethnic group of patients 
3. Seizure types 
4. Seizure frequency 
5. Baseline AEDs and/VNS 
6. Proportion of patients meeting target dose 
 
Other items of data extracted included the number of patients randomised to each arm, 
the dose of active intervention in each arm. Proportion of patients in each arm with > 
50% reduction in seizure frequency. Proportion of patients withdrawn from each arm. 
Proportion of patients seizure free. Proportion of patients with treatment emergent 
adverse events.  
 
7.3.14 Assessment of risk of bias 
 
Two reviewers conducted an assessment of the risk of bias. Cochrane risk of bias 
tables as described in Higgins 2011was used and related incorporated into RevMan 
5.0. See earlier chapters for an explanation of this.  
 
The risk of bias was rated as high, low or unclear on six domains, the details of these 
domains have been explained in chapter five, section 5.16 These domains included 
randomisation method, allocation concealment, blinding methods, incomplete outcome 
data, selective outcome reporting and other sources of bias. Risk of bias was illustrated 
using risk of bias matrix.  
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The ORBIT tool to assess the risk of bias in outcome reporting was also used, details 
of which were described in chapter five, section 5.16.1 
 
7.3.15 Measures of treatment effect 
 
The majority of the outcomes are categorical in nature and therefore are presented 
using relative risks. Relative risks were used instead of odds ratios to present measures 
of treatment effect as it is expected treatment effect sizes will be small and therefore 
relative risks would provide a better estimate than odds ratios. Quality of life measures 
were presented narratively as there is no consensus on which measure should be used 
in systematic reviews and clinical trials are not always consistent in their use off 
quality of life measures. 
 
7.3.16 Assessment of heterogeneity 
 
Clinical heterogeneity was assessed by comparing the distribution of patient 
demographics. We used the I2 statistic to calculate heterogeneity. This was included in 
RevMan 5.0. If there was no heterogeneity we used the fixed effects model. But we did 
not plan to carry out subgroup analysis for sensitivity to explore heterogeneity.  
 
7.4 RESULTS 
 
7.4.1 Results of the search 
 
Searches revealed 379 studies pertaining to Lacosamide. Of these only 19 were tagged 
as randomised controlled trials. Of these only three trials involved patients with 
epilepsy compared with placebo. The excluded studies were not used. 
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	Figure	48	Flow	diagram	of	disposition	of	studies	selected	
 
7.4.2 Excluded studies 
 
Excluded studies are shown in table 38. A total of three studies were included for 
review. We excluded one trial, which compared rates of infusion of lacosamide, as this 
did not include a placebo group. We also excluded a study comparing the oral 
formulation of lacosamide with intravenous lacosamide; this study was excluded, as it 
did not have a placebo group (Biton et al 2008). Four trials of lacosamide in peripheral 
neuropathy studies were excluded for this review. Four trials of lacosamide with 
pharmacokinetic data were excluded. There are no studies that are awaiting review.  
 
7.4.3 Included studies 
 
Three studies were included for review. All three studies were sponsored by UCB. The 
trials were part of a drug development programme to gain a licence for Lacosamide 
(Ben-Menachem 2007, Halasz 2009 and Chung 2010). A list of excluded studies is 
Search for RCTs 
using Medline and 
OVID 
 7 
Pharmacokinetic 
Trials  
2 Secondary 
reports of RCTs  
 2 Intravenous 
versus oral 
admission of 
Lacosamide  
 7 Placebo 
controlled RCTs  
 1 EEG RCT  
3 Epilepsy 
RCTs 
4 Neuropathy 
RCTs 
EX
C
LU
D
ED
 
INCLUDED 
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shown in table 38 and the included studies is shown in table 39. Trials details and 
characteristics of included studies are shown in table 41. Details of outcome reported 
in selected trials are shown in table 42. Table 40 highlights the key outcome measure 
results. 
 
The first study by Ben-Menachem was reported in 2007 (Ben-Menachem et al 2007). 
This was a phase 2b study comparing lacosamide to placebo in patients with focal 
epilepsy. The other two studies were phase 3 studies by Halasz and Chung (Halasz et 
al 2009)(Chung et al 2010). A total of 1311 patients were randomised in all three 
studies. Two hundred and seventy patients were allocated to 200mg of lacosamide. 
Four hundred and seventy one were allocated to 400mg of lacosamide and three 
hundred and sixty six patients were allocated to 600mg of lacosamide. One hundred 
and ninety patients were allocated to placebo. All three studies included data on the 
proportion of patients free from seizure during the 12-week maintenance period. In one 
study patients were on one or two AEDs (Ben-Menachem et al 2007), in the other two 
trials up to three AEDs were used by patients. (Halasz et al2009)(Chung et al 2010). 
The most common AEDs were carbamazepine (35%), lamotrigine (31%), 
levetiracetam (29%), valproate (24%), topiramate (22%), oxcarbazepine (18%) and 
phenytoin (14%).  	
Study Reason for exclusion 
Biton 2005 These studies compared intravenous lacosamide with oral lacosamide. There 
was no placebo group, therefore they were excluded Biton 2008 
Jatuzis 2005 
Pharmacokinetic studies 
 
Jatuzis 2006 
Kalvianinen 2007 
Raosenfeld 2005 
Rauck 2007 
These studies compared oral lacosamide with placebo in patients with painful 
diabetic neuropathy 
Shaibani 2009 
Wymer 2009 
Ziegler 2010 
Table 38 List of excluded lacosamide studies 	
Study Title Reason for 
inclusion 
Ben-Menachem 2007 Efficacy and safety of oral lacosamide as adjunctive 
therapy in adults with partial-onset seizures 
Compared oral 
lacosamide to 
placebo in patients 
with partial epilepsy 
and was a 
randomised 
controlled trial. 
Halasz 2009 Adjunctive lacosamide for partial-onset seizures: 
Efficacy and safety results from a randomized 
controlled trial 
Chung 2010 Lacosamide as adjunctive therapy for partial-onset 
seizures: A randomized controlled trial 
Table 39 List of included lacosamide studies 
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Ben Menachem 2007 
 
In this study patients were allocated in a 1:1:1:1 ratio to placebo, Lacosamide 200mg, 
400mg and 600mg. the baseline period was 8 weeks with a six week titration period of 
100mg/week. A single down titration was allowed of 100mg /week. Maintenance 
period was 12 weeks.  
 
All patients aged 18-65 years of age. Patients needed to have had seizures for at least 2 
years. 93% of patients were Caucasian and 82% of patients achieved the target dose. 
Lacosamide was superior to placebo for the 400mg and the 600mg dose; the 200mg 
(median 20% of doses) dose was not significant. The 400mg and 600mg doses 
included 39% and 40% of doses respectively.  
  
Halasz 2009 
 
This was a phase 3 randomised placebo controlled trial evaluating the 200mg and 
400mg dose of lacosamide compared to placebo. Patients here were allocated in a 
1:1:1 ratio to placebo, 200mg lacosamide and 400mg lacosamide. Again the baseline 
period was 8 weeks and the titration period was 4 weeks. Titration rate was the same 
as the other trials of 100mg/week. The treatment period was 12 weeks.  
Patients were adults with focal epilepsy. Here 99% of patients were Caucasian. In this 
study, 38 patients were excluded after screening and 61 patients were not randomised.	
Chung 2010 
This was a phase 3 randomised placebo controlled trial evaluating 400mg and 600mg 
dose of lacosamide compared to placebo. Patients were allocated to 1:2:1 to placebo, 
400mg Lacosamide and 600mg lacosamide. The baseline period was similar to other 
studies was 8 weeks and titration period was 6 weeks and treatment phase was 12 
weeks. Patients recruited were adults with focal epilepsy who had failed on at least 2 
AEDs. In this trial 81.1% of patients reached the target dose. This trial demonstrated 
efficacy of the 400mg and 600mg doses, as the 200mg dose was not significant in 
		 184	
above two trials. Seizure types were not discussed in Chung et al but was discussed the 
other two trials (2010).  
7.4.4 Comparison of primary outcome measures 
The three trials reported similar responder rates in the intention to treat analysis (ITT) 
for identical drug doses. There was very little difference in the 200mg, 400mg and 
600mg doses across three trials. On the other hand for the per-protocol (PP) analysis 
we found that the 400mg dose had a 49.4% responder rate in Ben-Menachem but only 
40% in Chung, reasons for this could be due to differences in the trial population (table 
40).  
 Dose Responder rate IIT analysis Responder rate PP analysis 
Ben Menachem 2007 Placebo 
200mg 
400mg 
600mg 
22% 
32.7%  (p = 0.08) 
41.1% (p <0.05) 
38% (p <0.05) 
21.2% 
38.1% (p <0.05) 
49.4% (p <0.05) 
49.2% (p <0.05) 
Halasz 2009 Placebo 
200mg 
400mg 
25.8%  
35.0% (p = 0.07) 
40.5% (p <0.05) 
27.5% 
35% (p = 0.19) 
46.3% (p <0.05) 
Chung 2010 Placebo  
400mg 
600mg 
18.3% 
38.3% (p <0.05) 
41.2% (p <0.05) 
18.4% 
40.0% (p <0.05) 
50.9 (p <0.05) 
Table 40 Comparison of Primary Outcome measures (ITT vs. PP analysis) 
.	
7.4.5 Clinical Heterogeneity 
Minimal clinical heterogeneity was found between studies. Mean ages were similar 
between groups. The distribution of age groups and seizures types were similar across 
all three trials. There were less Caucasians patients recruited in Chung 2010 compared 
to the other two trials. Demographics are shown in table 41. We deemed that there is 
little clinical heterogeneity and therefore trials are evaluable for systemic review.  
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7.4.6 Risk of outcome reporting bias from ORBIT tool 
Ben-Menachem (2007) was low risk in outcome reporting as all the outcomes that 
were planned were presented in the trial reports. This was true for the primary 
outcomes, secondary outcomes and additional outcomes as well.  
However, Halasz (2009) and Chung (2010) analysed quality of life outcomes, they did 
not report these in the published manuscript. Instead theses were published in abstracts 
and posters where data from all three trials were pooled together (Borghs et al 2010).  
Therefore, Halasz and Chung were deemed to have high risk of outcome reporting 
bias. Nevertheless, when assessing the overall risk of bias for purposes of this review it 
was deemed that the overall risk of bias is low. No trial reported the absolute change in 
seizure frequency from baseline. Determining if there is outcome reporting bias is 
important as if this exists then the effect sizes need to be interpreted with caution if 
outcome reporting affects the primary or secondary outcomes. In this review, the risk 
is low as the incomplete outcomes are quality of life measures.   
7.4.7 Risk of bias summary 
Using the unpublished data, one was able to obtain details of selection of patients and 
details of treatment allocation. For all three trials, it was deemed that allocation was 
adequate. Also, random sequence generation was also adequate and was done remotely 
by a computer for all three trials (fig 52 and 53).  
Patients and trial assessors were blinded to treatment allocation and which treatments 
they received. Therefore, the risk of bias was low.   
Incomplete outcome reporting is where the outcomes are poorly reported. Here for the 
items that were of key interest for this review was good.  
Some of the items discussed on page 190 with regards to the ORBIT tool were 
pertaining to the non-reporting of quality of life measures that were discussed in 
conference abstracts and not the published trials. The outcomes in question were the 
Patient’s Global Impression of Change score (PGIC) and the Seizure Severity Scale 
(SSS). Since these outcomes are quality of life outcomes, it was therefore deemed that 
the risk of reporting bias was low. These items are not primary or secondary outcomes 
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in this review. Tables 42 to 43 shows results of judgements made using the ORBIT 
assessment tool.  
Our risk of bias judgement showed that the risk of bias from selection, detection and 
performance bias was low. Detection and attrition bias was low. The risk of selective 
reporting bias was low. Outcome reporting bias was low in Ben-Menachem et al for all 
outcomes reported, but the risk of bias of the other two trials was high for certain 
quality of life measures. Nevertheless, the overall risk was deemed low, as these 
outcomes were not included in the analysis. 
 
7.4.8 Other sources of evidence  
Posters of lacosamide presented at epilepsy meetings were used. These reported data 
not found in the published trial reports or unpublished data. This included a pooled 
analysis of lacosamide for quality of life measures (De La Loge et al 2009). A list of 
all outcomes is shown in table 42.  
7.4.9 Funnel plots 
Funnel plots for the three main outcomes were made. These plotted the standard error 
of the log of relative risk against the relative risks. In the absence of bias these should 
show a symmetrical shape of a funnel. These are shown in the diagrams below (fig 49 
to 51). The funnel plots do not indicate a risk of reporting bias based on this analysis.  
 
		 187	
 
Figure 49 Funnel plot of comparison: Efficacy of lacosamide versus placebo: Proportion of patients with 
a 50% or greater reduction in seizure control 
 
Figure 50 Funnel plot of comparison: Efficacy of lacosamide versus placebo: Proportion of patients 
seizure free during maintenance period 
 
 
Figure 51 Funnel plot of comparison: Tolerability of lacosamide: proportion of patients who have 
treatment withdraws during maintenance period 	
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Table	41	Characteristics	of	lacosamide	studies	
Patient characteristics Ben-Menachem 2007 Halasz 2009 Chung 2010 
Number of patients 
randomised 
418 485 405 
Dose Placebo 200mg 400mg 600mg Placebo 200mg 400mg Placebo 400mg 600mg 
Age (mean years) 
Range 
38.8 
19-66 
39.9 
18-65 
41.2 
18-68 
39.4 
18-64 
38.5 
17-63 
36.9 
16-66 
37.9 
16-70 
38.1 
16-61 
39.1 
17-71 
36.8 
16-69 
Sex (%) M 48 
F 52 
M 43 
F 57 
M 49 
F 51 
M 42 
F 58 
M 55.8 
F 44.2 
M 44.4 
F 56.6 
M 51 
F 49 
M 47.1 
F 52.9 
M 51 
F 49 
M 48.5 
F 51.2 
Race (%) 
White 
Asian 
Black 
Other 
 
91 
0 
6 
3 
 
92 
2 
4 
3 
 
93 
0 
5 
3 
 
95 
0 
2 
3 
 
99.4 
0.6 
0 
0 
 
99.4 
0 
0.6 
0 
 
98.7 
1.3 
0 
0 
 
81.8 
1 
8.2 
1 
 
81.4 
1.6 
7 
1 
 
82.5 
1.7 
5 
2 
Mean time to diagnosis 
(years) 
24.6 25.1 24.7 23.6 21.1 22.9 22.8 25.4 24.5 23.4 
Seizure types (%) 
Simple partial 
Complex partial 
2° generalised 
 
34 
86 
75 
 
45 
94 
74 
 
38 
87 
71 
 
47 
91 
66 
 
37.4 
84.7 
79.8 
 
41.1 
87.1 
76.7 
 
36.5 
91.8 
79.9 
Not reported 
 
 
 
Baseline partial onset 
seizure frequency per 
28 days 
11-13 seizures, no data for individual dose 15 11.5 16.5 9.9 11.5 10.3 
AEDs 1 to 2 concomitant AEDs 1 to 3 concomitant AEDs 1 to 3 concomitant AEDs 
Randomisation scheme 1:1:1:1 1:1:1 1:2:1 
Duration 
 
Baseline phase 
Titration phase 
Maintenance phase 
 
 
 
8 weeks 
6 weeks 
12 weeks 
 
 
8 weeks 
6 weeks 
12 weeks 
 
 
8 weeks 
6 weeks 
12 weeks 	
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Table 42 Outcomes reported in included studies 
 Ben Menachem 2007 Halasz 2009 Chung 2010 
Outcomes Common to all 
studies 
• Change in seizure frequency per 28 days from baseline in ITT and PP population 
• Responder rate, defined as the proportion of patients with a greater than or equal to 50% reduction in seizure 
frequency in both the ITT and PP population (called the 50% responder rate 
• Responder rate 75% 
• Proportion of patients seizure free throughout the 12 week maintenance period 
• Percentage change in seizure free days compared to baseline 
• Adverse events 
• Serious Adverse events 
• Proportion of patients withdrawn due to adverse events 
• Proportion of patients meeting target dose 
• Pharmacokinetic outcomes 
• Quality of life outcome: QOLIE-31 
Other Outcomes Any adverse events PGIC quality of life outcome 
SSS quality of life outcome 
 
Note: Any adverse event was 
not reported in this trial 
• Responder rate by seizure type 
• Change in seizure frequency per 28 
days from baseline by seizure type 
• Number of patients seizure free during 
the maintenance period calculated in 
the ITT method 
• PGIC and SSS quality of life outcomes 
 
Note: Any adverse events was not reported in 
this trial 
Patient’s Global impression of change score (PGIC); Seizures severity scale (SSS); Quality of life in Epilepsy (QOLIE-31) 
 
 
 
 
		 190	
Table 43 ORBIT assessment tool results 
Trial ID Primary Outcome 
≥ 50% reduction in 
seizure frequency 
Other 
Outcome 
Treatment 
withdrawal 
Other 
Outcome 
Adverse events 
Other 
Outcomes 
Quality of life 
Measures 
Additional 
Outcomes 
Percentage 
change in 
seizure 
frequency from 
baseline 
Additional 
Outcomes 
Absolute 
change in 
seizure 
frequency 
from baseline 
Additional 
Outcomes 
ECG, physical 
neurological 
examinations and 
laboratory tests 
Pharmacokineti
c outcomes 
Judgement of 
risk of bias 
Ben  
Menachem 
2007 
Measured 
Presented Analysed 
 
Also reported ≥ 
75% reduction in 
seizure frequency 
 
Measured 
Presented 
Analysed 
 
Measured 
Presented 
Analysed 
Any adverse 
event 
Also reported 
proportion of 
patients with 
dose reduction 
due to AE 
Threshold of 
reporting > 5% 
Measured 
Presented 
Analysed 
 
QOLIE-31 
only 
 
Measured 
Presented 
Analysed 
 
Not measured Measured 
Presented 
Analysed 
 
Measured 
Presented 
Analysed 
 
Low risk of 
bias 
Halasz 
2009 
Measured 
Presented Analysed 
 
Measured 
Presented 
Analysed 
 
Measured 
Presented 
Analysed 
 
 
Threshold of 
reporting > 5% 
Measured only 
QOLIE-31 
PGIC 
SSS 
 
 
Measured 
Presented 
Analysed 
 
Not measured Measured 
Presented 
Analysed 
 
Measured 
Presented 
Analysed 
 
High risk of 
bias as quality 
of life 
outcomes 
measured but 
not reported. 
These were 
presented 
elsewhere 
Chung 2010 Measured 
Presented Analysed 
 
Also reported ≥ 
75% reduction in 
seizure frequency 
 
Measured 
Presented 
Analysed 
 
Measured 
Presented 
Analysed 
 
Threshold of 
reporting > 10% 
Measured only 
QOLIE-31 
PGIC 
SSS 
 
Measured 
Presented 
Analysed 
Also presented 
reduction in 
seizure 
frequency by 
seizure type 
 
Not measured Measured 
Presented 
Analysed 
 
Measured 
Presented 
Analysed 
 
High risk of 
bias as quality 
of life 
outcomes 
measured but 
not reported. 
These were 
presented 
elsewhere 
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Table 44 Risk of bias assessments using the ORBIT assessment tool 
Study Outcome Risk of Bias in Outcome reporting Overall Judgement 
Ben Menachem 2007 1. ≥ 50% reduction in seizure 
frequency 
2. ≥7 5% reduction in seizure 
frequency 
3. Treatment withdrawal 
4. Adverse events 
5. Any adverse event 
6. Proportion of patients with dose 
reduction due to AE 
7. QOLIE 31 
8. Percentage in seizure frequency 
from baseline 
1. No risk 
2. No risk 
3. No risk 
4. No risk 
5. No risk 
6. No risk 
7. No risk 
8. No risk 
No risk of bias 
Halasz 2009 1. ≥ 50% reduction in seizure 
frequency 
2. Treatment withdrawal 
3. Adverse events 
4. QOLIE 31 
5. PGIC 
6. SSS 
1. No risk 
2. No risk 
3. No risk 
4. High risk 
5. High risk 
6. High risk 
 
 
Risk of bias uncertain due to some 
outcomes having low risk and some 
outcomes having high risk. 
High risk because items were reported in 
published conference abstracts and 
posters but not in unpublished reports 
provided by UCB. 
Outcome any adverse event not reported  
Chung 2010 1. ≥ 50% reduction in seizure 
frequency 
2. Treatment withdrawal 
3. Adverse events 
4. QOLIE 31 
5. PGIC 
6. SSS 
1. No risk 
2. No risk 
3. No risk (>10% threshold but 
does not affect ORBIT) 
4. High risk 
5. High risk 
6. High risk  
 
Risk of bias uncertain due to some 
outcomes having low risk and some 
outcomes having high risk 
High risk because items were reported in 
published conference abstracts and 
posters but not in unpublished reports 
provided by UCB. 
Outcome any adverse event not reported 
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Figure 52 Risk of bias summary. Review authors judgements about each risk of bias item for each included study: Illustrating the low risk of bias across trials for all items 
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Figure 53 Risk of bias graph. Authors judgement about the risk of bias item presented as percentage across all included studies. Illustrating the low risk of bias across all 
items 						
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7.4.10 Efficacy outcomes 
 
7.4.10.1 Responder rate (proportion of patients with a > 50% reduction in seizure 
frequency) 
 
Fifty percent reduction rate in seizure frequency was analysed for all three trials. There 
was an incremental increase in relative risks as the dose of lacosamide increased. 
Heterogeneity and not significant was an I2 of 0% for all three doses and 5% for any 
dose of lacosamide (fig 54 page 204). 
 
Summary measures were calculated for 200mg 400mg, 600mg and any dose of 
lacosamide. For the 200mg dose the relative risks for two trials ((Ben-Menachem et al 
2007) and (Halasz et al 2009)) included unity and therefore the relative risks were not 
significant. However, when these two trials were summated the relative risk was 1.41 
(95% CI of 1.07 to 1.85). Therefore, the summary measures reached statistical 
significance in favour of lacosamide. Summary measures for the 400mg and 600mg 
doses were 1.80 (95% CI 1.43 to 2.25) and 1.98 (95% CI 1.42 to 2.73) respectively. 
For any dose of lacosamide the relative risk was 1.70 with a 95% CI of 1.38 to 2.10.  
 
The other outcome we used was the proportion of patients seizure free during the 
maintenance phase of three trials. Once again, the levels of heterogeneity were low for 
analysis conducted.  
 
7.4.10.2 Seizure freedom 
 
Proportions of patients seizure free when taking lacosamide were analysed (fig 55 page 
204). All three trials evaluated patients for 12 weeks. Again, the outcomes were 
subgroup by dose. For the 200mg dose the summary effect was in favour of 
lacosamide but due to wide confidence intervals it was not statistically significant. The 
relative risk of seizure freedom on lacosamide was 1.8 compared to placebo. (95% CI 
of 0.50 to 6.57). For the 400mg dose, the relative risk was 2.70 (95% CI of 0.85 and 
8.56). The resistive risk for the 600mg dose was 7.09 (95% CI of 0.9 to 55.7). For any 
dose of lacosamide the relative risk of seizure freedom compared to placebo was 2.50 
(95% CI 0.85 to 7.34). Overall the risk of seizure freedom was higher in the 
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lacosamide group but this was not statistically significant due to the wide confidence 
intervals.  
 
7.4.11 Tolerability outcomes 
 
Tolerability of lacosamide was assessed using the proportion of patients that withdrew 
due to adverse events (fig 56 page 205). This is a generic measure of overall 
tolerability. This too was sub-grouped by dose. For the 200mg dose the risk of 
withdrawing due to adverse events was 1.43 (95% CI of 0.95 to 2.15). Therefore, this 
was not statistically significant compared to placebo.  
 
For the 400mg the overall relative risk of withdrawals due to harms compared to 
placebo was 1.79 with a 95% CI of 1.31 to 2.46. This therefore was statistically 
significant. Furthermore, for the 600mg dose the risk of withdrawal due to harms was 
3.04 (95% CI of 2.02 to 4.59). 
 
When all doses were considered the overall relative risk of lacosamide was 1.88 with a 
95% CI of 1.40 to 2.52.  
 
7.4.11.1 Any Adverse Event 
 
The proportions of patients with any adverse events were analysed (fig 58 page 205). 
This outcome was reported in Ben-Menachem and not in the other two trials. For the 
200mg dose the risk of having any adverse event compared to placebo was 1.13 (95% 
CI 0.96 to 1.33. This increased to 1.15 (95% CI of 0.98 to 1.35) for the 400mg dose 
and 1.32 (95% CI of 1.15 to 1.52) for the 600mg dose. For any dose of lacosamide the 
relative risk of having any adverse event was 1.20 (95% CI of 1.04 to 1.38) compared 
to placebo. 
 
7.4.11.2 Serious Adverse Events 
 
Serious adverse events are those that are which are unexpected or cause serious harm 
to patients (fig 57 page 205). The risk of serious adverse events was not different in to 
trials; Ben-Menachem 2007 and Chung 2010 with relative risks of 1.21 (95% CI of 
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0.41-3.44) and 1.73 (95% CI of 0.51-5,39) respectively. This was not the case for 
Halasz (2009) with at least twice more serious adverse events in this trial. The relative 
risk was 2.36 (95% CI of 1.0 to 5.39). No deaths were reported in any of the trials. 
When all serious adverse events were meta-analysed, the relative risk of serious 
adverse event was 1.78 (95% CI of 1.02 to 3.12). This risk of serious adverse events is 
surprising given that Halasz used the lower doses of lacosamide. 
 
Also, paradoxically, the relative risk of serious adverse events was higher in the 
200mg and 400mg dose compared to the 600mg dose. The relative risk was 2.0 for the 
200mg dose (95% CI of 1.0 - 4.02) and 1.97 for the 400mg dose (95% CI of 1.07 - 
3.63).  The risk of serious adverse events for the 600mg dose was 0.74 (95% CI of 
0.26 and 2.07). 
 
7.4.12 Adverse Events 
 
Adverse events that were reported in patients taking lacosamide and placebo included: 
accident not otherwise specified (NOS); ataxia; blurred vision; co-ordination 
abnormal; diplopia; dizziness; fatigue; headache; nasopharyngitis; nausea; nystagmus; 
peripheral oedema; rash; somnolence; tremor; upper respiratory tract infection (URTI); 
vertigo and vomiting. The relative risk of some of the adverse events was significantly 
higher in magnitude compared to the efficacy measures. Differences in reporting of 
adverse events are shown in the table 45 on page 197.  
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 Ben-Menachem 2007 Halasz 2009 Chung 2010 
Accidental Injury Reported   
Ataxia Reported   
Blurred Vision Reported  Reported 
Coordination abnormal  Reported Reported 
Diplopia Reported Reported Reported 
Dizziness Reported Reported Reported 
Fatigue Reported Reported  
Headache Reported Reported Reported 
Nasopharyngitis  Reported  
Nausea Reported Reported Reported 
Nystagmus Reported  Reported 
Peripheral oedema   Reported 
Rash   Reported 
Somnolence Reported  Reported 
Tremor   Reported 
Upper resp. tract infection Reported   
Vertigo  Reported  
Vomiting Reported Reported Reported 
Table 45 List of adverse events reported in lacosamide studies; epilepsy trials 
 
7.4.12.1 Ataxia 
 
The risk of ataxia increased with increasing dose of lacosamide (fig 60 page 207). The 
risk of ataxia for any dose of lacosamide was 3.02 (95% CI of 1.49 to 6.14). The risk 
was even higher with 600mg dose of lacosamide (relative risk of 4.38 with 95% CI of 
2.10 to 9.17) and the relative risk of ataxia was 2.91 for the 400mg dose of lacosamide 
(95% CI of 1.35 to 6.27).  
 
7.4.12.2 Blurred vision 
 
The relative risk of blurred vision increased with increasing dose of lacosamide (fig 61 
page 207). The risk was not significant compared to placebo for the 200mg dose; 
relative risk was 0.73 (95% CI of 0.2 to 2.62). The risk increased to 2.91 (95% CI of 
1.35 to 6.27) for the 400mg dose and 4.38 (95% CI of 2.10 to 9.17) for the 600mg 
dose. The overall risk of blurred vision was 3.02 (95% CI of 1.49 to 6.14).  
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7.4.12.3 Coordination abnormal 
 
The risk of coordination abnormal increased with increasing dose of lacosamide (fig 
62 page 208). This was significant for the 400mg, 600mg and any dose of lacosamide. 
These were 6.13 (95% CI of 1.92 to 19.51) for the 400mg dose; 5.90 (95% CI of 1.34 
to 25.93) for the 600mg dose and 6.12 (95% CI of 1.94 to 19.34) for any dose of 
lacosamide.  
 
7.4.12.4 Diplopia 
 
The risk of diplopia was significant for all doses of lacosamide and for any dose of 
lacosamide (fig 63 page 208). Relative risk for diplopia was 4.10 (95% CI of 1.41 to 
11.95) for the 200mg dose; 5.18 (95% CI of 2.40 to 11.18) for the 400mg dose; 6.61 
(95% CI of 2.63 to 16.61) for the 600mg dose of lacosamide. The relative risk of 
diplopia for any dose of lacosamide was 5.29 (95% CI of 2.49 to 11.24).  
 
7.4.12.5 Dizziness 
 
The relative risk of dizziness compared to placebo increases with increasing dose of 
lacosamide (fig 64 page 209). The risk of dizziness was 2.26 (95% CI of 1.34 to 3.79) 
for 200mg of lacosamide; 3.33 (95% CI of 2.27 to 4.88) for the 400mg dose of 
lacosamide; and 5.04 (95% CI of 3.29 to 7.72) for the 600mg of lacosamide. The 
relative risk for dizziness for any dose of lacosamide was 3.53 (95% CI of 2.46 to 
5.07).  
 
7.4.12.6 Fatigue 
 
This harm outcome was reported in Ben-Menachem (2007) and Halasz (2009) but was 
not reported in Chung (2010) (fig 65 page 209). The relative risk of fatigue was 
significant for the 600mg dose of lacosamide. The risk was 3.84 (95% CI of 1.51 to 
9.80). The risk of fatigue for any dose of lacosamide was 2.11 (95% CI of 1.12 to 
3.97). 
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7.4.12.7 Nasopharyngitis 
 
This was reported in Halasz only (2009). All relative risk estimates included unity 
therefore the risk of nasopharyngitis was not significant compared to placebo for all 
doses of lacosamide (fig 67 page 210).  
 
7.4.12.8 Nausea 
 
The relative risk of patients with nausea increased with increasing dose (fig 68 page 
211). The 200mg dose was not significant. The relative risk of nausea was 2.46 (95% 
CI of 1.43 to 4.23) for the 400mg dose; 2.44 (95% CI of 1.36 to 4.38) for the 600mg 
dose. The overall relative risk of nausea was 2.37 (95% CI of 1.44 to 3.91). 
 
7.4.12.9 Vertigo 
 
The relative risk of vertigo was 3.67 (95% CI of 1.04 to 12.9) for the 200mg dose and 
3.42 (95% CI of 0.96 to 12.19) for the 400mg dose (fig 75 page 214).  
 
7.4.12.10 Vomiting 
 
The relative risk of vomiting increased with increasing dose (fig 76 page 215). The 
risk of vomiting was 2.52 (95% CI of 1 to 6.34) for the 200mg dose; 2.95 (95% CI of 
1.56 to 5.6) for the 400mg dose and 3.64 (95% CI of 1.70 to 7.78).  
 
7.4.12.11 Adverse events with non-significant relative risks 
 
A number of adverse events were not significantly different to placebo as the relative 
risks included unity. These were: accidental injury NOS (fig 59 page 206), headache 
(fig 66 page 210), nasopharyngitis (fig 67 page 210), Nystagmus (fig 69 page 211), 
peripheral oedema (fig 70 page 212), rash (fig 71 212), somnolence (fig 72 page213), 
tremor (fig 73 page 213) and upper respiratory tract infection (fig 74 page 214).  
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8.5 DISCUSSION 
 
Lacosamide is a novel drug licensed for use in focal epilepsy. Unlike other AEDs, 
lacosamide increases slow inactivation of sodium channels.  With a new mechanism of 
action, it was hoped that lacosamide would have a beneficial effect in patients with 
focal epilepsy.  
 
The efficacy and safety of lacosamide was studied in three regulatory trials. In two of 
these (Ben-Menachem 2007 & Halasz 2009), the 200mg dose was not statistically 
significant when compared to placebo. However, the 200mg dose was significantly 
different compared to placebo using the per-protocol analysis.  For the 400mg and 
600mg doses of lacosamide, there was significant difference between lacosamide and 
placebo in all three trials.  
 
Responder rates also varied in the three trials even though they used the same study 
protocol. Responder rates ranged from 32.7% to 35% for the 200mg dose; 40.5% to 
41.2% for the 400mg dose and 38% to 41.2% for the 600mg dose. Despite a trebling of 
dose from 200mg to 600mg, there were no marked difference in responder rates 
between doses and this was reflected in the corresponding relative risks. No clear 
explanation of this is possible and one can speculate that these differences are due to a 
phenomenon of a significant treatment response to placebo.  
 
This review looked at the efficacy of lacosamide compared to placebo from data 
obtained from the three controlled trials. The results showed that the effect sizes for 
the 200mg dose was statistically significant when two trials were combined This is due 
to larger power in combining both studies and this could detect a change which is 
possibly present but was not detected in the individual trials. The relative risk of the 
responder rate was higher in the 400mg and 600mg doses. The relative risks are 1.41 
for the 200mg dose, 1.80 for the 400mg dose and 1.98 for the 600mg dose. Relative 
risks presented here for lacosamide when compared to Cochrane reviews of other 
AEDs by comparison is smaller. One can hypothesise the smaller relative risks is due 
to a relatively larger placebo response (Rheims et al 2008).   
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Seizure freedom as an outcome was included in this review. This outcome is 
uncommonly used in systematic reviews as it is infrequently reported and the 
likelihood of patients being seizure free in a 12 week RCT is more likely to be due to 
random chance. The number of seizure free patients was too small leading to wide 
confidence intervals, to evaluate seizure freedom we may need longer trial duration.  
 
Markers of tolerability were the proportion of patients who withdrew due to adverse 
events. Tolerability for the 200mg dose of lacosamide was not different from placebo 
indicating that lacosamide 200mg was tolerated well. Tolerability for the 400mg and 
600mg dose was poorer with increasing risk of withdrawals due to adverse events. 
Patients with 600mg were about three times likely to stop treatment due to adverse 
events.  
 
Part of the systematic review process includes an assessment of the risk of bias. The 
included studies pose a low risk of bias and unpublished data reduced this risk of 
reporting bias further. It is deemed that there is low risk of bias as most outcomes were 
reported. There were some quality of life outcomes that were not reported in the 
published documents but were published in abstract form.  
 
Allocation concealment was not reported in the three published trial this is indicative 
of significant bias but in this review, we clarified allocation and concealment from the 
drug sponsors.  
 
The protocols of the three trials were identical in the methods of titration and length of 
follow up. Patients were homogenous but some minor differences were seen in race. 
Despite similarities in the trials, we found differences in the individual adverse events. 
Five adverse events were reported in all three trials; these include diplopia, dizziness, 
headache, nausea and vomiting.  
 
Ataxia was reported in Ben-Menachem but not reported in the other trials. 
Coordination abnormal was reported in the other two trials (Halasz and Chung). One 
might wonder if these two outcomes are synonymous as they would be to an astute 
clinician. However, without a review of the coding methods used one should not 
synonymise these two adverse events.  
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Rash and peripheral oedema were reported in Chung et al only, the reason for this 
could be related to a higher dose of lacosamide causing these adverse events being 
reported here.  
 
Serious adverse events were reported in all three trials however the risk of serious 
adverse events was greater in the lower dose trial (Halasz 2009) as compared to Chung 
and Ben-Menachem.  
 
7.6 Why was this review important for this thesis of adverse events? 
 
This review highlighted a number of issues for this thesis. Frist the heterogeneity of 
adverse events reported in three trials, which had nearly identical protocols but only 
differed in dose regiment and escalation. One would have expected that all three trials 
would be similar in the types of adverse events reported but this was not the case. To 
our surprise, is the effect sizes for serious adverse events were higher in the low dose 
study as compared to the other studies. Adverse events such as peripheral oedema, rash 
and tremor were reported in Chung et al but not in the lower dose trials. In another trial 
of lacosamide used in neuropathic pain, we find that tremor was reported in one patient 
taking 200mg of lacosamide, five patients taking 400mg and nine patients taking 
600mg (Wymer et al 2009). Moreover, asthenia is, reported in Wymer et al but not in 
the epilepsy trials. There are three other trials that used lacosamide in neuropathic 
pain.  
 
The next question is can the harms outcome from these other trials be used in meta-
analyses if there are no significant differences in protocol? 
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7.7 CONCLUSION 
 
The results demonstrate the efficacy and safety of lacosamide in reducing seizure 
frequency using the responder rate as the outcome measure. Two studies did not find 
the 200mg dose to be efficacious compared to placebo, but our meta-analysis showed a 
marginal superiority over placebo, which was statistically significant. This could imply 
that patients need not to be titrated up to a high dose for the treatment to work and this 
would minimise adverse events.  
 
Concluding remarks 
 
• This review of lacosamide is a useful model to study adverse events as we have 
three trials that were essentially the same but differed in dose strengths. One 
would therefore expect that confidence intervals of effect sizes would be small 
and may even yield significant results. Indeed, this was the case for the 200mg 
dose of lacosamide.  
• The lower 200mg per day dose of lacosamide can be considered to be of 
marginal benefit in patients with focal epilepsy. 
• Lacosamide is effective at the 400mg and 600mg per day dose. 
• This review of lacosamide is also unique in that the first two trials of 
lacosamide had failed to acquire a drug licence for UCB due to a nuisance 
placebo treatments effect. We therefore have three large trials of lacosamide for 
inclusion here. Effect sizes were relatively larger when harms were meta-
analysed and this too could be a consequence of the placebo treatments effect.  
• In this review four other randomised controlled trials of lacosamide that were 
similar in design to the epilepsy trials were mentioned. The next chapter 
explores harms in these four neuropathy trials. 
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Figure 54 Outcome: Proportion of patients with greater than or equal to 50% 
reduction in seizure frequency 
 
 
 
 
 
	
Figure 55 Outcome: Proportion of patients who become seizure free during the 
maintenance period. 
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Figure 56 Outcome: Proportion of patients withdrawing due to adverse events 
 
 
 
 
 
	
Figure 57 Outcome:  Proportion of patients with serious adverse events 
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Figure 58 Outcome: Proportion of patients with Any Adverse Event 
 
 
 
 
 
	
Figure 59 Outcome: Proportion of patients with Accidental injury not otherwise 
specified 
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Figure 60 Outcome: Proportion of patients with Ataxia 
 
 
 
 
 
 
	
Figure 61 Outcome: Proportion of patients with Blurred Vision 
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Figure 62 Outcome: Proportion of patients with Coordination Abnormal 
 
 
 
 
 
	Figure	63	Outcome:	Proportion	of	patients	with	Diplopia 
 
 
 
 
 
		 209	
	
Figure 64 Outcome: Proportion of patients with Dizziness 
 
 
 
 
 
	
Figure 65 Outcome: Proportion of patients with Fatigue 
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Figure 66 Outcome: Proportion of patients with Headache 
 
 
 
 
 
	
Figure 67 Outcome: Proportion of patients with Nasopharyngitis 
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Figure 68 Outcome: Proportion of patients with Nausea 
 
 
 
 
 
	
Figure 69 Outcome: Proportion of patients with Nystagmus 
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Figure 70 Outcome: Proportion of patients with Peripheral Oedema 
 
 
 
 
 
 
 
	
Figure 71 Outcome: Proportion of patients with Rash 
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Figure 72 Outcome: Proportion of patients with Somnolence 
 
 
 
 
 
 
	
Figure 73 Outcome: Proportion of patients with Tremor 
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Figure 74 Outcome: Proportion of patients with URTI 
 
 
 
 
 
 
	
Figure 75 Outcome: Proportion of patients with Vertigo 
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Figure 76 Outcome: Proportion of patients with Vomiting 
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Chapter 8 
 
 
 
 
Adverse Events across indications: The Lacosamide example 
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8.1 Introduction 
 
The previous chapters established that harms reporting is poor in RCTs and using 
lacosamide as an example we explored harms in systematic reviews.  We also learnt 
that poor reporting is heterogeneous and this affects some aspect of harms reporting 
more than others. Furthermore, items in the methods section are reported the poorest as 
opposed to the results and discussion sections. This therefore makes the ascertaining of 
the risk of bias harder for a reviewer.  
 
Antiepileptic drugs are used primarily to treat patients with epilepsy. These drugs can 
be used in other indications either as a licensed or as an off-license indication. These 
areas would include headache syndromes like cluster headache, migraine, SUNCT 
(short-lasting unilateral neuralgiform headache and conjunctival injection and tearing) 
and various painful peripheral neuropathies conditions like diabetic neuropathy and 
CIDP (chronic inflammatory demyelinating polyneuropathy). It would be likely that 
other trials of AEDs in indications other than epilepsy may exist and a drug company 
to obtain a licence may conduct these or they may be independent from industry as an 
exploratory trial.  
 
Writing a systematic review is a structured process with the selection of outcomes and 
analysis of outcomes followed by an evaluation of the risk of bias. Most systematic 
reviews and meta-analyses include placebo-controlled trials. These trials are 
commonly funded by industry to obtain a license. Once a license is obtained, it is 
unlikely there will be another placebo-controlled trial in the same area but it is 
conceivable there may be placebo-controlled trials in other indications. These 
additional trials may be useful for improving harms data in systematic reviews.  
 
Here I discuss how trials of lacosamide from other indications improve adverse events 
reporting.  
 
 
 
 
 
		 218	
8.2 Clinical trials of lacosamide: the other studies 
 
8.2.1 Other indications for lacosamide 
 
The use of lacosamide in partial epilepsy has now become common practice. When 
searching for studies of lacosamide in partial epilepsy; three placebo controlled trials 
of lacosamide for partial epilepsy were found. It was noted that there were other trials 
of lacosamide in the treatment of neuropathic pain. The idea that lacosamide can be 
used for neuropathic pain stemmed from experimental data, these showed that 
lacosamide reduced painful symptoms in rat models of diabetes (Beyreuther et al 
2007). Following this there have been four trials in patients with painful diabetic 
neuropathy (Rauck et al 2007) (Shaibani et al 2009) (Wymer et al 2009) (Ziegler et al 
2010). These trials did not meet regulatory approval for clinical use in neuropathy 
patients.  
 
8.3 Searches for clinical trials 
 
Using the search strategy of lacosamide in partial epilepsy. Searches were made in 
MEDLINE via the PubMed interface, the Cochrane database and OVID databases.  
Four trials of lacosamide in neuropathy were found. Description of inclusion and 
exclusion criteria is addressed in the next section.  A diagram of the search results is 
displayed in fig 77 page 219. Searches revealed four studies of lacosamide in painful 
diabetic neuropathy (PDN) and three studies in Lacosamide in partial epilepsy. One 
study of intravenous lacosamide was excluded. 
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Figure 77 Flow diagram of included and excluded lacosamide studies 
 
8.4 Inclusion and Exclusion criteria 
 
Included trials were those of lacosamide in patients with painful neuropathy Trials 
needed to have a comparator arm which should be placebo. Trials have to be 
conducted on human subjects. Observational studies and trials not in English were 
excluded. A list of inclusion and exclusion criteria is shown below. 
Included: 
1. Randomised trials 
2. Double blinded 
3. Placebo controlled 
4. Lacosamide studies 
Excluded: 
1. Observational studies 
2. Trials not in English 
 
Search for RCTs 
using Medline and 
OVID 
 7 
Pharmacokinetic 
Trials  
2 Secondary 
reports of RCTs  
 2 Intravenous 
versus oral 
admission of 
Lacosamide  
 7 Placebo 
controlled RCTs  
 1 EEG RCT  
4 Neuropathy 
RCTs 
3 Epilepsy 
RCTs 
EX
C
LU
D
ED
 
INCLUDED 
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8.5 Summary of clinical trials of painful diabetic neuropathy and partial epilepsy  
 
8.5.1 Description of studies 
 
All four trials used similar doses of lacosamide and all participants were with patients 
with painful diabetic neuropathy (PDN). The comparator group in seven trials was 
placebo.  The primary outcomes were a change in pain score of a greater than 2-point 
reduction of on numerical rating scales. The patients’ global impression of change 
(PGIC) is a generic validated tool to monitor a change in any patient related outcome 
(Hurst & Bolton 2004). The tables below describe the trials briefly. In addition, trials 
used in epilepsy are shown below although details of these trials are in chapter seven.  
 
One can see from tables 46 and 47, that in all seven trials, lacosamide doses were 
similar; titration rates are similar across all seven trials. The titration period was 6 
weeks in all seven trials. Maintenance phase for all six trials was the same. Therefore, 
there is no difference between these studies in terms of their methodological 
differences. Hence, as far as harms outcomes are concerned, these seven trials could 
undergo meta-analysis. 
 
Trial Patients Primary 
outcome 
Dose of 
Active 
interventio
n 
Compa
rator 
Harms 
outcomes 
Titration Phase 
Duration 
Rauck 
2007 
Patients 
with 
PDN 
Change in 
pain score  
& PGIC 
Lacosamide 
400mg 
Placebo Adverse 
events & 
withdrawals 
100mg/day/
week plus 
back 
titration 
from 400mg 
to 300mg 
6 wk 
Titration 
4wk 
Maintenance 
Shaibani 
2009 
Patients 
with 
PDN 
Change in 
pain score  
& PGIC 
Lacosamide 
200mg, 
400mg and 
600mg 
Placebo Adverse 
events & 
withdrawals 
100mg/day/
week 
6 wk 
Titration 
12 wk  
Maintenance 
Wymer 
2009 
Patients 
with 
PDN 
Change in 
pain score  
& PGIC 
Lacosamide 
200mg, 
400mg and 
600mg 
Placebo Adverse 
events & 
withdrawals 
100mg/day/
week 
6 wk  
Titration 
12 wk 
Maintenance 
Ziegler 
2010 
Patients 
with 
PDN 
Change in 
pain score  
& PGIC 
Lacosamide 
400mg and 
600mg 
Placebo Adverse 
events & 
withdrawals 
100mg/day/
week 
6 wk 
Titration 
12 wk  
Maintenance 
Table 46 Description of lacosamide trials used in neuropathy: peripheral diabetic neuropathy (PDN)		
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Trial Patients Primary 
outcome 
Dose of 
Active 
interventio
n 
Compa
rator 
Harms 
outcomes 
Titration Phase  
Duration 
Ben-
Menachc
hem 2007 
Patients 
with 
focal 
epilepsy 
Proportion 
of patients 
with >50% 
reduction in 
seizures 
Lacosamide 
200mg 
400mg and 
600mg 
Placebo Adverse 
events & 
withdrawals 
100mg/day/
week 
6 wk 
Titration 
4wk 
Maintenance 
Halasz 
2009 
Patients 
with 
focal 
epilepsy 
Proportion 
of patients 
with >50% 
reduction in 
seizures 
Lacosamide 
200mg, 
400mg  
Placebo Adverse 
events & 
withdrawals 
100mg/day/
week 
6 wk 
Titration 
4wk 
Maintenance 
Chung 
2010 
Patients 
with 
focal 
epilepsy 
Proportion 
of patients 
with >50% 
reduction in 
seizures 
Lacosamide  
400mg and 
600mg 
Placebo Adverse 
events & 
withdrawals 
100mg/day/
week 
6 wk 
Titration 
4wk 
Maintenance 
Table 47 Description of lacosamide trials used in epilepsy. 
 
8.5.2 Outcome measures in painful diabetic neuropathy trials 
 
The primary outcomes in trials for neuropathy and epilepsy are different; seizure 
outcomes are not the same as pain outcomes. However, adverse events could be 
summated in meta-analyses. It is further noted that all trials used a similar weekly 
titration scheme. Patients were allowed back titration is some arms (Chung et al 2010 
with the 600mg dose) and Wymer et al compared two 400mg doses one with a 6-week 
titration and one with a 4-week titration but both arms were at 100mg/day/week 
increments (2009). With similar titration schemes in these studies, one can assume that 
withdrawals due to harms can be compared.  
 
8.6 Hypothesis 
 
Given that the drug doses, titration schedules and duration of trial is similar in the 
included studies, one would hypothesize that any differences between outcomes 
measures in individual trials is due to clinical differences.  
 
The null hypothesis is that there will not be significant statistical heterogeneity and 
therefore these harms data can be combined in a meta-analysis. Where the null 
hypothesis is defined as: 
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H0 = Chi sq with n degrees of freedom has a p value > 0.05 
 
Or  
 
H0 = Tau squared is low with p > 0.05 
 
Some harms outcomes like headache, nystagmus and somnolence were not 
significantly different compared to placebo in the lacosamide trials. An important 
question is if data from neuropathy trials may change the direction of the effect in 
meta-analyse or yield a more precise summary estimate.  
 
Also, we took a more pragmatic approach to see if harms across indications could give 
us better precision in effect sizes  
 
8.7 Methods  
 
8.7.1 Results from epilepsy trials 
 
It is important to note that headache and somnolence were not significant compared to 
placebo in trials of epilepsy when these outcomes were meta-analysed. The relative 
risk of headache in lacosamide for any dose was 1.35 with 95% confidence interval of 
0.83 to 2.19 including unity. The relative risk of somnolence was 1.44 with 95% CI of 
0.81 to 2.57 including unity. It would be important to see if these outcomes became 
statistically significant when data from neuropathy trials were pooled. 
 
8.7.2 How the data was extracted. 
 
Harms data was extracted from selected trials, given that this was not a formal 
Cochrane review. Items of data that were collected include; the proportion of patients 
with Lacosamide or placebo that experienced adverse events. The proportion of 
patients that have any adverse events and the proportion of patient withdrawn due to 
adverse events.  
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8.7.3 Data analysis 
 
In the previous chapter a fixed effect model was used. However, when we meta-
analyse trials from other indications, this would not be appropriate and therefore the 
random effects model will be used. This may have an impact on the precision of 
summary estimates by producing estimates with a wider confidence interval and 
therefore less precise estimates  
 
Summary measures of the risk of adverse events were calculated using the Mantel-
Henszel method. Using measures of heterogeneity, decisions were made if harms from 
across indications can be used. These measures include: Chi squared statistic, I2 and 
tau squared statistics. Data was analysed using RevMan 5.0. Forest plots displaying 
summary measures and statistics of heterogeneity were used to make decisions if the 
null hypothesis is true or false.  
 
Details of the rationale and theory of meta-analyses have been described in preceding 
chapters. 
 
8.8 Results  
 
To decide which adverse events are evaluable, only those adverse events, which are 
reported in at least one epilepsy trial and one neuropathy trial, were included. The table 
below (table 48) shows those that are for inclusion. In addition to adverse events, , 
withdrawals due to adverse events and the total number of adverse events were also 
analysed.  
 
Thirty-six discreet adverse events were reported across all trials. Out of these 19 were 
reported in the neuropathy trials. Twelve adverse events are reported in both 
indications but not necessarily in all trials. Six adverse events were reported in 
epilepsy trials and not neuropathy trials.  
 
Adverse events that were reported only in neuropathy trials include: Abdominal pain; 
anxiety; asthenia; back pain; balance disorder; constipation; diarrhoea; erythematous 
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rash; flatulence; hypoesthesia; hypoglycaemia, influenza; memory impairment; 
myalgia; nervousness; paraesthesia; pruritus; sinusitis and tachycardia.  
 
Adverse events that were reported in epilepsy trials only include; accidental injury; 
ataxia; coordination abnormal; vision abnormal and nystagmus.  
 
There are twelve harms outcomes that are reported in both indications. These adverse 
events include; Diplopia; dizziness; fatigue; headache; nasopharyngitis; nausea; 
somnolence; tremor; URTI; vertigo; vision blurred and vomiting. Also evaluated were 
‘any adverse event’ and withdrawals due to adverse events.  
 
The table below (table 48 page 225) shows a list of adverse events reported in all seven 
lacosamide trials. Outcomes that are reported in at least one epilepsy and at least one 
neuropathy trials are highlighted in red. These outcomes are therefore included in 
analyses.  
 
Figures 78 to 89 on pages 226 to 237 display the forest plots and statistical tests of 
heterogeneity for outcome analysed.  
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Table 48 Harms outcomes reported in seven lacosamide trials 
Harms outcome Ben-Menachem 2007 Chung 2010 Halasz2007 Shaibani 2009 Rauck 2007 Wymer 2009 Ziegler 2010 
Abdominal pain     ✔   
Accident NOS ✔       
Anxiety     ✔   
Asthenia      ✔  
Ataxia ✔       
Back pain    ✔ ✔ ✔  
Balance disorder    ✔  ✔  
Constipation     ✔   
Coordination abnormal  ✔ ✔     
Diarrhoea    ✔ ✔ ✔  
Diplopia ✔ ✔ ✔   ✔  
Dizziness ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Erythematous rash     ✔   
Fatigue ✔  ✔ ✔  ✔ ✔ 
Flatulence    ✔    
Headache ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Hypoesthesia    ✔    
Hypoglycaemia     ✔   
Influenza      ✔  
Memory impairment      ✔  
Myalgia     ✔   
Nasopharyngitis   ✔   ✔  
Nausea ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Nervousness     ✔   
Nystagmus ✔ ✔      
Paraesthesia     ✔   
Pruritus    ✔    
Sinusitis    ✔    
Somnolence ✔ ✔  ✔ ✔   
Tachycardia     ✔   
Tremor  ✔  ✔ ✔ ✔  
URTI ✔    ✔ ✔  
Vertigo   ✔ ✔  ✔ ✔ 
Vision abnormal ✔       
Vision blurred  ✔  ✔    
Vomiting ✔ ✔ ✔ ✔   ✔ 
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8.8.1 Any Adverse Event: Meta-analysis using the Random effects model 
 
	
Figure 78 Proportion of patients with Any Adverse Event across indications 
 
Any adverse event was reported in Ben-Menachem (2007) only and not the other three 
epilepsy trials. (Halasz 2009) (Chung 2010). Any adverse event was reported in three 
neuropathy trials (Rauck 2007, Shaibani 2009 and Wymer 2009). All four subgroups 
showed a Tau squared of 0.00 to 0.01 indicating no variance between studies. A quick 
view of the chi squared shows that the chi squares relative the degrees of freedom is 
not significantly different therefore the p-values are non-significant. Using both these 
methods one can conclude there is no significant heterogeneity. The effect sizes 
showed moderate variation and this was reflected in the value of I2 proportions ranging 
from 39% to 59%.  
 
Null hypothesis therefore is true but there is an increase in variance of summary 
measures when outcome any adverse event is meta-analysed.  
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8.8.2 Dizziness: Meta-analysis using the Random effects model 
 
	
Figure 79 Proportion of patients with Dizziness across indications 
 
For dizziness, all seven trials were included in the analysis. Tau squared statistics in 
the subgroups is between 0 and 0.02. This indicates there is no between study variance. 
The effect sizes across the studies do not vary significantly and therefore the I2 
proportions are low. P values for chi-squared statistic show no significant differences 
therefore one can conclude there is no statistical heterogeneity between trials.  
 
Null hypothesis is true for this outcome. 
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8.8.3 Fatigue: Meta-analysis using the Random effects model 
 
	
Figure 80 Proportion of patients with Fatigue across indications 
 
For fatigue, two epilepsy trials (Ben-Menachem 2007 and Halasz 2009) were included 
and three neuropathy trials (Shaibani 2009, Wymer 2009 and Ziegler 2010). Tau 
squared across subgroups is low indicating no variance in between studies. I2 
proportions are low and chi squared statistic values are low and p values are non-
significant. These indicate that outcome fatigue has no statistical heterogeneity 
between studies.  
 
Null hypothesis is true for this outcome. 
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8.8.4 Headache: Meta-analysis using the Random effects model 
 
	
Figure 81 Proportion of patients with Headache across indications 
 
For outcome headache, all seven studies were included. There was no between study 
variance as Tau squared statistic values ranged from 0 to 0.06. Some heterogeneity 
was seen in the effect sizes for the 400mg subgroup with an I2 value of 27%. Chi 
squared values were low except for the 400mg dose with a Chi squared of 8.23 with 6 
degrees of freedom. However, the p value was 0.22 indicating that the null hypothesis 
can be accepted as true and there was no evidence of statistical heterogeneity between 
indications for this outcome.  
 
Null hypothesis is true for this outcome 
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8.8.5 Nasopharyngitis: Meta-analysis using the Random effects model 
 
	
Figure 82 Proportion of patients with Nasopharyngitis across indications 
 
For outcome nasopharyngitis, one epilepsy trial (Halasz 2009) and one neuropathy trial 
(Wymer 2009) was included. Both trials showed no significant difference in relative 
risks of nasopharyngitis compared to placebo. Calculated summary measures showed 
no significant difference compared to placebo for the three dose subgroups of 200mg, 
400mg and any dose. Tau squared statistics showed no or low variance between 
studies for the 200mg and any dose but there was significant variance in the 400mg 
dose between studies with a corresponding I2 value of 64% indicating significant 
statistical heterogeneity.  
 
Therefore, one can conclude that trials across indications for this outcome cannot be 
meta-analysed.  
 
Null hypothesis is not true for this outcome. 
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8.8.6 Nausea: Meta-analysis using the Random effects model 
 
	
Figure 83 Proportion of patients with Nausea across indications 
 
For outcome nausea, all seven trials were included. There was no variance between 
studies reflected by the low values of Tau squared. Heterogeneity was low reflected in 
low I2 values and chi squared values were low. For the 400mg dose the chi squared 
was 7.23 with 6 degrees of freedom, hence the p value was 0.30 indicating the null 
hypothesis is true. Therefore, one can conclude that trials across indications can be 
used for this outcome.   
 
Null hypothesis is true for this outcome. 
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8.8.7 Somnolence: Meta-analysis using the Random effects model 
 
	
Figure 84 Proportion of patients with Somnolence across indications 
 
For outcome somnolence two epilepsy trials (Ben-Menachem 2007 and Chung 2009) 
and two neuropathy trials (Shaibani 2009 and Rauck 2007) were included. The relative 
risk of somnolence from lacosamide in patients recruited into Shaibani (2009) was 
significantly greater compared to the other three trials. Statistical heterogeneity was 
present for only two subgroups; the 200mg and 600mg doses.  
 
Tau squared showed some variance between studies largely due to variance between 
Shaibani (2009) and the other studies. The differences in somnolence to some extent 
could be due to chance. Moreover, the I2 statistic suggested that about 60% of the 
variance could be due to chance alone and the remaining 39% is due to real 
differences.  
 
Null hypothesis is true for this outcome. 
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8.8.8 Tremor: Meta-analysis using the Random effects model 
 
	
Figure 85 Proportion of patients with Tremor across indications 
 
For outcome tremor, one epilepsy trial (Chung 2010) and three neuropathy trials 
(Rauck 2007, Shaibani 2009 and Wymer 2009) were included. The effect sizes for the 
neuropathy trials were significantly greater compared to the epilepsy trial. This was 
evident in the 400mg and 600mg subgroups. Tau squared in these two subgroups 
showed values of 0.59 and 2.26 indicating significant variability between studies. One 
can conclude that trials from neuropathy cannot be combined with epilepsy trials in a 
meta-analysis.   
 
Null hypothesis is not true for this outcome. 
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8.8.9 Vertigo: Meta-analysis using the Random effects model 
 
	
Figure 86 Proportion of patients with Vertigo across indications 
 
For outcome vertigo, one epilepsy trial was included (Halasz 2009) and three 
neuropathy trials (Shaibani 2009, Wymer 2009 and Ziegler 2010). There was little 
variance between studies reflected in the low Tau squared values. There was no 
significant statistical heterogeneity reflected in the low I2 values. The outcome vertigo 
can be used across indications for lacosamide.  
 
Vertigo was not reported in Chung 2010 and Ben-Menachem (2007) in the 600mg 
dose.  
 
Null hypothesis is true for this outcome 
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8.8.10 Vision Blurred: Meta-analysis using the Random effects model 
 
	
Figure 87 Proportion of patients with Vision Blurred 
 
For the outcome vision blurred, two epilepsy trials (Chung 2010 and Ben-Menachem) 
and one neuropathy trial (Shaibani 2009) were included. There was little variance 
between studies reflected in the low Tau squared values. P-value for I2 were non-
significant indicating no heterogeneity. One can therefore conclude that vision blurred 
can be used across indications for lacosamide.  
 
Null hypothesis is true for this outcome.  
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8.8.11 Vomiting: Meta-analysis using the Random effects model 
 
	
Figure 88 Proportion of patients with Vomiting across indications 
 
For outcome vomiting, three epilepsy trials (Halasz 2009, Ben-Menachem 2007 and 
Chung 2010) and two neuropathy trials (Shaibani 2009 and Ziegler 2010) were 
included. Tau squared values were low for all subgroups and p-values for chi squared 
were not significant. Therefore, there is no significant heterogeneity for outcome 
vomiting.  
 
Null hypothesis is true for this outcome. 
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8.8.12 Withdrawals due to Adverse Events: Meta-analysis using the Random 
effects model 
 
	
Figure 89 Proportion of patients withdrawing due to adverse events across indications 
 
For tolerability outcome of withdrawals due to adverse events, three epilepsy trials 
(Halasz 2009, Ben-Menachem 2007 and Chung 2010) and four neuropathy trials 
(Rauck 2007, Shaibani 2009, Wymer 2009 and Ziegler 2010) were included. 
Some heterogeneity was noted for the 200mg subgroups when we compared 
withdrawals due to harms. There were more withdrawals in Ben Menachem as 
compared to Halasz and the other two neuropathy trials (Shaibani 2009) (Wymer 
2009). This could possibly be explained by random chance, as withdrawals were 
similar for the 400mg and 600mg subgroups.  
 
Null hypothesis is true for this outcome. 
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8.9 Summary of Results 
 
Comparisons with adverse event results from systemic reviews of lacosamide in 
epilepsy trials showed that fatigue was the only outcome that changed effect size to 
yield a significant result when neuropathy trials were combined was fatigue. For the 
400mg dose of lacosamide, the summary measure was 2.0 (95% CI of 1.0 to 4.03) and 
this changed to 1.98 (95% CI of 1.11 to 3.52) when neuropathy trials were combined 
(figure 80). This is interesting as we used random effects models, had we used fixed 
effects model, then we would have expected the confidence intervals would have been 
narrower.  
 
For outcome somnolence, there was no significant change in the overall summary 
measures. The effect sizes for somnolence in Shaibani (2009) ranged from 6.97 to 11.9 
compared with 0.98 to 1.95 in the epilepsy trials; there was no overall change in the 
confidence intervals. A similar phenomenon occurred with outcome tremor where the 
effect sizes from the neuropathy trials were significantly greater but not enough to alter 
the overall result.  
 
The following adverse events did not change substantially in effect size or confidence 
intervals: any adverse event; dizziness; headache: nasopharyngitis; nausea: vertigo and 
vision blurred.  
 
A summary of the results is displayed in a table below (table 49 page 239). Only two 
outcomes were not possible to be summated, as the null hypothesis was not true. One 
can conclude that harms across indications for lacosamide can be utilised in meta-
analyses across indications.  
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Outcome Possible to combine effect sizes? 
Any AE Yes 
Dizziness Yes 
Fatigue Yes 
Headache Yes 
Nasopharyngitis No 
Nausea Yes 
Somnolence Yes 
Tremor No 
Vertigo Yes 
Vision Blurred Yes 
Vomiting Yes 
Withdrawals Yes 
Table 49 Final summary of judgements for harms due to lacosamide 
 
8.10 DISCUSSION 
 
This chapter discussed adverse events across indications for lacosamide.  Lacosamide 
is a novel antiepileptic drug that is used in neuropathy and epilepsy trials. Seven 
lacosamide trials were found with overall duration and design of trials to be similar. 
The only differences were attributable to clinical differences between patients. An 
important difference between the two groups of patients would be additional drugs 
taken by these patients in addition to the study drug. In the three epilepsy trials these 
may include other anticonvulsants. In the neuropathy trial patients, other 
anticonvulsants were barred from inclusion but antidepressants were allowed.  
 
One would have expected that effect sizes would be dramatically different in all 
outcomes as there are significant clinical differences in trial populations. However, 
differences in effect sizes were seen in only two outcomes namely somnolence and 
fatigue. Patients recruited in neuropathy trials experienced more somnolence and 
fatigue compared to epilepsy patients. One can speculate these are due to clinical 
differences caused by an effect of add-on drugs used by patients. In epilepsy trials the 
add-on drugs were other AEDs and in the neuropathy trials patients were barred if they 
took anticonvulsants, but were allowed to take antidepressants. Therefore, one can 
envisage that neuropathy trials are essentially lacosamide monotherapy studies and a 
comparison of harms is made between the two. One would expect that harms would be 
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greater in the epilepsy trials, especially with regards to fatigue and somnolence but we 
find that the opposite is true. The reasons for this cannot be fully explained.   
 
Fatigue and somnolence was greater in neuropathy trials compared to epilepsy trials 
and this may be reflective of clinical reasons- older age group and higher co-
morbidities.  
 
Only fatigue changed direction to reach statistical significance for the 400mg dose 
when data from neuropathy trials were summated. 
 
Lacosamide patients in neuropathy trials were not allowed AEDs but were allowed to 
take antidepressants. Lacosamide patients in epilepsy trials are allowed to take other 
AEDs.   
.  
Statistical tests of heterogeneity were used to compare if there was any in 
heterogeneity when trials were combined. It was demonstrated that the null hypothesis 
was true for all outcomes except nasopharyngitis and tremor. However, the null 
hypothesis was true for fatigue and somnolence largely because of wide confidence 
intervals. This is illustrative of the fact that statistical tests of heterogeneity like the 
chi-squared test have low power in detecting this. Therefore, one cannot completely 
rely on statistical tests of heterogeneity and other tests like the I-squared statistics and 
simply an observation of the effect sizes could be utilised in making judgements. 
Further tests, which can be used to explore heterogeneity, include meta-regression. 
However, this was not done in this chapter but will be explored in the next chapter.   
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8.11 Conclusions 
 
• Harms across indications can be used for meta-analysis of lacosamide in 
systematic reviews and these can be meta-analysed by the usual method found 
in RevMan 5.0.  
• Nineteen adverse events that were not reported in the epilepsy trials but were 
reported in the neuropathy trials. This  clearly suggests that outcome reporting 
bias exists. This result is contrary to what was discussed in the previous 
chapter. These harms could have occurred in epilepsy patients too but were not 
reported in the unpublished epilepsy data. A recent study by Hodkinson et al 
compared the reporting of harms in journal publications and clinical study 
reports of orlistat (2014). The authors found that published journals report 
subset of harms and not the entirety of the data in clinical study reports 
(Hodkinson et al 2014 unpublished). 
• The next question is if harms across indications can be used for the other 
antiepileptic drugs. This will be discussed in the next chapter. 
• Only one harms outcome yielded a change in significance when harms from 
other indications were summated. This may be an important finding for may be 
due to chance.  
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Chapter 9 
 
 
 
 
Harms across indications: Issues in Meta-analysis. 
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9.1 Introduction 
 
From previous chapters, we learnt that adverse event data from lacosamide neuropathy 
trials could be used in systematic reviews for epilepsy. A number of differences were 
noted, some adverse events reported in neuropathy trials were not reported in epilepsy 
trials and vice versa.  There were differences in the proportion of adverse events as 
well with some adverse events occurring more commonly in one trial than another. 
Despite some differences between trials, one can conclude that overall there was no 
significant heterogeneity between neuropathy and epilepsy trials and using these 
additional trials may provide additional harms data for analysis. This therefore raises 
the question if harms data from other indications can be incorporated in meta-analysis.  
 
This chapter formulates a hypothesis of how harms form other indications could be 
used and this is followed by the methodological problems encountered and the results.  
 
Several AEDs have been used in other indications. Broadly speaking these conditions 
include headache disorders and neuropathies. Headache conditions can be primary 
headache disorders like migraine or SUNCT (short lasting unilateral neuralgic 
headache and conjunctiva tearing) and some secondary headache disorders. 
Neuropathies that use AEDs include mostly diabetic neuropathy; idiopathic 
neuropathy or hereditary neuropathy. Description of every individual condition is 
beyond the scope of this thesis.  
 
9.2 Hypothesis 
 
Harms outcomes from trials of other indications could be summated in a meta-analysis 
if no or little significant statistical heterogeneity or variance exists in the effect sizes of 
adverse events.  The null hypothesis could be defined in two ways: 
 
H0 = Q i is low with p > 0.05  
 
Where H0 is the null hypothesis, Q i is the variance between indications and p is the 
significance level. 
Alternatively, the variance of the trials is not different between indications: 
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H0 = R2 is low.  
 
A description of R2 is provided in later sections. 
 
9.3 Aims 
1. To determine if harms data from epilepsy trials can be included in 
summated with harms data from either neuropathy or headache trials. 
2. To explore statistical methods used for analysis of harms across indications. 
3. To test the hypothesis using meta-analysis and meta-regression methods 
(Prove in the null hypothesis). 
4. To provide recommendations for further work. 
 
9.4 Methods  
 
9.4.1 Inclusion of AEDs 
 
To analyse harms in other indications, trials in at least one non-epilepsy indications 
and one-epilepsy indications were used. This is because to summate the indications 
one would need at least one of each indication. 
 
A list of AEDs that could be included is shown below. All of the AEDs with the 
exception of carisbamate are currently used in clinical practice. Some of the AEDs 
shown here may have had trials in other indications but are not in current clinical use 
for example topiramate is used in headache disorders, but is not used in neuropathic 
pain. Trials were selected regardless of whether they were in clinical use as any 
information on harms may be important.  
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 Headache Disorders Neuropathic disorders 
Lacosamide  ✔ 
Topiramate ✔ ✔ 
Lamotrigine ✔ ✔ 
Gabapentin ✔ ✔ 
Pregabalin  ✔ 
Oxcarbazepine ✔ ✔ 
Carisbamate ✔  
Valproate ✔ ✔ 
Table 50 AEDs for inclusion 
 
9.4.2 Clinical trials: Inclusion and Exclusion criteria 
 
Trials conducted in adults or mixed age populations were used.  Included trials would 
have to be placebo controlled as the comparator group. Trials published till 2011 were 
used, trials recruiting children were excluded as harms outcomes are reported poorly in 
these studies (Shukralla et al 2011). Trials excluded were those where the outcome was 
a neuropsychological outcome measure as these were secondary reports of other trials. 
Also excluded were observational studies as studies needed to have a placebo group. 
 
9.4.3 Selection and searches of clinical trials 
 
Search terms were: “epilepsy”, “headache” and “neuropathy” to search for trials across 
indications. Additional words used were “migraine” and “diabetic neuropathy”. Any 
trial that was not found via Medline was obtained from the Cochrane Register of 
Clinical Trials and the British Library. Given the large number of trials to be searched, 
inter-rater agreement statistical tests of selection of clinical trials were not carried out. 
No attempt was made to collect unpublished data as the anticipated number of trials 
was expected to be large, making it impossible to contact all relevant study sponsors. 
Selected studies were catalogued and data extracted from them. 
 
9.4.4 Data extraction. 
 
Only harms data and withdrawal data were collected, efficacy outcomes were not used 
as efficacy in not the focus of this thesis.  Tolerability outcome such as withdrawal 
data was collected too.  
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Data extracted from trials included harms data and details of the clinical trial that was 
relevant to the research question. Details of trial, authors and dates of publication were 
collected.  Harms data collected included proportion of patients with specific adverse 
events and proportion of patients that withdrew due to adverse events. Some trials 
would report the total number of patients that report any adverse events and this was 
extracted also.  
 
This was an observational study of harms and therefore selection of trials, extraction of 
data and analysis was not blinded and was not subject to random allocation.  
 
9.4.5 Outcomes measures 
 
When choosing which adverse events to compare across trials, problems were 
encountered with nomenclature. Terms of harms may vary between studies. Trials may 
use different terminology to mean a specific harms outcome. An example of this is the 
outcome fatigue. Some trials report this as fatigue whereas others use the term 
asthenia. These two outcomes in theory could be considered synonymous. However, 
asthenia is also synonymous with weakness. There is no consensus if these outcomes 
can be summated into a single outcome called fatigue. To combine synonymous 
outcomes together would seem reasonable but this was not done, as there are no rules 
in deciding which outcomes are synonymous.  
 
Thirty possible adverse events could be analysed however this would be an exhaustive 
task. Therefore, common harms were chosen and decided in a short list of harms 
shown below.  
 
1. Dizziness 
2. Ataxia 
3. Headache 
4. Fatigue 
5. Nausea 
6. Somnolence 
 
Other harms outcomes were used included: 
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• Any adverse events (if outcome reported)  
• Proportion of patients who withdraw due to adverse events (if outcome 
reported)  
 
9.4.6 Outline of analysis  
 
	
Figure 90 Outline if analysis methods used in exploring heterogeneity 
 
To test the hypothesis, RevMan 5.0 and Comprehensive Meta-Analysis Version 3.0 
(CMA 3.0) versions of software were used. RevMan was used to explore heterogeneity 
and CMA was used to explore heterogeneity further. Both methods were used to make 
a decision. An outline to the process is shown in the figure above. Details of meta-
analysis and meta-regression have been discussed in earlier chapters.  
 
Meta-analysis as a traditional method to explore heterogeneity lacks power and meta-
regression is a useful way to explore any additional heterogeneity.  
Pairs of indications compared 
 
Epilepsy vs. Epilepsy Plus other 
indication 
Meta-analysis using RevMan 5.0 
All indications compared 
Meta regression using CMA 3.0 
I2 and Summary measures Validity of Models, Goodness of Fit, I
2 
and log of summary measures 
AED and outcomes 
Judgments on if indication pairs can be 
summated 
Judgments if indications pair or pairs can 
be summated  
Overall Decision 
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To test the hypothesis, comparisons between summary measures of epilepsy trials and 
measures from combined indication trials. Differences in effect sizes though visual 
inspection were commented upon and if there were any difference between them.  A 
Student’s t-test would not be sensitive to detect small differences when comparing 
differences in effect sizes. To compare any differences in heterogeneity, I2,, Q statistics 
and Tau squared statistics to measure variance were used.  
 
Summary effect measures and heterogeneity data for harms were generated using 
RevMan Version 5.0.  The results and calculations are presented in a way where by 
summary measures of trials in epilepsy are displayed alongside summary measures 
with trials from two indications. Any differences were commented upon and if there 
existed any changes in I2 scores. If there was a decrease in heterogeneity this suggests 
that any clinical differences between indications are mild and do not affect the 
summary measures. If there is no change in heterogeneity then there may be a good 
argument in combining summary measures and if there was an increase in 
heterogeneity then clinical differences exist to the extent that harms outcomes could 
not be combined.  
 
9.4.7 Analyses using statistical tests of heterogeneity (RevMan 5.0) 
 
Using RevMan 5.0 calculations of the relative risks of an adverse event compared to 
placebo were made. Wherever possible, these were sub-grouped by dose. If dose data 
was not available, any dose as the sub-group was used.  
 
AEDs that were sub-grouped by dose were: pregabalin, topiramate and carisbamate. 
The other AEDs could not be sub-grouped by dose as these may have been non-
overlapping (gabapentin) or reporting of trials was poor and did not have this data 
available for a significant number of studies.  
 
Our aims are not to sub-total relative risks into summary measures, but to describe any 
heterogeneity and any variance in the effect sizes. We compared effect sizes when 
epilepsy trials were used for each dose and then compared the effect sizes when the 
trials from other indications are summated with those of epilepsy.  
		 249	
As discussed in chapter five, in-between study variance is given by the Tau statistic. 
This in-between study variance can be calculated in RevMan 5.0 and displayed as the 
Tau squared statistic (τ2).  Tau squared statistic is an indicator of the dispersion of the 
individual study effect size around the summary measure. If the precisions of the 
summary measures are wide and if the individual effect sizes are significantly varied, 
then this will not be reflected as a high tau squared value. Tau squared values can 
range from zero to 1.0.  
 
Another way of describing the variance between the summary measures is the chi-
squared statistic (χ2). If the chi squared value and the degrees of freedom are similar 
then the null hypothesis can be accepted as true This is interpreted by looking at he p-
value and if p is > 0.10 then there is no variance in the summary measures.  
 
As mentioned in chapter five, heterogeneity can be assessed by calculating I2, this is a 
measure of how much of the variance is real and how much of the variance is random 
error. Interpretation of finding was based on making qualitative judgments for each 
individual AED subgroup. If the values of tau or chi indicated no significant in-
between study variance then this could indicate that trials across indications could be 
used with epilepsy trials. However, the only caveat to this is if the effect sizes differed 
in magnitude by a significant amount, this could indicate there may be some 
unexplained variance cause for this other than indication. We commented on effect 
sizes for harms in epilepsy trials and when epilepsy and other indications were 
combined. 
 
The result of these was compared with the decisions from meta-regression and an 
overall decision was made.  
 
9.4.8 Analyses using meta-regression (CMA version 3.0) 
 
This complemented the earlier method. The aims of using meta-regression were to 
look for any other variance that could not be explained using RevMan.  
 
Separate analyses for each AED and adverse events pair were carried out. Similar to 
RevMan, numbers of patients with adverse events in the active and control groups 
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were inputted to calculate an effect size. The software calculated the relative risks and 
the natural log of relative risks. The natural log of relative risk was used in the meta-
regression analysis. The natural log of relative risks was the dependent variable and the 
indication was the independent variable. Other covariates that were inputted but were 
not analysed were dose and year of publication. The natural log of relative risk was a 
continuous variable and indication was a categorical variable.  To carry out regression 
using categorical variables - indication was coded as dummy variables; 0 for epilepsy; 
1 for neuropathy and 2 for headache.  
 
A regression plot with a regression line was produced. Epilepsy was the reference 
group used in all analyses conducted. An example of the regression plot is shown in 
figure 91. From this figure, one can extract the test of the model Q with p values and 
the goodness of fit data.  	
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Figure 91 Example of Meta-regression scatter plot for categorical variables. Epilepsy is the reference variable and neuropathy is the test variable. The test of the Model is the 
Q statistic. Also illustrated are the goodness of fit & the regression equation 
Regression of Log risk ratio on Indication
Indication
Lo
g 
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 r
at
io
Epilepsy Neuropathy
1.00
0.80
0.60
0.40
0.20
0.00
-0.20
-0.40
-0.60
Y = 0.1951 + 0.1179 if Indication = Neuropathy
Test of Model: Q statistic with df and p-value
Is indication related to effect size? 
Test of Goodness of Fit: Tau sq, I sq and Q with p-value
Any unexplained variance in effect size within a subgroup?
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The output from the analysis would include the epilepsy and neuropathy studies 
plotted on the regression lines. The circles represent the studies in proportion to their 
weights. In the example above, there are two categorical covariates (epilepsy and 
neuropathy). The horizontal lines indicate the regression lines and they intercept with 
the corresponding value of the natural log of relative risk. The regression equation is 
shown in the bottom left side.  
 
A Test of the Model was obtained. This is given by a Q statistic, the degrees of 
freedom and corresponding p-value. The degrees of freedom are the number of studies 
minus one. However, for this analysis there are two categorical variables (epilepsy and 
neuropathy) therefore the df is 1.0 and if all three indications were used the df is 2.0. If 
the p value is > 0.05 then the null hypothesis is true - that the variance of the effect 
sizes between the two indications is related to chance (hence trials across indications 
can be used). The test of the model tries to explain the variance between subgroups.  
 
The Goodness of Fit is another analyses conducted. This is a test to determine if there 
is any unexplained variance within a subgroup and not between subgroups (within 
epilepsy or neuropathy). This could be interpreted as a measure of any unexplained 
variance that may still linger, for example like a dose interaction or any other factor. 
The outputs in a Goodness of Fit analyses are a Tau statistic, a Q statistic and its 
corresponding p value.  
 
The output also includes an I2 statistic, which gives a measure of the degree of 
variance that is explained and the degree of variance that is unexplained. 
 
Also calculated was R2. This is the proportion of the between studies variance (tau) 
explained by the model to the total variance of all the studies. R2 can be defined as 
 !" = 	%&'()*+,-."%/01*)" 	 
 
Alternatively, R2 can be defined as 
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!"	 = 1 −	%40.-)"%/01*)"  
 
To test the hypothesis, the Q and p-values from the Test of the Model were used. The 
natural log of relative risks for each indication; the test of Goodness of Fit was only 
commented on when indicated. If the R2 is a very low value this too can suggest that 
the null hypothesis is true.  
 
9.4.9 How the results will be presented 
 
Because many comparisons for each individual AED were carried out, for the interests 
of space, the raw data is included in appendix J on page 360. 
 
Results from RevMan are presented first followed by the meta-regression results to 
arrive at the overall result.  
 
9.4.9.1 Tests of heterogeneity  
 
The RevMan analyses displays the AED, with the indication pairwise comparisons 
(either epilepsy with headache or epilepsy with neuropathy). Displayed here are the 
effect sizes (relative risks) as a pair for each outcome. The first number is the relative 
risk for epilepsy trials and the next is the relative risk when both indications are 
combined. A decision is made if relative risks are different or has changed 
significantly (either no change, increased or decreased). Next presented are changes in 
I2 before and after indications are combined followed by a decision of any changes to 
the I2 statistic has occurred. Next, we display the corresponding Tau squared, Chi 
squared statistics and p-values. Finally, presented are the corresponding tau squared, 
chi squared and corresponding p-values. A decision is then displayed on if the null 
hypothesis is accepted or rejected.  
 
9.4.9.2 Meta-regression 
 
Also presented are the results from meta-regression analyses. For each AED, presented 
are the natural log of the effect size (relative risk) for each indication followed by the 
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Q statistic of the model and the corresponding p-value of the model. Next presented 
are the Goodness of Fit data as a p-value, the I2 squared of any unexplained variance 
and the R2 ratio. This is followed by a judgement if the null hypothesis its true. 
Regression equations are not displayed, as these are only useful if we need to make 
predictions of effect size using covariates.   
 
9.4.9.3 Overall decision matrix 
 
Because two separate methods were used to either reject or accept the null hypothesis, 
one would need to summate the results to make a judgment of the overall result. This 
was displayed in a color-coded manner. The null hypothesis could both be accepted, 
rejected or, uncertain and colour coded accordingly. 
 
9.5 Results 
 
Analysis of harms across indications is a complex question that needed various 
methods to answer the hypothesis proposed. First, I will discuss the results of trial 
searches, then I will discuss the results of the analysis. 
 
9.5.1 Searches for trials 
 
Searches were carried out for seven placebo-controlled AED RCTs. We found one 
hundred and six trials in total. This included ninety-nine non-lacosamide trials and 
seven lacosamide studies. Included trials were placebo-controlled trials. Due to 
interests of time, we did not carry out any analysis of how data was extracted and there 
was no double blinding of data extraction process. A summary of the number of trials 
selected is shown in the table below and the details of these trials are shown in the 
appendix F on page 340.  
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AED Epilepsy Neuropathy Headache TOTAL 
Carisbamate 2 0 1 3 
Gabapentin 6 12 2 20 
Lamotrigine 8 8 1 17 
Pregabalin 5 15 0 20 
Topiramate 11 2 7 20 
Valproate 2 5 6 13 
Oxcarbazepine 2 3 1 6 
Lacosamide 3 4 0 7 
Table 51 Number of epilepsy, neuropathy and headache trials included 
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9.5.2 Lacosamide 
 
Seven trials of lacosamide were selected, three epilepsy trials and four neuropathy 
trials. Pairwise comparisons of relative risks using RevMan were made with epilepsy 
and neuropathy trials for 200mg, 400mg 600mg and any dose subgroups. For all harms 
outcomes in RevMan analyses the null hypothesis was found to be true, indicating 
there was no significant heterogeneity between effect sizes if neuropathy trials were 
combined.  
 
However, meta-regression analyses were in agreement with the RevMan analyses 
except for outcome ‘any adverse event’ where the p-value of Q statistic was 
significant, indicating heterogeneity between the effect sizes of epilepsy and 
neuropathy.  
 
Overall decision is shown below. The first column lists the harms outcomes, the next 
column displays the results from meta-analysis (MA) and the third column displays the 
results from meta-regression (MR). 
 
It was deemed that the meta-regression analyses for ‘any adverse event’ accepted the 
null hypothesis but there was still some unexplained variance. Thus, this was coded 
uncertain. Overall the null is hypothesis is true for lacosamide and trials across 
indication can be meta-analysed. 
 
	
Figure 92 Overall results of summating trials across indication for lacosamide 
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Table 52 Meta-analysis of epilepsy and neuropathy for lacosamide 200mg 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before 
and after 
Tau2 P-value 
of Chi2  Number of trial pairs Result 
Lacosamide 
(200mg) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.03- 1.00 No Δ 66%-39% ê 0.00 0.19 2 & 3 Null hypothesis is true 
Dizziness 2.16 -2.03 No Δ 0% -0% No Δ 0.00 0.84 2 & 4 Null hypothesis is true 
Ataxia 2.61-2.83 No Δ 48%-4% ê 0.04 0.35 2 & 4 Null hypothesis is true 
Headache 1.37-1.14 No Δ 0%-0% No Δ 0.00 0.72 2 & 4 Null hypothesis is true 
Fatigue 1.64-1.44 No Δ 0%-0% No Δ 0.00 0.88 2 & 4 Null hypothesis is true 
Somnolence 1.21-1.81 No Δ Na-30% ? 0.51 0.23 1 & 2 Null hypothesis is true 
Nausea 1.93-1.38 No Δ 22%-6% ê 0.02 0.35 2 & 4 Null hypothesis is true 
Withdrawals 1.75-1.24 No Δ 52%-27% ê 0.07 0.25 2 & 4 Null hypothesis is true 
 
 
Table 53 Meta-analysis of epilepsy and neuropathy for lacosamide 400mg 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before 
and after 
Tau2 P-value 
of Chi2  Number of trial pairs Result 
Lacosamide 
(400mg) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.15-1.05 No Δ NA-31% ? 0.00 0.22 1 & 5 Null hypothesis is true 
Dizziness 3.25- 2.22 No Δ 0%-0% No Δ 0.00 0.98 3 & 7 Null hypothesis is true 
Ataxia 5.04-5.00 No Δ 0%-0% No Δ 0.00 0.95 3 & 5 Null hypothesis is true 
Headache 1.47-1.20 No Δ 47%-22% ê 0.06 0.22 3 & 7 Null hypothesis is true 
Fatigue 2.0-1.98 No Δ 0%-0% No Δ 0.00 0.98 2 & 5 Null hypothesis is true 
Somnolence 1.70-1.71 No Δ 0%-0% No Δ 0.00 0.48 2 & 4 Null hypothesis is true 
Nausea 2.43-1.83 No Δ 33%-17% ê 0.06 0.30 3 & 7 Null hypothesis is true 
Withdrawals 3.29-2.53 No Δ 0%-0% No Δ 0.00 0.79 3 & 7 Null hypothesis is true 
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Table 54 Meta-analysis of epilepsy and neuropathy for lacosamide 600mg 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before 
and after 
Tau2 P-value 
of Chi2  Number of trial pairs Result 
Lacosamide 
(600mg) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.32-1.16 No Δ NA-59% ? 0.01 0.06 1 & 4 Null Hypothesis is true 
Dizziness 5.02-5.30 No Δ 0%-0% No Δ 0.00 0.98 3 & 7 Null hypothesis is true  
Ataxia 6.74-7.55 No Δ 0%-0% No Δ 0.00 0.94 2 & 4 Null hypothesis is true 
Headache 1.18-1.39 No Δ 0%-0% No Δ 0.00 0.46 2 & 5 Null hypothesis is true 
Fatigue 3.84-2.97 No Δ NA-0% No Δ 0.00 0.57 1 & 3 Null hypothesis is true 
Somnolence 1.21-1.53 No Δ 0-39% é 0.29 0.19 1 & 3 Null hypothesis is true * 
Nausea 2.43-1.83 No Δ 33%-17% ê 0.06 0.77 2 & 5 Null hypothesis is true 
Withdrawals 4.17-4.30 No Δ 0%-0% No Δ 0.00 0.75 2 & 5 Null hypothesis is true 
*Null is true but there may be an increase in statistical heterogeneity when trials across indications are combined.  
 
 
Table 55 Meta-analysis of epilepsy and neuropathy for lacosamide any dose 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before 
and after 
Tau2 P-value 
of Chi2  Number of trial pairs Result 
Lacosamide 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.2-1.19 No Δ NA-0% ? 0.00 0.78 1 & 2 Null hypothesis is true 
Dizziness 3.67-3.35 No Δ 0%-13% No Δ 0.02 0.33 3 & 4 Null hypothesis is true 
Ataxia Outcome not reported 
Headache 1.32-1.20 No Δ 0%-0% No Δ 0.00 0.49 3 & 4 Null hypothesis is true 
Fatigue Outcome not reported 
Somnolence 1.14-1.37 No Δ 0%-0% No Δ 0.00 0.87 2 & 3 Null hypothesis is true 
Nausea 2.36-2.12 No Δ 34%-5% ê 0.01 0.37 2 & 4 Null hypothesis is true 
Withdrawals Outcome not reported 
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Table 56 Meta-regression lacosamide, all indications and outcomes 
Outcome Natural log of Relative 
Risk (ln RR) 
Q statistic 
of Test of 
Model  
df = 1 
P value of 
Model  
 
 
P value of 
Goodness of 
Fit 
 
I2 
(Variance 
of data 
explained 
by model 
as being 
real) 
R2  
 
Ratio of 
variance 
explained 
by model 
divided by 
total 
variance 
 
Result 
Indication Epilepsy Neuropathy 
Any  0.19 0.07 4.16 0.04 0.1004  35% 0.41 Null hypothesis is true but there is still 
some unexplained variance. 
Ataxia 1.30 1.25 0.5 0.65 0.4523 0% 0.00 Null hypothesis is true 
Dizziness 1.26 1.14 0.3 0.58 0.414 3.4% 0.00 Null hypothesis is true 
Fatigue 0.75 0.58 0.21 0.64 0.9380 0% 0.00 Null hypothesis is true 
Headache 0.26 -0.02 2.09 0.15 0.7561 0% 0.00 Null hypothesis is true 
Nausea 0.76 0.56 0.76 0.38 0.5589 0% 0.00 Null hypothesis is true 
Somnolence 0.35 1.08 1.44 0.23 0.8018 0% 0.00 Null hypothesis is true 
Withdrawals 1.18 0.89 0.95 0.33 0.03 47% 0.00 Null hypothesis is true 
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9.5.3 Pregabalin 
 
Twenty trials of pregabalin were selected, five were epilepsy trials and fifteen were 
neuropathy trials. Pairwise comparisons of relative risks were made using RevMan 
with epilepsy and neuropathy trials. Dose groups used were 150mg, 300mg, 600mg 
and any dose subgroups when making comparisons.  
 
Null hypothesis was not true for adverse event headache in the any dose subgroup. 
Indicating heterogeneity. Null hypothesis was true for outcome ataxia in the 150mg 
subgroup but there was a high Tau-squared statistic value, indicating heterogeneity. 
 
Meta-regression analyses showed the null hypothesis was not true for headache and 
somnolence. Null hypothesis was true for any adverse event and dizziness but I2 
proportions showed unexplained variance. This is likely due to a dose interaction. Null 
hypothesis was true for outcomes fatigue, withdrawals due to AE, and ataxia.  
 
Overall result is shown in the figure below. The null hypothesis was true for ataxia in 
the meta-regression but uncertain in the meta-analysis (for 150mg dose). For outcome 
dizziness and any adverse event the meta-regression showed unexplained variance. 
Null was not true for outcome headache indicating significant heterogeneity. Overall 
pregabalin cannot be used across indication as some common adverse events show 
significant heterogeneity whereas some do not. 
 
	
Figure 93 Overall results for summating trials across indications for pregabalin 
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Table 57 Meta-analysis for epilepsy and neuropathy for pregabalin any dose 
 
 
 
Drug 
Pair of 
indications Outcome 
Change in effect size 
before and after 
Change in I2 before 
and after 
Tau2 P-value 
of Chi2  Number of 
trial pairs Result 
Pregabalin 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 3.52-3.01 No Δ 66%-44% ê 0.00 0.22 2 & 7 Null hypothesis is true 
Dizziness 3.52-3.01 No Δ 0%-27% No Δ 0.05 0.18 3 &1 3 Null hypothesis is true 
Ataxia 3.70-4.46 é 0%-0% No Δ 0.00 0.12 3 & 7 Null hypothesis is true 
Headache 0.62-0.87 No Δ 0%-56% é 0.13 0.005 4 & 14 Null hypothesis is not true 
Fatigue 1.82-1.47 No Δ NE-0% NE 0.00 0.55 1 & 5 Null hypothesis is true 
Somnolence 2.17-2.88 No Δ 0%-30% No Δ 0.08 0.11 5 &19 Null hypothesis is true 
Nausea Outcome not reported 
Withdrawals 3.11-2.19 ê 0%-8% No Δ 0.02 0.36 3 & 14 Null hypothesis is true 
 
 
Table 58 Meta-analysis for epilepsy and neuropathy for pregabalin 150mg 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2  P value 
of Chi2  Number of trial 
pairs 
Result 
Pregabalin 
(150mg) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitud
e 
Judgment Magnitude Judgment 
Any AE 1.07-1.09 No Δ 66%-44% ê 0.01 0.17 2 & 3 Null hypothesis is true 
Dizziness 2.05-2,14 No Δ 0%-0% No Δ 0.00 0.87 2 & 3 Null hypothesis is true 
Ataxia 1.70-2.64 é 56%-52% No Δ 0.98 0.12 2 & 3 Null hypothesis is true but 
there is heterogeneity  
Headache 0.54-0.69 No Δ 0%-0% No Δ 0.00 0.60 2 & 5 Null hypothesis is true 
Fatigue Outcome not reported 
Somnolence 1.29-1.73 No Δ 0%-0% No Δ 0.00 0.47 2 & 6 Null hypothesis is true 
Nausea Outcome not reported 
Withdrawals 0.78-1.29 No Δ 64%-0% ê 0.04 0.32 2 & 6 Null hypothesis is true 
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Table 59 Meta-analysis for epilepsy and neuropathy for pregabalin 300mg 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Pregabalin  
(300mg) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.14-1.25 No Δ NA-59% é 0.02 0.12 1 & 2 Null hypothesis is true 
Dizziness 3.46-3.75 No Δ NA-0% No Δ 0.00 0.98 1 & 7 Null hypothesis is true 
Ataxia 3.33-3.18 No Δ NA -0% No Δ 0.00 0.72 1 & 5 Null hypothesis is true 
Headache 0.43-0.65 No Δ NA-0% No Δ 0.00 0.91 1 & 5 Null hypothesis is true 
Fatigue Outcome not reported 
Somnolence 1.62-3.38 é NA-24% No Δ 0.10 0.25 1 & 7 Null hypothesis is true 
Nausea Outcome not reported 
Withdrawals 2.89-2.37 No Δ NA-24% No Δ 0.04 0.32 1 & 7 Null hypothesis is true 
 
 
Table 60 Meta-analysis for epilepsy and neuropathy for pregabalin 600mg 
Drug Pair of indications Outcome 
Change in effect size before 
and after 
Change in I2 before 
and after 
Tau2 P value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Pregabalin  
(600mg) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.38- 1.43 No Δ NA- 28% é 0.00 0.30 1 & 7 Null hypothesis is true 
Dizziness 4.52-4.48 No Δ 0%-2% No Δ 0.00 0.45 4 & 11 Null hypothesis is true 
Ataxia 4.49-5.03 No Δ 0%-0% No Δ 0.00 0.85 4 & 6 Null hypothesis is true 
Headache 0.78-0.87 No Δ 0%-0% No Δ 0.00 0.51 3 & 9 Null hypothesis is true 
Fatigue Outcome not reported 
Somnolence 2.56-3.57 é 0%-21% No Δ 0.06 0.24 4 & 11 Null hypothesis is true 
Nausea Outcome not reported 
Withdrawals 3.74-2.72 ê 0%-6% No Δ 0.01 0.39 4 & 11 Null hypothesis is true 
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Table 61 Meta-regression Pregabalin all indications all outcomes 
Outcome Natural log of Relative 
Risk (ln RR) 
Q statistic 
of Test of 
Model  
df = 1 
P value of 
Model  
 
 
P value of 
Goodness of 
Fit 
 
I2 
(Variance 
of data 
explained 
by model 
as being 
real) 
R2  
 
Ratio of 
variance 
explained 
by model 
divided by 
total 
variance 
 
Result 
Indication Epilepsy Neuropathy 
Any 0.19 0.31 1.98 0.1598  < 0.001  64% 0.04 Null hypothesis is true but there is 
variance still unexplained 
Ataxia 1.25 1.92 3.41 0.06  0.786  0% 0.0 Null hypothesis is true 
Dizziness 1.14 1.24 0.33 0.566  0.036  32% 0.0 Null hypothesis is true but there is 
variance still unexplained 
Fatigue 0.60 0.46 0.05 0.826  0.763  0% 0.0 Null hypothesis is true 
Headache -0.42 0.06 7.43 0.0064 0.3062  11% 0.80 Null hypothesis is not true 
Somnolence 0.69 1.26 8.05 0.0045 0.0751  27% 0.42 Null hypothesis is not true 
Withdrawals 1.03 0.76 2.15 0.1422 0.3194  9% 0.34 Null hypothesis is true 
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9.5.4 Gabapentin 
 
Twenty trials for gabapentin were selected, six were epilepsy studies, twelve were 
neuropathy studies and two were headache studies. Only the any dose subgroup was 
used, as there were no overlapping doses across indications.   
 
The null hypothesis was not true for ‘any adverse event’ and dizziness outcomes in the 
epilepsy and headache comparisons. The null hypothesis was not true for the ‘any 
adverse event’ and headache outcomes in the epilepsy and headache comparisons. 
 
Meta-regression showed the null hypothesis to be true for all outcomes except any 
adverse event and somnolence.  
 
For outcomes ‘any adverse event’ and somnolence, the null hypothesis was not true. 
For outcomes headache and dizziness, theses showed significant heterogeneity in the 
meta-analyses but when used in meta-regression, the models failed to detect any 
heterogeneity. This cannot be fully explained, as there is no dose interaction here. it is 
thought that meta-regression methods are superior and therefore heterogeneity can be 
explained away using this model. Therefore to conclude, trials across indications for 
gabapentin cannot be used in meta-analysis due to non-overlapping dose and possible 
heterogeneity.  
 
	
Figure 94 Overall results for summating trials across indications gabapentin 
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Table 62 Meta-analysis for epilepsy and headache gabapentin any dose 
Drug Pair of indications Outcome 
Change in effect size before 
and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Gabapentin 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Headache 
Magnitude Judgment Magnitude Judgment 
Any AE 1.27-1.37 No Δ 0-54% é 0.05 0.009 5 & 7 Null hypothesis is not true 
Dizziness 2.42-2.62 No Δ 0%-0% No Δ 0.16 0.03 6 & 8 Null hypothesis is not true 
Ataxia 2.01-2.07 No Δ 0-29% No Δ 0.33 0.30 3 & 4 Null hypothesis is true 
Headache  
Fatigue 
Somnolence 2.28-2.29 No Δ 0%-0% No Δ 0.00 0.83 6 & 8 Null hypothesis is true 
Nausea 0.89-1.12 No Δ 0-28% No Δ 0.13 0.24 5 & 5 Null hypothesis is true 
Withdrawals 1.39-1.65 No Δ 22-0% ê 0.00 0.60 3 & 5 Null hypothesis is true 
 
 
Table 63 Meta-analysis for epilepsy and neuropathy gabapentin any dose 
Drug Pair of indications Outcome 
Change in effect size before 
and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Gabapentin 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.27-1.30 No Δ 0%-51% é 0.05 0.02 5 & 12 Null hypothesis is not true 
Dizziness 2.42-2.88 No Δ 0%-0% No Δ 0.04 0.51 5 & 12 Null hypothesis is true 
Ataxia 2.55-2.87 No Δ 51%-26% ê 0.06 0.42 3 & 7 Null hypothesis is true 
Headache 0.73-1.12 No Δ 21%-43% é 0.42 0.08 5 & 9 Null hypothesis is not true 
Fatigue 1.64-1.62 No Δ 0%-29% No Δ 0.14 0.19 4 & 9 Null hypothesis is true 
Somnolence 2.14-2.59 No Δ 0%-1% No Δ 0.00 0.43 6 & 14  Null hypothesis is true 
Nausea 0.89-0.93 No Δ 0%-0% No Δ 0.00 0.83 4 & 13 Null hypothesis is true 
Withdrawals 1.78-1.77 No Δ 17%-0% ê 0.00 0.63 4 & 14 Null hypothesis is true 
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Table 64 Meta-regression for gabapentin 
Outcome Natural log of Relative Risk (ln 
RR) 
Q statistic of 
Test of Model  
df = 2 
P value of 
Model  
 
 
P value of 
Goodness of 
Fit 
 
I2 
(Variance 
of data 
explained 
by model 
as being 
real) 
R2  
 
Ratio of 
variance 
explained by 
model 
divided by 
total variance 
 
Result 
 Epileps
y 
Neurop
athy 
Headac
he 
Any 0.22 0.48 0.54  <0.01 0.4312  2% 0.98 Null hypothesis is not 
true 
Ataxia 0.56 1.08 2.30 3.68 0.16 0.5009  0% 1.00 Null hypothesis is true 
Dizziness 0.90 1.18 1.20 1.94 0.38 0.3285  10% 0.0 Null hypothesis is true 
Fatigue 0.53 0.77 -0.03 2.36 0.31 0.5414  0% 0.0 Null hypothesis is true 
Headache 0.00 -0.05 NA 0.04 0.84 0.4309  2% 0.0 Null hypothesis is true 
Nausea -0.07 0.25 1.39 4.20 0.13 0.9081  0% 0.0 Null hypothesis is true 
Somnolence 0.71 1.26 1.18 8.23 0.02 0.0510  0% 1.0 Null hypothesis is not 
true 
Withdrawals 0.77 1.26 0.63 3.11 0.21 0.5903  0% 0.0 Null hypothesis is true 
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9.5.5 Topiramate 
 
Twenty trials of topiramate were selected, 11 were epilepsy trials, two were 
neuropathy trials and seven were headache trials. Only the 200mg and any dose were 
used as subgroups in meta-analysis for headache and epilepsy trials. For the headache 
and neuropathy trials, any dose was used. 
 
Pairwise comparisons epilepsy and headache and epilepsy with neuropathy gave 
differing results. Adverse events were poorly reported in trials for headache and 
therefore a number of comparisons could not take place. For any adverse event, 
dizziness and withdrawals the null hypothesis was not true but this was true for 
somnolence and nausea. In neuropathy comparisons, we did not find any heterogeneity 
between indications. One cannot explain why there is unexplained variance between 
headache and epilepsy even when dose is taken into account.  
 
Meta-regression analyses showed that overall the null hypothesis is true but there may 
be dose interaction between indications and this makes sense, as topiramate doses used 
in headache is lower than doses used for seizures.    
 
Overall topiramate cannot be used across indications due to heterogeneity in effect 
sizes and a possible dose interaction. 
 
	
Figure 95 Overall results for summating trials across indications topiramate 
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Table 65 Meta-analysis for epilepsy and headache for topiramate any dose 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before 
and after 
Tau2 P-value 
of Chi2 
Number 
of trial 
pairs 
Result 
Topiramate 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Headache 
Magnitude Judgment Magnitude Judgment   
Any AE 1.05-1.34 No Δ 0%-80% é 0.04 0.001 3 & 4 Null hypothesis is not true 
Dizziness 1.23-1.13 No Δ 41%-30% No Δ 0.06 0.18 4 & 8 Null hypothesis is not true 
Ataxia 
Outcomes not reported Headache 
Fatigue 
Somnolence 1.73-1.76 No Δ 40% -18% ê 0.04 0.27 7 & 11 Null hypothesis is true 
Nausea 2.18-1.60 ê 0%-0% No Δ 0.00 0.62 2 & 8 Null hypothesis is true 
Withdrawals 2.03-2.07 No Δ 23%-24% No Δ 0.11 0.19 10 & 16 Null hypothesis is true 
 
 
Table 66 Meta-analysis for epilepsy and headache for topiramate 200mg 
Drug Pair of indications 
Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2  Number of trial 
pairs 
Result 
Topiramte  
(200mg) 
Epilepsy 
 vs. 
Epilepsy and 
Headache 
Magnitude Judgmen
t 
Magnitude Judgmen
t 
  
Any AE 0.57-1.71 é NA-90% é 1.9 0.002 1 & 2 Null hypothesis is not true 
Dizziness 
Outcomes not reported Ataxia Headache 
Fatigue 
Somnolence 3.11-3.31 No Δ NA-0%  0.00 0.84 1 & 2 Null hypothesis is true 
Nausea Outcomes not reported 
Withdrawals 1.75-2.55 é NA-90% é 1.14 <0.001 1 & 3 Null hypothesis is not true 
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Table 67 Meta-analysis for epilepsy and neuropathy for topiramate any dose 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 Number of trial pairs Result 
Topiramate 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment   
Any AE 1.05-1.10 No Δ 0%-0% No Δ 0.00 0.70 3 & 4 Null hypothesis is true 
Dizziness 1.35-1.31 No Δ 37%-17% ê 0.03 0.29 7 & 9 Null hypothesis is true 
Ataxia   Outcome not reported 
Headache 0.85-0.84 No Δ 46%-33% No Δ 0.05 0.16 6 & 8 Null hypothesis is true 
Fatigue   Outcome not reported 
Somnolence 1.73-1.76 No Δ 40% -18% ê 0.00 0.44 7 & 11 Null hypothesis is true 
Nausea 2.18-1.84 No Δ 0%-0% No Δ 0.00 0.94 2 & 3 Null hypothesis is true 
Withdrawals 1.96 -1.94 No Δ 3%-28% No Δ 0.23 0.19 8 &10 Null hypothesis is true 
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Table 68 Meta-regression for topiramate 
Outcome Natural log of Relative Risk (ln 
RR) 
Q statistic of 
Test of Model  
df = 2 
P value of 
Model  
 
 
P value of 
Goodness of Fit 
 
I2 
(Variance 
of data 
explained 
by model 
as being 
real) 
R2  
 
Ratio of 
variance 
explained 
by model 
divided by 
total 
variance 
 
Result 
 Epilepsy Neuropat
hy 
Headache       
Any 0.13 0.13 0.45 2.63 0.27 <0.01  78% 0.0 Null is true but 
unexplained 
varaince 
Dizziness 0.27 0.33 -0.05 1.43 0.49 0.2707  15% 0.0 Null hypothesis is 
true 
Headache 0.20 -0.26 NA 1.19 [df 1] 0.28 0.0386  45% 0.0 Null hypothesis is 
true 
Nausea 0.78 0.54 0.47 0.18 0.91 0.7539  0% 0.0 Null hypothesis is 
true 
Somnolence 0.78 1.07 0.48 1.17 0.56 0.0940  32% 0.0 Null hypothesis is 
true 
Withdrawals 0.84 0.48 0.90 0.51 0.77 0.0003  55% 0.0 Null hypothesis is 
true but there is still 
some unexplained 
variability 
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9.5.6 Lamotrigine 
 
Seventeen lamotrigine trials were selected, eight were epilepsy trials, eight were 
neuropathy trials and one was a headache trial. Pairwise comparisons were made with 
epilepsy and neuropathy; epilepsy and headache trials.  
 
Comparing epilepsy and neuropathy trials for lamotrigine, the null hypothesis was not 
true for any adverse events and somnolence. Fatigue was not reported in these trials. 
Null hypothesis was true with regards to the other outcomes. 
 
Comparing epilepsy and headache trials, the null hypothesis was not true for any 
adverse event. Ataxia, headache and fatigue were not reported in these trials. All other 
outcomes, the null hypothesis was true. 
 
Meta-regression of harms outcomes across indications showed for any adverse event 
was true or all except for ‘any adverse event’. 
 
Overall harms across indications for lamotrigine is a viable option given there was no 
heterogeneity for all outcome except any adverse event. 
 
	
Figure 96 Overall results for summating trials across indications lamotrigine 
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Table 69 Meta-analysis for epilepsy and neuropathy for lamotrigine any dose 
Drug Pair of indications Outcome 
Change in effect size before and 
after 
Change in I2 before 
and after 
Tau2  P value of 
Chi2  Number of trial pairs Result 
Lamotrigine 
(any dose) 
Epilepsy 
 vs. 
Epilepsy 
and 
Neuropathy 
Magnitude Judgment Magnitude Judgment 
Any AE 1.33-1.29 No Δ 76%-60% No Δ 0.03 0.01 4 & 9 Null hypothesis is not 
true 
Dizziness 2.5-2.17 No Δ 30%-33% No Δ 0.12 0.15 8 & 11 Null hypothesis is true 
Ataxia 2.46-2.49 No Δ 47%-34% No Δ 0.25 0.18 8 & 11 Null hypothesis is true 
Headache 1.22-1.18 No Δ 0%-0% No Δ 0.00 0.89 8 & 11 Null hypothesis is true 
Fatigue   Outcome not reported 
Somnolence 1.65-1.64 No Δ 23%-58% é 0.49 0.006 8 & 12 Null hypothesis is not 
true 
Nausea 1.86-1.67 No Δ 0%-0% No Δ 0.00 0.87 6 & 10 Null hypothesis is true 
Withdrawals 4.11-2,18 ê 0%-8% No Δ 0.05 0.37 6 & 14 Null hypothesis is true 
 
 
Table 70 Meta-analysis for epilepsy and headache for lamotrigine any dose 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and after Tau2  P value of 
Chi2  Number of trial pairs Result 
Lamotrigine 
(any dose) 
Epilepsy 
 vs. 
Epilepsy 
and 
Headache 
Magnitude Judgment Magnitude Judgment 
Any AE 1.34-1.38 No Δ 68%-64% No Δ 0.04 0.04 4 & 5 Null hypothesis is not 
true 
Dizziness 2.34-2.28 No Δ 18%-7% No Δ 0.07 0.25 7 & 8 Null hypothesis is true 
Ataxia 
Outcome not reported Headache 
Fatigue 
Somnolence 1.65-1.73 No Δ 23%-17% No Δ 0.12 0.29 8 & 9 Null hypothesis is true 
Nausea 1.85-1.76 No Δ 0%-0% No Δ 0.00 0.60 5 & 6 Null hypothesis is true 
Withdrawals 5.09-4.47 No Δ 0%-0% No Δ 0.09 0.31 8 & 9 Null hypothesis is true 
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Table 71 Meta-regression for lamotrigine 
Outcome Natural log of Relative Risk (ln 
RR) 
Q statistic of 
Test of Model  
df = 2 
P value of 
Model  
 
 
P value of 
Goodness of Fit 
 
I2 
(Variance 
of data 
explained 
by model 
as being 
real) 
R2  
 
Ratio of 
variance 
explained by 
model divided 
by total 
variance 
 
Result 
 Epilepsy Neuropa
thy 
Headache       
Any AE 0.41 0.13 -0.17 2.86 0.24  0.0093  63% 0.0 Null hypothesis is not 
true 
Ataxia 1.12 1.25 NA 0.01  0.95  0.1438  40% 0.0 Null hypothesis is true 
Dizziness 1.07 0.44 NA 1.60  0.45  0.1844  27% 0.0 Null hypothesis is true 
Headache 0.25 -0.04 NA 0.32  0.53  0.9047  0% 0.0 Null hypothesis is true 
Nausea 0.56 0.24 2.04 1.70 0.43  0.8804 0% 0.0 Null hypothesis is true 
Somnolence 0.52 0.40 1.69 0.59 0.74  0.1028  36% 0.13 Null hypothesis is true 
Withdrawals  1.55 0.63 1.06 3.97 0.14  0.4522  0% 1.0 Null hypothesis is true 
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9.5.7 Oxcarbazepine 
 
Six trials of oxcarbazepine were selected, two were epilepsy trials, three were 
neuropathy trials and one headache trial.  
 
Pairwise comparisons using meta-analysis showed that null hypothesis was true for all 
outcomes except for any adverse events. Meta-regression showed that all outcomes 
except headache and any adverse events accepted the null hypothesis. Residual 
heterogeneity was present for withdrawals due to harms.  
 
Overall harms across indications cannot be used as some outcomes were 
heterogeneous and others were not. 
 
	
Figure 97 Overall results for summating trials across indications oxcarbazepine 
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Table 72 Meta-analysis for epilepsy and neuropathy for oxcarbazepine any dose 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Oxcarbazepine 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Neuropathy 
Magnitude Judgment Magnitude Judgment   
Any AE   Outcome not reported 
Dizziness 2.36-3.03 No Δ 8%-50% é 0.08 0.19 2 & 4 Null hypothesis is true 
Ataxia   Outcome not reported 
Headache 1.13-1.46 No Δ 0-58% é 0.17 0.07 2 & 4 Null hypothesis is true 
Fatigue 2.14-2.21 No Δ 0%-0% No Δ 0.00 0.62 2 & 3 Null hypothesis is true 
Somnolence 3.82-4.12 No Δ 49%-51% No Δ 0.20 0.17 2 & 3 Null hypothesis is true 
Nausea 2.86-2.93 No Δ 0%-0% No Δ 0.00 0.85 2 & 4 Null hypothesis is true 
Withdrawals 3.60-4.02 No Δ 28%-0% ê 0.00 0.85 2 & 4 Null hypothesis is true 
 
 
Table 73 Meta-analysis for epilepsy and headache for oxcarbazepine any dose 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Oxcarbazepine 
(any dose) 
Epilepsy 
 vs. 
Epilepsy and 
Headache 
Magnitude Judgment Magnitude Judgment   
Any AE 1.20-2.43 é 0%-96% é 0.20 0.001 2 & 3 Null hypothesis if not true 
Dizziness 2.36-2.41 No Δ 8%-0% No Δ 0.02 0.62 2 & 3 Null hypothesis is true 
Ataxia 3.81-2.51 ê NA -0% No Δ 0.00 0.54 1 & 2 Null hypothesis is true 
Headache   Outcome not reported 
Fatigue 2.14-2.32 No Δ 0%-0% No Δ 0.00 0.50 2 & 3 Null hypothesis is true 
Somnolence 3.82-2.12 ê 49%-43% No Δ 0.01 0.40 2 & 3 Null hypothesis is true 
Nausea 2.86-2.96 No Δ 0%-0% No Δ 0.04 0.10 2 & 3 Null hypothesis is true 
Withdrawals 3.60-3.24 No Δ 28%-25% No Δ 0.01 0.09 2 & 3 Null hypothesis is true 
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Table 74 Meta-regression for oxcarbazepine 
Outcome Natural log of Relative Risk (ln 
RR) 
Q statistic of 
Test of Model  
df = 2 
P value of 
Model  
 
 
P value of 
Goodness of Fit 
 
I2 
(Variance 
of data 
explained 
by model 
as being 
real) 
R2  
 
Ratio of 
variance 
explained by 
model divided 
by total 
variance 
 
Result 
 Epilepsy Neuropa
thy 
Headache       
Any AE 0.18 NA 2.60 30.5 <0.01 0.2370  28% 0.95 Null hypothesis is not 
true 
Ataxia 1.44 NA 0.95 0.23 0.63 0.0720  57% 0.0 Null hypothesis is true 
Dizziness 1.20 1.98 1.04 5.18 0.07 0.1960  28% 0.53 Null hypothesis is true 
Fatigue 1.67 1.89 1.75 0.4 0.45 0.45 10% 0.0 Null hypothesis is true 
Headache 0.18 0.73 NA 4.18 [df 1] 0.04 0.6129  0% 1.0 Null hypothesis is not 
true 
Nausea 1.02 0.96 1.25 0.23 0.89 0.3373  12% 0.0 Null hypothesis is true 
Somnolence 0.84 0.93 0.15 1.55 0.46 0.3098 15% 0.0 Null hypothesis is true 
Withdrawals  1.63 1.51 0.74 0.62 0.74 <0.001 80 0.0 Null hypothesis is true 
but unexplained 
variability 
		 277	
9.5.8 Carisbamate 
 
Three trials of carisbamate were selected. Two were epilepsy trials and one headache 
trial. Carisbamate was not awarded a licence in either indication due to a significant 
placebo treatment effect. Dose ranges of carisbamate include 100mg 200mg 300mg 
400mg 500mg and 600mg tablets. However only the 100mg and 300mg doses were 
evaluable, as these were the two overlapping doses found in epilepsy and headache. 
Ataxia and dizziness were not reported in any of the trials.  
 
The null hypothesis was not true for outcome ‘any adverse event’ for the 100mg dose 
using meta-analyses methods.  The null hypothesis was not true for outcomes fatigue, 
headache and somnolence.   
 
Overall harms across indications cannot be used for carisbamate.  
 
 
	
Figure 98 Overall results for summating trials across indications carisbamate 
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Table 75 Meta-analysis for epilepsy and headache for carisbamate 100mg 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Carisbamate 
(100mg) 
Epilepsy 
 vs. 
Epilepsy and 
Headache 
Magnitude Judgment Magnitude Judgment   
Any AE 1.19-0.97 No Δ NA-0% No Δ 0.00 0.66 1 & 2 Null Hypothesis is true 
Dizziness Outcomes not reported 
Ataxia 
Headache 1.2-0.89 ê NA-45% é 0.29 0.18 1 & 2 Null hypothesis is true 
Fatigue 2.08-1.97 No Δ NA-0% No Δ 0.00 0.94 1 & 2 Null hypothesis is not true 
Somnolence 1.79-1.38 No Δ NA -6% No Δ 0.02 0.30 1 & 2 Null hypothesis is true 
Nausea 1.04-1.08 No Δ Na-0% No Δ 0.00 0.93 1 & 2 Null hypothesis is true 
Withdrawals 0.58-0.85 No Δ NA-0% No Δ 0.00 0.37 1 & 2 Null hypothesis is true 
 
 
Table 76 Meta-analysis for epilepsy and headache for carisbamate 300mg 
Drug Pair of indications Outcome 
Change in effect size 
before and after 
Change in I2 before and 
after 
Tau2 P-value 
of Chi2 
 Number 
of trial 
pairs 
Result 
Carisbamate 
(300mg)  
Epilepsy 
 vs. 
Epilepsy and 
Headache 
Magnitude Judgment Magnitude Judgment   
Any AE 2.60-1.56 ê NA-82% é 0.43 0.02 1 & 2 Null hypothesis is not true 
Dizziness Outcomes not reported 
Ataxia 
Headache 0.90-0.84 No Δ NA-0% No Δ 0.00 0.33 1 & 2 Null hypothesis is true 
Fatigue 4.63-3.19 ê NA- 0% No Δ 0.00 0.56 1 & 2 Null hypothesis is true 
Somnolence 1.91-1.42 No Δ NA-18% No Δ 0.08 0.27 1 & 2 Null hypothesis is true 
Nausea 1.87-1.34 No Δ NA-22% No Δ 0.08 0.26 1 & 2 Null hypothesis is true 
Withdrawals 0.69-0.79 No Δ NA-0% No Δ 0.00 0.71 1 & 2 Null hypothesis is true 
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Table 77 Meta-regression for carisbamate 
Outcome Natural log of Relative 
Risk (ln RR) 
Q statistic 
of Test of 
Model  
df = 1 
P value of 
Model  
 
 
P value of 
Goodness of 
Fit 
 
I2 
(Variance 
of data 
explained 
by model 
as being 
real) 
R2  
 
Ratio of 
variance 
explained 
by model 
divided by 
total 
variance 
 
Result 
Indication Epilepsy Headache 
Any -0.0165 0.0361 0.86 0.3610 0.9806 0% 0.00 Null hypothesis is true 
Fatigue 0.33 1.14 5.65 0.0203 0.4101 3% 0.95 Null hypothesis is not true 
Headache 0.17 -0.97 7.73 0.0055 0.3613 9% 0.9 Null hypothesis is not true 
Nausea 0.20 0.14 0.04 0.8468 0.5172 0% 0.0 Null hypothesis is true 
Somnolence 0.81 -0.42 8.83 0.0030 0.9594 0% 0.0 Null hypothesis is not true 
Withdrawals 0.11 0.01 0.09 0.7661 0.2874 17% 0.0 Null hypothesis is true 
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9.5.9 Valproate 
 
Harms outcomes in valproate trials were poorly reported. None of the outcomes were 
heterogeneous but one cannot make any judgments due to the paucity of data.  
 
	
Figure 99 Overall results for summating trials across indication for valproate 
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9.6 DISCUSSION 
 
This chapter discussed the use of meta-regression as an additional method of exploring 
heterogeneity. Comprehensive meta-analysis version 3.0 is a novel method whereby 
two or more categorical covariates can be meta-analysed. Two distinct methods were 
used to investigate heterogeneity. The first method utilised Higgins’s I2 statistics and 
other tests of heterogeneity. In this method, comparative changes to heterogeneity 
before and after indications were combined and the results commented upon. This was 
a pragmatic method and judgments were made if harms across indications could be 
meta-analysed. For the second method, meta-regression was used to further explore 
heterogeneity. Both methods yielded similar results. We found that for some 
antiepileptic drugs, there was satisfactory agreement between meta-analysis and meta-
regression methods. This was true for lacosamide, lamotrigine, oxcarbazepine, 
topiramate and gabapentin. Valproate was not evaluable due to poor outcome 
reporting. There were merits to the meta-regression method over meta-analysis 
method. The former method allows all three indications to be analysed and if dose was 
an interaction then this is evident in the results. A dose interaction would arguably 
imply that harms across indications cannot be used.  
 
The study by Majorowski et al showed that the greatest incidence of harms occurs 
during the titration phase of a trial (2006). This is an important finding as this implies 
that the duration of the trial may not be as significant as previously thought.  
 
Lacosamide and lamotrigine were the two AEDs whose harms data could be used 
across indications. The methods employed in this chapter have not been used before to 
compare harms across indications. The work presented here was purely and 
exploratory to answer the hypothesis if harms can be used across indications. One can 
now surmise that the null hypothesis is true for lacosamide and lamotrigine only.  
 
The results also showed that for AEDs like pregabalin and gabapentin there existed a 
significant dose interaction which explains a lot of the heterogeneity Also for these 
two AEDs the dose used in neuropathy may be very different to those used in epilepsy 
in routine clinical practice.  
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Therefore we conclude that lacosamide might represent a special case and possibly we 
can surmise the same for lamotrigine.  
 
Further meta-analysis could be done for lamotrigine to explore rare side effects like 
rash using data form trials across indications.   
 
Other significant source of heterogeneity is due to differences in data collection 
between studies. The frequency of follow up in trials may be very different in epilepsy 
trials as compared to say neuropathy trials. Also, trial protocol in an epilepsy trial 
would be very different from a neuropathy trial. This study shows that despite this 
some harms outcomes can still be summated. 
 
It would be reasonable to suggest that a significant limitation of this study is that the 
duration of follow-up was not controlled for when summating trials. An epilepsy trial 
may not have the same follow-up as a headache trial and not all headache and epilepsy 
trial would be of the same duration. Nevertheless, we would hope that the finding of 
Majorowski et al would apply here in that the duration of the trial has no significant 
impact on the proportion of harms detected in RCTs (2005).   
 
It was noted that several studies of AEDs for headache conditions did not report 
headache as an adverse event. Headache was reported as a common adverse event in 
many trials of epilepsy and neuropathy. When reviewing topiramate studies in 
neuropathy and epilepsy we see that the relative risk for headache is less than one. 
Indicating that compared to placebo, topiramate also has an analgesic effect.  
 
It is possible that future antiepileptic drugs manufactured by drug sponsors would not 
vary significantly in doses. Additional AEDs may be needed to determine if the results 
can be replicated. Any further work would require collaboration with a statistician.  
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9.7 Conclusion 
 
• Meta-analysis of harms from other indications is an important issue that needs 
further evaluation. 
• Due to commercial interests in a given AED, additional trials during the 
lifetime of an AED’s licence may not be forthcoming. Therefore, trials from 
other indications may fulfil this need as far as harms outcomes are concerned.  
• The methodologies demonstrated here could be used to make decisions if 
significant heterogeneity exists and if this is not the case then harms outcome 
can be used to make a more precise estimate. As demonstrated in chapter nine, 
that for outcome fatigue a more precise estimate was obtained.  
• Other potential sources of harms data could include trials of AEDs where the 
formulation of an AED is compared to placebo or pseudo placebo.  
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Chapter 10 
 
 
 
 
Conclusion and further work 
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10.1 Adverse events of antiepileptic drugs 
 
Epilepsy is a chronic condition that is commonly treated with antiepileptic drugs. 
There are currently several antiepileptic drugs available and this number is expected to 
grow. Clinicians therefore need to choose which antiepileptic drugs are best for their 
patients. This is usually reached by consultation with the patient and based on clinical 
need. The General Medical Council requires doctors to give a balanced discussion of 
harms. They state that serious risk of treatments be discussed even though the 
perceived risk is small (Consent & Guidance 2015). In order to have an informed 
discussion, a clinician must be able to correctly quantify the risk of treatment. Data 
pertaining to harm can be obtained from many sources of evidence like RCTs and 
observational studies.  
  
Harms of antiepileptic drugs are common and they have a considerable impact on the 
lives of patients with epilepsy. Epilepsy is a chronic condition and the benefits of these 
drugs have to be balanced against potential risks. Information on the risks of treatment 
is varied making it difficult for clinicians to search for this type of data. Current 
sources of data pertaining to risks are usually obtained from randomised controlled 
trials and observational studies.  
 
Randomised controlled trials are good sources of evidence for transient dose-related 
adverse events. Observational studies are better at longer-term adverse events. 
However, results from observational studies can be biased and effect sizes can be over 
inflated whereas randomised trials may provide less biased estimates. Systematic 
reviews can provide an additional source of harms data when harms outcome from 
several trials is meta-analysed to provide a more precise estimate.  
 
Most harms are type A reactions and therefore occur during the titration period 
(Majkowski et la 2005). This does not automatically mean that observational studies 
have less a role in harms as one would need to consider the harms occur throughout the 
trial period with an understanding that most of these occur at the begins of drug  
 
A number of significant barriers currently exist which can impede the reporting of 
harms in randomised controlled trials. Some of these are related to how trials are 
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conducted and some of the reasons are due to reporting practices of medical journals. 
Trial related factors include, inadequate methods of collecting harms data, lack of a 
validated tool like the AEP. Coding practices of harms reported in trials may vary, our 
analyses showed that the older clinical trial reported dictionaries but these were not 
reported in the more recent trials. I cannot explain why this is so but using lacosamide 
as an example, we see that some outcomes like ‘ataxia’ was reported in one epilepsy 
trial but two other epilepsy trials reported this as ‘coordination abnormal’.  Coding of 
harms of AEDs is heterogeneous. In a recent study, Perucca et al performed 
correlations between harms reported using the AEP (adverse event profile) and 
QOLIE-89 (Quality of life in epilepsy 89) (Perucca et al 2009). Five distinct classes of 
AE emerged from correlations and this has implications into how harms could be 
classified and clumped into novel categories thereby we can have uniformity of harms 
across trials. And finally, harms are poorly reported in journal possibly this is related 
to journal space.  
 
10.2 Reporting of harms of antiepileptic drugs 
 
Harms reporting in randomised trials were deemed to be poor by several authors and 
this was confirmed in several therapeutic areas (Ioannidis 2004). Many of these studies 
used the CONSORT extension of harms as a benchmarking tool. Consistently we have 
that adverse event reporting in RCTs is poor in several therapeutic areas. Overall there 
has been no change in adverse event reporting since the publication of the CONSORT 
guidelines. Poor reporting of harms can be predicted based on the journal of 
publication and in the source of funding. Empirical evidence shows that the 
conclusions in randomised controlled trials are more positive toward experimental 
interventions if funded by for profit organisations (Als-Nielsen et al 2003). Therefore, 
the role of funding in how harms are reported in RCTs was explored.  
 
In this thesis CONSORT guidelines were used as a tool to assess the reporting of 
harms in randomised controlled trials of antiepileptic drugs. This work has not 
previously been endeavoured in epilepsy. The findings presented in this thesis 
demonstrate the poor reporting of harms in RCTs and this is consistent with other 
studies (Hodkinson et al 2013). There has been no improvement in reporting of harms 
since the publication of the CONSORT guidelines. However certain aspects of adverse 
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event reporting in epilepsy trials were better compared to other therapeutic areas, for 
example the inclusion of a table for adverse events was far superior. The results 
showed a significant effect of funding in reporting of harms where this was better in 
commercially funded trials. Journals that endorse CONSORT and trials that are 
commercially funded may report harms better than other studies. Reporting of harms 
in trials in children is considerably poorer as compared to the reporting of harms of 
outcomes in adults is clearly an area of great concern.  
 
To raise awareness of this issue, several posters and platform presentations were 
presented in national and international meetings. These are listed in the appendix K 
page 378.____.  
 
10.3 Lacosamide systematic review 
  
Chapter 8 describes a systematic review of lacosamide. This AED is a novel drug used 
in the treatment of partial epilepsy. This systematic review highlighted a treatment 
effect caused by placebo. The 200mg dose was not significant compared to placebo in 
the intention to treat analysis. A meta-analysis showed that the 200mg was marginally 
superior to placebo and this was statistically significant. This therefore has 
implications for clinical practice as the 200mg dose could be prescribed with fewer 
side effects.  
 
This review was important for harms as more precise estimates for adverse events 
were obtained. Examples of harms estimates that are more precise were: coordination 
abnormal, relative risk of 6.12 (95% CI of 1.94 to 19.4); diplopia, relative risk of 5.24 
(95% CI of 2.49 to 11.24) and fatigue, relative risk of 2.11 (95% CI of 1.12 to 3.97).  
 
Summary measures for harms generated in this review showed a significantly larger 
effect size compared to the efficacy outcomes. This was an interesting observation and 
this could be related to a placebo drift effect. The work shown here led to further 
exploration of harms across indications.  
 
 
 
		
	 288	
10.4 Harms across indications- the lacosamide example 
 
The inclusion of additional trials into a meta-analysis could potentially improve the 
estimation of the effect sizes. If the number of studies included in meta-analysis were 
increased, this could certainly be of a beneficial value. In this thesis lacosamide was 
used as an example for analysing harms. Currently there are three placebo-controlled 
trials of lacosamide as add-on therapy for patients with epilepsy. The likelihood of 
another placebo-controlled trial using lacosamide as add on therapy is remote as the 
drug sponsor holds a licence for the next four years and therefore the sponsor does not 
have an incentive for funding another RCT. However, if data from RCTs of another 
indication of lacosamide were found, the data from this could be used. I found four 
lacosamide trials in neuropathy.  
 
When harms data from neuropathy trials were added to epilepsy studies, I found a 
more precise and significant estimate was found for outcome fatigue. Also, a number 
of harms outcomes were reported in neuropathy trials and not reported in epilepsy 
trials. I did not find any significant heterogeneity between the two indications.   
 
10.5 Harms of antiepileptic drugs: other AEDs 
 
Following the lacosamide example, I explored if harms across indications can be used 
in other AEDs. I selected a number of AEDs, which were used in headache and 
neuropathy indications. Here I used the traditional method of meta-analysis and 
statistical tests of heterogeneity I also used meta-regression to further explore 
heterogeneity and test my hypothesis that harms across indications can be used for 
analysing harms. 
 
The results showed that two AEDs namely lamotrigine and lacosamide can be used 
across indications. The implication of this work is that harms data of newer AEDs 
from other indications are invaluable source of additional data. Drug sponsors would 
want to maximise their revenue for a given AED by carrying out trials in other 
indications, therefore these trials are valuable for harms data. Such data would be 
valuable in systematic reviews as they can be utilised either in meta-analyses or 
described narratively.  
		
	 289	
10.6 Recommendations 
 
This thesis received the support of a grant from NIHR. One of the intended outputs 
was to improve the reporting of harms in systematic reviews and develop new tools for 
Cochrane reviews in relations to harms analysis. The following recommendations can 
be made: 
 
• Reporting of harms in randomised controlled trials is poor. To improve this one 
needs to raise awareness of this issue. This work was well received in 
neurology meetings. 
• Several publications have found similar results of inadequate reporting of 
harms in other therapeutic areas. CONSORT extensions for harms have been 
used extensively to highlight this point. Many journals endorse CONSORT but 
subspecialty journals are lagging behind in this regard. It is noted that  
• The CONSORT guidelines therefore need to be further developed where they 
can: 
o Be incorporated into the peer review process. This may encourage 
academia to adhere to CONSORT when drafting the trial report stage 
and also implement it at the trial design stage. To encourage academia 
to adhere to CONSORT at the trial design stage and not just at the 
reporting stage. CONSORT guidelines could be modified and 
simplified into a quick guide for prospective authors on journal 
websites.  
o Simplification of harms guidelines into a workable checklist that not 
only serves as a benchmarking tool but as a tool used by authors at the 
writing stage of a given article  
o Elements from the CONSORT guidelines be included into a novel ‘risk 
of poor harms reporting tool’ in RevMan 
• Currently all trials need to be registered in clinicaltrials.gov before they start 
recruiting patients. This is a new prerequisite by the FDA and EMA. This is a 
major step forward. Unfortunately, many published trials cannot be directly 
linked to trials published in the clincialtrials.gov website. This is attributable to 
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multiple web entries from different centres for the same study. Therefore, this 
has to be simplified. 
• Poor reporting of harms is still prevalent in epilepsy trials therefore one must 
try to obtain unpublished data from the drug sponsors when conducting 
systematic reviews. 
• If an AED is used in another indication, drug sponsors should be asked to make 
available unpublished data from these additional trials too. Attempts should be 
made to meta-analyse this data and if they show significant heterogeneity, then 
adverse events from these additional trials could be commented on by authors 
of systematic reviews. Such efforts may give clinicians a more balanced 
overview of harms. 
• If harms issues of AEDs are reported in several trials including trials across 
indications, one may consider a separate systematic review in the Cochrane 
database with harms as the primary outcomes.  
• Currently the Cochrane Group seeks to simplify their product by making the 
review process simpler. One would expect that harms might play a secondary 
role if this was to occur. One must therefore balance the needs for progress in 
light of external competition with the need to be explicit on harms reporting. 
Cochrane protocols and reviews need to be simplified and modified to include 
harms data.  
• Innovative statistical methods should be developed where harms from across 
indications can be further analysed. Comprehensive Meta-Analysis version 3.0 
allowed the use of multiple regression using more than one covariate. Similar 
statistical methods and tools need to be developed for novel harms outcomes.  
 
10.7 Further work 
 
A significant amount of raw data was collected from randomised controlled trials as 
raw data. A portion of the data was analysed in chapter 10. The remainder of this data 
was passed on to my colleague Sarah Donegan who refined the statistical methods.   
 
This thesis focused on randomised controlled trials. However a recent Cochrane 
review evaluated non-randomised studies of antidepressants in epilepsy (Maguire et al 
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2014). Although the quality of evidence from these studies may not be robust but in 
certain therapeutic areas where evidence is lacking there may be a role of using this 
evidence. Therefore, new methodologies need to be explored in this area.  
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Appendix B: An explanation of Cohen’s Kappa Statistic 
 
Cohen’s Kappa is a statistic used to assess the extent of reproducibility and reliability 
between rates of categorical variables. Where: κ		 = 		 $	%&'()*(+ − $	(-.(/0(+	1 − $	(-.(/0(+	 	
Equation	1	Kappa	Statistic		
To calculate the values of A expected and A observed, we used Cross tab function of SPPS 
version 21. Alternatively this can be calculated using the punnet square and formulas 
below. The values a, b c, and d represent the number of items extracted by each 
reviewer/reader.  
Reviewer B 
 
 
Reviewer A 
 Yes No TOTAL 
Yes a b a + b 
No c d  c + d 
  a + c b + d  
 
The observed probability of agreement is based on the number of yes and no outcomes 
that were agreed out of the total: 
Total is a + b + c + d 
A observed = (a + b)/ (a+b+c+d) 
The expected probability is calculated as below 
The probability that reader one will say yes is  
Preader one yes = (a + b)/ (a+b+c+d) 
The probability that reader two will say yes is  
Preader two yes = (a + c)/ (a+b+c+d) 
Conversely the probability of reader saying no is  
Preader one no = (c + d)/ (a+b+c+d), Preader two no = (b + d)/ (a+b+c+d) 
Therefore, the probability of both parties saying yes is the product of the two: 
Pyes = Preader one yes x Preader two yes  
Likewise, the probability of both parties saying no is:  
Pno =  Preader one no x Preader two no 
Therefore the A expected is the sum of the two: 
A expected = P yes + P no 
Finaly the values of A expected  and A observed  are known, hence kappa can be calculated. 
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Cohen’s Kappa is a statistic used to assess the extent of reproducibility and reliability 
between rates of categorical variables. It is based on the observed readings by two 
different observers on two different occasions with the proportion of agreements that 
would be expected by chance.  Cohen’s kappa is denoted by the Greek letter κ 
 
Where: κ		 = 		 $	%&'()*(+ − $	(-.(/0(+	1 − $	(-.(/0(+	 	
Equation 2 Kappa Statistic 
 
If there is complete agreement then A observed =1 and κ = 1 
If there is no more agreement than expected by chance then κ = 0 
Kappa values greater than 0.75 is taken as good agreement. Those between 0.4 and 
0.75 is fair to good agreement and less than 0.4 as moderate to poor agreement. 
 
Reviewer B 
 
 
Reviewer A 
 Yes No TOTAL 
Yes a b a + b 
No c d  c + d 
  a + c b + d  
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Appendix C: Other items of data collected for CONSORT data 
 
1. Name of study 
2. PubMed Reference number 
3. Journal 
4. Year of publication 
5. Type of study: Efficacy, safety or both 
6. Mono-therapy, add-on or polytherapy trial  
7. Types of seizures 
8. Inclusion and exclusion criteria 
9. Drugs used and dosages 
10. Number of intervention arms 
11. Number of authors 
12. Source of funding 
13. Number of centres 
14. Multi-centre or single study 
15. Number of patients randomised 
16. Blinding: single, double or open label 
17. Dose reduction allowed 
18. Duration of baseline phase, maintenance phase and withdrawal phase 
19. Number of patients in the ITT population 
20. Number of intervention arms 
21. Inclusion and exclusion criteria 
22. Blinding 
23. Primary outcomes 
24. Secondary outcomes 
25. Details of harms outcomes 
26. Number of patients with adverse events 
27. Serious adverse events 
28. Proportion of patients withdrawn due to adverse events 
29. Methods of ascertainment of adverse events: dairy, clinical interview, phone 
call or mixture of methods 
30. Details of dictionary used 
31. Harms reported above a threshold; 5% 10% or >10% 
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32. Adverse event scales used  
33. Total number of words used in report dedicated to harms and total number of 
words in article 
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Appendix D: Student t-test 
 
A t-test examines two samples and compared their means. The t-test compares the 
differences of the means with the difference variance of the samples. The t-static is 
therefore a ratio of the difference in means and the standard error of the difference 
between the means.  The t-test can only be used if the data is normally distributed. The 
t-statistic is denoted by:  
 0	 = 2(34	%5	'32.6(	3	–2(34	%5	'32.6(	&893):34/(	%5	'32.6(	3	 + 	*3):34/(	%5	'32.6(	&	
Equation	3	T-test 
 
There are two types of t-tests, which could be used, one for comparing two 
independent groups of variables or two dependent groups of variables.  
 
A p value of <0.05 indicates that the null hypothesis is not true and any observed 
differences between groups is not due to chance. However, even if a p value is 
statistically significant, the difference in values needs to be large enough to be 
considered clinically significant. 
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Appendix E: Pearson’s Correlation 
 
The strength of the relationship between variables is given by the R statistic. The 
values of R can range from -1.00 to 1.00. A value of zero indicated no relationship at 
all, a value of 1.0 indicated a perfect positive correlation and a value of 1.0 indicates a 
perfect negative correlation. Any values that are not 1 or 0 can be interpreted by 
categorically as suggested by Cohen (Cohen 1960).  
 
Size of r Strength of correlation 
r = 0.1 to 0.29 or r = -0.1 to -0.29  Small 
r = 0.3 to 0.49 or r = -0.3 to -0.49 Medium 
r = 0.5 to 1 or r = -0.5 to -1 Large 
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Appendix F: List of trials included in analysing harms across indications 
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Appendix G: Search strategy for randomised controlled trials of antiepileptic 
drugs 
 
Search strategy to search for randomised controlled trials of antiepileptic drugs in 
MEDLINE 
1. randomised controlled trial.pt. 
2. controlled clinical trial.pt. 
3. randomized.ab. 
4. placebo.ab. 
5. clinical trials as topic.sh. 
6. randomly.ab. 
7. trial.ti. 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. exp animals/ not humans.sh. 
10. 8 not 9 
11. exp Epilepsy/ 
12. Seizures/ 
13. (epilep$ or seizure$ or convuls$).tw. 
14. 11 or 12 or 13 
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Appendix H: Search strategy used to search for lacosamide trials. 
Search strategy to search MEDLINE (Ovid). Based on the Cochrane Highly Sensitive 
Search Strategy for identifying randomised trials published in Lefebvre 1994.  
1. randomised controlled trial.pt. 
2. controlled clinical trial.pt. 
3. randomized.ab. 
4. placebo.ab. 
5. clinical trials as topic.sh. 
6. randomly.ab. 
7. trial.ti. 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 
9. exp animals/ not humans.sh. 
10. 8 not 9 
11. exp Epilepsy/ 
12. Seizures/ 
13. (epilep$ or seizure$ or convuls$).tw. 
14. 11 or 12 or 13 
15. lacosamide.tw. 
16. erlosamide.tw. 
17. 15 or 16 
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Appendix I: Performa for data collection for harms  
 
18. 10 and 14 and 17 
Name	of	Study	 	
Journal	 	 □	RCT	□	RV	□	Other	
Year	of	publication	 □	Retrospective																		□	Prospective	
Scope	 □	Efficacy									□	Safety									□			Other	 Setting:	□	Inpt				□	Outpts					□Other	
Type	of	therapy	 □	Mono	tx															□	Polytherapy											□	Add	on				□			Other	
		
Multicentre	or	single	
centre	&	sponsorship	
□	Multi	Centre					□	Single	centre				□	Industry					□	non	Industry/NR	
□	Not	Clear										□	Not	Stated	
Describe	the	patient	
population	
	
	
	
	
	
	
□	First	Seizure				□	Newly	diagnosed	epilepsy				□	Chronic	epilepsy		
□	Epilepsy	type	not	categorized	⁯	Both	Chronic	and	new	dx		
□	Focal	epilepsy	□	Generalized	Epilepsy	□	Both	F	&	G	□	Specific	Syndrome	□	
Status	epilepticus	
□	Children	□	Adults	□	Children	and	Adults	
No	of	patients	
randomized	
	
		 No	of	patients	in	the	safety	
population			
	 No	of	pts	in	
the	ITT	
population	
	
No	of	patients	in	the	inf	
ITT	population	
		
	
No	of	patients	in	
the	PPR	
population	
			 			 			
Number	of	authors																											Number	of	contributors																	No	of	tx	key	Auth	publi	
	
Number	of	centres	
Inclusion	criteria	
	
	
	
Exclusion	criteria	
	
Ref	 Date	
□	C		□In	C	□	In	C	□Rd		
□		Relevant	□Not	
relevant	
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Blinding	chose	one	or	more	
□	Double	blinded						□	Single	Blinded			□	Open	label									□	Placebo	controlled	⁯Both	open	and	double	
blinded	phases	⁭	Both	open	and	single	blinded	
□	Parallel	arm,	No	of	arms				______						□	Cross	over		□	Other	□	Head	to	Head		
	
	
Drugs	used	 Dosage		 Drug	used	 Dosage	
	 	 	 	
	 	 	 	
	 	 	 	
Dosing	Policy	
□	Fixed	
□	Clinical	Practice	
□	Other	
Drug	selection	
□	Fixed	
□	Random	
□	Clinical	practice	
□	Not	stated	
Evaluation	period	
duration	dit	by?	
⁯	Fixed	
⁯	Until	pt	exits	
⁯	Until	last	pt	randomized	
⁯	Clinical	practice	
□	Not	stated	
Any	dose	reduction	
allowed?	
⁯Y	⁯	N	
Duration	of	study	(time	
line	for	PP)	
	 Year	of	study	
commencement	 	
Titration	methods	 				
Duration	of	baseline	
Period	
		 Duration	of	extension	phase		
Duration	of	titration	
period	
		
Duration	of	evaluation	
period	
⁯	specific	time	
⁯	as	per	Evaluation	period		
⁭	specific	time	and	or	as	per	EP	 Duration	of	withdrawal	phase		
Primary	outcome	
measures	
□	Seizure	remission/control	
□	Treatment	failure/retention		
□	Adverse	effect	
□	Other	
Units	
	
		 		
2◦	outcome	measures	 		 Units			 			
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Other	end	points	
⁭	Safety	end	points______________________________________________________________																																		
⁭Pharmacokinetic	end	points______________________________________________________	
⁭																																												______________________________________________________	
⁭																																												______________________________________________________	
⁭																																												______________________________________________________		
ADVERSE	EVENTS	
Excluding	SAE	(go	to	page	)			 Drug	name	and	dose			
Name	of	event	or	SE	 No	of	
events	
No	of	
pts	
Duration	in	
days	
%	 Outcome	 	
	 	 	 	 	 	 	
	 	 	 	 	 	 	
	 	 	 	 	 	 	
		
N	=	
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Serious	AE	
	
Event	descriptions	
	
	
Number	of	events																																									Number	of	patients	
	
Outcome												□	Resolved							□	Death									□	Major	morbidity	squeal				□	Minor	sequel	
	
	
	
	
	
Event	descriptions	
	
	
Number	of	events																																									Number	of	patients	
	
Outcome												□	Resolved							□	Death									□	Major	morbidity	squeal				□	Minor	sequel	
	
	
Event	descriptions	
	
	
Number	of	events																																									Number	of	patients	
	
Outcome												□	Resolved							□	Death									□	Major	morbidity	squeal				□	Minor	sequel	
		
Method	of	ascertainment	of	Adverse	events	
	
□	Pt	diary	only	
	
□	Clinical	interview	only	
	
□Diary	and	interview				⁭Diary	and	Phone	
	
□	Phone	call	only	
	
□	Phone	call	and	interview	
	
□	Other	
□	Not	Stated	
Physical	exam?	
							□	Y	
							□	N	
	
Comments	made	on	the	quality	of	reporting	of	AE	
□	Y							□	N	
		
	 357	
	
AE	tabulation	
	
□	WHOART	
□	COSART	
□	Other	
□	Not	stated	
Timing	of	AE/SAE	
	
□Screening	phase																□	Phase	or	timing	not	mentioned	
	
□Baseline	phase	
	
□Titration	phase	
	
□Double	blind	randomization	phase/	open	label	phase	
	
□Withdrawal	phase	
	
□Cross	over	to	new	drug	phase	
	
□Phase	not	mentioned	but	stated	in	weeks/months	give	details	
Did	they	use	an	adverse	event	scale	and	what	was	it?	
	
Scale	used?	□	Y				□	N			
□	Likert	
□	Mild/Mod/Severe	
□	Other	
□	LEAP	
Systematic	method	on	collection	of	AE	
□	Yes	□	No	□	Not	Stated	
Systematic	method	on	what	is	reported	
□	Yes	□	No	□	Not	Stated		
	
Trestment	of	AE/SAE	
	
		
□			Trial	drug	withdrawn							□	Pt	withdrawn	
	
□	New	Tx	added						□	trial	drug	dose	changed	
	
□	patient	crossed	over	to	another	arm	
	
□	Other		
□	Not	Stated		
Were	patients	with	AE	
included	in	ITT	analysis?	
	
	
	
□	Yes		
□	No	
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Presentation	of	AE	results													Drop	outs	or	AE	events	shown	in	a	randomization	chart?	□	Y	□	N	Demographics	chart?																																				□	Y	□	N	AE	table?																																																						□	Y	□	N		No	of	AE	Events?																																								□	Y	□	N	No	of	Subjects	having	AE?																										□	Y	□	N	Percentage	of	patients	having	AE?													□	Y	□	N		AE	tabulated	as:				
□	Systems	approach	□	Symptom	specific	approach	□	Other	approach		
List	all	the	AE	outcomes	shown	in	paper	 	
	 	
	Total	Number	of	words	in	article			Total	Number	of	words	attributed	to	adverse	events		Percentage			
Brief	results	of	Overall	
Study	
	
Did	AE	affect	the	results	and	
recommendations	 		
Limitation	of	study	 		 		
	Other	data	collected	in	second	Epi	info	file	that	is	directly	added	to	the	computer	without	paper	work	
1. Number	of	Add	on	drugs	if	relevant	2. AE	reported	by	>5%	>10%	or	not	stated	
3. Names	of	all	add-on	drugs	used	
4. Number	of	discrete	AE	reported	5. AE	in	abstract-Y?	N?	
What	denominator	was	used	to	calculate	the	percentage	of	pts	having	AE?			
Number	of	patients	dropped	out	due	to	AE:		Arm	1																					2																					3	Were	these	followed	up?			□Y					□	N	Included	in	final	analysis?		
□	Y						□	N			
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6. Number	of	tables	attributed	to	AE	
7. Number	of	Serious	adverse	events	(SAE)	reported	
8. Name	of	individual	SAE	
9. Number	of	patients	with	each	SAE	10. SAE	related	to	trial	drug-	Yes?	No?	Yes	some	not	all?	Not	Stated?	11. Causality-	All	AE	reported?	Only	treatment	emergent?	Not	stated?	12. SAE-	Discussed	separately?	Not	discussed	separately?	13. AE	frequency	compared	to	placebo-	Yes?	No?	14. Comments	made	on	AE	relationship	with	dose-Yes?	No?	15. Statistics	used	to	discuss	AE-	Descriptive?	Inferential?	Both?	Neither?	16. Did	adverse	events	change	trial	protocol-	Yes?	No?	17. AE	discussed	in	discussion-	Yes	with	clinical	and	dose	guidelines	given?	Yes,	with	clinical	implications	only?	Yes,	with	dose	implications	only?	AE	not	discussed	at	all?	
18. Trial	identification	code	in	Medline	19. Was	AE	the	primary	outcome?	Yes/No	it	was	secondary	outcome/	AE	not	outcome	at	all/	not	stated	
20. Total	number	of	adverse	events	recorded	including	placebo	
21. Total	number	of	patients	reporting	AE	including	placebo	22. Most	common	AE	in	trial	drug	1	(name	of	event)	
23. Max	percentage	of	patients	reporting	Above	(most	common	AE	in	trial	drug	1)	24. Tabulation	of	AE?	Quoted	in	both	number	and	percentage/	percentage	only/	number	only/	No	AE	table	25. Were	AE	in	each	arm	mentioned?	Yes,	each	arm	mentioned	and	quoted	separately	in	both	text	of	article	and	table/	Yes,	each	arm	mentioned	and	quoted	separately	but	only	in	the	table/	Yes,	mentioned	but	results	are	clumped	together/	No	data	given.	
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Appendix J: Raw data for chapter nine. 
 
Pregabalin in epilepsy and neuropathy trials 
 
 
Outcome: Any Adverse Event 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
150mg Two trials were evaluable Three trials were evaluable 
300mg One trial was evaluable Two trials were evaluable 
600mg Three trials were evaluable Zero trials were evaluable 
Any dose Two trials were evaluable Seven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
epilepsy and 
neuropathy 
150mg 1.07 (0.86-1.34) 1.09 (1.33-3.44) 66% 44% 
300mg 1.14 (0.99-1.32) 1.25 (0.98-1.59) NA as one RCT 59% 
600mg NA NA NA NA  
Any dose 3.52 (2.48-5.00) 3.01 (2.40-3.78) 0% 27%  
 
Outcome: Ataxia 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
150mg Two trials were evaluable Three trials were evaluable 
300mg One trial was evaluable Five trials were evaluable 
600mg Four trials were evaluable Six trials were evaluable 
Any dose Three trials were evaluable Seven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
epilepsy and 
neuropathy 
150mg 1.07 (0.86-1.34) 1.09 (1.33-3.44) 66% 44% 
300mg 1.14 (0.99-1.32) 1.25 (0.98-1.59) NA as one RCT 59% 
600mg NA NA NA NA  
Any dose 3.52 (2.48-5.00) 3.01 (2.40-3.78) 0% 27%  
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
150mg Two trials were evaluable Three trials were evaluable 
300mg One trial was evaluable Seven trials were evaluable 
600mg Four trials were evaluable Eleven trials were evaluable 
Any dose Three trials were evaluable Thirteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
epilepsy and 
neuropathy 
150mg 2.05 (1.18-3.57) 2.14 (1.33-3.44) 0% 0% 
300mg 3.46 (1.73-6.93) 3.75 (2.82-4.97) NA as one RCT 0% 
600mg 4.52 (3.33-6.15) 4.48 (3.57-5.62) 0% 2% 
Any dose 3.52 (2.48-5.00) 3.01 (2.40-3.78) 0% 27%  
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Outcome: Fatigue 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose One trial was evaluable Five trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
neuropathy 
Any dose 1.82 (0.53-6.27) 1.47 (1.00-2.16) NA as one RCT 0% 
 
 
Outcome: Headache 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
150mg Two trials were evaluable Five trials were evaluable 
300mg One trial was evaluable Five trials were evaluable 
600mg Three trials were evaluable Nine trials were evaluable 
Any dose Four trials were evaluable Fourteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
neuropathy 
150mg 0.54 (0.29-1.00) 0.69 (0.44-1.08) 0% 0% 
300mg 0.43 (0.16-1.15) 0.65 (0.43-0.97) NA as one RCT 0% 
600mg 0.78 (0.46-133) 0.87 (0.64-1.17) 0% 0% 
Any dose 0.62 (0.43-0.89) 0.87 (0.66-1.15) 0% 56%  
 
Outcome: Nausea Not reported in epilepsy trials 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
150mg Two trials were evaluable Six trials were evaluable 
300mg One trial was evaluable Seven trials were evaluable 
600mg Four trials were evaluable Eleven trials were evaluable 
Any dose Five trials were evaluable Nineteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
neuropathy 
150mg 1.29 (0.71-2.35) 1.73 (1.12-2.65) 0% 0% 
300mg 1.62 (0.79-3.30) 3.38 (2.20-5.44) NA as one RCT 24%  
600mg 2.56 (1.82-3.61) 3.57 (2.61-4.88) 0% 21% trials are  
Any dose 2.17 (1.58-2.99) 2.88 (2.25-3.68) 0% 30%  
 
 
Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
150mg Two trials were evaluable Six trials were evaluable 
300mg One trial was evaluable Seven trials were evaluable 
600mg Four trials were evaluable Eleven trials were evaluable 
Any dose Three trials were evaluable Fourteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
neuropathy 
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150mg 0.78 (0.12-5.11) 1.29 (0.76-2.19) 64% 0% 
300mg 2.89 (1.07-7.78) 2.37 (1.59-3.51) NA as one RCT 15%  
600mg 3.74 (2.44-5.73) 2.72 (2.11-3.49) 0% 6%  
Any dose 3.11 (1.82-5.30) 2.19 (1.73-2.78) 0% 8%  
 
Gabapentin in epilepsy and headache trials 
 
Outcome: Any AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Five trials were evaluable Seven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
headache 
Any dose 1.27 (1.16-1.39) 1.37 (1.19 -1.59) 0% 54% 
 
 
Outcome: Ataxia 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Three trials were evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
headache 
Any dose  (1.77-2.94) 2.07 (1.06 -4.04) 0% 29% 
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Six trials were evaluable Eight trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
headache 
Any dose 2.42 (1.63-3.59) 2.62 (1.86 -3.69) 0% 0% 
 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Four trials were evaluable Five trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
headache 
Any dose  0.89 (0.53-1.48) 1.12 (0.61 -2.07) 0% 28% 
 
 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Six trials were evaluable Eight trials were evaluable 
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Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
headache 
Any dose   2.28 (1.72-3.01) 2.29 (1.76 -3.00) 0% 0% 
 
Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Three trials were evaluable Five trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
headache 
Any dose  1.39 (0.51-3.81)  1.65 (0.92-2.96) 22% 0% 
 
Gabapentin in epilepsy and neuropathy trials 
 
 
Outcome: Any AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Five trials were evaluable Twelve trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 1.27 (1.16-1.39) 1.30 (1.30 -1.68) 0% 51% 
 
 
Outcome: Ataxia 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Three trials were evaluable Seven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 2.55 (0.76-8.54) 2.87 (1.35 -6.12) 51% 26% 
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Five trials were evaluable Twelve trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 2.42 (1.63-3.59) 2.88 (2.31 -3.58) 0% 0% 
 
 
Outcome: Fatigue 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Four trials were evaluable Nine trials were evaluable 
Dose RR Epilepsy RR Epilepsy and Statistical Statistical 
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only (95% CI) Headache heterogeneity 
(I2) epilepsy only 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 1.64  (0.96-2.81) 1.62 (1.01 -2.61) 0% 29% 
 
 
Outcome: Headache 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Five trials were evaluable Nine trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 0.73  (0.40-1.36) 1.12 (0.56 -2.20) 21% 43% 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Four trials were evaluable Thirteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 0.89  (0.53-1.48) 0.93 (0.68 -1.26) 0% 0% 
 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Six trials were evaluable Fourteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 2.14  (1.59-2.87) 2.59 (2.06 -3.25) 0% 1% 
 
 
Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Four trials were evaluable  Fourteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity 
(I2) epilepsy and 
Neuropathy 
Any dose 1.78 (0.84-3.77) 1.77 (1.31 -2.39) 17% 0% 
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Topiramate in epilepsy and headache trials 
 
 
Outcome: Any AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
200mg One trial was evaluable One trial was evaluable 
Any dose Three trials were evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Migraine 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
200 mg 0.57  (0.18-1.82) 1.71 (0.23-12.77) NA 90% 
Any dose 1.05 (0.91-1.20) 1.34 (1.11-1.61) 0% 80%  
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
200mg One trial was evaluable No headache trials were 
evaluable 
Any dose four trials were evaluable Eight trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Migraine 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 1.23 (0.82-1.85) 1.13 (0.83-1.54) 41% 30%  
 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Two trials were evaluable Eight trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Migraine 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 2.18 (0.52-9.20) 1.60 (1.15-2.23) 0% 0%  
 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
200mg One trial was evaluable Two trials were evaluable 
Any dose Seven trials were evaluable eleven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Migraine 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
200 mg 3.11 (1.73-6.01) 3.31 (1.90-5.79) NA 0% 
Any dose 1.73 (1.22-2.47) 1.76 (1.33-2.33) 40% 18%  
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Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
200mg One trial was evaluable Three trials were evaluable 
Any dose Ten trials were evaluable Sixteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Migraine 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
200 mg 1.75 (0.55-5.57) 2.55 (0.70-9.28) NA 90% 
Any dose 2.03(1.12-3.67) 2.07 (1.44-2.98) 23% 24%  
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Topiramate in epilepsy and neuropathy trials 
 
Outcome: Any AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Three trials were evaluable One trial was evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
neuropathy 
Any dose 1.05 (0.91-1.22) 1.10 (0.99-1.21) 0% 0%  
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Seven trials were evaluable Two trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
neuropathy 
Any dose 1.35 (0.91-1.99) 1.31 (0.98-1.75) 37% 17%  
 
 
Outcome: Headache 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Six trials were evaluable Two trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
neuropathy 
Any dose 0.85  (0.60-1.19) 0.84 (0.63-1.12) 46% 33%  
 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Two trials were evaluable One trial was evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
neuropathy 
Any dose 2.18  (0.52-9.20) 1.84  (0.86-3.90) 0% 0%  
 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Eight trials were evaluable Two trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
neuropathy 
Any dose 1.90 (1.44-2.50) 1.95 (1.53-2.48) 14% 0%  
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Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Eight trials were evaluable Two trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Neuropathy 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
neuropathy 
Any dose 1.96 (1.03-3.71)  1.94 (1.07-3.50) 3% 28% 
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Lamotrigine and Neuropathy trials 
 
 
Outcome: Any AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Four trials were evaluable Nine trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 1.33 (0.95-1.856) 1.29 (1.05 – 1.57) 76% 60% 
 
 
Outcome: Ataxia 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Eight trials were evaluable Eleven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 2.46 (1.11-5.45) 2.49 (1.22 – 5.07) 47% 34% 
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Eight trials were evaluable Eleven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 2.50 (1.56-4.02) 2.17 (1.44 – 3.29) 30% 33% 
 
 
Outcome: Headache 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Eight trials were evaluable Eleven trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 1.22 (0.90-1.64) 1.18 (0.89– 1.56) 0% 0% 
 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Six trials were evaluable Ten trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 1.86 (1.22-2.83) 1.67 (1.17– 2.40) 0% 0% 
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Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Eight trials were evaluable Twelve trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 1.65 (0.93-2.95) 1.64 (0.91– 2.96) 23% 58% 
 
 
Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Six trials were evaluable Fourteen trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 4.11 (1.49-11.35) 2.18 (1.37– 3.45) 0% 8% 
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Lamotrigine and headache trials 
 
 
Outcome: Any AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Four trials were evaluable Five trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
headache 
Any dose 1.34 (1.14-1.57) 1.38 (1.18 – 1.62) 68% 64% 
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Seven trials were evaluable Eight trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
headache 
Any dose 2.34 (1.71-3.19) 2.28 (1.69 – 3.07) 18% 7% 
 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Five trials were evaluable Six trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
headache 
Any dose 1.85 (1.20-2.85) 1.76 (1.15 – 2.69) 0% 0% 
 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Eight trials were evaluable Nine trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
headache 
Any dose 1.65 (0.93-2.95) 1.73 (1.00 – 2.99) 23% 17% 
 
 
Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Eight trials were evaluable Nine trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
headache 
Any dose 5.09 (2.28-11.37) 4.47 (2.27 – 8.79) 0% 0% 
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Oxcarbazepine in epilepsy and neuropathy trials 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Two trials were evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 2.36 (1.55-3.59) 3.03 (1.8-5.12) 8 % 50 % 
 
 
Outcome: Fatigue 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Two trials were evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 2.14 (1.21-3.76) 2.21 (1.37-3.57) 0 % 0 % 
 
 
Outcome: Headache 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Two trials were evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 1.13 (0.86-1.50) 1.46 (0.84-2.54) 0 % 58 % 
 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Two trials were evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 2.86 (1.76-4.65)  2.93 (1.98- 4.34) 0 % 0% 
 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Two trials were evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 3.82 (0.67-21.83) 4.12 (1.38- 12.29) 49 % 51% 
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Outcome: Withdrawal due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose Two trials were evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 3.60 (1.55-8.38)  4.02 (2.73- 5.92) 28 % 0% 
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Oxcarbazpeine in epilepsy and headache trials 
 
Outcome: Any AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Two trials were evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 1.20 (1.11-1.31)  2.43 (1.02- 5.79) 0 % 96% 
 
 
Outcome: Ataxia 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose One trials was evaluable Two trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 3.81 (1.97-7.37) 2.5 (1.95-6.61) NA 0 % 
 
 
Outcome: Dizziness 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Two trials were evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 2.36 (1.55-3.59) 2.41 (1.7-3.41) 8 % 0 % 
 
 
Outcome: Fatigue 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Two trials was evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 2.14 (1.21-3.76) 2.32 (1.44-3.73) 0% 0 % 
 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Two trials were evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 2.86 (1.76-4.65)  2.96 (1.91- 4.61) 0 % 0% 
 
		
	 375	
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Two trials were evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 3.82 (0.67-21.83)  2.12 (0.95-4.72) 49 % 43% 
 
 
Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose Two trials were evaluable Three trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 3.60 (1.55-8.38)  3.24 (1.71- 6.13) 28 % 25% 
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Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose One trials was evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 3.51 (1.90-6.52) 2.74 (1.84-4.09) NA 0% 
 
 
Outcome: Somnolence 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Headache) 
Any dose One trials was evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 2.20 (1.03-4.69) 2.41 (1.35-4.31) NA 0% 
 
 
Outcome: Withdrawal due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose One trials was evaluable Four trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Headache 
Any dose 4.40 (0.53-36.78)  2.0 (0.81-4.94) NA 0% 
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Valproate in epilepsy and neuropathy trials 
 
Outcome: Nausea 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose One trials was evaluable Two trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 3.51 (1.90-6.52) 3.56 (1.95– 6.52) NA 0% 
 
 
Outcome: Withdrawals due to AE 
Dose Trial description (Epilepsy 
only) 
Trial description (Epilepsy 
and Neuropathy) 
Any dose One trials was evaluable Five trials were evaluable 
Dose RR Epilepsy 
only (95% CI) 
RR Epilepsy and 
Headache 
Statistical 
heterogeneity 
(I2) epilepsy only 
Statistical 
heterogeneity  
(I2) epilepsy and 
Neuropathy 
Any dose 4.40 (0.53-36.78.) 2.96 (0.90– 9.70) NA 0% 
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Appendix K: Submitted publications  
 
Platform Presentations 
 
June 2009 An Analysis of adverse event reporting of antiepileptic drugs: A systematic 
review 
Association of British Neurologist meeting June 2009 
 
June 2010 Reporting of Adverse events in Randomised Controlled Trials is poor and 
has not changed since publication of the CONSORT guidelines 
European Congress in Epilepsy, Rhodes, Greece. 29th June 2010 
 
Papers 
 
November 2011 Reporting of adverse events in Randomised controlled trials of 
antiepileptic drugs using the CONSORT criteria for reporting harms.  
Arif Shukralla, Catrin Tudur-Smith, Graham Powell, Paula Williamson, Anthony 
Marson 
Epilepsy Research Vol 97 Issue (1-2), 20-29. 
 
June 2015 Lacosamide add-on for refractory epilepsy. 
Jenifer Weston, Arif Shukralla, Anthony Marson  
Cochrane Database of Systemic Reviews 2015 Issue  
DOI 10.1002/14651858.CD008841.pub2. 
 
November 2016 Oxcarbazepine add-on for drug-resistant partial epilepsy 
Sergio Castillo, Dieter Schmidt, Sarah White, Arif Shukralla 
Cochrane Database of Systemic Reviews, 2009 Issue 3  
DOI: 10.1002/14651858.CD002028.pub2 
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October 2009 Current reporting of adverse events in antiepileptic drug trials: A 
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August 2011 Adverse events of antiepileptic drugs, across indications: Can 
randomised controlled trial data from non-epilepsy indications be included in meta-
analysis for AEDs used in epilepsy?   
Arif Shukralla, Catrin Tudur-Smith, Anthony Marson  
Epilepsia Vol 52(Suppl 6) pg 120 
 
December 2011 Anti-epileptic drug harms: Issues for Meta-analysis 
Catrin Tudur-Smith, Arif Shukralla, Sarah Donnegan, Anthony Marson 
Trials vol 12 Suppl 1, A11 
 
February 2012 Can randomised controlled trial data from non-epilepsy indications be 
included in meta-analysis for AEDs used in epilepsy? An analysis of adverse event 
data. 
Arif Shukralla, Catrin Tudur-Smith, Anthony Marson 
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Summary
Purpose:  To  assess  the  reporting  of  adverse  events  (AEs)  in  randomised  controlled  trials  (RCTs)
of antiepileptic  drugs  (AEDs)  using  the  CONSORT  statement  for  harms  2004,  and  to  determine
if reporting  has  changed  since  introduction  of  this  standard.
Principal  results:  One  hundred  and  fifty  two  RCTs  were  included  from  a  search  of  papers  pub-
lished between  1999  and  2008  inclusive.  We  identified  23  criteria  in  the  CONSORT  statements.
The mean  number  of  criteria  met  per  trial  was  11.3  (95%CI  10.6—12.0).  Commercially  funded
studies met  12.6  and  non-commercially  funded  met  9.4  (p  <  0.001).  Trials  recruiting  adults  met
12.5 and  trials  recruiting  children  met  9.3  (p  <  0.001).  Trials  published  before  2004  met  11.6
and trials  published  after  2004  met  11.1  (p  =  0.53).  Commercially  funded  trials  met  the  majority
of criteria  more  than  non-commercially  sponsored  trials,  particularly  for  definition  of  AEs  (RR
3.15, CI  1.67—5.95)  and  the  use  of  a  validated  dictionary  of  terms  (RR  3.46,  CI  1.41—8.44).
Definitions  for  AEs  (RR  2.32,  CI  1.07—5.02)  and  details  of  analyses  (RR  2.05,  CI  1.01—4.15)  were
reported in  adult  trials  more  often  than  trials  in  children.
Major  conclusions:  Reporting  of  AEs  in  RCTs  of  AEDs  is  poor  and  has  not  improved
since the  publication  of  the  CONSORT  guidelines  on  the  reporting  of  harms.  Com-
mercially funded  trials  were  better  reported  than  non-commercially  funded  trials
Abbreviations: AE, adverse event; TEAE, treatment emergent adverse event; SD, standard deviation; CI, confidence interval; AED,
antiepileptic drug; RR, relative risk; RCT, randomised controlled trial; SAE, serious adverse event; CONSORT, consolidated standards of
reporting trials.
∗ Corresponding author at: Department of Neuroscience, Clinical Sciences Centre for Research and Education, Lower Lane, Liverpool,
L9 7LJ, UK. Tel.: +44 151 529 5770; fax: +44 151 529 5465.
E-mail addresses: arifshukralla@gmail.com (A.A. Shukralla), cat1@liverpool.ac.uk (C. Tudur-Smith), g.a.powell@doctors.org.uk
(G.A. Powell), prw@liverpool.ac.uk (P.R. Williamson), A.G.Marson@liverpool.ac.co.uk (A.G. Marson).
0920-1211/$ — see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.eplepsyres.2011.06.015
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and  trials  recruiting  adults  were  better  reported  than  trials  recruiting  children.  These  findings
have serious  implications  as  poor  reporting  precludes  bias  being  detected  and  hinders  adequate
risk benefit  analyses.  Journal  editors,  authors  and  reviewers  should  be  encouraged  to  follow
current guidance.
© 2011  Elsevier  B.V.  All  rights  reserved.
Introduction
Randomised  controlled  trials  (RCTs)  provide  the  best  source
of  information  about  the  effects  of  medical  interventions.
Consequently  they  have  been  pivotal  in  the  emergence  of
evidence  based  medicine.  The  primary  outcome  in  RCTs  is
usually  a  measure  of  benefit,  with  harms  usually  included
as  secondary  outcomes.  Treatment  decisions  often  involve
a  consideration  of  benefits  and  harms.  Therefore,  to  inform
these  decisions  we  need  reliable  evidence  about  potential
harms,  including  the  nature  of  the  adverse  events  (AEs),
their  likelihood  and  severity.
Informed  treatment  decisions  are  important  for  chronic
conditions  such  as  epilepsy,  where  antiepileptic  drug  (AED)
treatment  might  be  taken  for  many  years,  and  where  the
adverse  events  can  have  a  significant  effect  on  quality  of
life  (Baker  and  Jacoby,  2000). Adverse  events  like  memory
disturbance,  headaches  and  dizziness  are  common  among
people  with  epilepsy,  and  although  they  might  arise  dur-
ing  the  conduct  of  a  trial,  they  might  not  necessarily  be
caused  by  the  trial  treatment.  The  RCT  provides  a  means
of  assessing  whether  such  events  are  significantly  associated
with  a  specific  treatment,  either  by  comparison  with  placebo
or  with  other  treatments.  RCTs  can  therefore  provide  esti-
mates  of  incidence,  duration  and  severity  of  adverse  events
as  well  as  their  causality.  Adverse  events  investigated  in
RCTs  include  those  that  are  common  and  often  dose  related,
while  in  addition  the  overall  impact  of  numerous  AEs  can  be
assessed  by  using  adverse  event  scales  (Baker  et  al.,  1995),
and  risks  vs.  benefits  can  be  assessed  within  measures  of
quality  of  life.
RCTs  in  isolation  may  not  be  the  most  appropriate
research  design  to  assess  a  number  of  important  AEs.
This  is  because  RCTs  are  often  not  sufficiently  powered  to
detect  differences  in  AEs  and  patient  populations  are  not
representative  of  clinical  practice.  Therefore  longer  term
observational  studies  are  needed  to  discern  AEs  not  seen  in
RCTs.  Careful  examination  of  such  data  eventually  allows  the
distinction  between  AEs  which  may  be  associated  with  the
prescription  of  a  drug  but  are  not  directly  attributable  to  it
from  adverse  effects  which  are  attributable  to  the  drug.
Adverse  event  is  therefore  a  broad  term  to  encom-
pass  both  expected  and  clinically  plausible  consequences
of  drugs  and  unexpected  occurrences.  Adverse  effects  of
drugs  or  adverse  drug  reactions  are  those  occurrences  that
are  directly  and  clinically  attributable  to  a  drug.
Given  the  importance  of  RCTs,  it  is  especially  important
that  when  they  are  reported  in  medical  journals,  sufficient
and  appropriate  details  regarding  both  benefits  and  harms
are  provided  in  the  report.  Concerns  about  the  quality  of
reporting  of  RCTs  has  already  been  highlighted  and  as  a
result  guidance  on  reporting  has  been  produced  by  the  CON-
SORT  group,  which  constitutes  a  number  of  leading  medical
journal  editors  and  academics  (Altman,  1996).
Many  journals  now  require  authors  to  report  RCTs  accord-
ing  to  the  CONSORT  guidelines,  although  at  the  time  of
writing  the  CONSORT  guidelines  are  not  actively  endorsed
by  the  journal  Epilepsy  Research  or  other  subspecialty  jour-
nals.  The  CONSORT  guidance  gives  recommendations  on
the  reporting  of  methods,  outcomes,  analyses  and  results
(Altman  et  al.,  2001), and  more  recently  the  guidance  has
been  updated  to  provide  specific  and  comprehensive  recom-
mendations  on  AE  reporting  (Ioannidis  et  al.,  2004).
In  this  paper  we  assess  the  reporting  of  adverse  events
in  RCTs  of  AEDs  published  over  the  last  decade  against
the  standards  set  out  in  the  CONSORT  guidelines,  highlight
inadequacies  and  make  recommendations  for  improving
reporting.
Methods
Aims
The primary aim was to assess the quality of reporting of AEs in
RCTs using the extended CONSORT statement for harms. Secondary
aims were to compare the quality of trials (i) funded by industry vs.
those not funded by industry, (ii) trials recruiting adults vs. those
recruiting children, (iii) trials published before and after the pub-
lication of the amended CONSORT guidelines of 2004 and (iv) trials
published in epilepsy journals vs. those published in non-epilepsy
journals.
Eligibility  and  identification  of  studies
We searched for citations using MEDLINE, Cochrane Library and the
Epilepsy Group trials register for trials published between January
1999 and December 2008 inclusive. Search terms used in electronic
databases were ‘‘epilepsy’’, ‘‘antiepileptic drug’’ and ‘‘seizure’’.
Inclusion criteria for studies were: RCTs comparing AEDs; RCT
patient population with epilepsy; RCTs published in English. Trials
were assessed for inclusion by reading the abstract and, if necessary,
the full report.
Exclusion criteria for studies were: RCTs assessing surgical
interventions and vagus nerve stimulation; RCTs where neuropsy-
chological outcomes were the primary outcome since these were
secondary reports of studies where the primary report has included
data on seizures and AEs.
In order to assess the reliability of this selection process, two
authors (A.S. and G.P.) independently assessed for inclusion studies
published in 2007. If there was good agreement for this subset of
trials we planned for one author (A.S.) to assess the remainder of
studies for inclusion.
Data  collected: items  from  CONSORT  criteria  and  scoring
The CONSORT criteria make ten recommendations for reporting
harms (Ioannidis et al., 2004). These provide guidelines for each
section of an RCT report from the title to the discussion. Some of
these recommendations include more than one item of information.
Two authors (A.S. and G.P.) compiled a checklist of items for data
extraction based upon the CONSORT statements which were then
Author's personal copy
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Table  1  CONSORT  recommendations  and  data  items  collected  (modified  from  Ioannidis  et  al.  (2004)).
Section  of
paper
CONSORT  recom-
mendations
Descriptor  of  CONSORT
recommendations  pertaining  to
adverse  events
Checklist  of  data  collected
Title  &
abstract
1  If  the  study  collected  data  on
harms  and  benefits,  the  title  or
abstract  should  so  state
1.  Adverse  events  (AEs)  mentioned  in  title  or
abstract
Introduction 2 If  the  trial  addresses  both  harms
and  benefits,  the  introduction
should  so  state
2.  Information  on  AEs  mentioned  in  introduction
Methods 3 List  addresses  adverse  events
with  definitions  for  each  (with
attention,  when  relevant  to
grading  expected  vs.  unexpected
events,  reference  to
standardised  and  validated
definitions  and  descriptions  of
new  definitions)
3.  If  definition  of  AE  mentioned
4. If  article  mentioned  all  or  selected  sample  of  AE
5. If  article  mentions  treatment  emergent  adverse
events  (TEAEs)
6. If  article  mentions  use  of  a  validated  instrument
to report  AEs
7.  If  dictionaries  for  coding  of  AEs  mentioned
4 Clarify  how  harms  related
information  is  collected  (mode
of  data  collection,  timing,
attribution  methods,  intensity  of
ascertainment,  and  harms
related  monitoring  and  stopping
rules  if  pertinent)
8.  Description  of  how  harms  data  were  collected
e.g. diaries,  phone  interviews  or  face  to  face
interviews
9. Description  of  when  AE  data  were  collected
10. Description  of  how  AE  were  attributed  to  trial
drugs
5 Describe  any  plans  for  presenting
and  analysing  information  on
harms  (including  coding,
handling  of  recurrent  events,
specification  of  timing  issues,
handling  of  continuous  measures
and any  statistical  analysis)
11.  Description  of  methods  for  presenting  and
analysing  AEs  methods  section
12. Description  of  approach  for  the  handling  of
recurrent  AEs
Results 6 Describe  for  each  arm  the
participant  withdrawals  that  are
due  to  harms  and  the  experience
with  the  allocated  treatment
13.  Description  of  withdrawals  due  to  AEs  in  each
arm
14. If  article  contains  data  on  serious  adverse
events  and  death
7 Provides  denominators  for
describing  harms
15.  Provide  denominators  for  AEs
16. Provide  definitions  used  for  analysis  set  (Trials
may use  either  intention  to  treat  or  safety
population  as  the  analysis  set  for  harms  data.  If
trials explicitly  mentions  which  of  these  were  used,
then this  item  is  met.  This  is  not  to  be  confused
with item  3)
17.  If  trial  states  same  analysis  set  used  for  efficacy
and safety
8 Present  the  absolute  risk  of  each
adverse  event  (specifying  type,
grade  and  seriousness  per  arm)
and  present  appropriate  metrics
for  recurrent  events,  continuous
variables  and  scale  variables
whenever  pertinent
18.  Results  presented  separately  for  each
treatment  arm
19.  Severity  and  grading  of  AEs
20.  Provide  both  number  of  AEs  and  number  of
patients  with  AEs
9 Describe  any  subgroup  analysis
and exploratory  analysis  for
harms
Data  not  collected  as  very  few  trials  conduct
subgroup  analysis
Discussion 10  Provide  a  balanced  discussion  of
benefits  and  harms  with
emphasis  on  study  limitations,
generalizability  and  other
sources  of  information  on  harms
21.  If  prior  literature  is  cited  in  the  discussion  in
relation  to  adverse  events
22.  If  the  discussion  is  balanced  with  regards  to
efficacy  and  AEs
23. If  limitations  of  the  study  are  discussed
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discussed among the wider review team. The completed checklist
included twenty-three items that were most relevant to epilepsy
trials, which are summarised in Table 1.
We excluded CONSORT recommendation nine (describe any sub-
group analyses and exploratory analyses for harms)  because very
few trials carry out subgroup analysis on efficacy criteria, and such
analyses in AE outcomes would be rarer still and it would be unre-
alistic for papers to report subgroups for harm data. For each item
a score of one point was awarded. The minimum possible overall
score was zero and the maximum was twenty-three.
Information about study funding (commercially vs. non-
commercially funded studies) was taken from the text of the article,
including acknowledgements. Those that did not mention sources
of funding were classified as non-commercially funded trials. We
extracted participant ages from trial reports. We  defined a child as
any person less than or equal to 12 years of age. Trials were cat-
egorised into those recruiting adults only, trials recruiting children
only and trials with mixed populations.
Data  extraction
We designed data collection forms to extract data pertaining to the
twenty three items. Data extraction was carried out independently
by two authors (A.S. and G.P.) from a random sample of fourteen
trial reports. Results were compared to determine inter-rater reli-
ability. Any disagreements were clarified by mutual discussion. If
data extraction was deemed reliable, then the data for remaining
trials were to be extracted by one author (AS) with any further
difficulties resolved by discussion.
Data  analysis
Inter-rater agreement of extracted data was assessed by calculating
Cohen’s kappa statistic and 95% confidence interval (Cohen, 1968).
We calculated the mean number of items met for each trial and
each subgroup within each trial. Between group comparisons were
made using un-paired t-tests. The proportion of trials reporting each
item was calculated for the whole trial population and among the
subgroups of interest. Relative risks and 95% confidence intervals
were used to summarise comparative effects. Analyses were carried
out using SPSS (Version 17.0) using a two-sided significance level of
5%.
Results
Trial  disposition  and  inclusion
Two  hundred  and  fifty  seven  trials  that  were  published
in  2007  were  assessed  for  eligibility  by  both  AS  and  GP.
One  author  selected  13  articles,  while  the  second  author
selected  the  same  13  articles  plus  one  additional  article.
This  additional  article  was  excluded  by  mutual  agreement
and  we  concluded  that  the  assessment  of  study  eligibility
was  reproducible; the  remainder  of  studies  were  assessed
by  one  author  (A.S.).  Our  search  of  bibliographic  databases
identified  2052  citations,  of  which  152  trial  reports  met  our
inclusion  criteria  (Fig.  1).
Inter-rater  agreement  for  data  extraction
Overall  there  was  good  agreement  between  the  two  authors
(A.S.  and  G.P.)  in  data  extraction  from  studies  published  in
2007.  The  authors,  however,  differed  in  the  interpretation
of  CONSORT  recommendation  number  three  (checklist  item
140 Neuropsychological outcomes 
2052 citations 
652 citations 
576 citations 
292 citations 
1400 Not RCTs
76 Not English
Non AED studies
138 Other drugs 
146 Non Drug interventions 
152 AED Trials 
Included 
Fig.  1  Selection  of  studies.
four)  for  the  reporting  of  all  or  selected  sample  of  AEs.  After
further  discussion  all  152  trials  were  re-assessed  for  this  item
by  both  authors  and  results  compared  again.  Following  the
re-assessment  of  item  three  the  overall  agreement  across
all  items  was  good  with  a  kappa  value  of  0.78  (95%CI  of
0.64—0.92).  Data  extraction  for  remaining  trials  was  carried
out  by  one  author  (AS)  as  data  extraction  was  deemed  to  be
reliable.
Characteristics  of  studies
We  included  152  trials  published  between  1999  and  2008
(Table  2).  These  randomised  a  total  of  30,650  patients  with
a  median  number  recruited  per  trial  of  135  patients  (range
of  16—1721  patients).  Sixty  two  percent  of  trials  were  com-
mercially  funded  and  38%  were  non-commercially  funded.
Seventy  nine  percent  were  double  blinded,  3%  single  blinded
and  18%  unblinded.  Fifty  two  percent  of  studies  recruited
only  adults,  25%  recruited  both  adults  and  children  and  23%
of  studies  recruited  only  children.  Eighty  three  percent  of
trials  were  multicentre  and  17%  were  single  centre  studies.
Trial  reports  detailed  various  AEDs  as  interventions,  the
most  common  being  topiramate  (14%),  levetiracetam  (13%)
and  lamotrigine  (13%).  Forty  nine  percent  of  trials  were
placebo  controlled  and  51%  of  trials  were  actively  con-
trolled.  Forty  eight  percent  were  published  in  epilepsy
journals  and  the  remainder  in  general  neurology  journals.
Results  for  all  studies
Across  all  152  included  studies  the  mean  number  of  items
met  per  study  was  11.3  (95%CI  10.6—12.0); the  minimum
was  zero  and  the  maximum  was  21.  None  of  the  trials  met
all  23  items  (Table  3).  There  was  considerable  variation  in
Author's personal copy
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Table  2  Characteristics  of  included  studies.
Number  of  trials  (%)  total  =  152
Demographics Adults  79  (52)
Children  (age  <12  years)  35  (23)
Both  adults  and  children  38  (25)
Blinding Double  blinded  120  (79)
Single  blinded  4  (3)
Open  label  28  (18)
Epilepsy type  in  population Focal  epilepsy  102  (67)
Generalised  epilepsy 8 (5)
Both  focal  and  generalised  epilepsy 42 (28)
Funding Commercially  funded  94  (62)
Non-commercially  funded  58  (38)
Centre Multi-centre  126  (83)
Single-centre  26  (17)
Intervention Placebo  controlled 75  (49)
Actively  controlled 77 (51)
Journal
type
Epilepsy  journal  75  (49)
Non-epilepsy  journal  77  (51)
Median duration  of  trial  (weeks) 28  weeks  (range  4—294)
the  percentage  of  trial  reports  meeting  individual  criteria
(Table  4)  ranging  from  7.2%  of  trials  reporting  recurrent
adverse  events  to  87.5%  of  trials  reporting  harms  in  the  title
or  abstract.  The  single  trial  that  scored  zero  did  not  include
any  data  relating  to  harms  and  the  content  was  focused  on
recording  number  of  seizures  as  its  primary  outcome  (Wang
et  al.,  2001).
The  CONSORT  criteria  require  the  reporting  of  harms  in
either  the  title  or  abstract.  Our  results  indicate  that  87.5%
of  trials  do  this  and  this  was  the  most  commonly  met  item.
Other  items  that  were  frequently  satisfied  were; the  report-
ing  of  denominators  for  AEs  (78.3%  of  trials),  the  timing  of
AEs  (76.3%  of  trials),  the  mention  of  harms  in  the  introduc-
tion  (74.3%  of  trials),  the  reporting  of  serious  adverse  events
(SAEs)  or  death  (72.3%  of  trials)  and  withdrawals  due  to  AEs
(71.0%  of  trials).  Items  that  were  not  frequently  reported
were; use  of  a  validated  dictionary  (21.7%  of  trials),  use  of
a  validated  instrument  (15.8%  of  trials),  reporting  of  both
number  of  AEs  and  number  of  patients  with  AEs  (19.1%  of  tri-
als)  and  handling  of  recurrent  events  (7.2%  of  trials).  Table  4
provides  further  details.
Commercially  vs.  non-commercially  funded  studies
Significantly  more  items  were  reported  in  commercially
funded  studies  than  non-commercially  funded  studies  (mean
items  12.6  and  9.4  respectively)  with  difference  in  means  of
3.2  (95%CI: 1.8—4.5),  p  <  0.001  (Table  3).  All  criteria,  except
the  mention  of  harms  in  the  introduction,  were  met  more
Table  3  Comparison  of  means  of  CONSORT  scores.
Number
of  trials
Mean
CONSORT
items  met
Range  of
items
Difference
in  means
95%  CI  for
difference
of  means
P  Value
Commercially  funded  94  12.6  1—21
Non-commercially  funded  58  9.4  0—17  3.2  1.8  to  4.5  <0.001
Pre CONSORT  86  11.6  0—19
0.5 −0.9  to  1.8 0.529Post CONSORT  66  11.1  3—21
Adults 79  12.5  3—21
3.2 1.6  to  4.7 <0.001Children (excluded  38  trial
recruiting  adults  and  children)
35  9.3  3—16
Epilepsy  journal  75  11.4  0—22  0.0  NA  NA
Non-epilepsy journal  77  11.4  3—19
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frequently  in  reports  of  commercially  funded  trials  with  95%
confidence  intervals  (for  the  risk  ratio  comparing  funding
subgroups)  excluding  unity  for  11  of  the  23  criteria  (Table  4).
Items  with  significant  risk  differences  between  com-
mercially  and  non-commercially  funded  studies  were; use
of  a  validated  dictionary  (RR  3.46,  CI  1.41—8.44),  report-
ing  a  definition  of  AE  (RR  3.15,  CI  1.67—5.95),  mention  if
all  or  selected  sample  of  AE  were  reported  (RR  2.34,  CI
1.27—4.34).  Providing  a  definition  for  the  analysis  set  (RR
2.07,  CI  1.26—3.41)  and  reporting  if  the  same  analysis  sets
were  used  for  efficacy  and  safety  (RR  2.04,  CI  1.09—3.81)
were  also  reported  more  frequently  in  commercially  funded
studies.  Commercially  funded  trials  reported  a  balanced
account  of  efficacy  and  safety  in  discussion  section  better
compared  to  non-commercially  funded  studies  (RR  1.50,  CI
1.02—2.21).
Pre  vs.  post  CONSORT
We  found  no  difference  in  the  mean  number  of  items  met
in  studies  reported  before  or  after  the  publication  of  the
CONSORT  guidelines  (mean  items  met  11.6  and  11.1  respec-
tively)  with  difference  in  means  of  0.6  (95%CI  −0.9  to  1.8)
(Table  3).  For  individual  items  the  relative  risk  estimates
were  greater  than  one  for  some  items  and  less  than  one  for
others  with  unity  included  within  all  of  the  95%CIs  except  the
reporting  of  a  validated  dictionary  (RR  0.35,  CI  0.16—0.76).
Adults  vs.  children
This  analysis  included  35  trials  recruiting  only  children,  and
79  studies  recruiting  only  adults,  while  38  trials  recruit-
ing  both  adults  and  children  were  not  examined.  Trials
recruiting  adults  met  significantly  more  criteria  than  those
recruiting  children  (mean  items  met  12.5  and  9.3  respec-
tively)  with  a  difference  in  means  of  3.2  (95%CI  1.6—4.7)
(Table  3).  Items  that  were  met  more  frequently  in  adult  tri-
als  were  definition  of  AE  (RR  2.32,  CI  1.07—5.02),  details  of
presentation  and  statistical  analysis  (RR  2.05,  CI  1.01—4.15),
results  presented  separately  for  each  treatment  arm  (RR
1.80,  CI  1.21—2.69)  and  reporting  of  early  or  late  with-
drawals  (RR  1.66,  CI  1.16—2.37).
Epilepsy  vs.  non-epilepsy  journals
This  analysis  included  75  trials  published  in  epilepsy  jour-
nals  and  77  in  non-epilepsy  journals.  Trials  published  in  both
types  of  journals  met  11.4  mean  items.  For  individual  items
the  relative  risk  estimates  were  not  significantly  different
between  the  two  groups  except  for  reporting  of  early  or  late
withdrawals  (RR  0.79,  CI  0.64—0.97).
Specific  CONSORT  items
A  definition  of  what  constitutes  an  AE  was  reported  in  36.6%
of  trial  reports.  Commercially  funded  trials  were  more  likely
to  report  this  than  non-commercially  funded  trials  (RR  3.15,
CI  1.67—5.95),  as  were  trials  recruiting  adults  compared  to
trials  recruiting  children  (RR  2.32,  CI  1.07—5.02).  Treatment
emergent  adverse  events  (TEAEs)  are  summaries  for  AEs  that
have  either  arisen  de  novo  or  increased  from  baseline  fol-
lowing  treatment.  This  was  reported  in  46.7%  of  trials  and
was  more  likely  to  be  reported  in  commercially  funded  tri-
als  compared  to  non-commercially  funded  trials  (RR  1.69,  CI
1.12—2.55).
Withdrawals  due  to  AEs  is  a  useful  measure  of  tolerabil-
ity.  Our  analysis  showed  that  this  was  reported  in  71%  of  all
trials.  There  were  no  differences  between  the  subgroups  for
reporting  of  withdrawal  data.  Serious  adverse  events  includ-
ing  death  was  also  reported  well  with  72.3%  of  trials  in  our
analysis.  Commercially  funded  trials  were  better  at  this  than
non-commercially  funded  trials  (RR  1.27,  CI  1.10—1.59).
Reporting  of  both  number  of  AEs  and  number  of  patients
with  AEs  is  poor  in  epilepsy  trials,  with  only  19.1%  of  stud-
ies  citing  this  data.  However  studies  would  instead  report
either  absolute  numbers  of  events  or  numbers  of  patients
with  events.  Severity  and  grading  of  AEs  was  reported  in
nearly  half  of  studies  (47.3%),  and  this  was  more  likely  to
be  reported  in  commercially  funded  studies  compared  to
non-commercially  funded  studies  (RR  1.50,  CI  1.02—2.21).
Discussion
Accurate  knowledge  about  the  risks  and  seriousness  of  AEs
is  required  to  inform  treatment  decisions; particularly  for
long  term  conditions  such  as  epilepsy  where  there  are  mul-
tiple  treatment  alternatives  and  where  treatment  decisions
often  involve  a  consideration  of  benefit  and  harms.  It  is
vitally  important  therefore  that  data  about  AEs  are  reliably
provided  in  reports  of  RCTs.
This  is  the  first  study  carried  out  in  this  therapeutic  area,
although  similar  work  has  been  carried  out  in  other  areas
(Smith  et  al.,  2008; Chowers  et  al.,  2009; Breau  et  al.,  2010).
We  have  demonstrated  that  adherence  to  the  2004  CON-
SORT  guidelines  for  reporting  harms  is  poor  in  RCTs  of  AEDs.
None  of  the  trials  met  all  23  items.  We  also  demonstrated
that  reporting  is  heterogeneous  with  some  items  reported
more  poorly  than  others.  Such  heterogeneity  has  also  been
demonstrated  in  previous  work  (Smith  et  al.,  2008). We  spec-
ulate  that  this  heterogeneity  might  suggest  either  a  lack
of  awareness  of  the  guidelines  or  indicate  bias  in  reporting
some  items.  The  CONSORT  guidelines  recommend  adequate
space  be  given  to  the  reporting  of  harms.  Bias  in  reporting
could  be  related  to  the  length  of  journal  space  available
for  harms  data  and  much  of  this  data  is  collected  for  reg-
ulatory  authorities  and  not  reported.  Authors  and  journal
editors  should  take  necessary  steps  to  summarise  sufficient
harms  related  information  required  by  the  CONSORT  guide-
lines.  There  has  been  a  trebling  of  supplementary  content
published  online  in  recent  years  (Schringer  et  al.,  2007)
which  would  allow  an  alternate  area  for  harms  data  to  be
published.
Our  report  also  suggests  that  the  quality  of  reporting  of
harms  has  not  changed  since  publication  of  the  2004  guide-
lines.  However,  this  might  be  because  there  are  only  small
differences  that  could  not  be  detected,  or  could  also  be
accounted  for  by  the  fact  that  many  of  the  journals  do  not
endorse  the  CONSORT  guidelines.
The  initial  CONSORT  statement  was  published  in  2001
and  made  recommendations  for  all  areas  of  RCT  reporting,
but  made  only  limited  comments  on  AEs.  Studies  assessing
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changes  to  RCT  reporting  according  to  the  2001  CONSORT
guidance  indicate  that  reporting  of  RCTs  has  improved  since
the  2001  guidance  was  published  (Plint  et  al.,  2006; Han
et  al.,  2009). Thus  although  the  reporting  of  RCTs  has
improved  in  general,  our  results  indicate  that  the  reporting
of  harms  has  not  improved.  We  do  accept  that  an  edito-
rial  time  lag  would  impact  implementation  of  the  CONSORT
guidelines  even  for  trials  published  after  2006,  but  our
research  indicates  the  need  for  better  dissemination  and
implementation  strategies  for  the  CONSORT  statement  for
harms.
Reporting  of  harms  in  the  title  and  abstract  of  RCTs  of
AEDs  is  well  adhered  to,  and  this  implies  that  data  for  harms
will  be  accurately  indexed  in  databases  such  as  MEDLINE,
making  it  possible  to  accurately  mine  for  data  regarding
harms  in  published  trials  (Hopewell  et  al.,  2008).
Recurrent  AEs  in  the  same  patient  are  made  explicit  in
trials  by  reporting  both  numbers  of  patients  and  number  of
events,  our  results  show  that  this  was  very  poorly  reported;
the  definitions  of  AE  data  (use  of  a  validated  dictionary  and
use  of  a  validated  instrument)  were  also  poorly  reported.
Some  readers  of  published  studies  might  incorrectly  assume
that  the  reporting  of  AEs  would  be  to  agreed  terminology.
This  could  be  aided  by  the  use  of  dictionaries  with  defined
terms  and  the  use  of  validated  instruments  to  record  AEs.  We
found  poor  reporting  as  to  whether  such  instruments  were
used.  Similarly  we  found  that  only  36%  of  trials  mentioned
the  definition  of  adverse  events  and  56%  of  trials  men-
tioned  mode  of  AE  collection.  This  makes  the  interpretation
of  data  and  making  comparisons  of  data  among  trials  very
difficult.
Reporting  of  withdrawal  data  and  SAEs  is  good  in  epilepsy
trials,  this  is  important  as  withdrawals  data  is  compara-
ble  across  studies  and  is  a  useful  measure  of  tolerability.
However  poor  reporting  of  both  the  number  of  events  and
number  of  patients  with  AEs  makes  it  difficult  for  the  reader
to  appreciate  the  true  likelihood  of  a  given  AE.
Clinicians  make  judgments  of  reported  AEs  based  not  only
on  frequency  or  likelihood  but  also  on  severity.  Many  AEs
reported  in  RCTs  are  mild  and  often  dose  related,  however
our  report  suggested  that  only  half  of  epilepsy  trials  gave
some  indication  of  severity.
Commercially  funded  studies  adhered  to  the  guidelines
better  than  non-commercially  funded  studies.  Differences
were  found  in  almost  all  of  the  23  items  assessed  with
varying  proportions  in  each  item.  The  reason  for  this  dis-
crepancy  is  not  clear  but  we  suspect  could  be  due  to
greater  resource  available  for  commercially  funded  trials,
and  greater  experience  in  the  preparation  of  detailed  safety
reports  for  regulatory  authorities  such  as  the  European
Medicines  Authority  and  the  Food  and  Drug  Administra-
tion.  Also  use  of  validated  dictionaries  such  as  Medical
Dictionary  for  Regulated  Activities  (MedDRA)  is  expensive
and  may  be  prohibitive  for  non-commercially  funded  tri-
als.  To  address  this  issue,  non-commercial  investigators
could  create  a  dictionary  similar  to  MedDRA  for  use  in
studies.  Ideally  such  dictionaries  should  be  made  available
for  use  internationally.  If  any  dictionary  is  used  then  this
should  be  stated  in  the  trial  report  as  recommended  by
CONSORT.
A  recent  meta-analysis  showed  significant  improvement
in  quality  of  reporting  when  the  CONSORT  checklist  is  used
and  this  differs  between  CONSORT  adopters  vs.  non-adopters
(Plint  et  al.,  2006). It  has  been  shown  consistently  that  use  of
the  CONSORT  guidelines  has  improved  reporting  in  a  number
of  studies  (Plint  et  al.,  2006; Han  et  al.,  2009) but  these  did
not  evaluate  the  extension  guidelines  for  harms.
Reporting  of  AEs  did  not  differ  when  comparing  epilepsy
and  non-epilepsy  journals,  this  is  significant  because  none
of  the  epilepsy  specific  journals  have  adopted  the  CONSORT
guidelines  whereas  many  of  the  general  neurology  journals
have.  The  apparent  lack  of  difference  may  also  be  due  to
the  editorial  time  lag  in  adopting  the  guidelines,  hence
further  work  needs  to  be  done  to  see  if  trials  published
in  CONSORT  endorsing  journals  have  improved  from  2006
onwards.
Children  comprise  a  special  group  in  which  to  carry  out
RCTs  and  trials  in  children  can  pose  additional  ethical  chal-
lenges; nonetheless  reliable  data  about  harm  in  children  is
required.  Our  findings  suggest  that  trials  recruiting  children
reported  AEs  more  poorly  than  trials  in  adults.
Our  study  was  limited  by  the  potential  for  subjective
interpretation  of  the  CONSORT  criteria  for  harms.  These
criteria  were  open  to  individual  interpretation  and  they
differed  from  previous  publications  by  the  CONSORT  group
as  a  comprehensive  checklist  was  not  included.  We  limited
bias  in  our  analysis  by  using  double  data  extraction  methods
and  a  wider  review  team  carried  out  interpretation  of  the
guidelines.
Recommendations
Reporting  of  AEs  in  RCTs  is  an  important  issue  that  needs
to  improve  to  allow  judgements  to  be  made  between  ben-
efits  and  harms.  We  recognise  that  journals  have  limited
space  for  the  reporting  of  all  outcomes  and  this  can  lead
to  selective  outcome  reporting.  However  we  recommend
that  wherever  possible  authors  allow  adequate  space  for
this.  We  would  recommend  firstly  that  subspecialty  epilepsy
journals  endorse  the  CONSORT  statements.  We  would  rec-
ommend  that  journal  editors  should  provide  links  to  the
CONSORT  statements  on  their  websites  and  refer  to  them
in  their  instructions  to  authors.  At  the  peer  review  stage
we  recommend  that  referees  should  comment  on  adherence
to  the  guidance.  We  would  also  recommend  that  the  CON-
SORT  extension  for  harms  is  comprehensively  incorporated
in  future  updates  as  a  checklist,  making  it  easy  for  all  stake-
holders  to  follow  so  that  proper  evaluation  can  be  made
of  the  value  of  such  a  checklist,  with  the  aim  of  improving
quality  of  reporting  AEs  in  the  future.
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A B S T R A C T
Background
Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug,
but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence
regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy.
Objectives
To evaluate the effects of oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy.
Search methods
We searched the Cochrane Epilepsy Group’s Specialized Register (21 May 2012), the Cochrane Central Register of Controlled Trials
(CENTRAL Issue 5 of 12, The Cochrane Library 2012), MEDLINE (1946 to May week 2, 2012). No language restrictions were
imposed. We checked the reference lists of retrieved studies for additional reports of relevant studies. We also contacted Novartis
(manufacturers of oxcarbazepine) and experts in the field.
Selection criteria
Randomized, double-blinded, add-on trials of oxcarbazepine in patients with drug-resistant partial epilepsy.
Data collection and analysis
Two review authors independently assessed trials for inclusion and extracted the relevant data. For the update of this review, authors
(AS) and (AM) used published data of trials included in the previous review and searched for new or previously missed studies. The
following outcomes were assessed : (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) adverse
events. Primary analyses were intention-to-treat. Summary relative risk ratios were estimated for each outcome.
Main results
Four trials were included representing 1128 randomised patients. Two trials comparing oxcarbazepine to placebo recruited 961 patients
and the other two trails comparing two dosages of oxcarbazepine recruited 167 patients.
The overall relative risk for a 50% or greater reduction in seizure frequency compared to placebo was 2.51 (CI 1.89-3.34). The overall
relative risk for treatment withdrawal compared to placebowas 1.72 (CI 1.36- 2.19). The overall relative risks for efficacy and tolerability
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outcomes comparing high versus low dose could not be summarised in a meta analysis owing to differences in dosages used in the
studies.
Authors’ conclusions
Oxcarbazepine has efficacy as an add-on treatment in patients with drug-resistant partial epilepsy, both in adults and children. However,
trials reviewed were of relatively short duration, and provide no evidence about the long-term effects of oxcarbazepine. Results cannot
be extrapolated to monotherapy or to patients with other epilepsy types.
P L A I N L A N G U A G E S U M M A R Y
Oxcarbazepine add-on for drug-resistant partial epilepsy
Oxcarbazepine is effective as a short-term combination treatment for partial epilepsy.
Epilepsy is a disorder where recurrent seizures are caused by abnormal electrical discharges from the brain. Oxcarbazepine is an
antiepileptic drug which can be used as an add-on treatment for people with drug-resistant partial epilepsy who are resistant to other
antiepileptic drugs. The review of trials found that oxcarbazepine used in this way can reduce seizure frequency in the short-term for
adults and children. The review did not include people with generalized epilepsy or look at the long-term effects of oxcarbazepine.
B A C K G R O U N D
Epilepsy is one of the most disabling neurological disor-
ders.Epilepsy predisposes patients to seizures which can lead to
physical and psychosocial consequences. These would include de-
pression, social stigma and implications for driving. Epilepsy is
commonly treated with antiepileptic drugs with many patients
rendered seizure free. (Kwan 2000) With the introduction of sev-
eral new AEDs, there is a need for systematic reviews of these
drugs, which will provide a resource for informing clinical practice
(Marson 1997; Privitera 1999). New AEDs have been tested and
used mainly as add-on therapies, adding them to standard drugs
such as phenytoin, carbamazepine and valproate. The majority
of trials investigating add-on therapy with AEDs have recruited
patients with partial epilepsy (experiencing simple partial and/or
complex partial and/or secondary generalized tonic-clonic seizures
(Commission 1989)) that have been resistant to antiepileptic drug
treatment. In this review, we focus upon the effect of oxcarbazepine
when used as an add-on treatment for patients with drug-resistant
partial epilepsy.
Oxcarbazepine is an analogue of its parent compound carba-
mazepine, which is a well established treatment for epilepsy. Ox-
carbazepine is thought to have certain advantages over carba-
mazepine. In particular, the dose can be titrated to a therapeutic
dose more quickly, (Grant 1992). In this review we focus upon
oxcarbazepine’s effect on seizures, side effects, cognition and qual-
ity of life.
O B J E C T I V E S
To assess the effects of oxcarbazepine when used as an add-on
treatment for patients with drug-resistant partial epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
To be included in the review studies needed to meet all of the
following criteria:
(1) randomised controlled trials, in which a concealed mechanism
of randomisation was used (e.g. allocation of sequentially sealed
packages of medication, sealed opaque envelopes);
(2) double, single or unblinded trials;
(3) placebo controlled or actively controlled studies;
(4) add-on studies;
(5) parallel group or cross-over studies. For cross-over studies, we
planned to use the first treatment period as a parallel trial.
2Oxcarbazepine add-on for drug-resistant partial epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
rev
iew
 O
nly
Types of participants
Patients of any age with drug-resistant partial epilepsy.
Seizures will be considered drug-resistant if they continue despite
trying monotherapy with at least two of the standard antiepileptic
drugs.
Types of interventions
(1) The active treatment group received therapy with oxcar-
bazepine in addition to their usual treatment.
(2) The control group received either placebo in addition to their
usual treatment, or received a low dose of oxcarbazepine in addi-
tion to their usual treatment.
Types of outcome measures
(1) Fifty percent or greater reduction in seizure frequency
The proportion of patients with a 50% or greater reduction in
seizure frequency in the treatment period compared to the pre-
randomizationbaseline periodwas chosen as the primary outcome.
It was chosen because it is commonly reported in this type of study,
and can be calculated for studies that do not report it, provided
that baseline seizure data were recorded.
(2) Treatment withdrawal
The proportion of patients having treatment withdrawn during
the course of the treatment period was chosen as a measure of
’global measure of tolerability’. In studies of relatively short dura-
tion, treatment is unlikely to be withdrawn due to lack of efficacy,
and any treatment withdrawal is likely due to side effects.
(3) Side effects
The proportion of patients experiencing any of the following side
effects:
1. Ataxia
2. Dizziness
3. Fatigue
4. Nausea
5. Somnolence
6. Headache
7. Hyponatraemia
8. Vertigo
9. Diplopia
10. Rash
11. Tremor
12. Pyrexia
13. Abnormal gait
14. Abdominal pain
15. Nystagmus
16. Viral infection
17. Vomiting
18. Abnormal vision
19. Any Adverse Event
(4) Cognitive effects
At present, there is no consensus as to which instruments should
be used to assess the effects of AEDs on cognition, and as a re-
sult the assessment of cognitive effects has been approached in a
heterogeneous way (Cochrane 1998). In view of this difficulty, we
planned to tabulate the results, but make no attempt to combine
results in a meta-analysis.
(5) Quality of life
Once again, there is no consensus as to which instruments should
be used to assess this, and quality of life data was summarized
qualitatively.
Search methods for identification of studies
We searched the Cochrane Epilepsy Group’s Specialized Register
(21 May 2012) using the search term ’oxcarbazepine or trilep-
tal’. This register contains reports of trials identified from regu-
lar searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) and of MEDLINE. Relevant reports are also iden-
tified by handsearching selected journals and conference proceed-
ings.
In addition, we carried out searching as follows:
Electronic databases
We searched the following databases. There were no language re-
strictions.
(1) The Cochrane Central Register of Controlled Trials (CEN-
TRAL Issue 5 of 12,TheCochrane Library 2012) using the strategy
set out in Appendix 1.
(2) MEDLINE (Ovid, 1946 to May week 2, 2012) using the
search strategy set out in Appendix 2.
References from published studies
We reviewed the reference lists of retrieved studies to search for
additional reports of relevant studies.
Efforts to identify unpublished studies
Unpublished data were sought from Novartis (manufacturers of
oxcarbazepine). Following previous publication of this review un-
published studies were compared to corresponding published re-
ports for variation in data. If minor variations were found, author
used data from published studies only.
Other
We asked colleagues if they were aware of any studies which we
may have missed.
Data collection and analysis
Two review authors (SC and DS) independently assessed trials for
inclusion. Any disagreements were resolved by mutual discussion.
For purposes of the update, two authors (AS and AM) searched
for additional trials published after the year 2000 onwards, any
additional studies were included in the update of this review by
mutual agreement.
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The same review authors extracted the following information from
included trials (again, any disagreements were resolved by mutual
discussion).
Methodological trial design
(a) Method of concealed randomisation.
(b) Method of blinding.
(c) Whether any patients had been excluded from reported anal-
yses.
(d) Duration of baseline period.
(e) Duration of treatment period.
(f ) Dose(s) of oxcarbazepine tested.
Patient/demographic information
(a) Number of patients allocated to each treatment group.
(b) Age/sex.
(c) Seizure types.
(d) Seizure frequency during baseline period.
(e) Number of background drugs.
Where necessary, original authors were asked to confirm the fol-
lowing:
(a) the method of randomisation;
(b) the total number of patients randomised in each group;
(c) the number of patients in each group achieving a 50%or greater
reduction in seizure frequency per treatment group;
(d) the number of patients having treatment withdrawn post ran-
domisation per treatment group.
For those excluded:
(a) the reason for exclusion;
(b) whether any of those excluded completed the treatment phase;
(c) whether any of those excluded had a 50% or greater reduction
in seizure frequency during the treatment phase.
Outcomes
The number of patients experiencing each outcome (see types of
outcomes) were recorded per randomized group.
Analysis
(1) Fifty percent reduction in seizure frequency and treatment with-
drawal
Clinical heterogeneity was assessed by comparing the distribution
of several patient factors among included trials (age, predomi-
nant seizure type, duration of epilepsy, number of AEDs taken at
time of randomization), and trial factors (concealed randomisa-
tion, blinding, losses to follow up) (Schulz 1995). Statistical het-
erogeneity was assessed using an I2 summary statistic where 0%
to 40%: might not be important; 30% to 60%: may represent
moderate heterogeneity; 50% to 90%: may represent substantial
heterogeneity; 75% to 100%: considerable heterogeneity. If het-
erogeneity was found, potential causes would have been explored
(Kunz 1998). Provided no significant heterogeneity was found,
results were synthesized using a fixed-effect model. Our preferred
estimator is the relative risk ratio. For the outcomes 50% reduction
in seizure frequency, and treatment withdrawal, 95% Confidence
Intervals (CIs) are quoted.
Primary analysis included all patients in the treatment group to
which they were allocated, irrespective of the treatment they actu-
ally received (intention-to-treat). For the efficacy outcome (50%
or greater reduction in seizure frequency) three analyses were
planned:
- Primary (intention to treat) analysis: patients not completing
follow up or with inadequate seizure data were assumed non-re-
sponders.
-Worst case: patients not completing follow up or with inadequate
seizure data were assumed non-responders in the oxcarbazepine
group, and responders in the placebo group.
- Best case: patients not completing follow up or with inadequate
seizure data were assumed responders in the oxcarbazepine group,
and non-responders in the placebo group.
(2) Dose response analysis
We planned to examine the dose response relationships in the ac-
quired aggregate data, using logistic regression, calculating prob-
abilities for the following events for different doses:
(i) the percentage of patients having a 50% response (reduction in
seizure frequency);
(ii) the difference in the percentage of patients responding to each
dose compared to placebo.
A binary variable was defined with value 0 if the response was less
than 50% and value 1 if the response was 50% or greater. Dose re-
gression relationships were planned using logistic regression analy-
sis, based on generalized linear models. Analysis was planned using
the package GLIM, with that defined binary variable considered
as the outcome variable (McCullagh 1989).
(3) Side effects
For individual listed side effects, 99% CIs are quoted making
allowance for multiple testing.
(4) Cognitive and quality of life data
Data for these outcomes were summarized narratively.
R E S U L T S
Description of studies
We found four published parallel group studies meeting our in-
clusion criteria (Glauser 2000, Barcs 2000, Kraiprab 2005 and
Pina-Garza 2005). Two of these studies were included in the pre-
vious version of this review (Glauser 1998 and Halasz 1998) for
which we received unpublished data. Data for both trials were pro-
vided by Novartis, and both trials were undertaken as part of the
pre-licensing evaluation of oxcarbazepine. Review authors were
provided with copies of internal trial reports. We used data found
in published reports for the other two studies.
Among them, these studies recruited 1128 patients, 267 by
Glauser (Glauser 1998,Glauser 2000), 694 by Barcs (Halasz 1998,
Barcs 2000), 39 by Kraiprab (Kraiprab 2005) and 128 by Pina-
Garza (Pina-Garza 2005). Two studies were placebo controlled
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and two were actively controlled. The actively controlled studies
were included in this update.
One of the placebo controlled studies recruited only children
(Glauser 2000), and had two treatment groups (oxcarbazepine and
placebo). Dose was titrated according to weight: 20.0 - 29.0 kg,
900 mg/day; 29.1 - 39.0 kg, 1200 mg/day; 39.1 - 60.0 kg 1800
mg/day. The other placebo controlled study recruited adults (Barcs
2000), and had a placebo group and three oxcarbazepine groups
(600 mg/day, 1200 mg/day, and 2400 mg/day). A significant pro-
portion of patients in the 2400 mg group experienced problems
with side effects requiring a reduction of dose. As a result the pro-
tocol was amended during the trial, and 43 of the 174 allocated
to oxcarbazepine were titrated to 1800 mg/day.
Both placebo controlled studies had a similar design consisting of
three phases. Firstly, both had a pre-randomization baseline phase
of eight weeks duration. Secondly, both had a dose titration phase
of two weeks duration. Thirdly, a maintenance period of 14 weeks
in Glauser (Glauser 2000) and a maintenance period of 24 weeks
duration in Barcs (Barcs 2000).
One of the actively controlled studies recruited only young chil-
dren (Pina-Garza 2005), and compared doses 60mg/day and
10 mg/day. The other actively controlled study recruited adults
(Kraiprab 2005) and compared (600mg/day and 1200 mg/day).
The Kraiprab (Kraiprab 2005) study design consisted of three
phases. Firstly, a pre-randomization baseline phase of eight weeks
duration. Secondly, a dose titration phase of two weeks duration.
Thirdly, a maintenance period of 12 weeks duration. The Pina-
Garza (Pina-Garza 2005) study design consisted of four phases.
Firstly, had a pre-randomization screening phase phase of seven
days duration. Secondly, an inpatient baseline period of 3 days
duration. Thirdly, a dose titration phase of 26 days duration for
the 60 mg/day group and zero days duration for the 10 mg/day
group. Fourthly, a maintenance period of 9 days duration.
Three patients from Glauser (Glauser 2000) (one placebo, two
oxcarbazepine) had been excluded from analyses, but have been
reinstated for our intention-to-treat analysis, and contribute to our
best and worst case analyses. These patients had been excluded
because they failed to provide seizure data. Similarly, two patients
were excluded from analyses in Halasz (Barcs 2000), (one oxcar-
bazepine 600 mg per day, one oxcarbazepine 1200 mg per day),
but have been reinstated in our analyses. These two patients had
been lost to follow up before starting trial medication.
Risk of bias in included studies
For two studies, allocation was concealed by providing sequen-
tially numbered packages to each patient allocated to treatment.
Allocation sequence generationwas InBarcs (Barcs 2000), the ran-
dom list was generated using random permuted blocks of four. In
Glauser (Glauser 2000) the random list was computer generated,
which was confirmed to the review authors by Novartis Pharma.
For Pina Garza (Pina Garza 2005) sequence generation was made
via an automated voice response system, no details were given
however on how allocation was concealed.
In all four studies, medication was supplied by the drug sponsor.
Blinding was maintained by using identical packaging and medi-
cations for three studies (Glauser 2000, Barcs 2000 and Kraiprab
2005). In Pina-Garza (Pina-Garza 2005) patients were not blinded
but raters were blinded to the medication allocated. Randomiza-
tion codes were not broken until all data had been collected. In-
tention to treat data have been provided for all four of the tri-
als. Incomplte outcomes were addresses in three trials adequately
(Glauser 2000, Barcs 2000 and Pina-Garza 2005). There were no
incomplete outcomes in Kariparb.
Our analysis of the risk of bias we deemed that Glauser was free
form bias, Barcs 2000 gave no details of sequence generation.
Allocation concealment was deemed inadequate in Pina Garza.
Effects of interventions
Seperate analyses were undertaken for the placebo controlled and
the actively controlled trials. Each analysis included one trial re-
cruiting children and one trial recruiting adults.
50% or greater reduction in seizure frequency
For any dose of oxcarbazepine versus placebo from Glauser
(Glauser 2000) and Barcs (Barcs 2000), I2 = 71% which indicates
that there may be some substantial heterogeneity present. This
might be explained by the fact that there are only two studies, one
of which is in children and the other in adults, and which used
different dosing strategies. The overall risk ratio (95% CI) was
2.51 (1.89, 3.34). The estimate for the paediatric study (Glauser
2000) was 1.84 (1.25, 2.70), which was lower that the estimate
for the adult study (Barcs 2000), 3.11 (2.07, 4.66). The data here
are insufficient to comment upon the effect of age on response to
oxcarbazepine. The confidence intervals clearly overlap, and the
difference in estimates could be explained by random error.
Barcs (Barcs 2000) was the only study for which the effect of dose
could be investigated using aggregate data. As a result we were
unable to undertake planned dose regression analyses. We have
therefore estimated risk ratios for each dose compared to placebo
for this study with the following results: 600 mg per day 2.11
(1.32, 3.35); 1200 mg per day 3.24 (2.11, 4.98); 2400 mg per day
3.93 (2.59, 5.97). These results indicate increasing efficacy with
increasing dose, with no clear plateau at doses tested.
Three patients in the Glauser study (Glauser 2000) and two pa-
tients from Barcs (Barcs 2000) were excluded from the reported
analyses as no seizure data were recorded. All 3 patients in Glauser
(Glauser 2000) received trial treatment before withdrawal are re-
instated for our intention-to-treat analyses. The two patients in
Barcs (Barcs 2000) did not receive any trial treatment before with-
drawal so are not reinstated for our intention-to-treat analyses.
For high dose (1200 mg/day) versus low dose (600 mg/day) in
Kraiprab (Kraiprab 2005), the risk ratio (95% CI) for this adult
study was 1.17 (0.61, 2.23).
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For high dose (60 mg/day) versus low dose (10 mg/day) in Pina-
Garza (Pina-Garza 2005) the risk ratio (95%CI) for this paediatric
study was 1.37 (0.99, 1.88).
Treatment withdrawal
For any dose of oxcarbazepine versus placebo from Glauser
(Glauser 2000) and Barcs (Barcs 2000), I2 = 0% which indicates
heterogeneitymight not be important. The overall risk ratio (95%
CIs) for withdrawal for any reason was 1.72 (1.36, 2.19), indicat-
ing that patients are significantly more likely to withdraw from
oxcarbazepine than placebo. Estimates for individual doses from
Barcs (Barcs 2000) indicates that patients were increasingly more
likely to withdraw from oxcarbazepine with increasing dose: 600
mg 0.82 (0.57, 1.18); 1200 mg 1.62 (1.21, 2.15), 2400 mg 2.60
(2.02, 3.35).
For high dose of oxcarbazepine (1200 mg/day) versus low dose
of oxcarbazepine (600 mg/day) in Kraiprab (Kraiprab 2005), the
risk ratio (95% CI) for this adult study was 0.53 (0.05, 5.34).
For high dose of oxcarbazepine (60 mg/day) versus low dose of
oxcarbazepine (10 mg/day) in Pina-Garza (Pina-Garza 2005) the
risk ratio (95% CI) for this paediatric study was 1.60 (0.55, 4.63).
Side effects
For any dose of oxcarbazepine versus placebo from Glauser
(Glauser 2000) and Barcs (Barcs 2000), the following side ef-
fects were significantly associated with oxcarbazepine (risk ratio
99%CI): any adverse event 1.16 (1.06, 1.26); ataxia 3.54 (1.75,
7.13); dizziness 2.87 (1.82, 4.52); nausea 3.09 (1.74, 5.49); som-
nolence 2.36 (1.54, 3.62); diplopia 7.25 (3.12, 16.80); abnormal
gait 5.54 (1.74, 17.64); nystagmus 4.58 (1.91, 10.97). Data on
the number of patients with hyponatraemia were not reported in
Glauser (Glauser 2000).
For any high dose of oxcarbazepine (1200 mg/day) versus low dose
of oxcarbazepine (600 mg/day) from Kraiprab (Kraiprab 2005),
there were no side effects that were significantly associated with
the higher dose of oxcarbazepine. Data on the number of patients
with hyponatremia were not reported.
For any high dose of oxcarbazepine (60mg/day) versus low dose of
oxcarbazepine (10 mg/day) from Pina-Garza (Pina-Garza 2005),
the following side effects were significantly associated with the
higher dose of oxcarbazepine (risk ratio 95%CI): any adverse event
1.18 (1.30, 2.52); infections and infestations 2.78 (1.41, 5.48);
somnolence3.78 (1.11, 12.92). Data on the number of patients
with hyponatremia were not reported.
Cognitive and quality of life data
These outcomes were not assessed in included trials.
D I S C U S S I O N
We included four trials of oxcarbazepine in patients with refractory
focal epilepsy. Two trials compared oxcarbazepine with placebo
and two trials compared two dosages of oxcarbazepine. Results
of the placebo controlled trials have been summarised in a meta-
analysis, but could not be undertaken for the actively controlled
trials.
Glauser 2000 and Barcs 2000 used adequate methods of conceal-
ment of randomization and were double-blinded. In addition, we
were able to acquire data for intention-to-treat analyses. Both tri-
als included in this review were sponsored by Novartis as part of
their pre-licensing evaluation of oxcarbazepine. One trial recruited
children and the other adults. It seemed reasonable to the authors
to combine these two studies in a meta-analysis given that all those
recruited had drug-resistant partial epilepsy, and that the meth-
ods used in the trials were similar. Pina-Garza 2005 and Kraiprab
2005 compared high and low dose oxcarbazepine and it would
not be reasonable to meta-analyse these two due to disparity in
the comparator dose.
The results from the analysis of placebo controlled trials show that
oxcarbazepine reduces seizure frequency when used as an add-on
antiepileptic drug (AED) in patients with drug-resistant partial
epilepsy. Due to insufficient data, we were unable to undertake
the planned dose response regression analyses. However, analysis
of data from the adult study (Barcs 2000) shows increasing effi-
cacy with increasing dose, with no clear indication of plateauing of
effect at doses tested. Interestingly, the overall estimate of efficacy
was greater in the adult study than the paediatric study. Given the
fact that this result may represent random error, and differences in
dosing, no conclusions can be drawn about the relative effect of ox-
carbazepine on adults and children. Results for the outcome ’with-
drawal of allocated treatment’ show that oxcarbazepine is signifi-
cantly more likely to be withdrawn than placebo for doses higher
than 600 mg per day. In trials of relatively short duration, such
as the two reviewed here, this is likely to represent problems with
tolerability rather than poor seizure control.With respect to side
effects, ataxia, dizziness, fatigue, nausea, somnolence, and diplopia
were significantly more likely to occur in the oxcarbazepine treated
group. These findings are in keeping with the significant treatment
withdrawal associated with oxcarbazepine. Current data available
are insufficient to delineate a precise adverse effects profile for ox-
carbazepine.
Due to differences in design we were unable to undertake a meta-
analysis of the two trials that comparedhigh and lowdoses of oxcar-
bazepine. The individual trials found no difference between doses
for efficacy when comparing high and low dose oxcarbazepine,.
Kraiprab (Kraiprab 2005) found no difference in treatment with-
drawal or adverse effects, while adverse effects were poorly reported
in PinaGarza preventing a comprehensive analysis. Overall there
were more adverse events in the high dose group.
Although the results of this review indicate that oxcarbazepine is
an effective add-on AED for patients with drug-resistant partial
epilepsy in the short-term (four to six months), it does not tell us
how effective it is in the long-term. This is important given that
epilepsy is a chronic condition.This reviewdoes not informus how
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oxcarbazepine compares with other AEDs in the same scenario.
This is an extremely important issue for clinicians and those with
epilepsy who are faced with an ever increasing number of AEDs to
choose from. Reliable evidence informing that decision will need
to come from randomised head to head trials.
In addition, the results of this review do not inform us of the
effects of oxcarbazepine when used asmonotherapy. Monotherapy
trials comparing oxcarbazepine with carbamazepine, phenytoin
and valproate have been undertaken, and will contribute to future
individual patient data reviews to be undertakenbymembers of the
Cochrane Epilepsy Group. Also, the results of this review cannot
be extrapolated to those with a generalized epilepsy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In people with drug-resistant partial epilepsy, oxcarbazepine has
efficacy as an add-on treatment both in an adult population and a
paediatric one. In adults efficacy has been demonstrated for doses
between 600 mg and 2400 mg per day, however, the 2400 mg
per day dose was poorly tolerated. As stated in ’Characteristics of
the included studies’, the paediatric trial was conducted defining
the optimum daily dose as the lowest one which provided maxi-
mum seizure control with acceptable tolerability; therefore, oxcar-
bazepine has shown efficacy as add-on treatment in this popula-
tion between doses of 900 mg/day (20.0 to 29.0 kg) to 1800 mg/
day (39.1 to 60.0 kg). Two studies examined dose relationship in
adults and children, there was no difference in efficacy or safety
outcomes when a higher dose was used.
Twoother studies comparedhigh versus lowdose of oxcarbazepine.
The study in adults was poorly powered and failed to find any
difference between high versus low dose regimens.
Implications for research
Further trials of oxcarbazepine are required to assess the following:
(1) the long-term efficacy and safety of add-on oxcarbazepine;
(2) how oxcarbazepine compares with other add-on treatments in
drug-resistant partial epilepsy;
(3) the doses response relationship of add-on oxcarbazepine in
adults and children; using a larger cohort of patients to increase
the power of the study
(4) the role of oxcarbazepine in generalized epilepsy;
(5) how oxcarbazepine compares with standard AEDs such as
monotherapy;
(6) effects of oxcarbazepine on quality of life and cognition;
(7) economic aspects of oxcarbazepine therapy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barcs 2000
Methods Randomized double blind placebo controlled parallel group trial
4 treatment groups, placebo, 600, 1200 and 2400 mg/day oxcarbazepine
Randomization concealed by allocating sequentially packed containers
Double blinded using identical preparations and packaging.
Pre-randomization baseline period of 8 weeks. Treatment period of 26 weeks. Treatment
period consisted of a 2 week titration period and a 24 week maintenance period
Participants Multi-national, multi-centre study recruiting 694 adults aged 15 - 65 years
Taking no more than 3 standard antiepileptic drugs.
All had drug-resistant seizures.
Patients could have either simple or complex uncontrolled partial seizureswith or without
secondary generalisation
Interventions 169 allocated to 600 mg/day oxcarbazepine, 178 to 1200 mg/day oxcarbazepine, 174 to
2400 mg/day oxcarbazepine and 173 to placebo
Outcomes Percentage change in seizure frequency (simple or complex partial onset seizure with or
without generalisation)
50% or greater reduction in seizure frequency.
Total number of seizures.
Side effects.
Liverpool seizure severity scale.
Notes The 2400 mg/day was poorly tolerated, and the trial protocol was amended, with 43 out
of 174 patients titrated to 1800 mg/day instead
2 patients (1 taking 600 mg/day oxcarbazepine and the other 1200 mg/day placebo) had
been excluded from reported analyses as no seizure data were recorded. Both patients
received no trial treatment they will not contribute to the review primary (intention to
treat) analysis. These patients contribute to the best and worst case sensitivity analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random list generated by permutated
blocks of four
Allocation concealment (selection bias) Low risk Adequate.conclealed in packed containers
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double Blinded Study.
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Barcs 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double Blinded Study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double Blinded Study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two patients were excluded, one form the
1200mg group and one from the 600mg
group
Selective reporting (reporting bias) Low risk See ORBIT tool, this paper was deemed
low risk of bias of selective outcome report-
ing
Glauser 2000
Methods Randomized double blind placebo controlled parallel group trial
Randomization concealed by allocating sequentially packed containers. Allocation was
made using a computer generated schedule
Double blinded using identical preparations and packaging.
Pre-randomization baseline period of 8 weeks. Treatment period of 16 weeks (including
2 week titration period)
Participants Multi-national, multi-centre study recruiting 267 children aged between 3 and 17 years
All had drug-resistant partial seizures. Patients in either groups took the following back-
ground drugs: Carbamzepine, valproate and lamotrigine and phenytoin. There was no
difference in proportions between these groups. Patients were either on one or two con-
comitant AEDs
Median baseline partial seizure frequency per 28 days in the placebo group was 13 (range
2 to 554) and 12 in the oxcarbazepine group (range 3 to 1470)
Interventions 138 allocated oxcarbazepine, 129 placebo.
Dose of oxcarbazepine was allocated according to weight:
20.0 - 29.0 kg 900 mg/day
29.1 - 39.0 kg 1200 mg/day
39.1 - 60.0 kg 1800 mg/day
Outcomes Percentage change in seizure frequency.
50% or greater reduction in seizure frequency.
Percentage change in secondary generalised seizure frequency from baseline
Percentage change in simple partial seizure frequency from baseline
Percentage change in complex partial seizure frequency from baseline
Adverse events.
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Glauser 2000 (Continued)
Notes 3 patients (2 oxcarbazepine, 1 placebo) had been excluded from reported analyses as no
data were recorded. All 3 patients received trial treatment so will contribute to the review
primary (intention to treat) analysis as non-responders. These patients contribute to the
best and worst case sensitivity analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation made via computer generated
schedule.
Allocation concealment (selection bias) Low risk Adequate.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double Blinded Study.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double Blinded Study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double Blinded Study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for two patients excluded were
provided.
Selective reporting (reporting bias) Low risk See ORBIT tool, this paper was deemed
low risk of bias of selective outcome report-
ing
Kraiprab 2005
Methods Randomised double blind parallel group trial.
Two treatment groups, oxcarbazepine 600mg and 1200mg.
Double blinded using identical packaging and both concealed using identical capsules
Details of allocation were not reported.
Baseline Period of 8 weeks.
Treatment Period of 14 weeks (2 week titration and 12 week maintenance)
Participants Single-centre study recruiting thirty nine adults 18-65 years of age
Patients were taking one or more standard antiepileptic drugs having previously failed
treatment on any available AEDs
Patients with partial seizures.
Patients in each group were taking 1 to 3 AEDs but no details given in the names of
these. Sixty eight percent of the higher dose group (1200mg/day) were on monotherapy
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Kraiprab 2005 (Continued)
compared with 35% of the low dose group (600mg/day) taking monotherapy
Interventions Twenty patients were allocated to 600mg per day of oxcarbazepine
Nineteen patients were allocated to 1200mg per day of oxcarbazepine
Comparator in the low dose group.
Outcomes Percentage reduction in seizure frequency per 28 days during the double blind treatment
phase relative to the baseline
Fifty percent or more reduction in seizure frequency per 28 days
Incidence of adverse events.
Notes One patient in the 1200mg group was lost to follow up and three patients discontinued
due to adverse events. Both patients received trial treatment so will contribute to the
review primary (intention to treat) analysis as non-responders. These patients contribute
to the best and worst case sensitivity analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No mention of sequence generation given.
Allocation concealment (selection bias) High risk Details of allocation not given.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinded using identical packaging.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double Blinded Study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double Blinded Study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported.
Selective reporting (reporting bias) High risk Authors also quoted the reduction in
seizure frequency in the patients taking car-
bamazepine as a separate outcome but they
did not state they would do this in the
methods section
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Pina-Garza 2005
Methods Randomised rater blinded parallel group study.
Two treatment groups where one is the active comparator: oxcarbazepine 10mg/day
versus oxcarbazepine 10-60mg/day
Participants Children aged one month to less than four years of age.
Patients with partial seizures.
Patients with one to two concomitant AEDs.
Patients admitted for EEG monitoring to detect seizure activity
Sixty four patients randomised into the high dose groups but only 59 analysed and 64
randomised to the low dose group with only 57 analysed
Interventions Sixty four patients were allocated to the low dose group (10mg/day) for a period of nine
days maintenance
Sixty four patients were allocated to the high dose group (10-60mg/day) for a period of
26 titration and nine days maintenance
Outcomes Absolute change in seizure frequency per 24 hours during the treatment phase compared
to baseline
Percentage change in seizure frequency per 24 hours during the treatment phase com-
pared to baseline
Fifty percent or more reduction in seizure frequency per 24 hours
Notes Two patients in each group were dropped out as consent was withdrawn. Two patients
in the low dose group withdrew due to adverse events compared to three in the high dose
group. One patient in the low dose group withdrew due to lack of efficacy and three
in the high dose group withdrew due to lack of efficacy. All 13 patients received trial
treatment so will contribute to the review primary (intention to treat) analysis as non-
responders. These patients contribute to the best and worst case sensitivity analyses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Automated voice response system that al-
located treatment randomly
Allocation concealment (selection bias) Unclear risk No details of allocation provided in the
published reports.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were not blinded for ethical rea-
sons. Pharmacy was not blinded but raters
were blinded to treatment. Thus this trial
was single blinded
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients were not blinded for ethical rea-
sons. Pharmacy was not blinded but raters
were blinded to treatment. Thus this trial
was single blinded
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Pina-Garza 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Rater Blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy outcomes were fully reported
hence there was no incomplete reporting.
Tolerability outcomes were fully reported
too. Adverse events were reported but au-
thors did not use a validated dictionary
making it difficult to be used in this review
Selective reporting (reporting bias) Low risk
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Houtkooper 1987 This is a randomised, double-blind, cross-over study, replacing oxcarbazepine for carbamazepine in 48 in-patients
with epilepsy. Therefore, it was not an add-on placebo controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Efficacy of oxcarbazepine in add-on versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of responders : The
proportion of patients with a
50 % or greater reduction in
seizure frequency
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Oxcarbazepine 600
mg/day versus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [1.32, 3.35]
1.2 Oxcarbazepine 1200
mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 3.24 [2.11, 4.98]
1.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 3.93 [2.59, 5.97]
1.4 Oxcarbazepine any dose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 2.51 [1.89, 3.34]
Comparison 2. Global effectiveness of oxcarbazepine in add-on versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 The proportion of patients
having treatment withdrawn
during the course of the
treatment period
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Oxcarbazepine 600
mg/day versus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.57, 1.18]
1.2 Oxcarbazepine 1200
mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [1.21, 2.15]
1.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 2.60 [2.02, 3.35]
1.4 Oxcarbazepine any dose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [1.36, 2.19]
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Comparison 3. Side effects of oxcarbazepine in add-on versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Abdominal Pain 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1Oxcarbazepine 600mg/day
versus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 2.06 [0.91, 4.68]
1.2 Oxcarbazepine
1200mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 2.69 [1.23, 5.87]
1.3 Oxcarbazepine
2400mg/day versus placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [0.75, 4.04]
1.4 Oxcarbazepine Anydose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.89, 2.47]
2 Abnormal Gait 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Oxcarbazepine
600mg/dayversus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 4.63 [1.02, 21.13]
2.2 Oxcarbazepine
1200mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 8.31 [1.95, 35.42]
2.3 Oxcarbazepine
2400mg/day versus placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 12.93 [3.12, 53.62]
2.4 Oxcarbazepine Any dose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 5.54 [2.29, 13.38]
3 Ataxia 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [0.83, 4.00]
3.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 3.35 [1.64, 6.82]
3.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 6.19 [3.16, 12.11]
3.4 Oxcarbazepine any dose
versus placebo
2 961 Risk Ratio (M-H, Fixed, 95% CI) 3.54 [2.07, 6.03]
4 Diplopia 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 2.94 [1.35, 6.39]
4.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 6.56 [3.22, 13.38]
4.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 8.45 [4.19, 17.05]
4.4 Oxcarbazepine any dose
versus placebo
2 961 Risk Ratio (M-H, Fixed, 95% CI) 7.25 [3.82, 13.74]
5 Dizziness 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [1.22, 3.13]
5.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [1.58, 3.87]
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5.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [2.18, 5.13]
5.4 Oxcarbazepine any dose
versus placebo
2 961 Risk Ratio (M-H, Fixed, 95% CI) 2.87 [2.03, 4.05]
6 Fatigue 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [1.11, 4.11]
6.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.86, 3.35]
6.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [1.12, 4.13]
6.4 Oxcarbazepine any dose
versus placebo
2 961 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.15, 2.85]
7 Fever 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Oxcarbazepine any dose
versus placebo
1 267 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.56, 1.72]
8 Headache 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.95, 1.91]
8.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.79, 1.63]
8.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.66, 1.42]
8.4 Oxcarbazepine any dose
versus placebo
2 961 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [1.04, 1.70]
9 Hyponatremia 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Oxcarbazepine 600 mg/
day versus placebo
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Oxcarbazepine 1200 mg/
day versus placebo
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 Oxcarbazepine any dose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.05, 2.35]
10 Nausea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.98, 3.39]
10.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 2.99 [1.70, 5.26]
10.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 3.48 [2.00, 6.06]
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10.4 Oxcarbazepine any dose
versus placebo
2 961 Risk Ratio (M-H, Fixed, 95% CI) 3.09 [2.00, 4.78]
11 Nystagmus 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Oxcarbazepine
600mg/day versus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.64, 4.07]
11.2 Oxcarbazepine
1200mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 5.03 [2.30, 10.99]
11.3 Oxcarbazepine
2400mg/day versus placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 5.82 [2.69, 12.62]
11.4 Oxcarbazepine Any dose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 4.58 [2.35, 8.90]
12 Vertigo 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 2.82 [0.91, 8.67]
12.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 4.86 [1.70, 13.93]
12.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 5.97 [2.11, 16.83]
12.4 Oxcarbazepine any dose
versus placebo
1 694 Risk Ratio (M-H, Fixed, 95% CI) 4.57 [1.68, 12.41]
13 Rash 0 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Oxcarbazepine 600 mg/
day versus placebo
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 Oxcarbazepine 1200 mg/
day versus placebo
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.4 Oxcarbazepine any dose
versus placebo
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Somnolence 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Oxcarbazepine 600
mg/day versus placebo
1 342 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [1.01, 2.82]
14.2 Oxcarbazepine 1200
mg/day versus placebo
1 351 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [1.45, 3.76]
14.3 Oxcarbazepine 2400
mg/day (including cases
of amendment two) versus
placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 2.78 [1.75, 4.43]
14.4 Oxcarbazepine any dose
versus placebo
2 961 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [1.70, 3.27]
15 Tremor 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Oxcarbazepine
600mg/day versus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.30, 2.57]
15.2 Oxcarbazepine
1200mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [0.81, 4.73]
15.3 Oxcarbazepine
2400mg/day versus placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 3.55 [1.58, 7.99]
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15.4 Oxcarbazepine any dose
versus placebo
1 692 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.98, 4.66]
16 Viral Infection 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Oxcarbazepine
600mg/day versus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.49, 1.49]
16.2 Oxcarbazepine
1200mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.39, 1.24]
16.3 Oxcarbazepine
2400mg/day versus placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.20, 0.84]
16.4 Oxcarbazepine Any dose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.51, 1.04]
17 Any Adverse Event 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Oxcarbazepine
600mg/day versus placebo
1 341 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.99, 1.22]
17.2 Oxcarbazepine
1200mg/day versus placebo
1 350 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.08, 1.30]
17.3 Oxcarbazepine
2400mg/day versus placebo
1 347 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.17, 1.40]
17.4 Oxcarbazepine any dose
versus placebo
2 959 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.08, 1.24]
Comparison 4. Efficacy of oxcarbazepine in add-on; high dose versus low dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of responders: The
proportion of patients with a
50% or greater reduction in
seizure frequency
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 5. Global effectiveness of oxcarbazepine in add-on; high dose versus low dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients having
treatment withdrawn during
the course of treatment period
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 6. Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proprtion of patients having any
adverse event
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Infections 1 128 Risk Ratio (M-H, Fixed, 95% CI) 2.78 [1.41, 5.48]
3 Somnolence 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Ataxia 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.29, 1.96]
5 Dizziness 1 39 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.87, 9.03]
6 Headache 1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.24, 4.59]
7 Abnornal vision 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.20, 3.07]
8 Diplopia 1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.07, 15.66]
9 Vomiting 1 39 Risk Ratio (M-H, Fixed, 95% CI) 5.25 [0.27, 102.74]
10 Nausea 1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.07, 15.66]
11 Fatigue 1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.05, 5.34]
12 Rash 1 39 Risk Ratio (M-H, Fixed, 95% CI) 3.15 [0.14, 72.88]
Analysis 1.1. Comparison 1 Efficacy of oxcarbazepine in add-on versus placebo, Outcome 1 Proportion of
responders : The proportion of patients with a 50 % or greater reduction in seizure frequency.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 1 Efficacy of oxcarbazepine in add-on versus placebo
Outcome: 1 Proportion of responders : The proportion of patients with a 50 % or greater reduction in seizure frequency
Study or subgroup Treatment : OXC Control : Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 45/168 22/173 100.0 % 2.11 [ 1.32, 3.35 ]
Subtotal (95% CI) 168 173 100.0 % 2.11 [ 1.32, 3.35 ]
Total events: 45 (Treatment : OXC), 22 (Control : Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.15 (P = 0.0016)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 73/177 22/173 100.0 % 3.24 [ 2.11, 4.98 ]
Subtotal (95% CI) 177 173 100.0 % 3.24 [ 2.11, 4.98 ]
Total events: 73 (Treatment : OXC), 22 (Control : Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.39 (P < 0.00001)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment : OXC Control : Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barcs 2000 87/174 22/173 100.0 % 3.93 [ 2.59, 5.97 ]
Subtotal (95% CI) 174 173 100.0 % 3.93 [ 2.59, 5.97 ]
Total events: 87 (Treatment : OXC), 22 (Control : Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 6.42 (P < 0.00001)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 205/519 22/173 53.3 % 3.11 [ 2.07, 4.66 ]
Glauser 2000 55/138 28/129 46.7 % 1.84 [ 1.25, 2.70 ]
Subtotal (95% CI) 657 302 100.0 % 2.51 [ 1.89, 3.34 ]
Total events: 260 (Treatment : OXC), 50 (Control : Placebo)
Heterogeneity: Chi2 = 3.58, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 6.33 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
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Analysis 2.1. Comparison 2 Global effectiveness of oxcarbazepine in add-on versus placebo, Outcome 1 The
proportion of patients having treatment withdrawn during the course of the treatment period.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 2 Global effectiveness of oxcarbazepine in add-on versus placebo
Outcome: 1 The proportion of patients having treatment withdrawn during the course of the treatment period
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 39/168 49/173 100.0 % 0.82 [ 0.57, 1.18 ]
Subtotal (95% CI) 168 173 100.0 % 0.82 [ 0.57, 1.18 ]
Total events: 39 (Treatment), 49 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 81/177 49/173 100.0 % 1.62 [ 1.21, 2.15 ]
Subtotal (95% CI) 177 173 100.0 % 1.62 [ 1.21, 2.15 ]
Total events: 81 (Treatment), 49 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.29 (P = 0.0010)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 128/174 49/173 100.0 % 2.60 [ 2.02, 3.35 ]
Subtotal (95% CI) 174 173 100.0 % 2.60 [ 2.02, 3.35 ]
Total events: 128 (Treatment), 49 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.39 (P < 0.00001)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 248/519 49/173 86.6 % 1.69 [ 1.31, 2.17 ]
Glauser 2000 23/138 11/129 13.4 % 1.95 [ 0.99, 3.85 ]
Subtotal (95% CI) 657 302 100.0 % 1.72 [ 1.36, 2.19 ]
Total events: 271 (Treatment), 60 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.1. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 1 Abdominal
Pain.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 1 Abdominal Pain
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600mg/day versus placebo
Barcs 2000 16/168 8/173 100.0 % 2.06 [ 0.91, 4.68 ]
Subtotal (95% CI) 168 173 100.0 % 2.06 [ 0.91, 4.68 ]
Total events: 16 (Oxcarbazepine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
2 Oxcarbazepine 1200mg/day versus placebo
Barcs 2000 22/177 8/173 100.0 % 2.69 [ 1.23, 5.87 ]
Subtotal (95% CI) 177 173 100.0 % 2.69 [ 1.23, 5.87 ]
Total events: 22 (Oxcarbazepine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
3 Oxcarbazepine 2400mg/day versus placebo
Barcs 2000 14/174 8/173 100.0 % 1.74 [ 0.75, 4.04 ]
Subtotal (95% CI) 174 173 100.0 % 1.74 [ 0.75, 4.04 ]
Total events: 14 (Oxcarbazepine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
4 Oxcarbazepine Anydose versus placebo
Glauser 2000 12/138 13/129 52.8 % 0.86 [ 0.41, 1.82 ]
Barcs 2000 52/519 8/173 47.2 % 2.17 [ 1.05, 4.47 ]
Subtotal (95% CI) 657 302 100.0 % 1.48 [ 0.89, 2.47 ]
Total events: 64 (Oxcarbazepine), 21 (Placebo)
Heterogeneity: Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.50 (P = 0.13)
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Analysis 3.2. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 2 Abnormal
Gait.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 2 Abnormal Gait
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600mg/dayversus placebo
Barcs 2000 9/168 2/173 100.0 % 4.63 [ 1.02, 21.13 ]
Subtotal (95% CI) 168 173 100.0 % 4.63 [ 1.02, 21.13 ]
Total events: 9 (Oxcarbazepine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
2 Oxcarbazepine 1200mg/day versus placebo
Barcs 2000 17/177 2/173 100.0 % 8.31 [ 1.95, 35.42 ]
Subtotal (95% CI) 177 173 100.0 % 8.31 [ 1.95, 35.42 ]
Total events: 17 (Oxcarbazepine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
3 Oxcarbazepine 2400mg/day versus placebo
Barcs 2000 26/174 2/173 100.0 % 12.93 [ 3.12, 53.62 ]
Subtotal (95% CI) 174 173 100.0 % 12.93 [ 3.12, 53.62 ]
Total events: 26 (Oxcarbazepine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.53 (P = 0.00042)
4 Oxcarbazepine Any dose versus placebo
Barcs 2000 52/519 2/173 42.0 % 8.67 [ 2.13, 35.21 ]
Glauser 2000 14/138 4/129 58.0 % 3.27 [ 1.11, 9.68 ]
Subtotal (95% CI) 657 302 100.0 % 5.54 [ 2.29, 13.38 ]
Total events: 66 (Oxcarbazepine), 6 (Placebo)
Heterogeneity: Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 3.81 (P = 0.00014)
0.01 0.1 1 10 100
Favours experimental Favours control
24Oxcarbazepine add-on for drug-resistant partial epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
rev
iew
 O
nly
Analysis 3.3. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 3 Ataxia.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 3 Ataxia
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 16/169 9/173 100.0 % 1.82 [ 0.83, 4.00 ]
Subtotal (95% CI) 169 173 100.0 % 1.82 [ 0.83, 4.00 ]
Total events: 16 (Oxcarbazepine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 31/178 9/173 100.0 % 3.35 [ 1.64, 6.82 ]
Subtotal (95% CI) 178 173 100.0 % 3.35 [ 1.64, 6.82 ]
Total events: 31 (Oxcarbazepine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.33 (P = 0.00088)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 56/174 9/173 100.0 % 6.19 [ 3.16, 12.11 ]
Subtotal (95% CI) 174 173 100.0 % 6.19 [ 3.16, 12.11 ]
Total events: 56 (Oxcarbazepine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.32 (P < 0.00001)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 103/521 9/173 68.5 % 3.80 [ 1.97, 7.35 ]
Glauser 2000 19/138 6/129 31.5 % 2.96 [ 1.22, 7.18 ]
Subtotal (95% CI) 659 302 100.0 % 3.54 [ 2.07, 6.03 ]
Total events: 122 (Oxcarbazepine), 15 (Placebo)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.64 (P < 0.00001)
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Analysis 3.4. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 4 Diplopia.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 4 Diplopia
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 23/169 8/173 100.0 % 2.94 [ 1.35, 6.39 ]
Subtotal (95% CI) 169 173 100.0 % 2.94 [ 1.35, 6.39 ]
Total events: 23 (Oxcarbazepine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 54/178 8/173 100.0 % 6.56 [ 3.22, 13.38 ]
Subtotal (95% CI) 178 173 100.0 % 6.56 [ 3.22, 13.38 ]
Total events: 54 (Oxcarbazepine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.18 (P < 0.00001)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 68/174 8/173 100.0 % 8.45 [ 4.19, 17.05 ]
Subtotal (95% CI) 174 173 100.0 % 8.45 [ 4.19, 17.05 ]
Total events: 68 (Oxcarbazepine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.96 (P < 0.00001)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 145/521 8/173 92.1 % 6.02 [ 3.02, 12.01 ]
Glauser 2000 23/138 1/129 7.9 % 21.50 [ 2.95, 156.92 ]
Subtotal (95% CI) 659 302 100.0 % 7.25 [ 3.82, 13.74 ]
Total events: 168 (Oxcarbazepine), 9 (Placebo)
Heterogeneity: Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 6.06 (P < 0.00001)
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Analysis 3.5. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 5 Dizziness.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 5 Dizziness
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 42/169 22/173 100.0 % 1.95 [ 1.22, 3.13 ]
Subtotal (95% CI) 169 173 100.0 % 1.95 [ 1.22, 3.13 ]
Total events: 42 (Oxcarbazepine), 22 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 56/178 22/173 100.0 % 2.47 [ 1.58, 3.87 ]
Subtotal (95% CI) 178 173 100.0 % 2.47 [ 1.58, 3.87 ]
Total events: 56 (Oxcarbazepine), 22 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.98 (P = 0.000070)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 74/174 22/173 100.0 % 3.34 [ 2.18, 5.13 ]
Subtotal (95% CI) 174 173 100.0 % 3.34 [ 2.18, 5.13 ]
Total events: 74 (Oxcarbazepine), 22 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.54 (P < 0.00001)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 172/521 22/173 76.2 % 2.60 [ 1.72, 3.91 ]
Glauser 2000 40/138 10/129 23.8 % 3.74 [ 1.95, 7.16 ]
Subtotal (95% CI) 659 302 100.0 % 2.87 [ 2.03, 4.05 ]
Total events: 212 (Oxcarbazepine), 32 (Placebo)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 5.98 (P < 0.00001)
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Analysis 3.6. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 6 Fatigue.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 6 Fatigue
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 25/169 12/173 100.0 % 2.13 [ 1.11, 4.11 ]
Subtotal (95% CI) 169 173 100.0 % 2.13 [ 1.11, 4.11 ]
Total events: 25 (Oxcarbazepine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 21/178 12/173 100.0 % 1.70 [ 0.86, 3.35 ]
Subtotal (95% CI) 178 173 100.0 % 1.70 [ 0.86, 3.35 ]
Total events: 21 (Oxcarbazepine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 26/174 12/173 100.0 % 2.15 [ 1.12, 4.13 ]
Subtotal (95% CI) 174 173 100.0 % 2.15 [ 1.12, 4.13 ]
Total events: 26 (Oxcarbazepine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 72/521 12/173 61.3 % 1.99 [ 1.11, 3.58 ]
Glauser 2000 18/138 11/129 38.7 % 1.53 [ 0.75, 3.11 ]
Subtotal (95% CI) 659 302 100.0 % 1.81 [ 1.15, 2.85 ]
Total events: 90 (Oxcarbazepine), 23 (Placebo)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
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Analysis 3.7. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 7 Fever.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 7 Fever
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine any dose versus placebo
Glauser 2000 21/138 20/129 100.0 % 0.98 [ 0.56, 1.72 ]
Subtotal (95% CI) 138 129 100.0 % 0.98 [ 0.56, 1.72 ]
Total events: 21 (Oxcarbazepine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 8 Headache.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 8 Headache
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 54/169 41/173 100.0 % 1.35 [ 0.95, 1.91 ]
Subtotal (95% CI) 169 173 100.0 % 1.35 [ 0.95, 1.91 ]
Total events: 54 (Oxcarbazepine), 41 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 48/178 41/173 100.0 % 1.14 [ 0.79, 1.63 ]
Subtotal (95% CI) 178 173 100.0 % 1.14 [ 0.79, 1.63 ]
Total events: 48 (Oxcarbazepine), 41 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 40/174 41/173 100.0 % 0.97 [ 0.66, 1.42 ]
Subtotal (95% CI) 174 173 100.0 % 0.97 [ 0.66, 1.42 ]
Total events: 40 (Oxcarbazepine), 41 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 142/521 41/173 72.1 % 1.15 [ 0.85, 1.56 ]
Glauser 2000 44/138 23/129 27.9 % 1.79 [ 1.15, 2.79 ]
Subtotal (95% CI) 659 302 100.0 % 1.33 [ 1.04, 1.70 ]
Total events: 186 (Oxcarbazepine), 64 (Placebo)
Heterogeneity: Chi2 = 2.60, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 2.24 (P = 0.025)
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Analysis 3.9. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 9
Hyponatremia.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 9 Hyponatremia
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oxcarbazepine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Oxcarbazepine 1200 mg/day versus placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oxcarbazepine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Oxcarbazepine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Oxcarbazepine any dose versus placebo
Barcs 2000 2/519 2/173 100.0 % 0.33 [ 0.05, 2.35 ]
Glauser 2000 0/138 0/129 Not estimable
Subtotal (95% CI) 657 302 100.0 % 0.33 [ 0.05, 2.35 ]
Total events: 2 (Oxcarbazepine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 3.10. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 10 Nausea.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 10 Nausea
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 25/169 14/173 100.0 % 1.83 [ 0.98, 3.39 ]
Subtotal (95% CI) 169 173 100.0 % 1.83 [ 0.98, 3.39 ]
Total events: 25 (Oxcarbazepine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 43/178 14/173 100.0 % 2.99 [ 1.70, 5.26 ]
Subtotal (95% CI) 178 173 100.0 % 2.99 [ 1.70, 5.26 ]
Total events: 43 (Oxcarbazepine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.79 (P = 0.00015)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 49/174 14/173 100.0 % 3.48 [ 2.00, 6.06 ]
Subtotal (95% CI) 174 173 100.0 % 3.48 [ 2.00, 6.06 ]
Total events: 49 (Oxcarbazepine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.40 (P = 0.000011)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 117/521 14/173 74.4 % 2.78 [ 1.64, 4.70 ]
Glauser 2000 30/138 7/129 25.6 % 4.01 [ 1.82, 8.80 ]
Subtotal (95% CI) 659 302 100.0 % 3.09 [ 2.00, 4.78 ]
Total events: 147 (Oxcarbazepine), 21 (Placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.07 (P < 0.00001)
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Analysis 3.11. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 11
Nystagmus.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 11 Nystagmus
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600mg/day versus placebo
Barcs 2000 11/168 7/173 100.0 % 1.62 [ 0.64, 4.07 ]
Subtotal (95% CI) 168 173 100.0 % 1.62 [ 0.64, 4.07 ]
Total events: 11 (Oxcarbazepine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 Oxcarbazepine 1200mg/day versus placebo
Barcs 2000 36/177 7/173 100.0 % 5.03 [ 2.30, 10.99 ]
Subtotal (95% CI) 177 173 100.0 % 5.03 [ 2.30, 10.99 ]
Total events: 36 (Oxcarbazepine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.05 (P = 0.000052)
3 Oxcarbazepine 2400mg/day versus placebo
Barcs 2000 41/174 7/173 100.0 % 5.82 [ 2.69, 12.62 ]
Subtotal (95% CI) 174 173 100.0 % 5.82 [ 2.69, 12.62 ]
Total events: 41 (Oxcarbazepine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.46 (P < 0.00001)
4 Oxcarbazepine Any dose versus placebo
Barcs 2000 88/519 7/173 83.5 % 4.19 [ 1.98, 8.87 ]
Glauser 2000 14/138 2/129 16.5 % 6.54 [ 1.52, 28.23 ]
Subtotal (95% CI) 657 302 100.0 % 4.58 [ 2.35, 8.90 ]
Total events: 102 (Oxcarbazepine), 9 (Placebo)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.05, df = 3 (P = 0.17), I2 =41%
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Analysis 3.12. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 12 Vertigo.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 12 Vertigo
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 11/169 4/173 100.0 % 2.82 [ 0.91, 8.67 ]
Subtotal (95% CI) 169 173 100.0 % 2.82 [ 0.91, 8.67 ]
Total events: 11 (Oxcarbazepine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.071)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 20/178 4/173 100.0 % 4.86 [ 1.70, 13.93 ]
Subtotal (95% CI) 178 173 100.0 % 4.86 [ 1.70, 13.93 ]
Total events: 20 (Oxcarbazepine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 24/174 4/173 100.0 % 5.97 [ 2.11, 16.83 ]
Subtotal (95% CI) 174 173 100.0 % 5.97 [ 2.11, 16.83 ]
Total events: 24 (Oxcarbazepine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.37 (P = 0.00074)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 55/521 4/173 100.0 % 4.57 [ 1.68, 12.41 ]
Subtotal (95% CI) 521 173 100.0 % 4.57 [ 1.68, 12.41 ]
Total events: 55 (Oxcarbazepine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
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Analysis 3.14. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 14
Somnolence.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 14 Somnolence
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600 mg/day versus placebo
Barcs 2000 33/169 20/173 100.0 % 1.69 [ 1.01, 2.82 ]
Subtotal (95% CI) 169 173 100.0 % 1.69 [ 1.01, 2.82 ]
Total events: 33 (Oxcarbazepine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
2 Oxcarbazepine 1200 mg/day versus placebo
Barcs 2000 48/178 20/173 100.0 % 2.33 [ 1.45, 3.76 ]
Subtotal (95% CI) 178 173 100.0 % 2.33 [ 1.45, 3.76 ]
Total events: 48 (Oxcarbazepine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.47 (P = 0.00051)
3 Oxcarbazepine 2400 mg/day (including cases of amendment two) versus placebo
Barcs 2000 56/174 20/173 100.0 % 2.78 [ 1.75, 4.43 ]
Subtotal (95% CI) 174 173 100.0 % 2.78 [ 1.75, 4.43 ]
Total events: 56 (Oxcarbazepine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.31 (P = 0.000016)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 137/521 20/173 61.7 % 2.27 [ 1.47, 3.52 ]
Glauser 2000 48/138 18/129 38.3 % 2.49 [ 1.53, 4.05 ]
Subtotal (95% CI) 659 302 100.0 % 2.36 [ 1.70, 3.27 ]
Total events: 185 (Oxcarbazepine), 38 (Placebo)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 5.15 (P < 0.00001)
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Analysis 3.15. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 15 Tremor.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 15 Tremor
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600mg/day versus placebo
Barcs 2000 6/168 7/173 100.0 % 0.88 [ 0.30, 2.57 ]
Subtotal (95% CI) 168 173 100.0 % 0.88 [ 0.30, 2.57 ]
Total events: 6 (Oxcarbazepine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 Oxcarbazepine 1200mg/day versus placebo
Barcs 2000 14/177 7/173 100.0 % 1.95 [ 0.81, 4.73 ]
Subtotal (95% CI) 177 173 100.0 % 1.95 [ 0.81, 4.73 ]
Total events: 14 (Oxcarbazepine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
3 Oxcarbazepine 2400mg/day versus placebo
Barcs 2000 25/174 7/173 100.0 % 3.55 [ 1.58, 7.99 ]
Subtotal (95% CI) 174 173 100.0 % 3.55 [ 1.58, 7.99 ]
Total events: 25 (Oxcarbazepine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.06 (P = 0.0022)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 45/519 7/173 100.0 % 2.14 [ 0.98, 4.66 ]
Subtotal (95% CI) 519 173 100.0 % 2.14 [ 0.98, 4.66 ]
Total events: 45 (Oxcarbazepine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 4.16, df = 3 (P = 0.24), I2 =28%
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Analysis 3.16. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 16 Viral
Infection.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 16 Viral Infection
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600mg/day versus placebo
Barcs 2000 20/168 24/173 100.0 % 0.86 [ 0.49, 1.49 ]
Subtotal (95% CI) 168 173 100.0 % 0.86 [ 0.49, 1.49 ]
Total events: 20 (Oxcarbazepine), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Oxcarbazepine 1200mg/day versus placebo
Barcs 2000 17/177 24/173 100.0 % 0.69 [ 0.39, 1.24 ]
Subtotal (95% CI) 177 173 100.0 % 0.69 [ 0.39, 1.24 ]
Total events: 17 (Oxcarbazepine), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
3 Oxcarbazepine 2400mg/day versus placebo
Barcs 2000 10/174 24/173 100.0 % 0.41 [ 0.20, 0.84 ]
Subtotal (95% CI) 174 173 100.0 % 0.41 [ 0.20, 0.84 ]
Total events: 10 (Oxcarbazepine), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
4 Oxcarbazepine Any dose versus placebo
Barcs 2000 47/519 24/173 62.4 % 0.65 [ 0.41, 1.03 ]
Glauser 2000 19/138 21/129 37.6 % 0.85 [ 0.48, 1.50 ]
Subtotal (95% CI) 657 302 100.0 % 0.73 [ 0.51, 1.04 ]
Total events: 66 (Oxcarbazepine), 45 (Placebo)
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Chi2 = 2.67, df = 3 (P = 0.45), I2 =0.0%
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Analysis 3.17. Comparison 3 Side effects of oxcarbazepine in add-on versus placebo, Outcome 17 Any
Adverse Event.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 3 Side effects of oxcarbazepine in add-on versus placebo
Outcome: 17 Any Adverse Event
Study or subgroup Oxcarbazepine Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oxcarbazepine 600mg/day versus placebo
Barcs 2000 141/168 132/173 100.0 % 1.10 [ 0.99, 1.22 ]
Subtotal (95% CI) 168 173 100.0 % 1.10 [ 0.99, 1.22 ]
Total events: 141 (Oxcarbazepine), 132 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
2 Oxcarbazepine 1200mg/day versus placebo
Barcs 2000 160/177 132/173 100.0 % 1.18 [ 1.08, 1.30 ]
Subtotal (95% CI) 177 173 100.0 % 1.18 [ 1.08, 1.30 ]
Total events: 160 (Oxcarbazepine), 132 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00053)
3 Oxcarbazepine 2400mg/day versus placebo
Barcs 2000 170/174 132/173 100.0 % 1.28 [ 1.17, 1.40 ]
Subtotal (95% CI) 174 173 100.0 % 1.28 [ 1.17, 1.40 ]
Total events: 170 (Oxcarbazepine), 132 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.63 (P < 0.00001)
4 Oxcarbazepine any dose versus placebo
Barcs 2000 471/519 132/173 64.4 % 1.19 [ 1.09, 1.30 ]
Glauser 2000 125/138 106/129 35.6 % 1.10 [ 1.00, 1.21 ]
Subtotal (95% CI) 657 302 100.0 % 1.16 [ 1.08, 1.24 ]
Total events: 596 (Oxcarbazepine), 238 (Placebo)
Heterogeneity: Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 4.35 (P = 0.000014)
Test for subgroup differences: Chi2 = 5.44, df = 3 (P = 0.14), I2 =45%
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Analysis 4.1. Comparison 4 Efficacy of oxcarbazepine in add-on; high dose versus low dose, Outcome 1
Proportion of responders: The proportion of patients with a 50% or greater reduction in seizure frequency.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 4 Efficacy of oxcarbazepine in add-on; high dose versus low dose
Outcome: 1 Proportion of responders: The proportion of patients with a 50% or greater reduction in seizure frequency
Study or subgroup Favours experimental Low Dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 10/19 9/20 1.17 [ 0.61, 2.23 ]
Pina-Garza 2005 41/64 30/64 1.37 [ 0.99, 1.88 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 51 (Favours experimental), 39 (Low Dose)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 5.1. Comparison 5 Global effectiveness of oxcarbazepine in add-on; high dose versus low dose,
Outcome 1 Proportion of patients having treatment withdrawn during the course of treatment period.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 5 Global effectiveness of oxcarbazepine in add-on; high dose versus low dose
Outcome: 1 Proportion of patients having treatment withdrawn during the course of treatment period
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 1/19 2/20 0.53 [ 0.05, 5.34 ]
Pina-Garza 2005 8/64 5/64 1.60 [ 0.55, 4.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 9 (High dose), 7 (Low dose)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 6.1. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 1
Proprtion of patients having any adverse event.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 1 Proprtion of patients having any adverse event
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 16/19 17/20 0.99 [ 0.76, 1.30 ]
Pina-Garza 2005 47/64 26/64 1.81 [ 1.30, 2.52 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 63 (High dose), 43 (Low dose)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 6.2. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 2
Infections.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 2 Infections
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pina-Garza 2005 25/64 9/64 100.0 % 2.78 [ 1.41, 5.48 ]
Total (95% CI) 64 64 100.0 % 2.78 [ 1.41, 5.48 ]
Total events: 25 (High dose), 9 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 3
Somnolence.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 3 Somnolence
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 8/19 10/20 0.84 [ 0.42, 1.67 ]
Pina-Garza 2005 11/62 3/64 3.78 [ 1.11, 12.92 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 19 (High dose), 13 (Low dose)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 6.4. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 4
Ataxia.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 4 Ataxia
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 5/19 7/20 100.0 % 0.75 [ 0.29, 1.96 ]
Total (95% CI) 19 20 100.0 % 0.75 [ 0.29, 1.96 ]
Total events: 5 (High dose), 7 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 5
Dizziness.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 5 Dizziness
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 8/19 3/20 100.0 % 2.81 [ 0.87, 9.03 ]
Total (95% CI) 19 20 100.0 % 2.81 [ 0.87, 9.03 ]
Total events: 8 (High dose), 3 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 6
Headache.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 6 Headache
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 3/19 3/20 100.0 % 1.05 [ 0.24, 4.59 ]
Total (95% CI) 19 20 100.0 % 1.05 [ 0.24, 4.59 ]
Total events: 3 (High dose), 3 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 7
Abnornal vision.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 7 Abnornal vision
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 3/19 4/20 100.0 % 0.79 [ 0.20, 3.07 ]
Total (95% CI) 19 20 100.0 % 0.79 [ 0.20, 3.07 ]
Total events: 3 (High dose), 4 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 6.8. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 8
Diplopia.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 8 Diplopia
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 1/19 1/20 100.0 % 1.05 [ 0.07, 15.66 ]
Total (95% CI) 19 20 100.0 % 1.05 [ 0.07, 15.66 ]
Total events: 1 (High dose), 1 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 6.9. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome 9
Vomiting.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 9 Vomiting
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 2/19 0/20 100.0 % 5.25 [ 0.27, 102.74 ]
Total (95% CI) 19 20 100.0 % 5.25 [ 0.27, 102.74 ]
Total events: 2 (High dose), 0 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 6.10. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome
10 Nausea.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 10 Nausea
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 1/19 1/20 100.0 % 1.05 [ 0.07, 15.66 ]
Total (95% CI) 19 20 100.0 % 1.05 [ 0.07, 15.66 ]
Total events: 1 (High dose), 1 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 6.11. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome
11 Fatigue.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 11 Fatigue
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 1/19 2/20 100.0 % 0.53 [ 0.05, 5.34 ]
Total (95% CI) 19 20 100.0 % 0.53 [ 0.05, 5.34 ]
Total events: 1 (High dose), 2 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 6.12. Comparison 6 Side effects of oxcarbazepine in add on; high dose versus low dose, Outcome
12 Rash.
Review: Oxcarbazepine add-on for drug-resistant partial epilepsy
Comparison: 6 Side effects of oxcarbazepine in add on; high dose versus low dose
Outcome: 12 Rash
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kraiprab 2005 1/19 0/20 100.0 % 3.15 [ 0.14, 72.88 ]
Total (95% CI) 19 20 100.0 % 3.15 [ 0.14, 72.88 ]
Total events: 1 (High dose), 0 (Low dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 (oxcarbazepine or trileptal)
#2 MeSH descriptor Epilepsy explode all trees
#3 MeSH descriptor Seizures explode all trees
#4 epilep* or seizure* or convulsion*
#5 (#2 OR #3 OR #4)
#6 (#1 AND #5)
Appendix 2. MEDLINE search strategy
The following search is based on the Cochrane highly sensitive search strategy for identifying randomized trials in MEDLINE as set
out in Appendix 5b of the Cochrane Handbook for Systematic Reviews of Interventions (version 4.2.4, updated March 2005) (Higgins
2005).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. 1 or 2 or 3 or 4 or 5 or 6
8. (animals not humans).sh.
9. 7 not 8
10. clinical trial.pt.
11. Clinical Trial/
12. (clin$ adj trial$).ab,ti.
13. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
14. exp PLACEBOS/
15. placebo$.ab,ti.
16. random$.ab,ti.
17. exp Research Design/
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. (animals not humans).sh.
20. 18 not 19
21. 9 or 20
22. epilep$.tw.
23. exp EPILEPSY/
24. seizure$.tw.
25. exp SEIZURES/
26. convulsion$.tw.
27. 22 or 23 or 24 or 25 or 26
28. trileptal.tw.
29. oxcarbazepine.tw.
30. 28 or 29
31. 21 and 27 and 30
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A B S T R A C T
Background
Around half of people with epilepsy will not achieve seizure freedom on their first antiepileptic drug, many of whom will require add-
on treatment with another drug. Sometimes multiple treatment combinations are tried in order to achieve maximum seizure control,
although around a third of people do not achieve complete seizure control. Lacosamide is an antiepileptic drug that has been licensed
as an add-on treatment for focal epilepsy.
Objectives
To evaluate the effects of lacosamide when used as add-on treatment for drug-resistant partial epilepsy.
Search methods
We searched the Cochrane Epilepsy Group’s Specialised Register (15 October 2013), the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE (1950 to Febuarary 2011), SCOPUS, Clinical Trials.gov and ICTRP. No language restrictions were
imposed. We contacted UCB (sponsors of lacosamide) and experts in the field.
Selection criteria
Randomised controlled trials of add-on trials of lacosamide in people with drug-resistant partial epilepsy.
Data collection and analysis
Two authors independently assessed trials for inclusion and extracted the relevant data. The following outcomes were assessed: (i) 50%
or greater reduction in seizure frequency; (ii) seizure freedom; (iii) treatment withdrawal for any reason and (iv) adverse events. Primary
analyses were intention to treat. Summary risk ratios were estimated for each outcome.
Main results
Three trials were included in our review (1297 participants), which were classified as low risk of bias. All trials were placebo controlled
and assessed doses ranging from 200mg to 600mg per day. Trial duration ranged from 24 to 26 weeks. All trials used adequate methods
of randomisation and were double blind. Overall the quality of the evidence was rated as high quality. The overall risk ratio for a 50%
or greater reduction in seizure frequency for all doses of lacosamide compared to placebo was 1.70 (CI 1.38 to 2.10). The overall risk
ratio for seizure freedom for all doses of lacosamide compared to placebo was 2.50 (CI 0.85 to 7.34). The overall risk ratio for treatment
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withdrawal for all doses of lacosamide compared to placebo was 1.88 (CI 1.40 to 2.52). Adverse effects which were significantly
associated with lacosamide were abnormal coordination RR 6.12 (CI 1.35 to 27.77), blurred vision RR 3.02 (CI 1.19 to 7.68), diplopia
RR 5.29 (CI 2.49 to 11.24), dizziness RR 3.53 (CI 2.20 to 5.68), fatigue RR 2.11 (CI 1.12 to 3.97), nausea RR 2.37 (CI 1.23 to
4.58) and vomiting RR 3.10 (CI 1.38 to 6.95). Adverse effects not statistically significant were headache RR 1.35 (CI 0.83 to 2.19),
nystagmus RR 1.47 (CI 0.61 to 3.52) and somnolence RR 1.44 (CI 0.81 to 2.57).
Authors’ conclusions
This review has shown Lacosamide to be effective well tolerated in the short term when used as an add-on treatment for refractory focal
epilepsy in adults. More evidence is needed in children and the longer terms efficacy is unknown.
P L A I N L A N G U A G E S U M M A R Y
The use of Lacosamide in partial epilepsy: does it work and is it harmful?
Background
Lacosamide is an antiepileptic drug which can be added along with others to treat people who have certain types of epileptic seizures.
This may be a beneficial drug for people who have taken other antiepileptic medication but have had no success at reducing their
seizures. This review looked at how well lacosamide works when added to a patients daily medication and also looked at some of the
harms or side effects of the drug.
Participants
To be included in this review all participants had to be adults with a diagnosis of epilepsy, specifically having partial seizures. Patients
were required to have been already taking at least two other antiepileptic medications which were not currently working to reduce
seizures.
Studies
A search was carried out in October 2013 for all relevant studies. Three trials were included in the review which had a total of 1297
people with epilepsy. All three trials were randomised controlled trials which means the patients were randomly divided into groups
and compared. Across all the studies there were five different groups, one group was a placebo group. The patients in this group took
medication which was identical to lacosamide in shape and colour but was actually a sugar pill. The other four groups involved taking
lacosamide at four different doses.
Results
The review found that lacosamide was good at lowering the amount of seizures the patients experienced. The addition of the antiepileptic
drug was over one and a half times better at reducing seizures than the sugar pill. The higher the dose of lacosamide the better it was at
reducing the number of seizures. Also patients who took the lacosamide were more likely to have no seizures at all than those who took
the sugar pill but they were more likely to end the trial early. This review also looked at side effects of lacosamide and some patients
did experience having blurred or double vision, problems with coordination and feeling dizzy, tired and sickly or being sick.
Quality of the Evidence
Altogether the three trials were judged to use good methods and so the evidence in this review was rated as high in quality. More
research is need to look at the long term effects of lacosamide and to explore how well it works in children with epilepsy.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lacosamide compared to placebo for partial epilepsy
Patient or population: People with partial epilepsy
Settings: Outpatients
Intervention: Lacosamide
Comparison: Placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Lacosamide
50% Reduction in
Seizure Frequency - La-
cosamide Any dose
226 per 1000 384 per 1000
(311 to 474)
RR 1.7
(1.38 to 2.1)
1294
(3 studies)
⊕⊕⊕⊕
high
Seizure Freedom - La-
cosamide Any dose
8 per 1000 21 per 1000
(7 to 61)
RR 2.5
(0.85 to 7.34)
1294
(3 studies)
⊕⊕⊕⊕
high
TreatmentWithdrawals -
Lacosamide any dose
129 per 1000 243 per 1000
(181 to 325)
RR 1.88
(1.4 to 2.52)
1308
(3 studies)
⊕⊕⊕⊕
high
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
Epilepsy is a chronic condition often requiring lifelong medical
treatment. It predisposes patients to seizures which can lead to
physical and psychosocial consequences including depression, so-
cial stigma and the inability to drive. The prevalence of active
epilepsy is in the order of five to nine per 1000 population (ref-
erence). The incidence of epilepsy varies with age from a peak in
childhood, declining between the ages of 20 and 50 and increas-
ing after 50. The majority of people diagnosed with epilepsy have
their seizures controlled by antiepileptic drugs (AEDs) however up
to 20% of patients from population-based studies and up to 30%
clinical series will struggle to maintain control over their seizures
(Kwan 2000; Reynolds 1981). In order to maximise seizure con-
trol patients may require a further AED known as an add-on treat-
ment. Lacosamide is currently licensed as an add-on therapy for
focal epilepsy. In this review we assess the efficacy and safety of
lacosamide as an add-on therapy for patients with partial epilepsy
using both published and unpublished data.
Description of the intervention
Lacosamide is a functional amino acid and was licensed for add-on
therapy in 2009 for use with adult patients with partial epilepsy
(Chung 2010). Lacosamide has linear kinetics and reaches peak
concentrations in plasma in 1 to 4 hours, its half life is 13 hours
allowing for twice daily dosing (Doty 2007). Lacosamide is elim-
inated by renal clearance and does not interact with the P450 sys-
tem, hence limiting its interaction with the metabolism of other
drugs (Kellinghaus 2009). There are no known pharmacodynamic
interactions with lacosamide. In clinical practice, lacosamide is
started at 100 mg a day in divided doses, to a maximum of 400
mg a day until seizure freedom or reduction in seizure frequency is
achieved. The current formulations of lacosamide include a tablet,
oral syrup or intravenous form. Lacosamide is available in 50mg,
100mg 150mg and 200 mg doses. The maximum licensed dose is
currently 400 mg per day.
How the intervention might work
The drug works by enhancing the inactivation of slow sodium
channels.This is a novel mechanism of action as the traditional
AEDs act on inactivation of fast sodium channels thus lacosamide
selectively affects pathological currents caused by slow channels
versus inactivation of fast channels which occurs in normally func-
tioning neurons. This prevents the activation of synaptic currents
thereby preventing the formation of pathological currents from
propagating and thus stabilising the neural network (Doty 2007).
As an add-on therapy the drug is used in conjunction with stan-
dard therapy to help achieve freedom from seizures.
Why it is important to do this review
Current published randomised controlled trials have outlined the
efficacy and safety of lacosamide as an add-on therapy in adult pa-
tients with partial epilepsy. There are several alternatives currently
available for adjunctive therapy in adults and a systematic review
would inform clinicians better regarding efficacy and safety. La-
cosamide has recently been launched in the UK and this review
will inform clinicians of its efficacy and summarise data on the
adverse effects of it’s use.
O B J E C T I V E S
To evaluate the efficacy and tolerability of lacosamide when used
as an add-on treatment for patients with drug-resistant partial
epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies which met the following criteria:
(1) Randomised controlled trials (RCTs);
(2) Double or single blinded studies;
(3) Placebo controlled, active controlled studies or studies using
range of dose as controls;
(4) Add-on studies with a minimum treatment period of 8 weeks.
Types of participants
People of any age with drug-resistant partial epilepsy (i.e. expe-
riencing simple partial, complex partial or secondary generalised
tonic-clonic seizures).
Types of interventions
(1) The active treatment group received treatmentwith lacosamide
in addition to their usual AED treatment.
(2) The control group received a placebo or another AED in ad-
dition to their usual AED treatment.
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Types of outcome measures
Primary outcomes
50% or greater reduction in seizure frequency
The primary outcome is the proportion of people with a 50%
or greater reduction in seizure frequency in the treatment period
compared to the pre-randomisation baseline period. This outcome
was chosen as it is commonly reported in this type of study and
can also be calculated for studies that do not report it, provided
that baseline seizure data were available.
Secondary outcomes
Seizure freedom
The proportion of people with complete cessation of seizures dur-
ing the treatment period.
Treatment withdrawal
The proportion of people having treatment withdrawn during the
course of the treatment period as a measure of global effectiveness.
Treatment is likely to be withdrawn due to adverse effects, lack
of efficacy or a combination of both, and this is an outcome to
which the individual makes a direct contribution. In trials of short
duration it is likely that adverse effects will be the most common
reason for withdrawal.
Adverse Effects
The proportion of people experiencing the following adverse ef-
fects:
1. ataxia;
2. concentration impairment;
3. dizziness;
4. headache;
5. fatigue;
6. nausea/vomiting;
7. paraesthesias;
8. somnolence;
9. speech difficulties;
10. thinking abnormally;
11. weight loss/decrease.
The adverse effects were chosen as authors considered them to
be common and important adverse effects of other similarly pre-
scribed AEDs.
Quality of life
The difference in quality of life scores between groups measured
using a standardised measure.
Cognitive changes
The difference in cognition scores between groups measured using
a standardised measure.
Search methods for identification of studies
Electronic searches
We searched the following databases:-
1. The Cochrane Epilepsy Group’s Specialized Register (15/
10/2013) see Appendix 1;
2. The Cochrane Central Register of Controlled Trials
(CENTRAL 2013, Issue 9) (The Cochrane Library, October
2013) Appendix 2;
3. MEDLINE (Ovid) (1946 to October 2013) see Appendix
3;
4. SCOPUS (1823 to 2013) see Appendix 4;
5. Clinical Trials.gov; and
6. ICTRP.
We did not impose any date or language restrictions.
Searching other resources
We reviewed the reference lists of retrieved studies to search for
additional reports of relevant studies.
We contacted the manufacturers of lacosamide and experts in the
field for information about any unpublished or ongoing studies.
We define unpublished data as trial data obtained from manufac-
turers that is not reported or obtained from peer reviewed journals.
Other sources will include conference abstracts and posters.
Data collection and analysis
Selection of studies
Two authors (JP and AS) independently assessed trials for inclu-
sion. Any disagreements were resolved by discussion with another
author (AGM). Three review authors (JP, AS, AJM) extracted data
and assessed risk of bias; any disagreements were resolved by dis-
cussion.
Data extraction and management
We extracted the following information for each trial using a data
extraction form:
Methodological/trial design
• Method of randomisation and allocation concealment.
• Method of blinding.
• Missing participants.
• Length of baseline period.
• Length of treatment period.
• Dose(s) of lacosamide used.
Patient/demographic information
• Total number of participants allocated to each treatment
group.
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• Age/gender.
• Seizure types.
• Seizure frequency during baseline period.
• Number of background AEDs.
Outcomes
We recorded the number of people experiencing each outcome (see
Types of outcome measures) per randomised group. We contacted
trial authors for any missing information.
Assessment of risk of bias in included studies
Two review authors independently made an assessment of risk of
bias for each trial using Cochrane ’Risk of bias’ tables as described
in (Higgins 2011). We rated included studies as high, low or un-
clear on six domains applicable to randomised controlled trials:
randomisation method, allocation concealment, blinding meth-
ods, incomplete outcome data, selective outcome reporting and
other sources of bias. We created a ’Summary of findings’ table and
employed the GRADE approach for assessing quality of evidence.
Measures of treatment effect
The majority of outcomes are categorical and results are presented
as risk ratios with 95% confidence intervals. For the quality of life
measures, scores and statistics from scales used are summarised in
tables and text.
Dealing with missing data
All analyses were undertaken according to the principal of inten-
tion to treat. When data were missing from trial reports, addi-
tional data was requested from trialists and trial sponsors. We also
planned sensitivity analysis to determine the effect missing data
on results.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing participant and
trial characteristics across trials. Factors included age, seizure type,
number of AEDs taken at time of randomisation, trial design and
duration.
We assessed statistical heterogeneity using the I2 test, with a value
of greater than 75% indicating significant heterogeneity. Provided
no statistical heterogeneity was found (P>0.10), we synthesised the
results using a fixed-effect model. In the event that heterogeneity
was found, we planned to use a random-effects model using the
inverse variance method.
Assessment of reporting biases
We assessed the potential for outcome reporting bias using the
Outcome Reporting Bias in Trials (ORBIT) tool (Kirkham 2010).
Data synthesis
We employed a fixed-effect model meta-analysis to synthesise the
data. comparisons we expected to carry out included:
1. intervention group versus controls of seizure reduction;
2. intervention group versus controls on seizure freedom;
3. intervention group versus controls on treatment
withdrawal;
4. intervention group versus controls on adverse effects
5. intervention group versus controls on quality of life;
6. intervention group versus controls on cognition.
Each comparison was stratified by type of control group, that is
placebo or active control, and study characteristics to ensure the
appropriate combination of study data.
For the primary outcome our preferred estimator was the Mantel-
Haenszel risk ratio (RR). For the majority of outcomes we used
95% confidence intervals (CIs). For individual adverse effects we
used 99%CIs tomake allowance formultiple testing.Our analyses
included all participants in the treatment group to which they had
been allocated.
Subgroup analysis and investigation of heterogeneity
Other than analyses assessing dose effects, no subgroup analyses
were planned in this review.
Sensitivity analysis
Sensitivity analyses were planned to assess the impact of missing
data, but this was not necessary.
R E S U L T S
Description of studies
Results of the search
The search revealed 260 records from the databases outlined
in Electronic searches. After duplicates (89) were removed, 171
records remained and were screened for inclusion in the review.
At this point 162 records were excluded due to irrelevance leaving
9 full texts to be assessed for eligibility. Folowing this we excluded
6 studies (see Figure 1 and Characteristics of excluded studies for
reasons for exclusion). A total of three studies were included in the
review, all of which were included in meta-analysis.
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Figure 1. Study flow diagram.
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Included studies
Overall three RCTs examining lacosamide in comparison to a
placebo are included in this review (BenMenachem 2007; Halasz
2009; Chung 2010). All three trials were undertaken as part of
a drug development programme and were sponsored by UCB
Pharma. The first was a Phase IIb study (Ben Menachem 2007),
while the other two (Halasz 2009; Chung 2010) were phase III
studies. A total of 1311 patients were randomised; 270 patients
were allocated to 200 mg of lacosamide; 471 patients were allo-
cated to 400 mg of lacosamide; 366 patients were allocated to 600
mg of lacosamide and 190 patients were allocated to placebo. In
all trials participants recruited were currently experiencing either
simple or complex partial seizures with or without secondary gen-
eralised seizures and were previously taking a minimum of two
AED treatments.
Ben Menachem 2007 was a multicentre (58 centres worldwide)
double-blind, parallel trial with a baseline period of 8 weeks, titra-
tion phase of 6 weeks and treatment period of 12 weeks. There
were fours arms to the trial: lacosamide 200 mg per day (n=107),
lacosamide 400 mg per day (n=108), lacosamide 600 mg per day
(n=106) and placebo (n=86). Tablets were administered in a twice
daily fashion. Outcomes investigated included seizure frequency,
seizure freedom, quality of life and adverse events. The impact of
dose was also examined.
Chung 2010 was a multi-centre (US) double-blind, parallel trial
with a baseline period of 8 weeks, followed by a 6-week titration
period and a 12-week treatment period. This was a three armed
trial: lacosamide 400mgper day (n=204), lacosamide 600mgdaily
(n=97) and placebo (n=104). Outcomes reported were seizure fre-
quency, seizure freedom, withdrawals, and adverse events.
Halasz 2009 was an international multi-centre double-blind par-
allel trial with a baseline period of 8 weeks, a titration phase of
4 weeks and a treatment period of 12 weeks. Patients were ran-
domised to one of three groups: lacosamide 200 mg daily (n=
163), lacosamide 400 mg daily (n=159) or placebo (n=163). The
outcomes investigated were seizure frequency and freedom, with-
drawals and adverse events.
Formore details of each trial ands for a complete list of all outcomes
investigated see Characteristics of included studies.
Excluded studies
We excluded one trial comparing two rates of intravenous infu-
sion of lacosamide and further comparison of oral versus intra-
venous formation. This trial was excluded as this trial did not
include a placebo group. Another trial was excluded as it com-
pared the pharmacokinetic interaction of lacosamide to carba-
mazepine. Four other trials were published comparing lacosamide
and placebo in patients with diabetic neuropathy and hence were
beyond the scope of this review.
Risk of bias in included studies
All three studies however were funded by industry to acquire a
licence thiswould introduce an element of bias.Our analysis of risk
of bias deemed that one out of the three studies (Ben Menachem
2007)was superior to the other two in alleviating bias.Our analysis
using theORBIT tool however showed that two trials did conduct
quality of life measures but they were not published in the trial
report. Instead these results were published separately.
Allocation
All three trials adequately use methods to ensure lack of bias in
sequence generation and allocation concealment. This was done
via an interactive voice response service (IVRS) and the randomi-
sation schedule was pre-determined by a computer generated pro-
gram using generated pseudo-random numbers. Clinical investi-
gators had no way of finding out allocated medication unless the
patient was unblinded during the study.
Blinding
Blindingwas ensured by identical tablets and packaging in all three
trials included.
Incomplete outcome data
There were no patients for which outcomes were incompletely
reported. There were significant number of patients in the three
trials that were screen or randomisation failures. These were not
considered to contribute to incomplete outcomes.
Selective reporting
BenMenachem 2007 reported all outcomes planned in the meth-
ods section. Halasz 2009 and Chung 2010 did not report quality
of life outcomes in trial reports but these were reported at con-
ference proceedings and poster presentations. A judgement would
need to be made if reporting of outcomes as a separate publication
would be considered as selective reporting. We have deemed that
this does not constitute as selective reporting. Accidental injury as
an adverse event was not reported in the unpublished data but was
reported in the published trial reports. We included this outcome
in our analysis.
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Other potential sources of bias
All three trials were funded by the pharmaceutical industry and
to date there are no non-industry funded studies. This bias was
reduced however by requesting unpublished data from trial spon-
sors.
Effects of interventions
See: Summary of findings for the main comparison Lacosamide
compared to placebo for partial epilepsy
Lacosamide versus placebo
50% reduction in seizure frequency
Data from all three studies contributed to this outcome and the
following two outcomes. Across all doses no clinical or statistical
heterogeneity was found (I2=5%). A Chi2 test for heterogeneity
was non-significant (P<0.00001). The overall risk ratio (RR) for
any dose lacosamide compared to placebo is 1.70 (95% CI 1.38
to 2.10). For lacosamide 200 mg the RR is 1.41 (95% CI 1.07
to 1.85), for lacosamide 400 mg the RR is 1.80 (95% CI 1.43 to
2.25), and for lacosamide 600 mg the overall RR is 1.98 (95% CI
1.43 to 2.73). Increased doseswere found to increase the likelihood
of patients responding to lacosamide.
Seizure Freedom
We found no clinical or statistical heterogeneity across any dose
lacosamide (I2=0%), aChi2 test was also non-significant (P=0.47).
The overall RR for any dose lacosamide compared to placebo is
2.50 (95% CI 0.85 to 7.34). For lacosamide 200 mg the RR is
1.81 (95% CI 0.50 to 6.57), for lacosamide 400 mg the RR is
2.70 (95% CI 0.85 to 8.56), and for lacosamide 600 mg the RR is
7.09 (95% CI 0.90 to 55.70). Increased doses of lacosamide were
found to increase the likelihood of patients becoming seizure free.
Treatment Withdrawal
We found no clinical or statistical heterogeneity across any dose la-
cosamide (I2=16%), a Chi2 test was also non-significant (P=0.31).
The overall RR for any dose lacosamide compared to placebo is
1.88 (95%CI 1.40 to 2.52. For lacosamide 200 mg the RR is 1.43
(95% CI 0.95 to 2.15), for lacosamide 400 mg the RR is 1.79
(95% CI 1.31 to 2.46), and for lacosamide 600 mg the RR is 3.04
(95% CI 2.02 to 4.59). Increased doses of lacosamide were found
to increase the likelihood of patients withdrawing from the trials.
Quality of life measures
Quality of life was reported in one trial (Ben Menachem 2007),
the other two studies recorded the QOLIE-31, Seizure Severity
Scale (SSS) and PatientGlobal Impression of Change scale (PGIC)
measures but they were not reported in the published version. We
were able to view the poster presentations of these results which
contained pooled analyses of these outcomes. Key outcomes anal-
ysed were the QOLIE-31, the SSS and the PGIC. The QOLIE-
31 provides a range of sores in various epilepsy specific measures
and is not amenable to meta analysis. However the PGIC is a
change of numbers of patients entering or leaving a defined quality
of life state which would be amenable to analysis if results were
made available. We can state in this review that quality of life did
improve in patients who experienced either seizure freedom or a
significant reduction in seizure frequency.
Adverse Effects
Meta-analysis was able to be performed on 10 adverse effects. La-
cosamide was significantly associatedwith: abnormal coordination
RR 6.12 (99%CI 1.35 to 27.77), blurred vision RR 3.02 (99%CI
1.19 to 7.68), diplopia RR 5.29 (99%CI 2.49 to 11.24), dizziness
RR 3.53 (99% CI 2.20 to 5.68), fatigue RR 2.11 (99% CI 1.12
to 3.97), nausea RR 2.37 (99% CI 1.23 to 4.58), and vomiting
RR 3.10 (99% CI 1.38 to 6.95). Non-significant findings for ad-
verse effects included: headache RR 1.35 (99% CI 0.83 to 2.19),
nystagmus RR 1.47 (99% CI 0.61 to 3.52) and somnolence RR
1.44 (99% CI 0.81 to 2.57).
Serious Adverse Events
Any dose lacosamide was associated with serious adverse events
RR 1.78 (99% CI 0.85 to 3.73). Higher doses were found to be
less associated with serious adverse events: lacosamide 200 mg RR
2.00 (99% CI 0.80 to 5.00), lacosamide 400 mg RR 1.97 (99%
CI 0.88 to 4.40) and lacosamide 600 mg RR 0.74 (99% CI 0.19
to 2.86).
D I S C U S S I O N
Summary of main results
Our results have demonstrated the efficacy and safety of lacosamide
in reducing seizure frequency using the responder rate as an out-
comemeasure. Two studies did not find the 200 mg dose to be effi-
cacious compared to placebo but our meta-analysis showed a mar-
ginal superiority over placebo which was statistically significant.
The clinical implications are that patients need not be titrated up
to a higher or medium dose range for lacosamide to work. Adverse
events are more common at the higher doses hence a low dose that
is found to be efficacious with less probability of adverse events is
desirable. Our results also show that lacosamide is efficacious at
400 mg and 600 mg at reducing seizure frequency compared to
placebo this was suggested in previous studies.
There was no statistically significant difference between treatment
and control with regard to seizure freedom. This was due to the
small number of patients who did become seizure free and the
short duration of themaintenance period for this outcome. Depite
this result it is worth noting that the small number of patients who
were seizure free were having frequent seizures after having failed
on poly therapy previously. There is however no further clinical
details given on this subgroup of patients regarding their duration
of illness compared to the rest of the cohort.
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Lacosamide 200 mg per day compared to placebo was tolerated
well with no significant difference between proportion of patients
withdrawing for any reason. Tolerablity of the 400 mg dose com-
pared to placebo was less and the summary statistic suggests that
patients are almost two times as likely to withdraw for any reason
compared to placebo. Tolerability of the 600 mg doser was poorer
still with patients three times a likely to withdraw for any reason.
The adverse events profile of lacosamide shown here and in the
published reports suggest that adverse events are common and are
likely to occur at increasingly higher doses. Adverse events that
were significantly more with lacosamide compared to placebo are;
vomiting, vertigo, nausea, fatigue, dizziness, diplopia, coordina-
tion abnormal, blurred vision and ataxia. Only vertigo, dizziness
and diplopia were significantly more likely compared to placebo
using the 200 mg dose.
Two trials showed no increase in serious adverse events in the treat-
ment groups compared to placebo (Chung 2010; Ben Menachem
2007) but was significantly greater in Halasz 2009.
Overall lacosamide is a novel treatment for epilepsy with efficacy
at low, medium and high doses. Lacosmide is tolerated well at low
to medium doses but not at high dose. Some patients after having
tried standard AEDs for epilepsy have become seizure free with
lacosamide.
Overall completeness and applicability of
evidence
The evidence presented here highlights the efficacy and safety of
lacosamide compared to placebo. The three studies have reported
efficacy and safety data to allow a credible review, however quality
of life measures (PGIC and SSS) are incompletely and poorly
reported in two studies (Halasz 2009 and Chung 2010). This data
was not available from the sponsors in the unpublished repots.
Futher studies are needed to refine the data presented here.
Quality of the evidence
The trials used in our analyses were of high quality withmost of the
outcomes reported.Wewere able to get further details of outcomes
form the trial sponsors. Key primary and secondary outcomes
were reported well in both published and unpublished reports.
We however had to clarify with the trial sponsors on details of
allocation concealments and allocation sequence generation. We
listed the bias for this as low in risk of bias tables as we received
clarification from trial sponsors. The published reports however
did not report sequence generation for Ben Menachem 2007 and
Chung2010. Allocation concealmentwas not reported in the three
published trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We conclude that lacosamide is efficacious, and tolerable at 200
mg per day with the possibility of having fewer adverse events,
this does not mean that the treatment effect size of this dose has
changed from that reported in clinical trials but meta-analysis has
shown that this effect is real and the implications are that a less
that 400mg dose is effective with the chance of fewer side effects.
Implications for research
We conclude that further studies are need to be conducted to add
to the body of evidence presented here.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ben Menachem 2007
Methods Phase IIb, multicentre, multinational, randomised, double-blinded, parallel-group,
placebo-controlled, dose-response trial
Four treatment groups: Placebo, Lacosamide 200 mg, Lacosamide 400 mg and La-
cosamide 600 mg
Baseline period: 8 weeks Titration period: 6 weeks (titration rate of 100mg per week
until target dose) Treatment period:12 weeks
ITT was defined as the proportion of patients who received one dose of trial drug and
who produced one seizure diary entry
Safety population was defined as all randomised patients who took one dose of trial
medication
Participants Adults aged 18 to 65
Simple or complex partial seizures for at least two years having being uncontrolled on at
least two AEDs
Concomitant allowed drugs were a stable dose regimen of 1 or 2 AEDs with or without
VNS. Approximately 84% of patients were taking at least 2 AEDs with the rest taking 1
8 weeks prior to the baseline period and during the 8-week baseline period, patients
must have had at least 4 partial-onset seizures per 28-days on average, with no seizure-
free period longer than 21 days
The numbers of patients in each treatment group had roughly equal numbers. Age, sex
and ethnicity are similar in each arm with most patients being Caucasian (93%)
Interventions Placebo
Lacosamide 200 mg/day
Lacosamide 400 mg/day
Lacosamide 600 mg/day
82% of patients achieved target dose
Outcomes This list includes all outcomes reported in the published study:
Change in seizure frequency per 28 days from baseline analyses in both the ITT and PP
populations
Responder rate defined as the proportion of patients with a 50% reduction in seizure
frequency in both the ITT and PP populations. Also, 75% responder rate
Proportion of patients experiencing a 25% increase in seizure frequency
Percentage change in seizure frequency
Achievement of seizure-free status
Proprtion of patients seizure free throughout the 12 week maintenance period
Percentage change in seizure free days compared to baseline
Change in median of QOLIE 31 scores compared to baseline
Proprtion of patients showing a CGIC change from baseline to “very much improved”
or “much improved”
Adverse Events (adverse events reported above a threshold of 5%)
Proprtion of patients meeting target dose
Proportion of patients having dose reduction due to adverse events
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Ben Menachem 2007 (Continued)
Proprtion of patients discontinued due to adverse events
Proportion of patients with Serious Adverse Events
Pharmacokinetic outcomes
Notes Five hundred and forty two patients were screened, and 421 were randomised into
the four groups. Three patients were not included in the safety or efficacy populations
because site audit findings suggested site protocol non-compliance (treatment allocations
not indicated in trial paper) and a further three were excluded from the ITT population
due to not having any post-baseline efficacy measurements. Thus 415 are included in
the efficacy analyses. AEs that occurred in at least 5% of patients are shown in the trial
paper
Accident (Not otherwise specified) (NOS) is one AE outcome reported in the published
paper but was not reported in the unpublished data provided by the study sponsors. This
outcome was included in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out centrally by
the trial sponsor. This was done via an au-
tomated voice response system. Randomi-
sation list was made by a random number
generator. Patientswere randomly allocated
to either Lacosamide or placebo
Allocation concealment (selection bias) Low risk Clinical investigators were blinded to treat-
ment allocated centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk All placebo and Lacosamide tablets and
their accompanying packaging (blister
cards, boxes) were identical in appearance
(size and colour)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All patients and personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome of seizure frequency was carried
out by patients and assessors who were
blinded to interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no patients with incomplete
outcomes
Selective reporting (reporting bias) Low risk For further information see ORBIT tool
below
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Chung 2010
Methods Phase III, randomised, multicentre, double-blinded, parallel-group, placebo-controlled
trial
Patients were allocated in a 1:2:1 ratio to Placebo, Lacosamide 400 mg and Lacosamide
600 mg
Baseline period:8 weeks Titration period: 6 weeks (titration rate of 100mg per week till
target dose) Treatment period: 12 weeks
ITT was defined as the proportion of patients who received one dose of trial drug and
who produced one seizure diary entry
Safety population was defined as all randomised patients who took one dose of trial
medication
Participants Adults aged 16 to 70 years
Simple or complex partial seizures documented on EEG and either MRI or CT scan
consistent with diagnosis of epilepsy
Patients would need to have a two year history of intractable epilepsy and have perilously
failed two AEDs
During the 8-week baseline period, patientsmust have had at least 4 partial-onset seizures
per 28-days on average, with no seizure-free period longer than 21 days
Patients would need to be on a stable dose regimen of 1 to 3 AEDs with or without
VNS. Approximately 27% of patients were taking 3 AEDs, 55% taking 2 AEDs and
18% taking 1 AED. Approximately 37% of patients were taking 3 AEDs, 50% taking 2
AEDs and 13% taking 1 AED
This study had a higher proportion of non-Caucasian population (18.5%) compared to
Ben Menachem 2007 (7%)
Interventions Placebo
Lacosamide 400 mg
Lacosamide 600 mg
81.1% of patients achieved target dose
Outcomes This list includes all outcomes reported in the published study:
Change in seizure frequency per 28 days from baseline analyses in both the ITT and PP
populations
Change rate defined as the proportion of patients with a 50% reduction in seizure
frequency in both the ITT and PP populations. Also, 75% responder rate
Reduction in seizure frequency per 28days frombaseline and the 50%responder ratewere
also categorised by seizure type. Subgroups were; all seizure types; secondary generalised
tonic clonic seizures; complex partial seizures and simple partial seizures
Percentage change in seizure frequency per 28 days from baseline to maintenance period
Number and proportion of patients with seizure-free status during the maintenance
period calculated in an ITT method
Percentage of seizure-free days throughout maintenance period
Adverse Events (adverse events reported above a threshold of 10%)
Proprion of patients withdrawing from adverse event
Pharmocokinetic outcomes
Atlhough quality of life outcomes were conducted they are not reported in the final
published report
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Chung 2010 (Continued)
Notes 151 patients were screen failures: 67 at initial screening prior to the 8-week baseline
phase and 84 at the end of the 8-week baseline phase screened prior to randomisation.
AEs that occurred in at least 10% of patients are shown in the trial paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A central pre-determined computer gener-
ated (pseudo-random number generated)
randomisation schedule, via IVRS, was
used. The investigator (or his/her name
designee) called the IVRS on the toll-free
number provided. The IVRS asked the in-
vestigator to identify the subject by con-
firming the subject initials and his/her date
of birth. The investigator was required to
confirm that the subject fulfilled all inclu-
sion criteria and none of the exclusion cri-
teria, and that the subject had provided
written informed consent. A randomisa-
tion number was assigned by the IVRS
Allocation concealment (selection bias) Low risk Clinical investigators were blinded to treat-
ment allocated centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk All placebo and Lacosamide tablets and
their accompanying packaging (blister
cards, boxes) were identical in appearance
(size and colour)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All patients and personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome of seizure frequency was carried
out by patients and assessors who were
blinded to interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcomes. Adverse events
were reported above a 10% threshold com-
pared to the other two reports which re-
ported AEs above or equal to 5%
Selective reporting (reporting bias) Low risk All outcomes stipulated in the published ar-
ticle were reported but conference abstracts
and posters pertaining to this study repot-
ted quality of life outcomes that were pub-
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Chung 2010 (Continued)
lished separately. For further information
see ORBIT tool below
Halasz 2009
Methods Phase III, randomised, multicentre, double-blinded, parallel-group, placebo-controlled
trial
Patients were allocated in a 1:1:1 ratio to Placebo, Lacosamide 200 mg and Lacosamide
400 mg
Baseline period: 8 weeks Titration period: 4 weeks (titration rate of 100mg per week till
target dose) Treatment period: 12 weeks
ITT was defined as the proportion of patients who received one dose of trial drug and
who produced one seizure diary entry
Safety population was defined as all randomised patients who took one dose of trial
medication
Participants Adults aged 16 to 70 years
Simple or complex partial seizures documented on EEG and either MRI or CT scan
consistent with diagnosis of epilepsy
Patients would need to have a two year history of intractable epilepsy and have perilously
failed two AEDs
During the 8-week baseline period, patientsmust have had at least 4 partial-onset seizures
per 28-days on average, with no seizure-free period longer than 21 days
Patients would need to be on a stable dose regimen of 1 to 3 AEDs with or without
VNS. Approximately 27% of patients were taking 3 AEDs, 55% taking 2 AEDs and
18% taking 1 AED
Patients were predominantly Caucasian (99%)
Interventions Placebo
Lacosamide 200 mg
Lacosamide 400 mg
Outcomes This list includes all items reported in this study
Change in seizure frequency per 28 days from baseline analyses in both the ITT and PP
populations
Responder rate defined as the proportion of patients with a 50% reduction in seizure
frequency in both the ITT and PP populations
Percentage change in seizure frequency per 28 days from baseline to maintenance period
Proprtion of patients seizure free
Proportion of seizure free days
Withdrawals due to any reason and due to Adverse Events
Adverse Events. (Adverse events reported above a threshold of 5%)
Serious Adverse Events
Pharmacokientic outcomes
Notes Thirty eight patients were excluded after screening and 61 patients were not randomised.
AEs that occurred in at least 5% of patients are shown in the trial paper
Risk of bias
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Halasz 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A central pre-determined computer gener-
ated (pseudo-random number generated)
randomisation schedule, via IVRS, was
used. The investigator (or his/her named
designee) called the IVRS on the toll-free
number provided. The IVRS asked the in-
vestigator to identify the subject by con-
firming the subject initials, subject number,
and his/her date of birth. The investigator
was required to confirm that the subject
fulfilled all inclusion criteria and none of
the exclusion criteria, and that the subject
had provided written informed consent. A
randomisation number was assigned by the
IVRS
Allocation concealment (selection bias) Low risk Clinical investigators were blinded to treat-
ment allocated centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk All placebo and LCM tablets and their ac-
companying packaging were identical in
appearance (size and colour) and packaging
so that neither the investigator nor the sub-
ject was able to tell whether the trial medi-
cation was active or placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All patients and personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome of seizure frequency was carried
out by patients and assessors who were
blinded to interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcomes were reported
Selective reporting (reporting bias) Low risk All outcomes stipulated in the published ar-
ticle were reported but conference abstracts
and posters pertaining to this study repot-
ted quality of life outcomes that were pub-
lished separately. For further information
see ORBIT tool below
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Biton 2005 See Biton 2008
Biton 2008 This study compared intravenous lacosamide and oral lacosamide and could not be used in the current review
as there was no placebo group. This study might be used if future data becomes available
Jatuzis 2005 Pharmacokinetic study
Jatuzis 2006 Pharmacokinetic study
Kalvianinen 2007 Pharmacokinetic study
Rosenfeld 2005 Pharmacokinetic study
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D A T A A N D A N A L Y S E S
Comparison 1. Lacosamide versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 50% Reduction in Seizure
Frequency
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Lacosamide 200 mg 2 522 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [1.07, 1.85]
1.2 Lacosamide 400 mg 3 825 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [1.43, 2.25]
1.3 Lacosamide 600 mg 2 402 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [1.43, 2.73]
1.4 Lacosamide Any dose 3 1294 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.38, 2.10]
2 Seizure Freedom 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Lacosamide 200 mg/day 2 522 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [0.50, 6.57]
2.2 Lacosamide 400 mg/day 3 825 Risk Ratio (M-H, Fixed, 95% CI) 2.70 [0.85, 8.56]
2.3 Lacosamide 600 mg/day 2 402 Risk Ratio (M-H, Fixed, 95% CI) 7.09 [0.90, 55.70]
2.4 Lacosamide Any dose 3 1294 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [0.85, 7.34]
3 Treatment Withdrawals 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Lacosamide 200 mg 2 530 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.95, 2.15]
3.2 Lacosamide 400 mg 3 835 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [1.31, 2.46]
3.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 95% CI) 3.04 [2.02, 4.59]
3.4 Lacosamide any dose 3 1308 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [1.40, 2.52]
4 Abnormal Coordination 2 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
4.1 Lacosamide 200 mg 1 326 Risk Ratio (M-H, Fixed, 99% CI) 7.0 [0.45, 108.28]
4.2 Lacosamide 400 mg 2 630 Risk Ratio (M-H, Fixed, 99% CI) 6.13 [1.34, 28.07]
4.3 Lacosamide 600 mg 1 201 Risk Ratio (M-H, Fixed, 99% CI) 5.90 [0.84, 41.30]
4.4 Lacosamide Any dose 2 890 Risk Ratio (M-H, Fixed, 99% CI) 6.12 [1.35, 27.77]
5 Accident NOS 1 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
5.1 Lacosamide 200 mg 1 204 Risk Ratio (M-H, Fixed, 99% CI) 1.13 [0.45, 2.87]
5.2 Lacosamide 400 mg 1 205 Risk Ratio (M-H, Fixed, 99% CI) 0.45 [0.13, 1.55]
5.3 Lacosamide 600 mg 1 203 Risk Ratio (M-H, Fixed, 99% CI) 0.38 [0.10, 1.43]
5.4 Lacosamide Any dose 1 418 Risk Ratio (M-H, Fixed, 99% CI) 0.65 [0.28, 1.53]
6 Ataxia 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
6.1 Lacosamide 200 mg 2 204 Risk Ratio (M-H, Fixed, 99% CI) 1.21 [0.17, 8.36]
6.2 Lacosamide 400 mg 2 205 Risk Ratio (M-H, Fixed, 99% CI) 4.19 [0.85, 20.73]
6.3 Lacosamide 600 mg 1 203 Risk Ratio (M-H, Fixed, 99% CI) 7.32 [1.58, 33.99]
6.4 Lacosamide Any dose 3 418 Risk Ratio (M-H, Fixed, 99% CI) 4.23 [0.93, 19.15]
7 Blurred Vision 2 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
7.1 Lacosamide 200 mg 1 204 Risk Ratio (M-H, Fixed, 99% CI) 0.73 [0.13, 3.93]
7.2 Lacosamide 400 mg 2 513 Risk Ratio (M-H, Fixed, 99% CI) 2.91 [1.06, 7.98]
7.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 99% CI) 4.38 [1.66, 11.57]
7.4 Lacosamide Any dose 2 823 Risk Ratio (M-H, Fixed, 99% CI) 3.02 [1.19, 7.68]
8 Diplopia 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Lacosamide 200 mg 2 530 Risk Ratio (M-H, Fixed, 95% CI) 4.10 [1.41, 11.95]
8.2 Lacosamide 400 mg 3 835 Risk Ratio (M-H, Fixed, 95% CI) 5.18 [2.40, 11.18]
8.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 95% CI) 6.61 [2.63, 16.61]
8.4 Lacosamide Any dose 3 1308 Risk Ratio (M-H, Fixed, 95% CI) 5.29 [2.49, 11.24]
9 Dizziness 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
9.1 Lacosamide 200 mg 2 530 Risk Ratio (M-H, Fixed, 99% CI) 2.26 [1.14, 4.46]
9.2 Lacosamide 400 mg 3 835 Risk Ratio (M-H, Fixed, 99% CI) 3.33 [2.02, 5.50]
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9.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 99% CI) 5.04 [2.88, 8.82]
9.4 Lacosamide Any dose 3 1308 Risk Ratio (M-H, Fixed, 99% CI) 3.53 [2.20, 5.68]
10 Fatigue 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Lacosamide 200 mg 2 530 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.80, 3.38]
10.2 Lacosamide 400 mg 2 527 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [1.00, 4.03]
10.3 Lacosamide 600 mg 1 203 Risk Ratio (M-H, Fixed, 95% CI) 3.84 [1.51, 9.80]
10.4 Lacosamide Any dose 2 903 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [1.12, 3.97]
11 Headache 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
11.1 Lacosamide 200 mg 2 530 Risk Ratio (M-H, Fixed, 99% CI) 1.37 [0.68, 2.75]
11.2 Lacosamide 400 mg 3 837 Risk Ratio (M-H, Fixed, 99% CI) 1.50 [0.89, 2.51]
11.3 Lacosamide 600 mg 2 406 Risk Ratio (M-H, Fixed, 99% CI) 1.09 [0.54, 2.21]
11.4 Lacosamide Any dose 3 1310 Risk Ratio (M-H, Fixed, 99% CI) 1.35 [0.83, 2.19]
12 Proportion of patients with
Nasopharyngitis
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Lacosamide 200 mg 1 326 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.47, 3.76]
12.2 Lacosamide 400 mg 1 322 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.64, 4.59]
12.3 Lacosamide Any dose 1 485 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.61, 3.75]
13 Nausea 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
13.1 Lacosamide 200 mg 2 530 Risk Ratio (M-H, Fixed, 99% CI) 1.70 [0.67, 4.29]
13.2 Lacosamide 400 mg 3 835 Risk Ratio (M-H, Fixed, 99% CI) 2.46 [1.21, 5.01]
13.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 99% CI) 2.44 [1.13, 5.26]
13.4 Lacosamide Any Dose 3 1308 Risk Ratio (M-H, Fixed, 99% CI) 2.37 [1.23, 4.58]
14 Nystagmus 2 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
14.1 Lacosamide 200 mg 1 204 Risk Ratio (M-H, Fixed, 99% CI) 0.54 [0.09, 3.45]
14.2 Lacosamide 400 mg 2 513 Risk Ratio (M-H, Fixed, 99% CI) 1.31 [0.49, 3.51]
14.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 99% CI) 2.08 [0.80, 5.40]
14.4 Lacosamide Any dose 2 823 Risk Ratio (M-H, Fixed, 99% CI) 1.47 [0.61, 3.52]
15 Peripheral Edema 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Lacosamide 200 mg 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Lacosamide 400 mg 1 308 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [0.12, 52.86]
15.3 Lacosamide 600 mg 1 201 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.13, 77.97]
15.4 Lacosamide Any dose 1 405 Risk Ratio (M-H, Fixed, 95% CI) 2.43 [0.13, 46.73]
16 Rash 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Lacosamide 200 mg 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 Lacosamide 400 mg 1 308 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.36, 3.64]
16.3 Lacosamide 600 mg 1 201 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.03, 2.36]
16.4 Lacosamide Any dose 1 405 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.28, 2.70]
17 Somnolence 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Lacosamide 200 mg 1 204 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.43, 3.36]
17.2 Lacosamide 400 mg 2 513 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.92, 3.14]
17.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.60, 2.46]
17.4 Lacosamide Any dose 2 823 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.81, 2.57]
18 Tremor 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 Lacosamide 200 mg 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 Lacosamide 400 mg 1 308 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.55, 2.67]
18.3 Lacosamide 600 mg 1 201 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.82, 4.27]
18.4 Lacosamide Any dose 1 405 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.68, 2.99]
19 Upper Respiratory Tract
Infection
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 Lacosamide 200 mg 1 204 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.46, 2.14]
19.2 Lacosamide 400 mg 1 205 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.50, 2.26]
19.3 Lacosamide 600 mg 1 203 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.19, 1.30]
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19.4 Lacosamide Any dose 1 418 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.44, 1.63]
20 Vertigo 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Lacosamide 200 mg 1 326 Risk Ratio (M-H, Fixed, 95% CI) 3.67 [1.04, 12.90]
20.2 Lacosamide 400 mg 1 322 Risk Ratio (M-H, Fixed, 95% CI) 3.42 [0.96, 12.19]
20.3 Lcaosamide 600 mg 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.4 Lacosamide Any dose 1 485 Risk Ratio (M-H, Fixed, 95% CI) 3.54 [1.07, 11.71]
21 Vomiting 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
21.1 Lacosamide 200 mg 2 530 Risk Ratio (M-H, Fixed, 99% CI) 2.52 [0.75, 8.47]
21.2 Lacosamide 400 mg 3 835 Risk Ratio (M-H, Fixed, 99% CI) 2.95 [1.27, 6.85]
21.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 99% CI) 3.64 [1.34, 9.87]
21.4 Lacosamide Any dose 3 1308 Risk Ratio (M-H, Fixed, 99% CI) 3.10 [1.38, 6.95]
22 Serious Adverse Events 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
22.1 Lacosmaide 200 mg 2 530 Risk Ratio (M-H, Fixed, 99% CI) 2.00 [0.80, 5.00]
22.2 Lacosamide 400 mg 3 835 Risk Ratio (M-H, Fixed, 99% CI) 1.97 [0.88, 4.40]
22.3 Lacosamide 600 mg 2 404 Risk Ratio (M-H, Fixed, 99% CI) 0.74 [0.19, 2.86]
22.4 Lacosamide Any dose 3 1308 Risk Ratio (M-H, Fixed, 99% CI) 1.78 [0.85, 3.73]
Analysis 1.1. Comparison 1 Lacosamide versus placebo, Outcome 1 50% Reduction in Seizure Frequency.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 1 50% Reduction in Seizure Frequency
Study or subgroup Favours Placebo Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Ben Menachem 2007 35/107 21/96 35.0 % 1.50 [ 0.94, 2.38 ]
Halasz 2009 56/160 41/159 65.0 % 1.36 [ 0.97, 1.90 ]
Subtotal (95% CI) 267 255 100.0 % 1.41 [ 1.07, 1.85 ]
Total events: 91 (Favours Placebo), 62 (Placebo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
2 Lacosamide 400 mg
Ben Menachem 2007 44/107 21/96 25.1 % 1.88 [ 1.21, 2.92 ]
Chung 2010 77/201 19/104 28.4 % 2.10 [ 1.35, 3.26 ]
Halasz 2009 64/158 41/159 46.4 % 1.57 [ 1.14, 2.17 ]
Subtotal (95% CI) 466 359 100.0 % 1.80 [ 1.43, 2.25 ]
Total events: 185 (Favours Placebo), 81 (Placebo)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 5.09 (P < 0.00001)
3 Lacosamide 600 mg
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(. . . Continued)
Study or subgroup Favours Placebo Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ben Menachem 2007 40/105 21/96 54.5 % 1.74 [ 1.11, 2.73 ]
Chung 2010 40/97 19/104 45.5 % 2.26 [ 1.41, 3.61 ]
Subtotal (95% CI) 202 200 100.0 % 1.98 [ 1.43, 2.73 ]
Total events: 80 (Favours Placebo), 40 (Placebo)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 4.11 (P = 0.000039)
4 Lacosamide Any dose
Ben Menachem 2007 119/319 21/96 28.0 % 1.71 [ 1.14, 2.55 ]
Chung 2010 117/298 19/104 24.5 % 2.15 [ 1.40, 3.30 ]
Halasz 2009 120/318 41/159 47.5 % 1.46 [ 1.09, 1.97 ]
Subtotal (95% CI) 935 359 100.0 % 1.70 [ 1.38, 2.10 ]
Total events: 356 (Favours Placebo), 81 (Placebo)
Heterogeneity: Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 4.94 (P < 0.00001)
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Analysis 1.2. Comparison 1 Lacosamide versus placebo, Outcome 2 Seizure Freedom.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 2 Seizure Freedom
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg/day
Ben Menachem 2007 1/107 0/96 14.9 % 2.69 [ 0.11, 65.37 ]
Halasz 2009 5/160 3/159 85.1 % 1.66 [ 0.40, 6.81 ]
Subtotal (95% CI) 267 255 100.0 % 1.81 [ 0.50, 6.57 ]
Total events: 6 (Lacosamide), 3 (Placebo)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Lacosamide 400 mg/day
Ben Menachem 2007 5/107 0/96 12.6 % 9.88 [ 0.55, 176.36 ]
Chung 2010 4/201 0/104 15.8 % 4.68 [ 0.25, 86.07 ]
Halasz 2009 3/158 3/159 71.6 % 1.01 [ 0.21, 4.91 ]
Subtotal (95% CI) 466 359 100.0 % 2.70 [ 0.85, 8.56 ]
Total events: 12 (Lacosamide), 3 (Placebo)
Heterogeneity: Chi2 = 2.41, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.69 (P = 0.090)
3 Lacosamide 600 mg/day
Ben Menachem 2007 1/105 0/96 52.0 % 2.75 [ 0.11, 66.59 ]
Chung 2010 5/97 0/104 48.0 % 11.79 [ 0.66, 210.36 ]
Subtotal (95% CI) 202 200 100.0 % 7.09 [ 0.90, 55.70 ]
Total events: 6 (Lacosamide), 0 (Placebo)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
4 Lacosamide Any dose
Ben Menachem 2007 7/319 0/96 13.9 % 4.55 [ 0.26, 78.90 ]
Chung 2010 9/298 0/104 13.4 % 6.67 [ 0.39, 113.64 ]
Halasz 2009 8/318 3/159 72.6 % 1.33 [ 0.36, 4.96 ]
Subtotal (95% CI) 935 359 100.0 % 2.50 [ 0.85, 7.34 ]
Total events: 24 (Lacosamide), 3 (Placebo)
Heterogeneity: Chi2 = 1.51, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.096)
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Analysis 1.3. Comparison 1 Lacosamide versus placebo, Outcome 3 Treatment Withdrawals.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 3 Treatment Withdrawals
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Ben Menachem 2007 22/107 11/97 34.4 % 1.81 [ 0.93, 3.54 ]
Halasz 2009 27/163 22/163 65.6 % 1.23 [ 0.73, 2.06 ]
Subtotal (95% CI) 270 260 100.0 % 1.43 [ 0.95, 2.15 ]
Total events: 49 (Lacosamide), 33 (Placebo)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
2 Lacosamide 400 mg
Ben Menachem 2007 28/108 11/97 22.3 % 2.29 [ 1.20, 4.34 ]
Chung 2010 43/204 14/104 35.8 % 1.57 [ 0.90, 2.73 ]
Halasz 2009 37/159 22/163 41.9 % 1.72 [ 1.07, 2.79 ]
Subtotal (95% CI) 471 364 100.0 % 1.79 [ 1.31, 2.46 ]
Total events: 108 (Lacosamide), 47 (Placebo)
Heterogeneity: Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.63 (P = 0.00029)
3 Lacosamide 600 mg
Ben Menachem 2007 45/106 11/97 46.0 % 3.74 [ 2.06, 6.81 ]
Chung 2010 32/97 14/104 54.0 % 2.45 [ 1.39, 4.31 ]
Subtotal (95% CI) 203 201 100.0 % 3.04 [ 2.02, 4.59 ]
Total events: 77 (Lacosamide), 25 (Placebo)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 5.33 (P < 0.00001)
4 Lacosamide any dose
Ben Menachem 2007 95/321 11/97 25.2 % 2.61 [ 1.46, 4.67 ]
Chung 2010 75/301 14/104 31.1 % 1.85 [ 1.09, 3.13 ]
Halasz 2009 64/322 22/163 43.7 % 1.47 [ 0.94, 2.30 ]
Subtotal (95% CI) 944 364 100.0 % 1.88 [ 1.40, 2.52 ]
Total events: 234 (Lacosamide), 47 (Placebo)
Heterogeneity: Chi2 = 2.37, df = 2 (P = 0.31); I2 =16%
Test for overall effect: Z = 4.21 (P = 0.000026)
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Analysis 1.4. Comparison 1 Lacosamide versus placebo, Outcome 4 Abnormal Coordination.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 4 Abnormal Coordination
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Halasz 2009 7/163 1/163 100.0 % 7.00 [ 0.45, 108.28 ]
Subtotal (99% CI) 163 163 100.0 % 7.00 [ 0.45, 108.28 ]
Total events: 7 (Lacosamide), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
2 Lacosamide 400 mg
Chung 2010 18/204 2/104 72.8 % 4.59 [ 0.69, 30.51 ]
Halasz 2009 10/159 1/163 27.2 % 10.25 [ 0.70, 150.46 ]
Subtotal (99% CI) 363 267 100.0 % 6.13 [ 1.34, 28.07 ]
Total events: 28 (Lacosamide), 3 (Placebo)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0022)
3 Lacosamide 600 mg
Chung 2010 11/97 2/104 100.0 % 5.90 [ 0.84, 41.30 ]
Subtotal (99% CI) 97 104 100.0 % 5.90 [ 0.84, 41.30 ]
Total events: 11 (Lacosamide), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
4 Lacosamide Any dose
Chung 2010 29/301 2/104 69.1 % 5.01 [ 0.78, 32.19 ]
Halasz 2009 17/322 1/163 30.9 % 8.61 [ 0.61, 120.46 ]
Subtotal (99% CI) 623 267 100.0 % 6.12 [ 1.35, 27.77 ]
Total events: 46 (Lacosamide), 3 (Placebo)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
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Analysis 1.5. Comparison 1 Lacosamide versus placebo, Outcome 5 Accident NOS.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 5 Accident NOS
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 15/107 12/97 100.0 % 1.13 [ 0.45, 2.87 ]
Subtotal (99% CI) 107 97 100.0 % 1.13 [ 0.45, 2.87 ]
Total events: 15 (Lacosamide), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 Lacosamide 400 mg
Ben Menachem 2007 6/108 12/97 100.0 % 0.45 [ 0.13, 1.55 ]
Subtotal (99% CI) 108 97 100.0 % 0.45 [ 0.13, 1.55 ]
Total events: 6 (Lacosamide), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
3 Lacosamide 600 mg
Ben Menachem 2007 5/106 12/97 100.0 % 0.38 [ 0.10, 1.43 ]
Subtotal (99% CI) 106 97 100.0 % 0.38 [ 0.10, 1.43 ]
Total events: 5 (Lacosamide), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
4 Lacosamide Any dose
Ben Menachem 2007 26/321 12/97 100.0 % 0.65 [ 0.28, 1.53 ]
Subtotal (99% CI) 321 97 100.0 % 0.65 [ 0.28, 1.53 ]
Total events: 26 (Lacosamide), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 4.02, df = 3 (P = 0.26), I2 =25%
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Analysis 1.6. Comparison 1 Lacosamide versus placebo, Outcome 6 Ataxia.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 6 Ataxia
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 4/107 3/97 100.0 % 1.21 [ 0.17, 8.36 ]
Halasz 2009 0/0 0/0 Not estimable
Subtotal (99% CI) 107 97 100.0 % 1.21 [ 0.17, 8.36 ]
Total events: 4 (Lacosamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 Lacosamide 400 mg
Ben Menachem 2007 14/108 3/97 100.0 % 4.19 [ 0.85, 20.73 ]
Halasz 2009 0/0 0/0 Not estimable
Subtotal (99% CI) 108 97 100.0 % 4.19 [ 0.85, 20.73 ]
Total events: 14 (Lacosamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
3 Lacosamide 600 mg
Ben Menachem 2007 24/106 3/97 100.0 % 7.32 [ 1.58, 33.99 ]
Subtotal (99% CI) 106 97 100.0 % 7.32 [ 1.58, 33.99 ]
Total events: 24 (Lacosamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.34 (P = 0.00084)
4 Lacosamide Any dose
Ben Menachem 2007 42/321 3/97 100.0 % 4.23 [ 0.93, 19.15 ]
Chung 2010 0/0 0/0 Not estimable
Halasz 2009 0/0 0/0 Not estimable
Subtotal (99% CI) 321 97 100.0 % 4.23 [ 0.93, 19.15 ]
Total events: 42 (Lacosamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
0.01 0.1 1 10 100
Favours Lacosamide Favours Placebo
27Lacosamide add-on therapy for partial epilepsy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fo
r P
rev
iew
 O
nly
Analysis 1.7. Comparison 1 Lacosamide versus placebo, Outcome 7 Blurred Vision.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 7 Blurred Vision
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 4/107 5/97 100.0 % 0.73 [ 0.13, 3.93 ]
Subtotal (99% CI) 107 97 100.0 % 0.73 [ 0.13, 3.93 ]
Total events: 4 (Lacosamide), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
2 Lacosamide 400 mg
Ben Menachem 2007 12/108 5/97 57.0 % 2.16 [ 0.57, 8.09 ]
Chung 2010 23/204 3/104 43.0 % 3.91 [ 0.83, 18.42 ]
Subtotal (99% CI) 312 201 100.0 % 2.91 [ 1.06, 7.98 ]
Total events: 35 (Lacosamide), 8 (Placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
3 Lacosamide 600 mg
Ben Menachem 2007 21/106 5/97 64.3 % 3.84 [ 1.12, 13.14 ]
Chung 2010 15/97 3/104 35.7 % 5.36 [ 1.10, 26.24 ]
Subtotal (99% CI) 203 201 100.0 % 4.38 [ 1.66, 11.57 ]
Total events: 36 (Lacosamide), 8 (Placebo)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000087)
4 Lacosamide Any dose
Ben Menachem 2007 37/321 5/97 63.3 % 2.24 [ 0.68, 7.35 ]
Chung 2010 38/301 3/104 36.7 % 4.38 [ 0.96, 19.94 ]
Subtotal (99% CI) 622 201 100.0 % 3.02 [ 1.19, 7.68 ]
Total events: 75 (Lacosamide), 8 (Placebo)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
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Analysis 1.8. Comparison 1 Lacosamide versus placebo, Outcome 8 Diplopia.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 8 Diplopia
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Ben Menachem 2007 4/107 2/97 51.2 % 1.81 [ 0.34, 9.68 ]
Halasz 2009 13/163 2/163 48.8 % 6.50 [ 1.49, 28.35 ]
Subtotal (95% CI) 270 260 100.0 % 4.10 [ 1.41, 11.95 ]
Total events: 17 (Lacosamide), 4 (Placebo)
Heterogeneity: Chi2 = 1.29, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 2.59 (P = 0.0097)
2 Lacosamide 400 mg
Ben Menachem 2007 12/108 2/97 26.2 % 5.39 [ 1.24, 23.48 ]
Chung 2010 21/204 3/104 49.3 % 3.57 [ 1.09, 11.69 ]
Halasz 2009 16/159 2/163 24.5 % 8.20 [ 1.92, 35.09 ]
Subtotal (95% CI) 471 364 100.0 % 5.18 [ 2.40, 11.18 ]
Total events: 49 (Lacosamide), 7 (Placebo)
Heterogeneity: Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 4.19 (P = 0.000028)
3 Lacosamide 600 mg
Ben Menachem 2007 15/106 2/97 41.9 % 6.86 [ 1.61, 29.24 ]
Chung 2010 18/97 3/104 58.1 % 6.43 [ 1.96, 21.16 ]
Subtotal (95% CI) 203 201 100.0 % 6.61 [ 2.63, 16.61 ]
Total events: 33 (Lacosamide), 5 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 4.02 (P = 0.000058)
4 Lacosamide Any dose
Ben Menachem 2007 31/321 2/97 30.2 % 4.68 [ 1.14, 19.22 ]
Chung 2010 39/301 3/104 43.8 % 4.49 [ 1.42, 14.23 ]
Halasz 2009 29/322 2/163 26.1 % 7.34 [ 1.77, 30.38 ]
Subtotal (95% CI) 944 364 100.0 % 5.29 [ 2.49, 11.24 ]
Total events: 99 (Lacosamide), 7 (Placebo)
Heterogeneity: Chi2 = 0.31, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
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Analysis 1.9. Comparison 1 Lacosamide versus placebo, Outcome 9 Dizziness.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 9 Dizziness
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 26/107 10/97 56.7 % 2.36 [ 0.97, 5.73 ]
Halasz 2009 17/163 8/163 43.3 % 2.13 [ 0.73, 6.18 ]
Subtotal (99% CI) 270 260 100.0 % 2.26 [ 1.14, 4.46 ]
Total events: 43 (Lacosamide), 18 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0021)
2 Lacosamide 400 mg
Ben Menachem 2007 28/108 10/97 31.9 % 2.51 [ 1.05, 6.05 ]
Chung 2010 86/204 11/104 44.1 % 3.99 [ 1.86, 8.56 ]
Halasz 2009 25/159 8/163 23.9 % 3.20 [ 1.17, 8.76 ]
Subtotal (99% CI) 471 364 100.0 % 3.33 [ 2.02, 5.50 ]
Total events: 139 (Lacosamide), 29 (Placebo)
Heterogeneity: Chi2 = 1.06, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 6.18 (P < 0.00001)
3 Lacosamide 600 mg
Ben Menachem 2007 58/106 10/97 49.6 % 5.31 [ 2.37, 11.86 ]
Chung 2010 49/97 11/104 50.4 % 4.78 [ 2.19, 10.41 ]
Subtotal (99% CI) 203 201 100.0 % 5.04 [ 2.88, 8.82 ]
Total events: 107 (Lacosamide), 21 (Placebo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 7.44 (P < 0.00001)
4 Lacosamide Any dose
Ben Menachem 2007 112/321 10/97 36.3 % 3.38 [ 1.53, 7.50 ]
Chung 2010 135/301 11/104 38.6 % 4.24 [ 2.00, 9.00 ]
Halasz 2009 42/322 8/163 25.1 % 2.66 [ 1.02, 6.96 ]
Subtotal (99% CI) 944 364 100.0 % 3.53 [ 2.20, 5.68 ]
Total events: 289 (Lacosamide), 29 (Placebo)
Heterogeneity: Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 6.85 (P < 0.00001)
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Analysis 1.10. Comparison 1 Lacosamide versus placebo, Outcome 10 Fatigue.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 10 Fatigue
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Ben Menachem 2007 11/107 5/97 46.6 % 1.99 [ 0.72, 5.54 ]
Halasz 2009 8/163 6/163 53.4 % 1.33 [ 0.47, 3.76 ]
Subtotal (95% CI) 270 260 100.0 % 1.64 [ 0.80, 3.38 ]
Total events: 19 (Lacosamide), 11 (Placebo)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
2 Lacosamide 400 mg
Ben Menachem 2007 13/108 5/97 47.1 % 2.34 [ 0.86, 6.31 ]
Halasz 2009 10/159 6/163 52.9 % 1.71 [ 0.64, 4.59 ]
Subtotal (95% CI) 267 260 100.0 % 2.00 [ 1.00, 4.03 ]
Total events: 23 (Lacosamide), 11 (Placebo)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
3 Lacosamide 600 mg
Ben Menachem 2007 21/106 5/97 100.0 % 3.84 [ 1.51, 9.80 ]
Subtotal (95% CI) 106 97 100.0 % 3.84 [ 1.51, 9.80 ]
Total events: 21 (Lacosamide), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
4 Lacosamide Any dose
Ben Menachem 2007 45/321 5/97 49.1 % 2.72 [ 1.11, 6.66 ]
Halasz 2009 18/322 6/163 50.9 % 1.52 [ 0.61, 3.75 ]
Subtotal (95% CI) 643 260 100.0 % 2.11 [ 1.12, 3.97 ]
Total events: 63 (Lacosamide), 11 (Placebo)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
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Analysis 1.11. Comparison 1 Lacosamide versus placebo, Outcome 11 Headache.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 11 Headache
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 12/107 9/97 44.0 % 1.21 [ 0.41, 3.55 ]
Halasz 2009 18/163 12/163 56.0 % 1.50 [ 0.60, 3.75 ]
Subtotal (99% CI) 270 260 100.0 % 1.37 [ 0.68, 2.75 ]
Total events: 30 (Lacosamide), 21 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
2 Lacosamide 400 mg
Ben Menachem 2007 26/108 9/97 25.5 % 2.59 [ 1.03, 6.57 ]
Chung 2010 26/204 12/106 42.5 % 1.13 [ 0.48, 2.62 ]
Halasz 2009 13/159 12/163 31.9 % 1.11 [ 0.41, 2.99 ]
Subtotal (99% CI) 471 366 100.0 % 1.50 [ 0.89, 2.51 ]
Total events: 65 (Lacosamide), 33 (Placebo)
Heterogeneity: Chi2 = 3.68, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 2.00 (P = 0.045)
3 Lacosamide 600 mg
Ben Menachem 2007 14/106 9/97 41.3 % 1.42 [ 0.50, 4.02 ]
Chung 2010 11/97 14/106 58.7 % 0.86 [ 0.32, 2.27 ]
Subtotal (99% CI) 203 203 100.0 % 1.09 [ 0.54, 2.21 ]
Total events: 25 (Lacosamide), 23 (Placebo)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
4 Lacosamide Any dose
Ben Menachem 2007 52/321 9/97 29.1 % 1.75 [ 0.72, 4.21 ]
Chung 2010 37/301 12/106 37.4 % 1.09 [ 0.49, 2.43 ]
Halasz 2009 31/322 12/163 33.5 % 1.31 [ 0.56, 3.03 ]
Subtotal (99% CI) 944 366 100.0 % 1.35 [ 0.83, 2.19 ]
Total events: 120 (Lacosamide), 33 (Placebo)
Heterogeneity: Chi2 = 1.06, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
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Analysis 1.12. Comparison 1 Lacosamide versus placebo, Outcome 12 Proportion of patients with
Nasopharyngitis.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 12 Proportion of patients with Nasopharyngitis
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Halasz 2009 8/163 6/163 100.0 % 1.33 [ 0.47, 3.76 ]
Subtotal (95% CI) 163 163 100.0 % 1.33 [ 0.47, 3.76 ]
Total events: 8 (Lacosamide), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Lacosamide 400 mg
Halasz 2009 10/159 6/163 100.0 % 1.71 [ 0.64, 4.59 ]
Subtotal (95% CI) 159 163 100.0 % 1.71 [ 0.64, 4.59 ]
Total events: 10 (Lacosamide), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
3 Lacosamide Any dose
Halasz 2009 18/322 6/163 100.0 % 1.52 [ 0.61, 3.75 ]
Subtotal (95% CI) 322 163 100.0 % 1.52 [ 0.61, 3.75 ]
Total events: 18 (Lacosamide), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.37)
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Analysis 1.13. Comparison 1 Lacosamide versus placebo, Outcome 13 Nausea.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 13 Nausea
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 11/107 9/97 82.5 % 1.11 [ 0.37, 3.33 ]
Halasz 2009 9/163 2/163 17.5 % 4.50 [ 0.61, 33.03 ]
Subtotal (99% CI) 270 260 100.0 % 1.70 [ 0.67, 4.29 ]
Total events: 20 (Lacosamide), 11 (Placebo)
Heterogeneity: Chi2 = 2.59, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.48 (P = 0.14)
2 Lacosamide 400 mg
Ben Menachem 2007 16/108 9/97 52.4 % 1.60 [ 0.58, 4.39 ]
Chung 2010 24/204 5/104 36.6 % 2.45 [ 0.72, 8.35 ]
Halasz 2009 13/159 2/163 10.9 % 6.66 [ 0.96, 46.15 ]
Subtotal (99% CI) 471 364 100.0 % 2.46 [ 1.21, 5.01 ]
Total events: 53 (Lacosamide), 16 (Placebo)
Heterogeneity: Chi2 = 2.97, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 3.27 (P = 0.0011)
3 Lacosamide 600 mg
Ben Menachem 2007 19/106 9/97 66.1 % 1.93 [ 0.73, 5.13 ]
Chung 2010 16/97 5/104 33.9 % 3.43 [ 0.96, 12.20 ]
Subtotal (99% CI) 203 201 100.0 % 2.44 [ 1.13, 5.26 ]
Total events: 35 (Lacosamide), 14 (Placebo)
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
4 Lacosamide Any Dose
Ben Menachem 2007 46/321 9/97 57.8 % 1.54 [ 0.63, 3.76 ]
Chung 2010 40/301 5/104 31.1 % 2.76 [ 0.84, 9.05 ]
Halasz 2009 22/322 2/163 11.1 % 5.57 [ 0.84, 36.72 ]
Subtotal (99% CI) 944 364 100.0 % 2.37 [ 1.23, 4.58 ]
Total events: 108 (Lacosamide), 16 (Placebo)
Heterogeneity: Chi2 = 3.01, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 3.37 (P = 0.00074)
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Analysis 1.14. Comparison 1 Lacosamide versus placebo, Outcome 14 Nystagmus.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 14 Nystagmus
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 3/107 5/97 100.0 % 0.54 [ 0.09, 3.45 ]
Subtotal (99% CI) 107 97 100.0 % 0.54 [ 0.09, 3.45 ]
Total events: 3 (Lacosamide), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
2 Lacosamide 400 mg
Ben Menachem 2007 5/108 5/97 44.3 % 0.90 [ 0.18, 4.40 ]
Chung 2010 16/204 5/104 55.7 % 1.63 [ 0.45, 5.88 ]
Subtotal (99% CI) 312 201 100.0 % 1.31 [ 0.49, 3.51 ]
Total events: 21 (Lacosamide), 10 (Placebo)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
3 Lacosamide 600 mg
Ben Menachem 2007 11/106 5/97 52.0 % 2.01 [ 0.53, 7.70 ]
Chung 2010 10/97 5/104 48.0 % 2.14 [ 0.55, 8.38 ]
Subtotal (99% CI) 203 201 100.0 % 2.08 [ 0.80, 5.40 ]
Total events: 21 (Lacosamide), 10 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
4 Lacosamide Any dose
Ben Menachem 2007 19/321 5/97 50.8 % 1.15 [ 0.33, 4.05 ]
Chung 2010 26/301 5/104 49.2 % 1.80 [ 0.53, 6.11 ]
Subtotal (99% CI) 622 201 100.0 % 1.47 [ 0.61, 3.52 ]
Total events: 45 (Lacosamide), 10 (Placebo)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 1.15. Comparison 1 Lacosamide versus placebo, Outcome 15 Peripheral Edema.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 15 Peripheral Edema
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Lacosamide), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Lacosamide 400 mg
Chung 2010 2/204 0/104 100.0 % 2.56 [ 0.12, 52.86 ]
Subtotal (95% CI) 204 104 100.0 % 2.56 [ 0.12, 52.86 ]
Total events: 2 (Lacosamide), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Lacosamide 600 mg
Chung 2010 1/97 0/104 100.0 % 3.21 [ 0.13, 77.97 ]
Subtotal (95% CI) 97 104 100.0 % 3.21 [ 0.13, 77.97 ]
Total events: 1 (Lacosamide), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
4 Lacosamide Any dose
Chung 2010 3/301 0/104 100.0 % 2.43 [ 0.13, 46.73 ]
Subtotal (95% CI) 301 104 100.0 % 2.43 [ 0.13, 46.73 ]
Total events: 3 (Lacosamide), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
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Analysis 1.16. Comparison 1 Lacosamide versus placebo, Outcome 16 Rash.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 16 Rash
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Lacosamide), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Lacosamide 400 mg
Chung 2010 9/204 4/104 100.0 % 1.15 [ 0.36, 3.64 ]
Subtotal (95% CI) 204 104 100.0 % 1.15 [ 0.36, 3.64 ]
Total events: 9 (Lacosamide), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
3 Lacosamide 600 mg
Chung 2010 1/97 4/104 100.0 % 0.27 [ 0.03, 2.36 ]
Subtotal (95% CI) 97 104 100.0 % 0.27 [ 0.03, 2.36 ]
Total events: 1 (Lacosamide), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
4 Lacosamide Any dose
Chung 2010 10/301 4/104 100.0 % 0.86 [ 0.28, 2.70 ]
Subtotal (95% CI) 301 104 100.0 % 0.86 [ 0.28, 2.70 ]
Total events: 10 (Lacosamide), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
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Analysis 1.17. Comparison 1 Lacosamide versus placebo, Outcome 17 Somnolence.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 17 Somnolence
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Ben Menachem 2007 8/107 6/97 100.0 % 1.21 [ 0.43, 3.36 ]
Subtotal (95% CI) 107 97 100.0 % 1.21 [ 0.43, 3.36 ]
Total events: 8 (Lacosamide), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Lacosamide 400 mg
Ben Menachem 2007 13/108 6/97 40.5 % 1.95 [ 0.77, 4.92 ]
Chung 2010 21/204 7/104 59.5 % 1.53 [ 0.67, 3.48 ]
Subtotal (95% CI) 312 201 100.0 % 1.70 [ 0.92, 3.14 ]
Total events: 34 (Lacosamide), 13 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
3 Lacosamide 600 mg
Ben Menachem 2007 10/106 6/97 48.1 % 1.53 [ 0.58, 4.04 ]
Chung 2010 6/97 7/104 51.9 % 0.92 [ 0.32, 2.64 ]
Subtotal (95% CI) 203 201 100.0 % 1.21 [ 0.60, 2.46 ]
Total events: 16 (Lacosamide), 13 (Placebo)
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
4 Lacosamide Any dose
Ben Menachem 2007 31/321 6/97 47.0 % 1.56 [ 0.67, 3.63 ]
Chung 2010 27/301 7/104 53.0 % 1.33 [ 0.60, 2.97 ]
Subtotal (95% CI) 622 201 100.0 % 1.44 [ 0.81, 2.57 ]
Total events: 58 (Lacosamide), 13 (Placebo)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
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Analysis 1.18. Comparison 1 Lacosamide versus placebo, Outcome 18 Tremor.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 18 Tremor
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Lacosamide), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Lacosamide 400 mg
Chung 2010 19/204 8/104 100.0 % 1.21 [ 0.55, 2.67 ]
Subtotal (95% CI) 204 104 100.0 % 1.21 [ 0.55, 2.67 ]
Total events: 19 (Lacosamide), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Lacosamide 600 mg
Chung 2010 14/97 8/104 100.0 % 1.88 [ 0.82, 4.27 ]
Subtotal (95% CI) 97 104 100.0 % 1.88 [ 0.82, 4.27 ]
Total events: 14 (Lacosamide), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
4 Lacosamide Any dose
Chung 2010 33/301 8/104 100.0 % 1.43 [ 0.68, 2.99 ]
Subtotal (95% CI) 301 104 100.0 % 1.43 [ 0.68, 2.99 ]
Total events: 33 (Lacosamide), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 1.19. Comparison 1 Lacosamide versus placebo, Outcome 19 Upper Respiratory Tract Infection.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 19 Upper Respiratory Tract Infection
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Ben Menachem 2007 12/107 11/97 100.0 % 0.99 [ 0.46, 2.14 ]
Subtotal (95% CI) 107 97 100.0 % 0.99 [ 0.46, 2.14 ]
Total events: 12 (Lacosamide), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 Lacosamide 400 mg
Ben Menachem 2007 13/108 11/97 100.0 % 1.06 [ 0.50, 2.26 ]
Subtotal (95% CI) 108 97 100.0 % 1.06 [ 0.50, 2.26 ]
Total events: 13 (Lacosamide), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
3 Lacosamide 600 mg
Ben Menachem 2007 6/106 11/97 100.0 % 0.50 [ 0.19, 1.30 ]
Subtotal (95% CI) 106 97 100.0 % 0.50 [ 0.19, 1.30 ]
Total events: 6 (Lacosamide), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
4 Lacosamide Any dose
Ben Menachem 2007 31/321 11/97 100.0 % 0.85 [ 0.44, 1.63 ]
Subtotal (95% CI) 321 97 100.0 % 0.85 [ 0.44, 1.63 ]
Total events: 31 (Lacosamide), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 1.20. Comparison 1 Lacosamide versus placebo, Outcome 20 Vertigo.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 20 Vertigo
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lacosamide 200 mg
Halasz 2009 11/163 3/163 100.0 % 3.67 [ 1.04, 12.90 ]
Subtotal (95% CI) 163 163 100.0 % 3.67 [ 1.04, 12.90 ]
Total events: 11 (Lacosamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
2 Lacosamide 400 mg
Halasz 2009 10/159 3/163 100.0 % 3.42 [ 0.96, 12.19 ]
Subtotal (95% CI) 159 163 100.0 % 3.42 [ 0.96, 12.19 ]
Total events: 10 (Lacosamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
3 Lcaosamide 600 mg
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Lacosamide), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Lacosamide Any dose
Halasz 2009 21/322 3/163 100.0 % 3.54 [ 1.07, 11.71 ]
Subtotal (95% CI) 322 163 100.0 % 3.54 [ 1.07, 11.71 ]
Total events: 21 (Lacosamide), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
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Analysis 1.21. Comparison 1 Lacosamide versus placebo, Outcome 21 Vomiting.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 21 Vomiting
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosamide 200 mg
Ben Menachem 2007 11/107 3/97 51.2 % 3.32 [ 0.65, 17.11 ]
Halasz 2009 5/163 3/163 48.8 % 1.67 [ 0.26, 10.70 ]
Subtotal (99% CI) 270 260 100.0 % 2.52 [ 0.75, 8.47 ]
Total events: 16 (Lacosamide), 6 (Placebo)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Lacosamide 400 mg
Ben Menachem 2007 13/108 3/97 24.8 % 3.89 [ 0.78, 19.47 ]
Chung 2010 24/204 5/104 52.0 % 2.45 [ 0.72, 8.35 ]
Halasz 2009 9/159 3/163 23.2 % 3.08 [ 0.57, 16.72 ]
Subtotal (99% CI) 471 364 100.0 % 2.95 [ 1.27, 6.85 ]
Total events: 46 (Lacosamide), 11 (Placebo)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.31 (P = 0.00093)
3 Lacosamide 600 mg
Ben Menachem 2007 13/106 3/97 39.4 % 3.97 [ 0.79, 19.83 ]
Chung 2010 16/97 5/104 60.6 % 3.43 [ 0.96, 12.20 ]
Subtotal (99% CI) 203 201 100.0 % 3.64 [ 1.34, 9.87 ]
Total events: 29 (Lacosamide), 8 (Placebo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.34 (P = 0.00085)
4 Lacosamide Any dose
Ben Menachem 2007 37/321 3/97 28.8 % 3.73 [ 0.82, 16.99 ]
Chung 2010 45/301 5/104 46.4 % 3.11 [ 0.96, 10.10 ]
Halasz 2009 14/322 3/163 24.9 % 2.36 [ 0.47, 11.94 ]
Subtotal (99% CI) 944 364 100.0 % 3.10 [ 1.38, 6.95 ]
Total events: 96 (Lacosamide), 11 (Placebo)
Heterogeneity: Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.61 (P = 0.00030)
0.01 0.1 1 10 100
Favours Lacosamide Favours Placebo
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Analysis 1.22. Comparison 1 Lacosamide versus placebo, Outcome 22 Serious Adverse Events.
Review: Lacosamide add-on therapy for partial epilepsy
Comparison: 1 Lacosamide versus placebo
Outcome: 22 Serious Adverse Events
Study or subgroup Lacosamide Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Lacosmaide 200 mg
Ben Menachem 2007 10/107 5/97 46.6 % 1.81 [ 0.46, 7.09 ]
Halasz 2009 13/163 6/163 53.4 % 2.17 [ 0.63, 7.48 ]
Subtotal (99% CI) 270 260 100.0 % 2.00 [ 0.80, 5.00 ]
Total events: 23 (Lacosamide), 11 (Placebo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
2 Lacosamide 400 mg
Ben Menachem 2007 7/108 5/97 34.7 % 1.26 [ 0.29, 5.44 ]
Chung 2010 12/204 3/104 26.2 % 2.04 [ 0.40, 10.44 ]
Halasz 2009 15/159 6/163 39.1 % 2.56 [ 0.76, 8.60 ]
Subtotal (99% CI) 471 364 100.0 % 1.97 [ 0.88, 4.40 ]
Total events: 34 (Lacosamide), 14 (Placebo)
Heterogeneity: Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
3 Lacosamide 600 mg
Ben Menachem 2007 3/106 5/97 64.3 % 0.55 [ 0.09, 3.48 ]
Chung 2010 3/97 3/104 35.7 % 1.07 [ 0.14, 8.51 ]
Subtotal (99% CI) 203 201 100.0 % 0.74 [ 0.19, 2.86 ]
Total events: 6 (Lacosamide), 8 (Placebo)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
4 Lacosamide Any dose
Ben Menachem 2007 20/321 5/97 38.2 % 1.21 [ 0.35, 4.23 ]
Chung 2010 15/301 3/104 22.2 % 1.73 [ 0.35, 8.58 ]
Halasz 2009 28/322 6/163 39.6 % 2.36 [ 0.76, 7.33 ]
Subtotal (99% CI) 944 364 100.0 % 1.78 [ 0.85, 3.73 ]
Total events: 63 (Lacosamide), 14 (Placebo)
Heterogeneity: Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
0.01 0.1 1 10 100
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Group Specialised Register search strategy
#1 Lacosamide or Erlosamide or Harkoseride or Vimpat
#2 monotherap* not (adjunct* or “add-on” or “add on”)
#3 (#1 NOT #2) AND INREGISTER
Appendix 2. CENTRAL search strategy
#1 Lacosamide or Erlosamide or Harkoseride or Vimpat
#2 (epilep* or seizure* or convuls*):ti,ab,kw (Word variations have been searched)
#3 MeSH descriptor: [Epilepsy] explode all trees
#4 MeSH descriptor: [Seizures] explode all trees
#5 (#2 or #3 or #4)
#6 MeSH descriptor: [Eclampsia] explode all trees
#7 #5 not #6
#8 #1 and #7
#9 monotherap* not (adjunct* or “add-on” or “add on”)
#10 #8 not #9 in Trials
Appendix 3. MEDLINE search strategy
1. (Lacosamide or Erlosamide or Harkoseride or Vimpat).mp.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp Pre-Eclampsia/ or exp Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial).pt. or (randomized or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or “add-on” or “add on”)).tw.
16. 14 not 15
Appendix 4. SCOPUS search strategy
((TITLE-ABS-KEY(lacosamideOR erlosamideORharkoserideORvimpat)) ANDNOT(TITLE(monotherap* ANDNOT(adjunct*
OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*)))) AND ((TITLE-ABS-KEY(epilep* OR “infantile
spasm” OR seizure OR convuls* OR (syndrome W/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons OR “landau
kleffner” OR “lennox gastaut” OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR “sturge weber” OR tassinari OR “un-
verricht lundborg” OR west)) OR “ring chromosome 20” OR “R20” OR “myoclonic encephalopathy” OR “pyridoxine dependency”)
ANDNOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia))) OR (TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*)) AND
NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine)))) AND (TITLE((randomiz* OR randomis* OR controlled
OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR “head to head”) PRE/2 (trial
OR method OR procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR
“parallel group” OR crossover OR “cross over” OR cluster OR “head to head”) PRE/2 (trial OR method OR procedure OR study)))
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Adverse Event reporting in Randomised Controlled Trials
A Systematic Review of Anti Epileptic Drugs using the CONSORT guidelines 2004
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ØRandomised Controlled Trials(RCTs) form the 
corner stone of evidence based medicine1
ØTreatment decisions require both an assessment 
of benefits and harms. One source of adverse event 
data is randomised controlled trials
ØThe CONSORT group established in 1993 is a 
collaboration of scientists, clinicians , journal editors 
and members of the Cochrane Collaboration2.
ØThey provide clinicians and journal editors a 
comprehensive checklist of minimum requirements 
for adequate reporting of RCTs.
ØThis list was revised in 2004 to incorporate 
adverse events and reporting of harms.
ØThe CONSORT guidelines for RTCs can be used 
as a quality measurement tool.
1. A total of 2050 abstracts between January 1999 
and Dec 2008 were reviewed.  
2. Only 150 trials met the inclusion criteria and 
were reviewed in full
3. Mean inter-rater reliability for 15 trials analyzed 
was 90 percent.
ØTo review the reporting of adverse events in RCTs 
of antiepileptic drugs.
ØTo assess both qualitatively and quantitatively the 
current standards of Adverse Event reporting.
ØTo address any deficiencies.
ØTo provide recommendations for improvement
SEARCH CRITERIA
Ø We used MEDLINE  and The Cochrane Library for 
RCTs dated between 1999 and 2008.
Ø Key words used: ‘Epilepsy’ ‘Anti epileptic Drugs’ 
and ‘Seizures’
Ø Limits imposed: English language, Phase 1, 2, 3 
and 4.
ELIGIBILTY CRITERIA
Ø RCT assessing an antiepileptic drug.
Ø Minimum of two comparison groups including 
placebo.
EXCLUSION CRITERIA
Ø Surgical or Vagus nerve interventions.
Ø Clinical trials with a neuropsychological test as 
primary outcome.
DATA  COLLECTION
Ø We collected data on, trial design, funding, year of 
publication, journal of publication and patient 
demographics.
Ø We analyzed data using the 10 recommendations 
published by CONSORT.
ANALYSIS
ØEach of the ten CONSORT recommendations had 
a number of  sub items. 
ØThis totalled the number of sub items to 20 per 
RCT as shown in fig 1 and 2.
ØEach RCT was compared with the CONSORT 
guidelines to determine if each guideline was met as 
seen in figure 5 and 6.
Introduction
Aim
Methods
Results
Conclusion
References
Item CONSORT Section in 
article
Description
1 1 Title & 
abstract 
Title and abstract must state of adverse events if 
study collected data.
2 2 Introduction Intention to address adverse  events
3 3 Methods All or treatment emergent adverse events
4 3 Methods Validated instrument used to collect adverse events
5 3 Methods Validated dictionary of adverse events used 
6 4 Methods How adverse events are collected 
7 4 Methods Is the timing of collection of adverse events stated
8 4 Methods Indicate details of attribution of adverse events
9 5 Methods Describe plans for any statistical analysis
Item CONSORT Section in 
article
Description
10 6 Results Report early or late withdrawals due to AE
11 6 Results Report Serious adverse events including deaths
12 6 Results Provide tabular description of AE
13 7 Results Provide denominators for analysis on harms
14 8 Results Presented separately for each group
15 8 Results Provide the severity or grade of events
16 8 Results Provides both the number of adverse events and 
the number of patients with adverse events
17 9 Results Provide any subgroup analysis for AE
18 10 Discussion Prior literature with reference to AE discussed
19 10 Discussion Gives a balanced discussion of harms vs. efficacy
20 10 Discussion Limitations of study with regard to adverse event
data is presented 
Figure one: Consort criteria one to five
Figure two: Consort criteria six to ten
ØInter-rater reliability was assessed by comparing 
completed forms for 10% of the total sample. 
ØTwo reviewers randomly selected studies and 
compared collected data.
Number of Trials n= 150
Demographics Adults 77
Children 29
Adults and Children 44
Epilepsy type Focal 101
Generalised 7
Both Focal and General 42
Therapy Add on 85
Monotherapy 65
Funding Industry 94
Non Industry 56
Scope Efficacy and Safety 137
Efficacy only 9
Safety only 4
Centre Multi centre 124
Single Centre 26
Median duration in wks 28 weeks
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Consort 1Title and abstract
Consort 2 Introduction
Consort 3All or tx emergent AE
Consort 3 Validated instrument
Consort 3 Validated dictionary
Consort 4 Collection methods
Consort 4 Timing
Consort 4 Attribution
Consort 5 Statistics
Criteria met Criteria Not met
Figure five: Percentage of trials meeting each individual CONSORT 
criteria (Criteria 1 to 5 shown)
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Consort 6 Early or late
Consort 6 SAE death
Consort 6 AE table
Consort 7 Denominators
Consort 8 Presented seperately
Consort 8 Severity graded
Consort 8 Events and patients cited
Consort 9 Subgroup analysis
Consort 10 Prior data
Consort 10 Balanced discussion
Consort 10 Limitations of study
Criteria met Criteria not met
Figure Three: Summary of collected papers
Figure six: Percentage of trials meeting each individual CONSORT 
criteria (Criteria 6 to 10 shown)
63, 68%
19, 21%
10, 
11%
No of subjects
83, 75%
16, 15%
11, 10%
Percentage of patients
27, 24%
69, 63%
14, 
13%
No of adverse events
yes
No
Not Stated
ØAdverse event reporting in the methodology
section is poor.
ØVery few trials provide details of attribution of
adverse events or use a validated tool for the
collection of adverse events as shown in figure
5.
Ø Adverse events are better reported in the
results section but fewer trials report both the
number of events and patients as illustrated in
figure 4 and 6.
Figure four: Proportion of trials reporting  Adverse event data as 
number of patients, percentage of patients and number of adverse 
events
ØMajority of trials report the results of adverse 
events in accordance to the CONSORT criteria. 
RCTs report results better than methods of AE 
collection.
ØRCTs meet minimum requirements for reporting it 
but the quality of the data is still poor due to limited 
reporting of statistical analysis, details of attribution 
and lack of valid tools for adverse event collection.
ØIf only trials that meet the minimum standards are 
allowed to formulate systematic reviews then this 
automatically introduces bias. Current reporting of 
adverse events may result in bias in systematic 
reviews and limit the assessment of benefit and 
harm.
1 John M. Lachin, John P. Matts and L.J. Wei: Randomization in clinical trails: Conclusions and 
recommendations Controlled Clinical trails 1998 Vol 9 Issue 4 pg 365-375
2 John P.A Ioannidis et al: Better reporting o Harms in Randomized Trials: An Extension of 
the CONSORT statement Annals of Internal Medicine 2004 Vol 141 pg 781-788
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Dr Arif Shukralla1 Dr Graham Powell1 Dr Catrin Tudur Smith2 Prof Anthony Marson1
Dept of Molecular and Clinical Pharmacology1 & Dept of Biostatistics2
CONCLUSION
1. Reporting of adverse events is poor in current 
literature.
2. Reporting of outcomes is heterogeneous with some 
reported well and others being under reported.
3. Reporting has not changed since the CONSORT 
guidelines were published.
4. Industry sponsored trials are better at reporting 
harms outcomes.
5. Poor reporting adversely affects future prospects of 
including harms data into systematic reviews.
6. Our results reinforce work highlighting poor 
reporting in RCTs of antiretroviral drugs3.
7. We recommend that journal editors should make 
authors aware of the guidelines relating to harms as 
there is evidence that other aspects of trial reporting 
has improved since publication of the original 
guidelines2.
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INTRODUCTION
¾ Randomised controlled trials (RCTs) form the 
cornerstone of evidence based medicine.
¾ Treatment decisions require an assessment of 
harms  and benefits. 
¾ Efficacy outcomes  are reported well in RCTs but 
few studies have evaluated adverse event (AE) 
reporting.
¾ Guidelines for reporting harms were published by 
the CONSORT group in 20041.
¾These could be used as a quality assessment tool 
for assessing current deficiencies.
AIMS
 To asses the reporting of adverse events in RCTs of 
antiepileptic drugs. 
To highlight current inadequacies of reporting 
adverse events. 
To provide recommendations for improvements in 
reporting.
METHODS
Inclusion Criteria:
¾ We searched for reports of RCTs published 
between 1999 and 2008 using MEDLINE and the 
Cochrane Library database.
¾ Reports of antiepileptic drugs were included.
¾ RCTs should have a minimum of two comparator 
groups, one of which could be placebo.
Exclusion Criteria:
¾ Observational studies.
¾ Surgical interventions or vagus nerve stimulation 
studies.
¾ Neuropsychological outcomes as the primary 
outcomes  or secondary reports of RCTs where this is 
the key outcome.
Analysis:
¾ We selected 23 items relating to harms from the 
CONSORT guidelines.
¾ We scored trial reports using the guidelines. 
Scores could range from a minimum of zero to 23. 
¾ We compared proportions of trials meeting 
individual items. Subgroups used were: Industry 
funded versus non Industry funded, trials recruiting 
children versus adults, trials published before and 
after the publication of the CONSORT guidelines.
¾Cohen's Kappa statistic was used to determine 
inter-rater agreement.
¾ We used unpaired t test to compare score totals 
and we calculated relative risks for meeting 
individual criteria.
RESULTS
¾ Our search revealed 152 eligible trial reports
¾ Inter-rater agreement for scoring was deemed to be 
good. Cohen's kappa value of 0.78 (95% CI 0.64-
0.92).
Industry funded trials.
¾ Scored better than non industry funded studies.
¾ Relative risks comparing industry funded and non 
industry funded trials showed industry funded trials 
significantly excelled at a number of items. Examples 
include: providing definitions for AE, if all or selected 
sample of AE was reported, and if a validated 
dictionary was used.
Post CONSORT trials.
¾ Scored no different to Pre CONSORT trials.
¾Relative risks were heterogeneous in size effect and 
direction.
Adult vs. Children.
¾ Trials recruiting adults scored better than those 
recruiting children. 
¾Relative risks showed trials recruiting adults were 
better at proving definitions for AE, providing details 
of statistical analysis, reporting withdrawals from AE 
and presenting results separately.
Item CONSORT Section in 
article
Description
1 1 Title or
abstract 
Title or abstract must state if adverse events 
outcomes were analysed
2 2 Introduction Intention to address adverse events
3 3 Methods Definitions of adverse events
4 3 Methods All or selected sample of adverse events
5 3 Methods Treatment emergent adverse events
6 3 Methods Validated instrument used to collect adverse 
events
7 3 Methods Validated dictionary of adverse events used 
8 4 Methods How adverse events are collected 
9 4 Methods Is the timing of collection of adverse events 
stated
10 4 Methods Indicate details of attribution of adverse events
11 5 Methods Describe plans for any statistical analysis
12 5 Methods Describe plans for handling recurrent events
Item CONSORT Section in 
article
Description
13 6 Results Report early or late withdrawals due to AE
14 6 Results Report serious adverse events including deaths
15 7 Results Provide definitions used for analysis set
16 7 Results If same analysis set used for efficacy and safety
17 7 Results Provide denominators for analysis of harms
18 8 Results Presented separately for each group
19 8 Results Provide the severity or grade of events
20 8 Results Provides both the number of adverse events and 
the number of patients with adverse events
21 10 Discussion Prior literature with reference to AE discussed
22 10 Discussion Gives a balanced discussion of harms vs. 
efficacy
23 10 Discussion Limitations of study with regard to adverse event
data is presented 
Figure one: CONSORT criteria one to five
Figure two: CONSORT criteria six to ten
Figure three: Subgroup analysis of mean CONSORT scores.
Figure four: Relative risks of meeting individual CONSORT items
0 20 40 60 80 100
Harms in title and abstract
Harms in introduction
Definition of AE
All or selected sample
Treatment emergent AE
Validated Instrument
Validated Dictionary
Mode of AE Collection
Timing of AE
Details of attribution
Details of presentation and analysis
Handling of recurrent AE
Percentage of all trials meeting criteria 1 to 5
ACKNOWLEDGEMENTS
• This work part funded by the National Institute for Health Research programme grant for applied research and the 
University of Liverpool
0 20 40 60 80 100
Early or late withdrawals
Serious AE or death
Provide denominators for AE
Provide defintions for anlaysis set
Same analysis set for efficacy and …
Results presented seperately
Severity and grading
Both number of patients and events
Discusses prior AE
Discussion is balanced
Discusses Limitations
Percentage of trials meeting criteria 6 to 10
Adverse events of antiepileptic drugs across indications.
Can randomised controlled trial data from non-epilepsy indications be included in meta-analysis for AEDs used in epilepsy?
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CONCLUSION
1. Adverse events across indications is a useful means 
of increasing power in meta-analysis.
2. Heterogeneity is a limiting factor in using trials from 
other indications in meta-analysis.
3. Heterogeneity is dependent on dose, outcome used 
and intervention.
4. Meta-regression methods to eliminate the effect of 
dose can not totally explain heterogeneity.  This 
indicated that there are other factors that determine 
it.
5. We report that patients with epilepsy report a higher 
relative risk of adverse events than patients with 
other indications.
6. This could be explained by clinical differences 
between patients that impact on reporting of adverse 
events.
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INTRODUCTION
¾ Randomised controlled trials (RCTs) form the 
cornerstone of evidence based medicine.
¾ Treatment decisions require an assessment of 
harms  and benefits. 
¾ Meta-analysis is one method of summarizing  
efficacy and harms data from several RCTs.
¾AEDs which are used in epilepsy are  also used in 
other conditions like neuropathy and headache 
syndromes.
¾Using harms outcomes from other indications in 
meta-analyses of AEDs  provides additional data thus 
increases statistical power of the analysis.
AIMS
 To asses if harms data from  indications other than 
epilepsy be used in meta-analyses of AEDs. 
To determine if heterogeneity between patients 
from trials in other indications is significant.
To determine the sources of heterogeneity using 
meta-regression2.
METHODS
Inclusion Criteria:
¾ We searched for reports of placebo controlled 
RCTs of AEDs in MEDLINE and the Cochrane 
Library database.
¾RCTs recruited patients with either epilepsy, 
peripheral or CNS pain, and headache syndromes.
¾Only AEDs of adults patents were included.
¾AEDs included were: Topiramate, gabapentin, 
lacosamide, oxycarbazepine, valproate, carisbamate, 
pregabalin and zonisamide.
Exclusion Criteria:
¾ Observational studies.
¾ Surgical interventions or vagus nerve stimulation 
studies.
¾ Neuropsychological outcomes as the primary 
outcomes  or secondary reports of RCTs where this is 
the key outcome.
Analysis:
¾ We selected 6 adverse events outcomes: dizziness, 
ataxia, headache, fatigue, somnolence nausea and 
proportion of patients with any AE and proportion of 
patients withdrawing due to AEs. 
¾ We used RevMan 5.0 to calculate relative risks 
comparing placebo and active treatment.
¾We sub grouped outcomes by indication to 
calculate I2 test of statistical heterogeneity1. 
Meta-regression:
¾To investigate on further sources of heterogeneity 
we eliminated the effect of dose using meta-
regression.
¾Intercept  of regression curve would allow 
calculation of relative risks for each subgroup.
RESULTS
¾ Our search revealed 106 eligible trial reports.
¾ Feasibility of using AE data from other indications 
varied by drug and outcome. 
¾We found that lacosamide showed the greatest 
feasibility. This was followed by topiramate, 
oxycarbazepine and lamotrigine.
Statistical Heterogeneity
¾ We show here the results for dizziness.
¾Heterogeneity was reduced for three AEDs 
(lacosamide, gabapentin, topiramate and lamotrigine) 
but not for oxycarbazepine when dizziness is the 
outcome.
Meta-regression
¾ Calculated relative risks after the effect of dose was 
minimised showed a consistent higher risk in patients 
with epilepsy than those from other indications.
¾Thus any statistical heterogeneity is accounted by 
patient factors which would be difficult to eliminate.
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Outcome Indication
Slope 
(dlnRR/dDose)
Intercept
lnRR
Intercept 
RR
Ataxia Epilepsy 0.176 0.984 2.67
Ataxia Neuropathy 0.517 -0.543 0.58
Dizziness Epilepsy 0.205 0.376 1.45
Dizziness Neuropathy 0.364 -0.375 0.68
Fatigue Epilepsy 0.202 0.376 1.45
Fatigue Neuropathy 0.159 -0.375 0.68
Nausea Epilepsy 0.002 1.054 2.87
Nausea Neuropathy 0.170 -0.136 0.87
Somnolence Epilepsy 0.159 -0.160 0.85
Somnolence Neuropathy -0.032 0.475 1.61
Outcome Indication
Slope 
(dlnRR/dDose)
Intercept
lnRR
Intercept 
RR
Ataxia Epilepsy
No Data
Ataxia Neuropathy
Dizziness Epilepsy 0.017 0.626 1.87
Dizziness Neuropathy 0.120 0.010 1.01
Fatigue Epilepsy 0.015 0.545 1.72
Fatigue Neuropathy 0.093 -0.750 0.47
Nausea Epilepsy 0.031 0.550 1.73
Nausea Neuropathy 0.136 -0.995 0.37
Somnolence Epilepsy 0.048 0.298 1.35
Somnolence Neuropathy 0.155 -1.281 0.28
Fig 1. Forest plot of relative risk of dizziness by Lacosamide, sub grouped  by dose . Data showing 
epilepsy and neuropathy trials
Fig 2. Forest plot of Relative Risk of Dizziness with Gabapentin, sub-grouped by indication. Data 
showing epilepsy, headache and neuropathy trials.
DIZZINESS I2 Test of Heterogeneity
Indication
Intervention
Headache Neuropathy Epilepsy Total  when 
combine 
trials 
subgroups
Gabapentin 63% 22% 0% 0%
Lacosamide na 0% 56% 19%
Topiramate 24% 0% 0% 0%
Oxcarbazepine 0% na 8% 59%
Lamotrigine na 38% 39% 0%
Table 1. Results of reduction in statistical heterogeneity when trails from other indications are 
pooled.
Table 2. Meta-regression when effect of dose is minimised of all outcomes for Lacosamide.
Fig 3. Forest plot of Relative Risk of Dizziness with Gabapentin, sub-grouped by indication. Data 
showing epilepsy, headache and neuropathy trials.
Table 3. Meta-regression when effect of dose is minimised of all outcomes for Oxcarbazepine.
Fig4. Meta-regression curves for Lacosamide, (a) dizziness in epilepsy trials and (b) dizziness in 
neuropathy trials 
